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Abstract 
Human essential hypertension is a highly heritable disorder with complex 
aetiology and is a major risk factor for cardiovascular events such as ischaemic 
heart disease and stroke. A combination of multiple environmental and lifestyle 
factors contribute to blood pressure variation alongside a strong genetic 
component. Only a small proportion of the genetic factors that regulate blood 
pressure in the population are currently known, although there is strong 
evidence that the adrenal cortex and the steroid hormones it produces 
contribute. Several research strategies have been utilised to dissect the genetic 
aetiology of hypertension, including candidate gene studies and association 
studies. Two recent genome-wide association studies aimed to identify variations 
associated with altered blood pressure and hypertension. A total of ten variants 
were identified with genome-wide significance after a combined analysis 
between the two consortia, including a polymorphism located within intron 3 of 
the CYP17A1 gene. This variant was reported to be associated with a systolic 
blood pressure increase of 1.16 mmHg. The CYP17A1 gene codes for a dual-
function enzyme (17α-hydroxylase/17,20 lyase) expressed primarily in the 
adrenal cortex and gonads that plays a key role in the steroidogenic pathway. 
Mutations in its coding region and splice sites are known to cause a rare form of 
congenital adrenal hyperplasia, suggesting that more common genetic variations 
at this locus might result in more subtle effects on blood pressure.  
A detailed examination of the variation across the CYP17A1 locus was required to 
establish patterns of linkage disequilibrium and is presented in Chapter 3. Some 
information on the polymorphic variation in this region was already available in 
public databases but precise details on linkage disequilibrium and the 
corresponding haplotype blocks were lacking. The entire CYP17A1 gene was 
directly sequenced, including approximately 2.5kb upstream from the 
transcriptional start site, in 62 subjects drawn from a normotensive population. 
Polymorphic variations were identified mainly in the promoter and introns. Two 
seemingly unrelated blocks of SNPs were identified as being worthy of follow-up 
investigations, particularly those located in the promoter region, as these could 
be responsible for alterations in the transcriptional activity of the gene. A total 
of seven promoter polymorphisms were then genotyped in a larger hypertensive 
population where the relationship between SNPs was less clear. 
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In Chapter 4 the effect of CYP17A1 genotype on intermediate corticosteroid 
phenotype is explored in a hypertensive population. Corticosterone, cortisol and 
androgen production were not significantly altered in the population when 
stratified by genotype for each polymorphism. However when further split by 
gender, increased cortisol excretion rates were found to associate with the 
minor allele at position -362 in males and at positions -1204 and -2205 in 
females. Ratios of various corticosteroid intermediary metabolites were also 
compared as indices of CYP17A1 enzymatic activity. Ratios of THDOC:THS were 
significantly reduced in the presence of the minor allele at positions -34, -1204 
and -2205, suggesting increased 17α-hydroxylase efficiency. In addition, 
aldosterone excretion was significantly elevated in individuals with CC genotype 
at position -1877; an indirect genotype-dependent effect has been speculated.  
A bioinformatic search was conducted to identify putative transcription factor 
binding sites at the polymorphic locations. This is presented in Chapter 5. This 
confirmed the hypothesis that single base changes at each of the seven 
polymorphic sites could lead to altered transcriptional activity. Using reporter 
gene assays in vitro, the G allele at position -362 (rs248658) associated with 
greater transcriptional activity than the A allele. The T allele at position -1877 
(rs138009835) was transcriptionally less active than its alternative C allele. 
Similarly, the C allele at position -2205 (rs2150927) showed lower activity than 
the T allele. These data provide strong evidence that common variation at this 
locus may be of functional significance. 
The studies in Chapter 6 investigate a potential regulatory role of microRNA 
(miRNA) at the CYP17A1 locus. MiRNAs are a class of small non-coding RNA 
molecules that have recently emerged as novel post-transcriptional regulators of 
gene expression. They function by targeting the 3’ untranslated region (3’UTR) 
of specific mRNAs and cause repression either through mRNA destabilisation 
followed by degradation, or by mRNA translational repression. Previous research 
utilised a siRNA approach to knock down Dicer, a protein required for miRNA 
maturation, and noted significantly increased CYP17A1 mRNA levels in the H295R 
human adrenocortical cell line. The investigation presented here cross-
referenced bioinformatic analysis with microarray expression data in order to 
predict which adrenal miRNAs are most likely to regulate CYP17A1 expression. 
Predicted miRNAs also shown to be differentially expressed between normal and 
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diseased adrenal tissue were then selected for further analysis. In vitro 
investigation involved artificial manipulation of the specific miRNA levels in 
H295R cells followed by measurement of CYP17A1 mRNA levels. Increased 
amounts of hsa-miR-320a significantly raised CYP17A1 mRNA levels, although 
subsequent reporter construct assays showed that this was not due to direct 
miRNA binding of the CYP17A1 3’UTR. The studies in this chapter are the first to 
demonstrate miRNA-mediated regulation of CYP17A1 expression. 
In summary, this work aimed to investigate polymorphic variation in the human 
CYP17A1 gene and its association with hypertension. Patterns of linkage 
disequilibrium across the CYP17A1 gene were identified and the association of 
several polymorphisms with intermediate corticosteroid phenotype examined. 
The functional effects of candidate polymorphisms have also been assessed in 
vitro. Further studies will be required to determine whether observed changes in 
transcriptional activity are the direct result of altered transcription factor 
binding at polymorphic sites. Finally, the role of miRNA in the post-
transcriptional regulation of CYP17A1 has been confirmed. 
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1 Introduction 
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High blood pressure affects around one-third of adults worldwide and is a major 
risk factor for cardiovascular events such as ischaemic heart disease and stroke. 
The exact cause of essential hypertension is unknown; however it is known that 
both environmental and genetic factors play key roles in the regulation of blood 
pressure and it is possible that variations in either of these may predispose to 
hypertension. A clearer understanding is required of why and how hypertension 
develops in individuals so that the probability of its onset can be assessed 
accurately and its consequences pre-empted. The following sections outline the 
components of blood pressure, the numerous factors that control them and, 
briefly, the nature of the damage caused by hypertension. This is followed by a 
more detailed examination of factors predisposing to hypertension and their 
study. 
1.1 Blood Pressure and Hypertension 
Arterial blood pressure is the pressure exerted by the circulating blood on vessel 
walls. Blood pressure is highest when the heart contracts, known as systolic 
blood pressure (SBP) and lowest when the heart relaxes, the diastolic blood 
pressure (DBP). Blood pressure is a continuous trait and therefore selecting an 
upper normal limit is arbitrary.  A desirable adult level might be 120/80 
(Chobanian et al., 2003). 
Recently, recommendations for the management of hypertension have been 
updated whereby thresholds for pharmacological intervention are clearly defined 
(James et al., 2013). Treatment should be provided for individuals in the general 
population ≥60 years when SBP ≥150 mmHg or DBP ≥90 mmHg. The same 
threshold for DBP is recommended for treatment in the general population <60 
years, however, expert opinion suggests pharmacological intervention when SBP 
≥140 mmHg.  
1.1.1 Physiological Regulation of Blood Pressure 
Several physical factors are involved in the regulation of blood pressure, which, 
in turn, can be influenced by physiological and genetic factors, some of which 
are outlined in Section 1.1.2. Changes in blood pressure can arise from 
alterations in cardiac output, defined as heart rate multiplied by the stroke 
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volume. Also, peripheral resistance, i.e. diameter and smooth muscle tone of 
the arteries in which the blood is flowing, small arteries at the periphery and 
viscosity of the blood itself also affect arterial blood pressure. These 
components are mainly regulated by neural, endocrine and paracrine factors 
influencing kidney function and vascular tone (Figure 1-1). The regulation of 
fluid and electrolyte balance by the kidney is of primary importance in 
determining blood pressure (Guyton et al., 1972; Guyton 1991). One key 
element affecting the efficiency of the kidney is angiotensin II (Ang II), the 
active product of the renin-angiotensin system (RAS) (Figure 1-2). In response to 
stimuli, such as low sodium, the enzyme renin is synthesised and released from 
juxtaglomerular cells, initiating an enzymatic cascade, converting 
angiotensinogen to angiotensin I. In turn, this is converted (predominantly within 
pulmonary vasculature) by the Angiotensin-Converting Enzyme (ACE) into the 
vasoconstrictor and primary active product angiotensin II. Ang II stimulates 
aldosterone production, increasing sodium re-absorption in the kidney, and 
contraction of vascular smooth muscle. Both tend to increase blood pressure. 
The action of Ang II is mediated through two receptors. Binding to the AT1 
receptor promotes vasoconstriction and leads to increased sodium retention in 
the kidneys. Interaction of Ang II with the AT2 receptor, however, counteracts 
this effect by stimulating vasodilation (Unger 2002). This is an excellent 
illustration of how a detailed knowledge of a blood pressure-regulating system is 
valuable in the treatment of hypertension. Antagonists of ACE and blockers of 
angiotensin-receptor binding have found effective use. As outlined in Figure 1-1, 
there are many complex body systems and physiological factors which control 
the regulation of blood pressure. It is with one of these, adrenocortical activity, 
that this thesis is mainly concerned. 
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Figure 1-1 Factors involved in the regulation of arterial pressure. 
Arrows show interactions between the different factors; dashed lines indicate negative feedback. 
Adapted from Cowley (2006). 
 
 
Figure 1-2 The Renin-Angiotensin System. 
AT1R: angiotensin II receptor type 1; AT2R: angiotensin II receptor type 2. 
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1.1.2 Essential Hypertension 
In a small proportion (approximately 5%) of individuals, hypertension can be 
attributed to an underlying cause, such as renal, endocrine or neurological 
disorders. In the majority, however, no cause has yet been identified. This is 
classed as essential hypertension, also known as primary or idiopathic 
hypertension. Non-modifiable risk factors (e.g. age and gender) have been 
shown to have some influence on blood pressure; systolic blood pressure 
increases with age and men tend to have higher blood pressure than women 
(Franklin et al., 2001; Chobanian et al., 2003). For the development of essential 
hypertension, the greatest contribution probably arises from a combination of 
genetic and environmental factors. Diet, including salt intake, and lifestyle 
(exercise, smoking, alcohol intake etc.) are known contributory factors and are 
clearly modifiable (see Section 1.1.2.1). Still, about 35% of variation in blood 
pressure can be attributed to genetic factors (Ward 1990), with a positive family 
history significantly increasing relative risk of hypertension and cardiovascular 
disease (Ehret and Caulfield 2013; Williamson et al., 2013).  Importantly, 
environmental and genetic factors contribute separately and probably also 
interact with each other (see Section 1.1.2.1). 
While most of this thesis will focus on the genetic influence and the 
pathophysiological mechanisms leading to hypertension, it is important to 
discuss briefly contributing environmental factors, since these will certainly 
modify genetic predisposal.  
1.1.2.1 Environmental Risk Factors 
Excess body weight, diet, lack of physical activity, stress and smoking have all 
been shown to associate with increased blood pressure.  
There is compelling evidence that a high sodium intake correlates with increased 
blood pressure. The INTERSALT study examined urinary sodium and potassium 
excretion levels and their relationship with blood pressure in 10,079 individuals 
from 52 centres located in 32 different countries (Stamler et al., 1989). It 
reported that increased sodium excretion had a significant positive association 
with increased blood pressure. These findings were corroborated by the EPIC-
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Norfolk and NHANES III studies (Hajjar and Kotchen 2003; Khaw et al., 2004). 
Intervention studies, like the DASH-Sodium Trial, varied sodium intake and 
evaluated its effect on blood pressure (Vollmer et al., 2001). Here, decreasing 
sodium intake lowered blood pressure in both normotensive and hypertensive 
individuals. 
The INTERSALT study also reported an inverse relationship between blood 
pressure and potassium excretion levels. The effects of dietary potassium were 
explored further through meta-analysis of thirty-three controlled trials by 
Whelton et al., (1997). Potassium supplementation reduced both blood pressure 
and the requirement for medication. 
Epidemiological studies have shown that populations with diets based on natural 
foods, which are low in sodium and high in potassium, have considerably lower 
rates of hypertension than those in industrialised areas with diets high in 
processed foods (Adrogue and Madias 2007). The ability of various body systems 
to adapt to this balance change is important in maintaining blood pressure. This 
ability may be genetically determined and, as will be shown later, the adrenal 
cortex may be influential. 
1.1.2.2 Genetic Risk Factors 
Blood pressure is a highly heritable trait.  Heritability for blood pressure has 
been reported as 15-40% for systolic blood pressure and 15-30% for diastolic 
blood pressure, with a combined rate of approximately 35% (Ward 1990).  
Population studies demonstrate that there is greater similarity in blood pressure 
levels within families than between families (Longini et al., 1984). Furthermore, 
monozygotic twins have a greater concordance of blood pressure than dizygotic 
twins (Feinleib et al., 1977). Several comparisons of blood pressure between 
biological and adopted siblings corroborate these findings; in a shared 
environment, biological siblings display greater similarity in blood pressure than 
their adopted counterparts (Biron et al., 1976; Perusse et al., 1989). 
It is not surprising, since so many different physiological systems contribute to 
blood pressure, that essential hypertension is probably a heterogeneous 
condition in which small differences in the structure of genes coding for the 
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active proteins contribute to different degrees of final pressure.  How might 
these contributing factors be identified and their relative contributions 
established?  Various approaches are outlined in the next sections.   
1.1.3 Genetic Basis of Hypertension 
Various techniques have been employed to identify the genetic loci affecting 
blood pressure and to quantify their effects. Rare monogenic disorders of which 
hypertension is a feature provide a starting point, offering an insight into 
pathways and mechanisms involved in the development of hypertension. A 
summary of these is provided below. To investigate the genetic aetiology of 
hypertension, recent research strategies adopted include candidate gene studies 
and association studies. The progress and utility of each method is reviewed in 
the following sections. 
1.1.3.1 Candidate Gene Analysis 
High blood pressure has been the subject of research for more than a century 
and much is known of the systems contributing to its physiology and 
pathophysiology. It is therefore logical to study genes – ‘candidate genes’ – that 
code for key proteins within these systems. Predictably, some of these relate to 
the RAAS and, particularly relevant to this review, aspects of 
corticosteroidogenesis. The candidate gene approach has been used in many 
hypertension investigations, with varying degrees of success. 
Angiotensinogen 
The angiotensinogen gene (AGT) has been described in Section 1.1.1. Numerous 
single nucleotide polymorphisms (SNPs) have been identified in its coding and 
regulatory regions. Jeunemaitre et al. (1992) reported an association between 
the SNPs T174M and M235T and hypertension. However, attempts to replicate 
these findings produced conflicting results (see review by Dickson and Sigmund 
2006). A meta-analysis of several case-control studies also failed to repeat these 
findings but did report that the T allele at position 235 correlates with increased 
relative risk of hypertension (Sethi et al., 2003). 
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Angiotensin Converting Enzyme 
The ACE gene encoding angiotensin converting enzyme (ACE) has a 287 base-pair 
insertion/deletion polymorphism within its intron 16 that has been associated 
with coronary artery disease, endothelial dysfunction and increased ACE plasma 
levels. Investigations attempting to identify associations between ACE and 
essential hypertension have, however, produced conflicting results. Some have 
reported a sex-specific correlation whereby an association of ACE with 
hypertension is seen only in men (O'Donnell et al., 1998), while others have 
reported that there is no association at all (Jeunemaitre 2008). No definitive 
conclusion about the involvement of ACE gene variation in essential hypertension 
can be drawn at the moment. 
Corticosteroidogenic Genes 
The adrenal steroidogenic pathway is the focus of this thesis and several of its 
genes have also been studied as candidates. The CYP11B1 and CYP11B2 genes, 
which encode for 11β-hydroxylase and aldosterone synthase respectively, 
catalyse the terminal stages of cortisol and aldosterone production in the 
adrenal gland (see Figure 1-7 later). Both have been implicated in the 
development of hypertension. A review of the studies involving these genes can 
be found in Section 1.3.3.1 and Section 1.3.3.2.  
Monogenic Disorders of Hypertension 
 
Studying monogenic or Mendelian forms of hypertension provides an insight into 
the underlying mechanisms that control blood pressure and can yield strong 
clues to aid identification of candidate genes. These rare disorders with high 
blood pressure account for around 1% of all hypertensive cases (Rafiq et al., 
2010) and are summarised in Table 1-1.  It is of interest that salt and water 
metabolism is disturbed in nearly all cases. Again, the adrenal cortex features 
prominently. 
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Table 1-1 Monogenic disorders featuring hypertension. 
AR: autosomal recessive; AD: autosomal dominant ACTH: adrenocorticotropic hormone; ENaC: 
epithelial sodium channel. 
Disorder Gene 
Inheritance 
Pattern 
Clinical Features 
AME 
(Mune and White 
1996; Li et al., 
1998) 
HSD11β2 AR 
Decreased conversion of cortisol to cortisone 
leading to excess stimulation of MR. Patient 
has low aldosterone and suppressed renin. 
CAH – subtype IV 
(Krone and Arlt 
2009) 
CYP11B1 AR 
Decreased cortisol production, increased 
mineralocorticoid production. Increased 
androgen levels. 
CAH – subtype V 
(Krone and Arlt 
2009) 
CYP17A1 AR 
Decreased cortisol production, increased 
mineralocorticoid production. Decreased 
androgen levels. 
GRA 
(Lifton et al., 
1992a; Lifton et 
al., 1992b) 
CYP11B1 / 
CYP11B2 
AD 
Ectopic expression of aldosterone synthase 
controlled by ACTH leading to increased 
aldosterone/renin ratio. 
Gordon’s 
Syndrome 
(Wilson et al., 
2001) 
WNK1 
WNK4 
AD 
Increased activity of Na-Cl co-transporter in 
distal nephron leading to excess sodium 
retention and hyperkalaemia. 
Liddle’s 
Syndrome 
(Hansson et al., 
1995) 
SCNN1B 
SCNN1G 
AD 
Activation of ENaC leading to increased sodium 
reabsorption and plasma volume. 
 
The study of these monogenic disorders emphasises that several distinct 
mechanisms can lead to high blood pressure through the common cause of 
increased sodium reabsorption and plasma volume expansion. Mutation of 
enzymes participating in the adrenal steroidogenic pathway (see Figure 1-7) 
leads to various monogenic disorders such as the syndrome of apparent 
mineralocorticoid excess (AME) and congenital adrenal hyperplasia (CAH). The 
genes responsible for CAH are of particular relevance to this thesis and are 
discussed in Section 1.3.3.1. An inactive 11β-hydroxysteroid dehydrogenase type 
2 (HSD11β2) enzyme is found in individuals with AME, preventing the conversion 
of cortisol to cortisone (Mune and White 1996; Li et al., 1998). In the distal renal 
tubule, the mineralocorticoid receptor (MR) has the same affinity for cortisol 
and aldosterone so in AME patients; the MR is no longer protected from excess 
cortisol and is free to bind it. Patients with glucocorticoid-remediable 
aldosteronism (GRA) experience failure of the regulatory mechanisms to 
suppress aldosterone synthase, leading to volume-dependent hypertension and 
suppressed renin (Lifton et al., 1992a; Lifton et al., 1992b). GRA is caused by an 
unequal recombination event during meiosis that creates a hybrid gene 
composed of the CYP11B1 ACTH-responsive promoter and the coding region of 
 31 
 
aldosterone synthase (CYP11B2). In such cases, aldosterone production is 
controlled by ACTH rather than Angiotensin II, causing an increase in 
mineralocorticoid production and, subsequently, increased sodium reabsorption 
and potassium excretion. Finally, mutations in post-receptor mechanisms (e.g. 
Na-Cl and ENaC transporters) as in Gordon’s syndrome and Liddle’s syndrome are 
described as gain-of-function as they cause increased sodium and chloride 
retention and subsequent increased plasma volume (Hansson et al., 1995; Wilson 
et al., 2001).  
There is no doubt that numerous studies of monogenic disorders that cause high 
blood pressure and subsequent investigations into the underlying causative 
mechanisms have furthered our knowledge of blood pressure regulation. This has 
prompted investigation of candidate genes in order to test their impact on 
essential hypertension. 
The candidate gene approach has several disadvantages. It makes various 
assumptions. It requires prior knowledge of possible disease mechanisms and 
therefore does not explore unknown pathways. Many association studies produce 
conflicting results, with weak correlation significance that is difficult to 
replicate. Possible flaws in the experimental approach have been identified. 
Most candidate gene studies have been statistically underpowered due to 
relatively small sample sizes, so that the small genetic effects of individual 
systems may be missed. In response to these limiting factors, linkage analysis 
and genome-wide association studies were developed.   
1.1.3.2 Linkage Analysis & Genome-Wide Association Studies  
Linkage Analysis 
Linkage analysis studies compare genetic markers within the entire genomic DNA 
of individuals drawn from families comprising both affected and unaffected 
members. The term linkage refers to the tendency of particular genetic loci to 
be co-inherited during meiosis.  
Family-based genetic linkage studies take into account the proportion of the 
genome expected to be shared by two family members, e.g. siblings share 
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approximately 50% of their genomes. If both are affected by hypertension, the 
study design hypothesises that the alleles closest to a causative region on the 
chromosome will be shared more frequently. Such regions are identified as 
quantitative trait loci (QTL) and warrant further study. Linkage is assessed by 
logarithm of the odds (LOD) scores, where a positive LOD score is indicative of 
linkage. This should not be confused with the term ‘linkage disequilibrium’, used 
later in this thesis, which relates to the phenomenon seen in cohorts whereby 
two or more loci are found together in the same haplotype more often than by 
random chance, i.e. the non-random association of alleles. It is also useful to 
have knowledge of linkage disequilibrium (LD) patterns, as the allele under 
investigation may be in LD with others elsewhere on the chromosome. 
In the last decade, various genetic linkage studies for hypertension have been 
conducted but few have achieved LOD scores of genome-wide significance, 
generally held to be LOD ≥ +3.0. This arbitrarily-selected threshold indicated 
odds of 1000 to 1 that the linkage observed has not occurred by chance. 
Successful linkage studies are summarised in Table 1-2, although the lack of 
replication within the published literature is apparent (Binder 2007). The genetic 
heterogeneity of different study cohorts may be a key factor and, therefore, 
although linkage analysis has generated novel QTLs, its limited success and lack 
of reproducibility deem it less than ideal for studying the complex genetic 
contribution to hypertension. In some cases, single QTLs may constitute long 
portions of the genome and individual genes within such sections remain to be 
identified. 
 
Table 1-2 Examples of linkage studies in hypertension. 
Study 
Chromosomal 
Region 
Population 
(Levy et al., 2000) 17q (60-76cM) Framingham Study 
(Kristjansson et al., 2002) 18q (80-94cM) Icelandic cohort 
(Allayee et al., 2001) 4p (13-43cM) 18 Dutch families 
(Angius et al., 2002) 2p (26.5-27.1cM) 
Hypertensive probands from isolated 
Sardinian village 
(Caulfield et al., 2003) 6q Bright hypertensive sibling-pairs 
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Genome-Wide Association Studies 
The currently favoured method for identifying genomic variation associated with 
hypertension is termed the genome-wide association study (GWAS). GWAS aims 
to identify genotype associations with a particular trait by examining variation 
across the entire genome. The successful completion of the Human Genome 
Project and the development of the International Hapmap Project, have 
provided greater understanding of variation within the human genome (Lander 
et al., 2001; Venter et al., 2001; Gibbs et al., 2003). This knowledge, together 
with more advanced understanding of LD patterns within the genome, have 
meant that the genetic linkage analysis technique can be expanded to 
incorporate ‘tagSNPs’: a single SNP that represents a portion of a chromosome 
within an LD block. The development of microarray chips has enabled high-
throughput genotyping of up to a million SNPs in thousands of subjects. A 
comparison of allele frequencies in cases and controls should therefore reveal 
any associations between variants and hypertension or other disease traits. 
Despite the initial optimism surrounding this approach, early GWA studies failed 
to provide major insights into the genetic basis of hypertension. The Wellcome 
Trust Case Control Consortium (WTCCC) performed the first GWAS for 
hypertension and, although it identified several risk variants, genome-wide 
significance, p<5x10-7, was not achieved (Burton et al., 2007). The WTCCC study 
did, however, identify significant associations with other traits including 
coronary artery disease; this appeared to indicate that this method had the 
potential to identify associations with hypertension but that greater sample sizes 
would be required to attain sufficient statistical power to detect relatively small 
blood pressure effects. In addition, a greater number of chip probes achieving 
more detailed genomic coverage were recommended for future studies. Of 
concern to the WTCCC study was the discrepancy between the average age of 
the cases (68 years) and controls (48 years). This was a fundamental flaw in the 
study design, given that the risk of developing hypertension increases with age, 
it being likely that a significant proportion of the controls would develop the 
trait over the next 10-20 years. As a result, a more stringent recruitment process 
should be incorporated into future study designs. 
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Several other smaller GWA studies had little success (Org et al., 2009; Sabatti et 
al., 2009; Wang et al., 2009). Both Wang et al. and Org et al. identified variants 
of significance only following meta-analyses that combined various cohorts, 
again confirming the need for very large cohorts. 
To address this requirement, subject data sourced from various large 
international studies were combined. The Global BP-Gen consortium included 
34,433 individuals from 17 studies (Newton-Cheh et al., 2009) in which hundreds 
of thousands of common genetic variants had been genotyped. Computational 
imputation of 2.5 million SNPs were combined in a meta-analysis and analysed 
for their association with systolic and diastolic blood pressure and hypertension. 
The Cohorts for Heart and Ageing Research in Genome Epidemiology (CHARGE) 
BP consortium utilised 29,136 individuals of European descent from 6 studies 
(Levy et al., 2009) in a large meta-analysis. An in silico comparison between the 
two studies was then performed in an attempt to replicate their findings. The 
Global BP-Gen study identified 8 SNPs attaining genome-wide significance: 3 for 
SBP and 5 for DBP. The CHARGE consortium reported 13 SNPs for SBP, 20 for DBP 
and 10 for hypertension, all with p<4x10-7 for genome-wide significance. The 
results from the combined meta-analyses are summarised in Table 1-3. Variance 
in the levels of significance of each SNP obtained from these two studies may 
partly be explained by differences in the analytical methods as much as genetic 
heterogeneity between study populations.  
Table 1-3 Summary of results from meta-analysis of CHARGE and Global BP-Gen. 
SNP Chromosome Nearest Gene Affected Phenotype p-value 
rs9815354 3 ULK4 DBP 2.54E-09 
rs11014166 10 CACNB2 DBP 1.24E-08 
rs1004467 10 CYP17A1 SBP 1.28E-10 
rS381815 11 PLEKHA7 SBP 1.89E-09 
rs2681472 12 ATP2B1 DBP 1.47E-09 
rs3681492 12 ATP2B1 SBP 3.76E-11 
rs3184504 12 SH2B3 
SBP 
DBP 
4.52E-09 
2.58E-14 
rs2384550 12 TBX3/TBX5 DBP 3.75E-08 
rs6495122 15 CSK/ULK3 DBP 1.84E-10 
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Other studies are attempting to replicate these findings. Takeuchi et al., (2010) 
conducted a GWAS in a Japanese cohort consisting of 25,826 individuals. 
Significant blood pressure and hypertension associations were identified with 
variants within the MTHFR, FGF5, CYP17A1, ATP2B1 and CSK-ULK3 genes, all 
previously reported by the Global BP-Gen and CHARGE studies. Two additional 
loci, located within the CASZ1 and ITGA9 genes, were also statistically 
significant. A smaller study of 3,210 Chinese Han participants replicated the 
significant association of four variants found in the CHARGE and BP-Gen studies 
(Liu et al., 2011) identifying a similar effect size of both CYP17A1 variants and 
the MTHFR intronic variant in relation to systolic blood pressure. The 
polymorphism located near FGF5, however, had a more pronounced effect in the 
Chinese Han population compared to the European cohorts. The authors 
acknowledge that the study was underpowered to detect significant associations 
with other previously reported variants. These results, while replicating the 
findings of the major GWA studies, suggest that the genetic contribution to the 
regulation of blood pressure is likely to be different between ethnic groups. 
While pro-GWAS researchers view the latest findings as a substantial 
advancement in understanding the genetic basis of hypertension, there is a case 
for some criticism of the approach. Little more than a handful of new loci have 
been identified despite thousands of participants within the various studies and 
expensive analytical techniques. It is clear from GWAS results that the 
hypertensive effect size of each significant variant identified must be small 
(~1mmHg). Given the relatively low number of candidate genes reported, much 
of the heritability of hypertension remains unexplained. Furthermore, it is also 
clear that, for most of the genes identified, no clear mechanism has yet been 
derived. One important exception is CYP17A1 (Section 1.3). GWA studies were 
designed to identify common alleles with frequencies above 5%, leaving the 
contribution from multiple rare alleles unexamined.  Studying the effects of such 
rare alleles is difficult by this method as even large-scale combined meta-
analyses, as described above, are underpowered for their detection. 
The reported GWAS findings are also controversial as they fail to identify most of 
the genes already known to be involved in blood pressure regulation (e.g. those 
regulating renal sodium handling and the renin-angiotensin-aldosterone systems) 
inviting scepticism from some researchers. However the intent of linkage and 
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GWA studies is to identify individual influential genes that can then be studied 
more intensively.  
CYP17A1 
While some novel variants may offer promise for future research, the possibility 
remains that at least some of the reported variants are simply markers for other 
causative SNPs within the same LD block. While this may, of course, apply to the 
reported association with CYP17A1, the main focus of research in this thesis, 
more drastic changes to this gene are already known to affect blood pressure 
(see Section 1.3.3.1). The CHARGE consortium assessed 29,136 participants of 
European descent and reported that the major allele or polymorphism 
rs1004467, located within intron three of the CYP17A1 gene, raises SBP by 1.05 
mmHg, giving a p-value of 1.28E-10 in the BP-Gen combined meta-analysis. The 
Global BP-Gen study reported another highly significant SNP in their analysis of 
an initial 34,433 subjects, with rs11191548 giving a p-value of 3E-07. Their 
follow-up genotyping in an expanded cohort displayed a p-value of 9E-15 and in 
silico exchange with the CHARGE consortium provided p=9E-05. A combined 
analysis of all three stages examined by the BP-Gen consortium found that the 
major allele increased SBP by 1.16 mmHg (p=7E-24). The genome-wide 
significance of these loci was confirmed by Takeuchi et al., (2010) in a large 
Japanese population and by Liu et al. (2011) in a modest Chinese Han cohort. 
The variant examined by the BP-Gen study, rs11191548, lies upstream of 
CYP17A1 but is in LD with that reported by the CHARGE consortium, with this 
particular LD block spanning 6 genes. This is summarised in Table 1-4 (Gomez-
Rubio et al., 2010). 
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Table 1-4 Genes within a block of SNPs in linkage disequilibrium. 
Gene Strand Function 
C10orf26 (also 
WBP1L and 
OPAL1) 
Forward 
Two protein-coding transcripts implicated in acute 
lymphoblastic leukaemia (Holleman et al., 2006) 
CYP17A1 Reverse Crucial CYP450 enzyme involved in steroidogenesis 
C10orf32 Forward 
Two protein-coding transcripts with unknown function. 
Conserved across many species 
AS3MT Forward 
Arsenic (3+ oxidation state) methyltransferase: associated 
with arsenic metabolism (Gomez-Rubio et al., 2010) 
CNNM2 Forward 
Cyclin M2: Member of the ancient conserved domain-
containing protein family important in magnesium 
homeostasis (Stuiver et al., 2011) 
NT5C2 Reverse 
5’ nucleotidase cytosolic 2: Encodes a hydrolase 
important in cellular purine metabolism (Pesi et al., 2010) 
 
The CYP17A1 (17α-hydroxylase/17,20 lyase) enzyme is part of a system of 
enzymes synthesising corticosteroids, compounds which participate in the 
control of intermediary metabolism, the immune system, salt and water 
homeostasis and - most relevant here - blood pressure. It also plays a key role in 
androgen and oestrogen synthesis. The CYP17A1 gene therefore lies at a crucial 
point in the synthetic pathway that determines the balance of these various 
systems.  Most importantly abnormalities in its function affect blood pressure. 
The following sections will explain the position, structure and function of the 
gene in the corticosteroid pathway, known disorders caused by mutations in the 
coding regions as well as an overview of the regulatory mechanisms that may 
contribute to altered expression and lead to a hypertensive phenotype. 
 
1.2 The Steroidogenic Pathway 
Steroid hormones are synthesised by endocrine glands and released into the 
blood circulation. The CYP17A1 gene is primarily expressed in the cortex of the 
adrenal glands and gonadal tissue. The main focus of this section will be its role 
within the adrenal cortex. 
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1.2.1 The Adrenal Glands 
The adrenal glands are pyramidal-shaped, functionally distinct endocrine glands 
situated above each kidney. Each gland is surrounded by an outer fibrous capsule 
and contains an outer cortex and inner medulla that are derived from two 
separate embryonic tissues and essentially function as separate glands. As shown 
in Figure 1-3 below, the cells of the adrenal medulla secrete the 
catecholamines, adrenaline, noradrenaline and dopamine, released under 
conditions including emotional excitement, stress and exercise; their function 
will not be discussed further. The adrenal cortex, on the other hand, can be 
further divided into three roughly concentric zones: the innermost section 
closest to the medulla is the zona reticularis (ZR). Next to that is the distinctly 
larger section of the zona fasciculata (ZF). The outermost layer is the zona 
glomerulosa (ZG), the principal product of which is the mineralocorticoid, 
aldosterone. Glucocorticoids, such as cortisol and corticosterone, and the 
adrenal androgens dehydroepiandrosterone (DHEA) and androstenedione are 
synthesised by the ZF and ZR. The terms glucocorticoid and mineralocorticoid 
are further defined in Section 1.2.1.1. 
 
 
 
Figure 1-3 Cross-sectional illustration of the layers of the adrenal gland. 
Image cannot be displayed due to copyright restrictions. 
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1.2.1.1 Products of the Adrenal Cortex 
Steroid hormones are derived from a basic cyclopentanoperhydrophenanthrene 
structure (Figure 1-4). The numbering of the carbon atoms of the substrate 
cholesterol molecule is shown in Figure 1-5. 
The principal steroid products and components of the adrenal cortex are 
outlined in Table 1-5. The relationships between these components and how they 
produce the end products is further described in Section 1.2.1.2. 
 
 
Figure 1-4 The cyclopentanoperhydrophenanthrene structure. 
This basic structure is present in all steroid hormones. The rings are identified by letter according to 
the universally recognised International Union of Pure and Applied Chemistry (IUPAC). 
 
 
Figure 1-5 The chemical structure of cholesterol. 
Cholesterol is the basic molecule from which steroid hormones are derived. The numbering of the 
carbon atoms is according to the International Union of Pure and Applied Chemistry (IUPAC). 
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Table 1-5 Identities and abbreviations of key adrenal steroids. 
Common Name Abbreviation Systematic Name 
Aldosterone Aldo 11β,21-dihydroxy-18-al-pregn-4-ene-3, 20-dione 
Androstenedione A’dione Androst-4-ene-3,17-dione 
Cholesterol C Cholest-5-en-3β-ol 
Corticosterone B 11β,21-dihydroxypregn-4-ene-3,20-dione 
Cortisol F 11β,17α,21-trihydroxypregn-4-ene-3, 20-dione 
Dehydroepiandrosterone DHEA/DHA 3β-hydroxyandrost-5-ene-17-one 
Pregnenolone PREG 3β-hydroxypregn-5-ene-20-one 
Progesterone P pregn-4-ene-3,20-dione 
11-Deoxycortisol S 17α,21-dihydroxypregn-4-ene-3,20-dione 
11-Deoxycorticosterone DOC 21-hydroxypregn-4-ene-3,20-dione 
17-Hydroxypregnenolone 17-OH-PREG 3β-hydroxypregn-5-ene-20-one 
17-Hydroxyprogesterone 17-OH-P 17α-hydroxypregn-4-ene-3,20-dione 
18-Hydroxycorticosterone 18-OH-B 11β-21-dihydroxypregn-4-ene-3,20-dione-18-al 
 
Mineralocorticoids 
The mineralocorticoids help to regulate the extracellular balance of sodium and 
potassium in the body, the most potent being aldosterone Mineralocorticoids 
bind to the mineralocorticoid receptor (MR) in the cytosol. The MR is encoded by 
the NR3C2 gene and is expressed in many tissues including colon, kidney and 
heart. The specificity of the MR is poor as it exhibits an ability to bind both 
mineralocorticoids and glucocorticoids with equal affinity. The MR, however, can 
preferentially bind mineralocorticoids through its co-localisation with the 11β-
hydroxysteroid dehydrogenase type 2 (HSD11β2) enzyme (Edwards et al., 1988; 
Funder et al., 1988). This enzyme catalyses the conversion of cortisol to 
cortisone, which cannot bind the MR. The effects of mutant HSD11B2 genes 
described in Section 1.1.3.1.  
Glucocorticoids 
Glucocorticoids, such as cortisol and corticosterone, are a class of steroid 
hormone released in response to stress. They are also key regulators of 
intermediary metabolism and the immune system, and essential in the 
maintenance of blood pressure and cardiovascular function. The glucocorticoid 
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exerts its effects by binding to the specific intracellular glucocorticoid receptor 
(GR) within target cells, forming a complex capable of activating transcription of 
target genes (Mangelsdorf et al., 1995). For example, the binding of cortisol to 
the GR has been demonstrated to activate cis-acting elements called 
glucocorticoid response elements (GREs) located in or near hormone-responsive 
genes (Eberwine 1999). The GR is present in almost every vertebrate animal cell, 
hence the widespread importance of glucocorticoids in the regulation of whole-
body homeostasis. 
Of the glucocorticoids, cortisol predominates in humans and is under the control 
of the hypothalamic/pituitary axis, where corticotropin-releasing hormone (CRH) 
is released from the hypothalamus and stimulates the anterior pituitary to 
secrete adrenocorticotropic hormone (ACTH). Circulating ACTH stimulates 
glucocorticoid production via the intracellular second messenger cyclic 
adenosine monophosphate (cAMP), which subsequently activates the protein 
kinase A pathway. This leads to the phosphorylation of various proteins and an 
increase in mRNA production. The resultant cortisol acts to inhibit CRH/ACTH 
production, thus creating a negative feedback loop (Figure 1-6). ACTH release 
from the pituitary gland exhibits a diurnal rhythm. Under normal circumstances, 
release of ACTH occurs in brief episodic bursts. These pulses of ACTH release are 
typically greatest in the early hours of the morning due to pulses of greater 
intensity (Veldhuis et al., 1990). The amplitude of the pulses declines during the 
course of the day, an effect mirrored by levels of plasma cortisol.  
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Figure 1-6 Hypothalamic pituitary axis regulation of cortisol secretion. 
CRH: corticotrophin-releasing hormone; ACTH: adrenocorticotropic hormone. 
 
Cortisol is produced in the zona fasciculata of the adrenal gland. The effects of 
excess cortisol on blood pressure are well-documented and contribute to 
increased cardiovascular risk (reviewed by Whitworth et al., 2005). Surprisingly, 
however, there is little understanding of the mechanisms responsible for these 
effects. Glucocorticoid-induced hypertension is normally associated with 
increases in cardiac output or peripheral resistance and is only partly explained 
by excess sodium and water reabsorption through promiscuous activation of 
kidney MR (Whitworth et al., 2000). Several studies attribute raised pressure to 
an increased sensitivity of tissues to cortisol, possibly due to mutant 
glucocorticoid receptors or impaired cortisol inactivation by type 2 11β-
hydroxysteroid dehydrogenase (Walker et al., 1996; Walker 2007; Goodwin and 
Geller 2012). In addition, GR is present in vascular smooth muscle and in vitro 
studies of smooth muscle cells showed a significant increase in AT1 receptor 
gene expression following incubation with synthetic glucocorticoids (Sato et al., 
1994). As outlined in Section 1.1.1, the AT1 receptor is a key mediator of 
vasoconstriction effects and is expressed in the heart, blood vessels, lung, 
kidney and brain as well as the adrenal cortex.  
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The effect of glucocorticoids on other hormones has also been investigated in 
relation to blood pressure. Following the administration of exogenous 
glucocorticoids to a cohort of healthy male subjects, both systolic blood pressure 
and erythropoietin concentration increases significantly (Kelly et al., 2000). 
Erythropoietin is a key regulator of red cell production, known to promote 
vasoconstriction and the proliferation of endothelial cells, and a positive 
correlation between it and total peripheral resistance had previously been 
shown (Langenfeld et al., 1997). Glucocorticoid effects on catecholamine 
production have also been demonstrated. Conversion of adrenaline from 
noradrenaline in the adrenal cortex requires the enzyme phenylethanolamine N-
methyl-transferase (PNMT), and the synthesis and activity of PNMT requires a 
very high intra-adrenal concentration of glucocorticoids (Wurtman and Axelrod 
1965). However, it remains unclear whether levels of glucocorticoid in the 
healthy adult influence adrenaline effects on heart rate and blood pressure. 
The inhibition of the vasodilator nitric oxide system is another candidate 
mechanism whereby glucocorticoids may affect blood pressure. In the body, 
nitric oxide has key roles in the control of vascular tone, dilating vessels and 
relaxing vascular smooth muscles, and hence reducing blood pressure. 
Administration of synthetic glucocorticoids in vitro (to human endothelial cells) 
and in vivo (to male Wistar-Kyoto rats) results in significantly lower transcript 
levels of nitric oxide synthase (Wallerath et al., 1999). More recent studies, 
however, yield conflicting evidence (reviewed by Goodwin and Geller 2012); 
better understanding of glucocorticoid effects on the nitric oxide stsem and its 
contribution to blood pressure is clearly required.  
Inappropriate levels of cortisol production are known to occur in rare disorders 
like Cushing’s syndrome and Addison’s disease. Cushing’s syndrome is 
characterised by long-term high cortisol levels and is described in further detail 
below. Addison’s disease is the result of cortisol deficiency, whereby the patients 
exhibit hypotension, hypoglycaemia and weight loss. Cortisol levels are also 
altered in individuals with congenital adrenal hyperplasia (described in Section 
1.3.3.1). 
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Cushing’s Syndrome 
 
Patients with Cushing’s syndrome and Cushing’s disease exhibit myriad clinical 
features including persistent hypertension, weight gain, muscle weakness, 
diabetes mellitus and osteoporosis. Cushing’s syndrome arises when the body has 
prolonged exposure to inappropriately high levels of glucocorticoids, and 
specifically cortisol. The causes can be exogenous or endogenous. Exogenous 
synthetic glucocorticoids are routinely administered clinically to treat other 
conditions such as asthma and rheumatoid arthritis (Wei et al., 2004). 
Endogenous increases in cortisol production may arise in several ways. Pituitary 
tumours secreting excess ACTH cause approximately 70% of cases; this is termed 
Cushing’s disease. Another 15% have adrenal tumours which secrete excess 
cortisol; Cushing’s syndrome (Nieman and Ilias 2005). Patients within this 
category typically have normal to low levels of ACTH secretion due to the 
negative feedback system (Figure 1-6). Thus the terms Cushing’s syndrome and 
Cushing’s disease cannot be used interchangeably. The remaining 15% exhibit 
ectopic ACTH secretion from tumours located outside the pituitary/adrenal 
systems. 
Adrenal Androgens 
The adrenal androgens DHEA and, to a lesser extent, androstenedione, serve as 
precursors of testosterone and oestrogens. The most abundant product of the 
adrenal cortex is DHEAS, a sulphated version of DHEA, reversibly catalysed by 
the enzyme sulfotransferase (SULT2A1) in the adrenal glands and liver. DHEAS is 
more water soluble and stable than DHEA, and its measurement in plasma or 
urine is commonly used in the assessment of adrenal cancers and polycystic 
ovarian syndrome (Banaszewska et al., 2003). 
1.2.1.2 Synthesis of Steroid Hormones 
Cholesterol is the precursor of all adrenal and gonadal steroid hormones. The 
ovaries secrete oestrogens and progestins, while the testes secrete mainly 
androgens. Despite the different products of these tissues, the biochemical 
pathways involved are remarkably similar. The presence or absence of the 
expression of specific enzymes within each tissue can account for differences in 
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their secretory capacities. Therefore, it is possible to provide a general outline 
of the major biosynthetic pathway applicable to these steroid-secreting glands, 
as shown in Figure 1-7. 
The enzymes involved in the biosynthetic pathway are cytochrome P450 enzymes 
and hydroxysteroid dehydrogenases. To convert cholesterol to aldosterone 
(referred to later as the 17-deoxy-corticosteroid pathway) and cortisol (17-
hydroxy-corticosteroid pathway), a series of reactions modify the pregnane 
structure and remove part of the side chain. Complete removal of the side chain 
is required for androgen and oestrogen synthesis. The focus of this thesis is on 
the CYP17A1 gene within the adrenal cortex; the chemical changes that result 
from the action of this enzyme are depicted in Figure 1-8. 
  
 
 
 
Figure 1-7 Human corticosteroid biosynthetic pathway. 
Pathway of corticosteroid synthesis in the adrenal cortex, ovaries and testes. Dashed lines indicate where each reaction occurs. -OH: hydroxyl; A’dione: 
Androstenedione. 
 
 
 
 
Figure 1-8 Structures of intermediate compounds involved in 17α-hydroxylase and 17, 20 lyase reactions.  
The carbon atoms are numbered on the cholesterol molecule. 
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Cytochrome P450 Enzymes 
 
Cytochrome P450 enzymes (CYP450) are a large superfamily of haemoproteins 
present in a wide range of species; in human subjects, 57 putative functional 
genes exist (Nelson et al., 2004).  They catalyse reactions using molecular 
oxygen to oxidise many substrates and influence a wide range of cellular 
functions, including xenobiotic metabolism (drug degradation), lipid synthesis 
and steroid synthesis. CYP450 enzymes can be further classified on the basis of 
their location of action. Five cytochrome P450 enzymes participate in 
corticosteroid synthesis: CYP11A1, CYP11B1 and CYP11B2 are located in the 
mitochondria; CYP17A1 and CYP21A1 are associated with the endoplasmic 
reticulum and are termed microsomal.  
In the adrenal glands and gonads, CYP450s catalyse a monooxygenase reaction, 
adding an oxygen atom into the steroid substrate R-H utilising an electron donor, 
usually nicotinamide adenine dinucleotide phosphate (NADPH). The locus and 
orientation of the resulting hydroxyl group are specific to the enzyme.  The basic 
reaction stoichiometry is: 
R-H + NADPH + H+ + O2  R-OH + NADP
+ + H2O 
Mitochondrial and microsomal CYP450 enzymes use different mechanisms of 
electron transfer (Figure 1-9). Mitochondrial enzymes receive electrons via an 
electron transfer chain. Two electrons are transferred to the flavoprotein 
adrenodoxin (ferredoxin) reductase (FDXR) upon binding to NADPH, and are 
subsequently transferred to adrenodoxin (FDX1), a non-haem iron-sulphur 
protein (Miller 2005b). This then interacts and donates the electrons to the 
haem iron of the CYP450 before being transferred to the substrate. In contrast, 
microsomal CYP450s employ a single flavoprotein, P450 oxidoreductase (POR), 
with two flavins: flavinadenine dinucleotide (FAD) and flavin mononucleotide 
(FMN). In certain circumstances, cytochrome b5 can also be utilised in this 
process (Miller 2005b) (see Section 1.3.1). The differing electron transport 
mechanisms described above may play an important role in regulating enzymatic 
function. This applies to CYP17A1 and will be further explained in Section 1.3.1. 
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Figure 1-9 A schematic representation of the systems of electron transfer.  
Panel A shows the mitochondrial system and Panel B the microsomal system. Adapted from Payne 
and Hales (2004). FAD: flavin adenine dinucleotide; FMN: flavin mononucleotide; Ad
r
: adrenodoxin 
reductase; Ad
0
: adrenodoxin; S: substrate 
Hydroxysteroid Dehydrogenases 
 
Hydroxysteroid dehydrogenases are non-metalloenzymes with two essential roles 
(reviewed by Payne and Hales 2004). Within the steroidogenic tissues, they are 
essential, particularly 3β-hydroxysteroid dehydrogenase (3β-HSD), for the 
biosynthesis of steroid hormones. They are also expressed in peripheral tissue, 
(e.g. the kidney), where they have a key role in steroid metabolism, e.g. 
HSD11B2 (see Section 1.1.3.1).  In contrast to cytochrome P450 enzymes, which 
are the products of individual genes, the dehydrogenases have several isoforms 
or isozymes, each encoded by a different gene. Each isoform has a specific 
expression pattern, cellular localisation and catalytic activity (reductase or 
dehydrogenase). All dehydrogenase enzymes utilise co-factors that donate or 
accept hydrogen molecules. For example, NAD+/NADP+ are co-factors for 3β-
HSD. 
1.2.1.3 Metabolism and Excretion of Steroid Hormones  
Following their synthesis in the endocrine glands, steroid hormones are released 
immediately into the bloodstream. Due to their lipophilic properties, steroid 
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molecules are usually bound to carrier proteins, for example, plasma albumin, 
corticosteroid-binding globulin (CBG) or the sex hormone-binding globulin 
(SHBG). Alternatively, they may be in a conjugated form within the circulation 
(linked to hydrophilic substances, such as sulphate or glucuronide derivatives). 
The unbound molecules, sometimes known as the ‘free fraction’, are considered 
the biologically active portion. Therefore, in addition to the rate of synthesis 
from the endocrine glands, the effective concentration of a steroid hormone can 
also be affected by the proportion of ‘free’ hormone, blood flow rate, and the 
rate of metabolism and excretion (i.e. clearance rate).  
Steroid hormones must be inactivated after they have served their purpose in a 
tissue-specific setting. Peripheral steroid inactivation occurs mainly in the liver, 
but also may occur in the kidneys or within target tissues. For corticosteroids, 
this involves modifications to the chemical structure, commonly the saturation, 
or reduction, of the A ring. Inactive steroid hormones are usually then excreted 
as urinary metabolites. The corticosteroid metabolites are conjugated with 
glucuronic acid to increase water solubility. DHEA, on the other hand, is 
sulphated to form DHEAS. Urinary metabolite excretion rates can be used as a 
measure of steroid production although, interpretation of urinary steroid 
metabolite analyses is complicated by the fact that a single steroid hormone is 
converted to several metabolites and some metabolites originate from more 
than one hormone. The major corticosteroid hormones and their urinary 
metabolites are shown in Table 1-6. 
Table 1-6 Major corticosteroid hormones and their urinary metabolites. 
Steroid Hormone Urinary Metabolite Abbreviation 
Cortisol 
Tetrahydrocortisol 
allotetrahydrocortisol 
THF 
aTHF 
Cortisone Tetrahydrocortisone THE 
Deoxycortisol Tetrahydrodeoxycortisol THS 
Corticosterone 
Tetrahydrocorticosterone 
allotetrahydrocorticosterone 
Tetrahydro-11-dehydrocorticosterone 
THB 
aTHB 
THA 
Deoxycorticosterone Tetrahydrodeoxycorticosterone THDOC 
Aldosterone Tetrahydroaldosterone THAldo 
Dehydroepiandrosterone 
Dehydroepiandrosterone 
Androsterone 
Aetiocholanolone 
DHEA/DHA 
ANDRO 
AETIO 
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The complex biosynthetic role of 17α-hydroxylase / 17,20 lyase was shown in 
Figure 1-8. The following section examines this key steroidogenic phase in more 
detail. 
 
1.3 The CYP17A1 Gene 
The CYP17A1 gene encodes a dual-function cytochrome P450 (CYP450) enzyme 
expressed primarily in the adrenal cortex, ovarian thecal cells and testes (Chung 
et al., 1987). This thesis focuses on its role within the adrenal cortex. The gene 
product of CYP17A1, often referred to as the 17α-hydroxylase enzyme, functions 
as a hydroxylase in the zona fasciculata, converting pregnenolone and 
progesterone at carbon 17 (C17) to 17α-hydroxypregnenolone and 17α-
hydroxyprogesterone respectively. In the zona reticularis, it functions as a 17,20-
lyase on these hydroxylated products and cleaves the C17,20 bond, producing 
dehydroepiandrosterone (DHEA) and androstenedione (Figure 1-8). Evidence 
suggests DHEA is the predominant adrenal androgen product, with 
androstenedione formed through conversion of DHEA by the enzyme 3βHSD2, as 
opposed to conversion from 17α-hydroxyprogesterone by CYP17A1 (Auchus et 
al., 1998). Until the 1980s, it was believed that 17α-hydroxylase and 17,20 lyase 
were separate enzymes but biochemical studies in the pig revealed that the 
CYP17A1 protein catalysed both reactions at a single active site (Nakajin and 
Hall 1981). Studies in other species yielded similar results. That both enzymatic 
activities were the result of a single gene in humans was confirmed in 1991 when 
non-steroidogenic cells were transfected with vectors containing the CYP17A1 
gene and both activities detected (Lin et al., 1991). As described in Section 
1.2.1.2, CYP17A1 locates to the endoplasmic reticulum and therefore falls into 
the microsomal sub-group of CYP450 enzymes.  
Scientific evidence indicates the importance of the CYP17A1 gene in foetal 
development. Bair and Mellon (2004) used a specific vector to target and 
knockout CYP17A1 in mice. In the first generation offspring, apparently healthy 
and fertile offspring were obtained. These were heterozygous for the CYP17A1 
knockout, meaning they had one copy of the gene (+/-). Subsequent breeding of 
the first generation offspring resulted in two categories of mice: (+/+) or (+/-). 
52 
 
Noticeably there were no (-/-) offspring. Further investigations established that 
mice homozygous for the knocked-out gene (-/-) experienced early embryonic 
lethality around day 7. The exact role of steroidogenesis in foetal development 
is unclear; however this study suggests that having at least one functional copy 
of CYP17A1 is essential to life. The translation of these findings to humans is not 
straightforward as there are clear differences in steroidogenesis between 
rodents and humans. In humans, CYP17A1 is expressed in the gonads and adrenal 
cortex, but not the placenta whereas, in rodents, it is expressed in the gonads 
and placenta but not the adrenals (Chung et al., 1987; Durkee et al., 1992; 
Greco and Payne 1994). Studies of CYP17A1 expression within the human foetus 
are obviously difficult, although recent evidence indicates a possible novel role 
for CYP17A1 in the development of the human nervous system. CYP17A1 
expression was detected in both the spinal cord and dorsal root ganglia in 9-11 
week human foetuses (Schonemann et al., 2012). The electron donor, POR, 
however, is not present. This opens new avenues of investigation concerning 
CYP17A1 within the nervous system, termed ‘neurosteroids’, in order to 
elucidate its role in foetal development 
CYP17A1 also plays a key role in later human development, particularly at 
adrenarche. Around the age of 6-8 years, the zona reticularis develops and 
results in a profound increase in adrenal DHEA synthesis (Nakamura et al., 2009). 
The 17,20 lyase activity facilitates an increase in adrenal androgens, whilst 17α-
hydroxlase activity maintains glucocorticoid levels. Thus, the correct enzymatic 
expression and regulation are central to normal sexual maturity.  
Finally, as noted previously in Section 1.1.3, mutation within the coding regions 
of the human gene are known to cause a significant reduction in enzymatic 
activity, resulting in individuals with congenital adrenal hyperplasia (CAH), a 
rare but severe disorder. 
1.3.1 17α-Hydroxylase / 17, 20 Lyase 
The ratio of 17α-hydroxylase activity to 17,20 lyase activity is important in 
determining the ratio of C21 to C19 steroids, which are the precursors of sex 
steroids (Miller 1988). Recent research has identified three important factors 
which influence this ‘switch’ in enzymatic function post-translationally. Being a 
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microsomal CYP450 type II enzyme, 17α-hydroxylase/17,20 lyase receives 
electrons from NADPH via P450 oxidoreductase (POR). Initial research using the 
porcine model found POR to be more abundant in testes than the adrenal glands 
(as reviewed by Miller 2005a). As the testes have a higher ratio of lyase to 
hydroxylase activity, it was concluded that POR has a key role in the 
determination of this ratio. Further studies in yeast also implicated cytochrome 
b5 (CYB5A). They confirmed that POR is required for the hydroxylase and lyase 
reactions but that cytochrome b5 selectively enhances 17,20 lyase activity 
(Auchus et al., 1998). The presence of cytochrome b5 alone is not sufficient for 
the enzyme to function; it acts as an allosteric facilitator and not as an electron 
donor. Cytochrome b5 is expressed in the zona reticularis of the adrenal gland 
(Yanase et al., 1998) where it facilitates the production of DHEA and other 
androgens. 
Understanding of the mechanisms behind the 17α-hydroxylase / 17,20 lyase 
switch has been assisted by the study of patients with isolated 17,20 lyase 
deficiency. In this rare disorder, patients have normal 17α-hydroxylase activity 
but absent or abnormal 17,20 lyase activity. The first proven case was in 1997, 
when it was reported that two Brazilian patients had each presented with 
hormonal levels suggestive of this disorder (Geller et al., 1999). Each was 
homozygous for a different mutation in CYP17A1 (R347H and R358Q). The 
mutants were investigated in vitro and, through the addition of excess 
cytochrome b5, lyase activity was partly restored (Geller et al., 1999). The near-
normal hydroxylase activity suggested that the active site was not altered by 
these mutations but rather the redox binding sites associated with electron 
transfer. Indeed, molecular modelling showed that these mutations altered the 
electrostatic charge of the protein, inhibiting its interaction with POR, and 
emphasising the importance of redox partner interactions in 17,20 lyase 
regulation (Auchus and Miller 1999).  
The final recognised factor influencing the hydroxylase/lyase switch is cAMP. As 
described in Section 1.2.1.1, circulating ACTH activates adenylyl cyclase, which 
increases intracellular levels of cAMP, thereby promoting phosphorylation events 
through a cascade of events via the protein kinase A pathway. Phosphorylation is 
a relatively well-studied form of post-translational modification, whereby the 
addition or removal of phosphate groups (PO4
3-) induces conformational changes 
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to the structure of a protein resulting in activation or deactivation of function.  
Phosphorylation sites have been identified on serine and threonine residues and 
shown to affect 17,20 lyase activity selectively (Zhang et al., 1995), although 
the mechanisms underlying this enhancement are not fully understood and the 
specific phosphorylation sites are currently unknown (Souter et al., 2006; Tee et 
al., 2008; Wang et al., 2010). It is hoped that the elucidation of such sites will 
provide further insight into the switch mechanism (Miller 2005a). 
1.3.2 Molecular Structure 
The human CYP17A1 gene is located on the reverse strand of chromosome 10q24 
(Sparkes et al., 1991), spanning approximately 7000 base pairs. Transcription of 
the gene can generate three isoforms, although only one is known to produce 
protein. As depicted in Figure 1-10, the protein-coding gene consists of 8 exons 
which code for 508 amino acids. The locations of the intron/exon boundaries are 
conserved between species, confirming their functional importance. 
 
 
Figure 1-10 Diagram showing the exon/intron structure of CYP17A1 gene. 
 
55 
 
1.3.3 The Role of CYP17A1 in Hypertension 
CYP17A1 has been identified as a candidate gene for the development of 
essential hypertension through recent GWAS and by the study of rare monogenic 
disorders (see Section 1.1.3). This section will review the relationship between 
the abnormal CYP17A1 gene and blood pressure.  
1.3.3.1 CYP17A1 Monogenic Disorders 
Congenital adrenal hyperplasia (CAH) is a rare disorder, first described by Biglieri 
et al. (1966). Around 1% of cases are caused by a deficient CYP17A1 gene (New 
2003). Mutations in other genes within the steroidogenic pathway also cause this 
condition; these and their resultant characteristics are described in Table 1-7. 
Patients with CAH have altered levels of mineralocorticoids, glucocorticoids and 
androgens, with varying severity depending on the causative mutation. A mutant 
CYP17A1 gene causes defective androgen production which influences sexual 
development and maturation of the individual, and the reduction in 
glucocorticoids leads to increased ACTH production, which massively stimulates 
pathways that do not require the CYP17A1 enzyme (see Figure 1-7). Affected 
females fail to undergo puberty or to develop secondary sex characteristics. 
Males develop as immature, phenotypic females. Excess 11-deoxycorticosterone 
(DOC), a weak mineralocorticoid, causes hypertension, hypokalaemia and 
patients have low aldosterone concentrations (Hahm et al., 2003; Martin et al., 
2003). Paradoxically, low or absent cortisol is not lethal because the excessive 
levels of corticosterone provide a substitute. Mutations causing 17α-
hydroxylase/17,20-lyase deficiency are most often located within one of the 
eight exons although also, occasionally, at intronic splice sites (Figure 1-11).  
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Table 1-7 Characteristics of CAH arising from mutations in steroidogenic genes. 
Gene CYP21A CYP11B1 CYP11B2 CYP17A1 HSD3B2 
Enzyme 
21-
Hydroxylase 
11β-
Hydroxylase 
Aldosterone 
Synthase 
17α-
Hydroxylase / 
17,20 lyase 
3β-
Hydroxysteroid 
dehydrogenase 
Incidence 1:14,000 1:10,000 Rare Rare Rare 
Ambiguous 
Genetalia 
Females Females No 
Males. No 
puberty in 
females 
Males. 
Mild in females 
Blood 
Pressure 
     
Mineralo-
corticoids 
     
Gluco-
corticoids 
  Normal   
Androgens   Normal  
 males 
 females 
Elevated 
Steroids 
17-OH-P 
DOC, 11-
Deoxycortisol 
Cortico-
sterone 
DOC, cortico-
sterone 
DHEA, 17-OH-
Preg 
  
Figure 1-11 Mutations known to cause 17α-hydroxylase/17, 20 lyase deficiency. 
Mutations occurring within each exon are depicted by yellow arrows and the corresponding amino acid changes provided. Red arrows indicate the locations of 
mutations occurring within intronic splice sites.  
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Thus, aberrant activity of the CYP17A1 gene product affects blood pressure.  The 
cases described above result from severe changes in the structural gene and are 
rare. Given that the enzyme is crucial in controlling the substrate flow through 
the different arms of corticosteroid biosynthesis. It is plausible to suggest that 
smaller changes in structure (i.e. polymorphisms) might have more subtle effects 
that contribute to the much more common condition of essential hypertension.  
There is little information on the relationship between CYP17A1 activity and 
essential hypertension. Surprisingly, no specific studies have yet followed up on 
the GWAS findings (Section 1.1.3.2), which seems to obviate the purpose of such 
an expensive study. Several questions remain to be addressed. Firstly, does the 
GWAS correctly identify the CYP17A1 locus as causative or is it merely a marker? 
Secondly, is there a functional polymorphism at this locus? Thirdly, can this 
polymorphism be related to hypertensive risk? It has been postulated that more 
common genetic variants may cause a very mild form of enzyme dysfunction 
(Levy et al., 2009). This hypothesis is the basis of the work presented in this 
thesis. Do minor alterations in the expression of CYP17A1 have the potential to 
disturb corticosteroidogenesis? The following sections review what is known of 
variation within the gene and how its expression is regulated. 
1.3.3.2 Polymorphic Variation 
Although the terms ‘mutation’ and ‘polymorphism’ are sometimes used 
interchangeably, in terms of this thesis, the conventional definitions are 
followed. Mutations are rare, with a frequency of <1% in the population and 
usually cause a “large” phenotypic alteration. Polymorphisms occur more 
frequently and are generally thought to cause little or no change to the 
structural gene, although such variations are now being studied in more detail in 
an attempt to explain complex polygenic disorders. The more common allele at 
a given locus is termed the major allele, and the rarer termed minor. Reported 
polymorphic variations are identified by ‘rs’ followed by a number, allocated by 
the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/). Where 
polymorphisms are due to a single base change, they are known as single 
nucleotide polymorphisms (SNPs). 
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The association of polymorphic variants within the CYP17A1 gene has recently 
been studied in disorders such as polycystic ovary syndrome (PCOS), breast and 
prostate cancer as well as obesity and premature male baldness. Women with 
PCOS have excess androgen secretion. Certain types of breast and prostate 
cancer are hormone-related. CYP17A1 is a key enzyme involved in androgen 
biosynthesis, particularly in the ovaries and testes, and is therefore a candidate 
gene for these hormone-associated disorders. 
Evidence from in vitro studies of thecal cells isolated from the human ovary 
show that transcription and expression of CYP17A1 is significantly increased in 
individuals with PCOS (Wickenheisser et al., 2000). This finding has led to 
numerous studies of association between PCOS and a T/C variant that lies 34 
bases upstream from the CYP17A1 transcriptional start site (rs743572). Results 
from such studies have been conflicting. Some PCOS case-control studies have 
reported a significant association with PCOS in patients homozygous for the 
minor C allele (Diamanti-Kandarakis et al., 1999; Pusalkar et al., 2009). The 
number of affected participants in these studies was ≤100 and were derived 
from Greek and Indian populations respectively. Other studies in a wide range of 
ethnic populations found no association with PCOS (Marszalek et al., 2001; 
Kahsar-Miller et al., 2004; Echiburu et al., 2008; Park et al., 2008; Unsal et al., 
2009; Chua et al., 2012; Ramos Cirilo et al., 2012). Some interesting findings, 
however, did arise from this research. Echiburu and colleagues failed to identify 
significant association of rs743572 with PCOS in a Chilean cohort, but did report 
a correlation between the minor C allele and increased body weight. In a Korean 
cohort of 134 affected individuals and 100 matched controls, Park et al. 
reported that a particular haplotype of CYP17A1 SNPs, which included the major 
rs743573 T allele within the CYP17A1 gene shows significant association with 
PCOS (p=0.001). A GWAS conducted using 744 PCOS cases, and replicated in over 
3000 Chinese Han participants, identified three loci significantly associated with 
PCOS, but none were situated at the CYP17A1 locus (Chen et al., 2011). These 
rs743572 association studies had modest sample sizes and so, in 2012, a meta-
analysis was conducted on 1320 PCOS cases and 1017 controls, from 10 different 
studies. This found no overall association in the combined group but sub-group 
analysis found the minor C allele to be a significant marker of PCOS risk in 
studies with ≤200 participants (Li et al., 2012). The authors propose ‘small-study 
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bias’ as an explanation for the previous inconsistent findings, where selection 
bias is more likely to occur; small studies showing a small effect are less likely to 
be published. Alternatively, it may be the case that recruitment was inadequate 
and therefore case/control groups were not ideally matched.  
Similar inconsistent and contradictory findings resulted from studies 
investigating association between rs743572 and hormone-related cancers such as 
breast and prostate cancer (Miyoshi and Noguchi 2003; Mononen and Schleutker 
2009). In an attempt to provide a definitive conclusion, a large meta-analysis 
combined 24 breast cancer studies (Chen and Pei 2010). The authors 
hypothesised that the inconsistency and variability seen in previous studies 
might be due in part to contributions from other risk factors. The combined 
analysis revealed no association with breast cancer risk, but suggested that this 
was due largely to sample heterogeneity (e.g. age, ethnicity, tumour stage and 
grade). Further sub-group analyses provided evidence of a possible link between 
age at menarche, BMI, menopausal status, rs743573 and breast cancer risk. A 
meta-analysis examining prostate cancer risk was also conducted, combining 10 
cohorts of European, Asian and African men (Ntais et al., 2003) which, again, 
reported no significant association with rs743572. Sub-group analyses found that 
the minor allele associated with increased prostate cancer susceptibility but only 
in men of African descent. The quest to uncover the genetic alterations that 
predispose individuals to cancer and other disorders is a challenging task. While 
the studies discussed above are inconsistent and sometimes contradictory, such 
research highlights the need for a focused approach. Heterogeneity is an 
apparent issue in these types of studies and the necessity to assess other risk 
factors in such analyses is becoming ever clearer.  
In considering the role of CYP17A1 polymorphisms in hypertension, it is useful to 
assess other studies that associate hypertension with polymorphic sites within 
other steroidogenic genes.  Polymorphisms G-1889C and A-1859G in CYP11B1 
have been associated with decreased 11β-hydroxylase efficiency and with an 
altered transcriptional response to ACTH (Barr et al., 2007). Variant T-344C in 
CYP11B2 is the most commonly studied polymorphism in this region, displaying 
significant associations with altered plasma aldosterone levels and hypertension 
(Iwai et al., 2007; Sookoian et al., 2007). First described by White and Slutsker, 
this site corresponds to a steroidogenic factor-1 (SF-1) binding site, a 
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transcription factor involved in the regulation of many steroidogenic genes. 
Despite the C allele binding to SF-1 with significantly greater affinity than the T 
allele (White and Slutsker 1995; Bassett et al., 2002), in vitro analysis has found 
this to have no effect on gene transcription (Clyne et al., 1997; Bassett et al., 
2002). CYP11B1 and CYP11B2 lie in tandem on chromosome eight and many of 
the polymorphisms in this region are in strong LD i.e. there is non-random 
inheritance of alleles at these polymorphic sites. The lack of functional 
importance at this site led to the belief that it may simply be a marker for 
another functional allele, with which it is in LD. McManus and colleagues (2012) 
identified a possible functional variant at position -1651 of CYP11B2 and found 
that the T allele at this site reduces transcriptional activity in vitro and 
associates with lower excretion rates of aldosterone in man. It is possible to 
draw some parallels between these studies and those of CYP17A1 in 
hypertension and other disorders, which raises several questions. Are the SNPs 
reported by recent GWAS simply markers for a functional SNP located elsewhere 
in the region? Are the GWAS polymorphisms in LD with the commonly studied SNP 
rs743572? What influence might SNPs in the promoter region of a gene have on 
its expression and activity? What other factors could influence gene expression? 
There are several mechanisms of gene regulation that may alter expression. As 
described in Section 1.3.3.1, mutations in the coding regions and splice sites 
have been reported to affect hydroxylase and/or lyase activity severely. 
Combined with the recent GWAS findings, it is therefore reasonable to 
hypothesise that common polymorphisms occurring throughout the gene may 
contribute to minor alterations in the structure and folding of the gene product 
and thus may account for some subtle changes in enzymatic activity. 
Furthermore, polymorphisms occurring immediately upstream of the 
transcription start site may affect the binding of necessary transcription factors, 
in a manner similar to other components of the steroidogenic pathway, as 
described above. In addition, the recent discovery of post-transcriptional 
regulation by microRNAs has opened new avenues of investigation mainly by 
mRNA destabilisation followed by degradation, or by mRNA translational 
repression. MicroRNAs (miRNAs) are short, non-coding RNAs of approximately 20 
nucleotides, which inhibit gene expression. There is now an expanding list of 
thousands of known miRNAs, some of which have been implicated in the 
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regulation of genes involved in cancer and cardiovascular disease. The data 
presented in Chapters 5 and 6 of this thesis investigate both the transcriptional 
and post-transcriptional regulation of CYP17A1. Firstly, Sections 1.4 and 1.5 of 
this review explain these regulation mechanisms and summarise recent research 
concerning CYP17A1 and the adrenal gland. 
 
1.4 Transcriptional Regulation  
In 1956, Francis Crick first described the ‘central dogma’ of molecular biology; 
the concept that DNA is transcribed to RNA, which is then translated to protein 
(Crick 1956). Gene transcription is an integral part of this process, regulated and 
controlled by many complex mechanisms, not all of which are fully understood. 
1.4.1 Gene Transcription 
RNA transcription is an essential and complex process, which utilises DNA as a 
template for RNA synthesis. The region immediately upstream (5’) of the 
transcriptional start site (TSS) is termed the promoter region. Typically, a 
distinct ‘core’ sequence known as the TATA-box, located within the promoter 
region in close proximity to the TSS, encodes a binding site for a transcription 
factor known as the TATA-binding protein (TBP). The binding of TBP promotes the 
association of various other transcription factors and the enzyme RNA 
polymerase II (Pol II), forming the pre-initiation complex. The hydrogen bonds of 
the DNA double helix are broken allowing Pol II to synthesise the RNA transcript 
in the 5’ to 3’ direction by pairing ribonucleotides complementary to those of 
the DNA nucleotides. RNA nucleotides differ from DNA nucleotides in two ways: 
DNA thymine bases are replaced by uracil bases in RNA, and the sugar-phosphate 
backbone of the nucleotides are comprised of a ribose sugar, as opposed to the 
deoxyribose of DNA. When transcription is complete, the hydrogen bonds of the 
RNA/DNA complex break, and the newly-formed RNA transcript is released. 
The rate of transcription by the pre-initiation complex of a typical eukaryotic 
gene is regulated by complex mechanisms, often cell- or tissue-specific. 
Transcription rate can be modulated by the presence of proteins known as 
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activators and repressors. In addition, enhancer element sequences, which can 
be located almost anywhere in the genome, can interact with both activator and 
repressive proteins for further regulation (Banerji et al., 1981; Barolo and 
Posakony 2002). The rate of transcription can be controlled by regulatory 
sequence elements up to 1 Mb away from the gene, as DNA looping will permit 
transcription factors bound there to lie in close physical proximity to the TSS 
(Maston et al., 2006). 
There are several other mechanisms of transcriptional control. DNA methylation 
is an epigenetic modification and is associated with transcriptional silencing. 
This can occur in two ways. Firstly, methylation of CG dinucleotides within CpG 
islands (CG-rich regions in the genome) can prevent transcription factors from 
binding to this region. Secondly, proteins that bind to methylated cytosines 
recruit co-repressor complexes which modify the chromatin structure and affect 
transcription initiation.  Mechanisms that regulate chromatin structure, including 
histone modification, are beyond the scope of this thesis but do provide an 
alternative mechanism of transcriptional regulation. A general review is provided 
by Clouaire and Stancheva (2008). 
Alterations in any of the mechanisms described above will affect the nature or 
rate of formation of the RNA transcript and lead to altered physiological effects 
of the gene’s expression unless compensated for by another mechanism. Section 
1.4.2 summarises studies of the transcriptional regulation of adrenal CYP17A1. 
While many of the pathways and transcription factors regulating this gene are 
likely to be the same in both the adrenal and gonadal glands, some would be 
expected to be different to meet their unique hormonal demands. 
1.4.2 Studies on Transcriptional Regulation of Adrenal CYP17A1 
Considerable research interest has focused on the transcriptional regulation of 
CYP17A1 because of its branchpoint role in glucocorticoid and androgen 
synthesis and its implication in rare but severe disorders. Reporter construct 
studies have found that approximately 60-80% of the basal transcriptional 
regulation of CYP17A1 can be accounted for by the 227 base pairs immediately 
upstream of the TSS (Lin et al., 2001). Numerous interacting factors have been 
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identified (Figure 1-12). The majority of these have been reviewed by Sewer and 
Jagarlapdui (2009) and the best understood are described below. 
 
 
Figure 1-12 Transcription factor binding sites characterised in the human adrenally-
expressed CYP17A1 promoter region. 
DNA binding regions are provided beneath each transcription factor. SREBP-1:  sterol regulatory 
element binding protein 1; SF-1: steroidogenic factor 1; Sp1/3: specificity protein-1/3; GATA-6: 
family member 6 of GATA transcription factor family; NF-1: nuclear factor 1; TSS: transcription start 
site. 
 
Steroidogenic Factor-1 
The orphan nuclear receptor, steroidogenic factor-1 (SF-1) (also known as 
NR5A1), is the best characterised transcription factor in adrenal steroidogenesis. 
Disruption of the gene encoding SF-1 in mice has demonstrated its importance in 
adrenal and gonadal development and in sexual differentiation (Luo et al., 
1994). As evidenced by a heterozygous mutation in its gene, it is likely that SF-1 
is essential to these processes in humans also (Achermann et al., 1999). Reporter 
construct studies identified both basal and cAMP-responsive elements within the 
first 63bp immediately upstream from the transcriptional start site of CYP17A1 
(Rodriguez et al., 1997). A SF-1 binding site has been identified within this region 
at -57/-37, where a complex containing SF-1, p54nrb (RNA and DNA-binding 
protein) and the polypyrimidine-tract-binding protein-associated factor (PSF) 
have been shown to bind (Sewer et al., 2002). This complex appears to be 
crucial in cAMP-dependent activation of CYP17A1 transcription. Repression of 
transcription occurs upon the recruitment of the corepressor mSin3A by PSF. 
Upon cAMP stimulation, however, mSin3A is released from the SF-1/ p54nrb/ PSF 
complex, and transcription of CYP17A1 is activated. In vitro studies produce 
differing results. Studies of the human adrenocortical cell line H295R found that 
the binding of SF-1 alone is not sufficient to induce transcription of the human 
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gene; the entire SF-1/ p54nrb/ PSF complex is required. On the other hand, 
similar experiments involving the transfection of reporter constructs containing 
the human CYP17A1 promoter into mouse adrenocortical Y1 cells require only 
the binding of SF-1 (Rodriguez et al., 1997). This highlights the need to study 
regulation of steroidogenic genes in homologous cell systems.  
Through experiments on the human foetal adrenal gland, Hanley and colleagues 
(2001) identified three additional functional SF-1 binding sites in the human 
gene. These are located -150/-142, -211/-204 and -290/-276 bases upstream 
from the TSS of CYP17A1. The authors also provide evidence that the nuclear 
receptor DAX1 (dosage-sensitive sex reversal, adrenal hypoplasia congenita, 
critical region on the X chromosome gene 1) represses transcriptional activation 
of SF-1 in a dose-dependent manner. However, it is unclear from these studies 
whether a direct interaction occurs between SF-1 and DAX1. Furthermore, there 
is evidence of DAX1 expression within the adult adrenal gland (Shibata et al., 
2003). These data support the role of DAX1 as a transcriptional repressor: in 
deoxycorticosterone-producing adenomas, Western blot analyses show both 
CYP17A1 and SF-1 protein levels to be significantly reduced relative to those 
from normal adrenal tissue, while DAX1 levels are substantially increased. This 
supports the hypothesis that DAX1 has an inhibitory effect on SF-1 and, 
subsequently, CYP17A1 production. The same authors also presented evidence of 
association between SF-1 and chicken ovalbumin upstream promoter-
transcription factors (COUP-TFs). In the bovine CYP17 promoter, COUP-TF was 
shown to bind the same region as SF-1, but acted as a transcriptional repressor 
as opposed to SF-1, which activated transcription (Shibata et al., 2003). The role 
of COUP-TF in the human CYP17A1 promoter is unclear, although expression 
profiles from cortisol-producing adenomas show both COUP-TFI and COUP-TFII 
levels to be significantly reduced, while CYP17A1 is significantly increased. 
It is clear from the above review that SF-1 is an important regulator of human 
CYP17A1 both in the developing embryonic and adult adrenal cortex. There have 
been some attempts to elucidate the mechanisms and transcriptional elements 
SF-1 exploits to exert transcriptional control but much of this puzzle has yet to 
be solved. Nevertheless the studies comparing expression of various transcription 
factors in both normal and diseased adrenal tissue have proved a useful tool to 
aid in the explanation of altered enzymatic expression in adrenal disorders. 
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GATA-6 
GATA-6 is a member of a family of zinc-finger transcription factors (GATA 1-6). 
Primarily expressed in the zona reticularis of the adrenal cortex, GATA-6 is 
believed to play a key role in adrenal androgen biosynthesis at the gene 
transcription level (Jimenez et al., 2003). Interestingly, another member of the 
GATA family, GATA-4, has been shown to be expressed in human gonadal tissue, 
alongside GATA-6, but not in adrenal tissue; this suggests GATA-6 may be of 
importance in adrenal androgen production (Kiiveri et al., 2002). In vitro studies 
in H295R cells co-transfected reporter constructs containing the CYP17A1 
promoter alongside an expression vector containing the GATA-6 coding region. 
This increased promoter activity 6-fold, but this effect could not be replicated in 
a non-steroidogenic cell line (Jimenez et al., 2003). This indicates that GATA-6 
requires other transcriptional elements to produce this effect.  
Study of the GATA transcription factor family’s role in gene promoters of 
importance in gonadal tissue identified a functional GATA-4 site within the 
promoter of SF-1 (Tremblay and Viger 2001). It is possible that GATA-6 promotes 
transcription of CYP17A1 in a similar manner in the zona reticularis of the 
adrenal cortex. The combined effect of GATA-6 and SF-1 has been examined in 
vitro. Using non-steroidogenic cells, transfection of both SF-1 and GATA-6 
expression plasmids increases CYP17A1 promoter activity when compared to 
GATA-6 alone. Furthermore, promoter activity is increased to levels similar to 
those observed following transfection with GATA-6 alone in steroidogenic cells 
(Jimenez et al., 2003). These data suggest that there is greater induction of 
CYP17A1 transcription in the presence of both SF-1 and GATA-6, although 
evidence of a direct interaction between the two within adrenal tissue is 
lacking.  
Within the promoter region of CYP17A1, there is an apparent GATA binding site 
at -64/-59, but mutation of this site in reporter construct studies does not affect 
transcription in the presence of GATA-4 or GATA-6 (Flück and Miller 2004). 
Instead, the authors present evidence that the ability of GATA-4 or GATA-6 to 
induce transcription requires interaction with the Sp1 transcriptional element 
within the Sp1:Sp3 complex site. The Sp1:Sp3 binding site is located -196/-188 
bases upstream of CYP17A1 TSS (Lin et al., 2001).  
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Furthermore, GATA-6 has also been shown to associate with SF-1 in the 
transcriptional regulation of cytochrome b5 (Flück and Miller 2004; Huang et al., 
2005), providing additional evidence of its importance in 17, 20 lyase expression 
and subsequent adrenal androgen production. 
NF-1 
Binding sites for the transcription factor nuclear factor 1 (NF-1) have been 
identified and confirmed at positions -107/-85 and -178/-152 of the CYP17A1 
proximal promoter region using electrophoretic mobility shift assays (EMSAs) (Lin 
et al., 2001). Mutation at both sites halved transcriptional activity in vitro, 
indicating that these transcriptional elements play a key role in the regulation of 
CYP17A1 transcription. 
1.4.2.1 ACTH Effect on Transcription 
In the zona fasciculata, the peptide hormone adrenocorticotropin (ACTH) 
increases levels of the intracellular second-messenger cAMP via activation of 
adenylyl cyclase. This results in the activation of the cAMP-mediated protein 
kinase A (PKA) pathway and a subsequent increase in the transcription of 
steroidogenic genes. The direct targets of the PKA pathway are still to be 
elucidated but it appears to promote binding of transcription factors to cAMP-
responsive sequences within the promoters of steroidogenic genes.  
It has been shown that both basal (required for constitutive expression) and 
cAMP-responsive elements are located within the 63 bases immediately 
upstream of the CYP17A1 TSS (Rodriguez et al., 1997). As described above, a 
complex containing the transcription factor SF-1 binds to a site located at 
position -57/-50 of the human CYP17A1 promoter and regulates expression in the 
adrenal cortex. Aside from the regulatory control exerted by PSF through its 
recruitment and release of mSin3A, the phosphorylation state of SF-1 plays a key 
role in the stimulation of transcription by ACTH/cAMP.  SF-1 is dephosphorylated 
following cAMP stimulation of the H295R adrenocortical cell line (Sewer and 
Waterman 2002). Mitogen-activated protein kinase phosphatase-1 (MKP-1) has 
been identified as an essential phosphatase in this process (Sewer and Waterman 
2003). Both mRNA and protein levels of MKP-1 are increased upon stimulation 
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with cAMP in vitro and, importantly, the increase in MKP-1 expression 
immediately precedes increased CYP17A1 expression, suggesting a role in cAMP-
dependent expression of CYP17A1 (Sewer and Waterman 2003). The authors 
therefore postulate that MKP-1 is responsible for the dephosphorylation of SF-1 
and the subsequent increase in CYP17A1 transcription but evidence of direct 
associations is lacking, meaning that there may be a number of intermediary 
factors involved in this process. 
Further studies have identified roles for sterol regulatory element binding 
protein 1 (SREBP-1) and other proteins in cAMP-induced CYP17A1 expression 
(Ozbay et al., 2006). A binding site for SREBP has been identified within the 
region -520/-331 upstream of the CYP17A1 TSS (Figure 1-12). Activation of the 
PKA pathway following stimulation by ACTH decreases intracellular levels of 
numerous sphingolipids, which are essential components of cellular plasma 
membranes. This decrease triggers the release of sphingosine-1-phosphate (S1P) 
which promotes the recruitment of the SREBP-1 transcription factor to the site 
upstream of CYP17A1 (Ozbay et al., 2006). 
Thus, much information on a complex mixture of factors is available.  How many 
other such factors exist, how they are organised into a clear scheme of 
regulation and, importantly, how they differ between organs, remain to be 
discovered. 
 
1.5 Post-Transcriptional Regulation 
RNA interference (RNAi) is a naturally-occurring process used by cells to post-
transcriptionally silence or diminish the effect of a gene by hastening the 
destruction of its mRNA products. RNAi was first observed in plants (Napoli et 
al., 1990), when scientists introduced a pigment-producing gene to intensify 
petal colour. Instead, the resulting petals were colourless. The molecular 
mechanisms behind this gene silencing effect - a Nobel-prize-winning discovery - 
were fully described by Fire et al. (1998). RNAi uses short, non-coding, double-
stranded RNA, which binds to a complementary region on messenger RNA, 
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leading to post-transcriptional gene silencing. Similar single-stranded molecules 
were shown to have a modest effect by comparison. 
Following its discovery, RNAi has become a powerful research tool, with several 
classes of small RNA molecules now commonplace in research. Short interfering 
RNA (siRNA) is frequently used and relevant to the class of molecules described 
in this thesis: microRNA (miRNA). 
1.5.1 MicroRNA 
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules, 
approximately 20-25 nucleotides in length. They are thought to play key roles in 
various human disease pathologies, including several cancers (Lu et al., 2005; 
Suzuki et al., 2009). The role of miRNAs in post-transcriptional gene regulation 
will be discussed in the following sections, as well as what is known about their 
involvement in human adrenal disease. 
1.5.1.1 Discovery 
The inaugural miRNA, lin-4, was first described by Lee et al. (1993). Conducting 
their research in the nematode worm C.elegans, Lee and colleagues established 
that the product of the lin-4 gene was not translated into a peptide product but 
instead generated a small non-coding RNA that displayed sequence 
complementarity to a 3’ untranslated region (3’UTR) section of lin-14 mRNA. The 
LIN-14 protein is critical to the timing of larval events in C.elegans. The first 
functional characterisation of a miRNA was published in the same issue of Cell by 
Wightman et al. (1993), showing that lin-4 binds directly, though imperfectly, to 
the 3’UTR of lin-14, reducing protein production. The importance of these 
studies was not fully appreciated until the discovery of a second miRNA some 
seven years later. Reinhart et al. (2000) described the importance of the 21-
nucleotide RNA molecule, let-7, in coordinating the timing of C. elegans 
development and noted its conservation across species. 
The turn of the millennium saw a vast increase in miRNA-mediated gene 
regulation research, with the latest release of miRBase (v. 19, August 2012, see 
Section 1.5.1.2) listing 25,141 mature miRNA entries across 193 species. 
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1.5.1.2 Nomenclature 
When a research article describing a novel and experimentally-validated miRNA 
is submitted for publication, the miRNA sequence is entered confidentially into 
the miRBase database (formally Rfam) for official naming 
(http://microrna.sanger.ac.uk/) (Griffiths-Jones 2006). Strict expression and 
biogenesis criteria must be met to ensure the finding is a novel miRNA, and not 
another form of small RNA, e.g. siRNA (Ambros et al., 2003). Each miRNA is first 
identified by species – e.g. hsa (human) or mmu (mouse) - and then numbered 
according to time of submission, with mature sequences labelled ‘miR’ and 
precursor hairpins ‘mir’ (Griffiths-Jones et al., 2006). Identical sequences found 
in different species are assigned the same numbers. Identical sequences found 
within a species but arising from different genomic locations are given numerical 
suffixes (e.g. hsa-miR-1-1, hsa-miR-1-2). MiRNAs with similar sequences are 
grouped into a ‘miRNA family’ and have an additional lowercase letter to aid 
identification (e.g. hsa-miR-320a, hsa-miR-320b, hsa-miR-320c). Mature miRNAs 
derive from a hairpin precursor (see section 1.5.1.3) and it is therefore possible 
for a miRNA to originate from either arm of the hairpin pre-miRNA. The current 
nomenclature for such miRNAs assigns either a -5p or -3p suffix, depending on 
whether the miRNA was generated from the 5’ or 3’ hairpin arm (e.g. hsa-miR-
34c-5p and hsa-miR-34c-3p). Before this particular nomenclature was developed, 
some early studies assigned an asterisk to the apparently non-functional miR 
from the hairpin as a means of differentiating between the two miRs (e.g. hsa-
let-7c and hsa-let-7c*)(Griffiths-Jones 2004). 
1.5.1.3 MiRNA Synthesis in Animals 
MiRNAs are synthesised in a multistep process, summarised in Figure 1-13 and 
outlined in the following sections. The majority of known miRNA genes are 
located in intergenic or intronic regions of chromosomes, with a smaller 
proportion being transcribed from exonic regions (Lau et al., 2001; Rodriguez et 
al., 2004). 
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Figure 1-13 Overview of miRNA biogenesis and post-transcriptional repression 
mechanisms.  
MicroRNA genes are transcribed in the nucleus as primary transcripts (Pri-miRNA) before being 
processed into ~70 nucleotide pre-miRNAs by Drosha endocuclease. The pre-miRNA is 
transported from the nucleus into the cytoplasm by Exportin-5 where it is processed further by 
Dicer. The mature miRNA (red) is then loaded into Argonaute 1-4 and assembled into the miRNA-
induced silencing complex (miRISC), which is subsequently guided to the 3’UTR  of the target 
mRNA. mRNA translation is then inhibited through one or more repressive mechanisms, including 
mRNA cleavage, degradation and translational repression. 
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Nuclear Processing 
A miRNA is initially transcribed in the nucleus as part of a longer primary 
transcript (Pri-miRNA) by RNA polymerase II or, less commonly, RNA polymerase 
III (Lee et al., 2004; Borchert et al., 2006). Such transcripts are usually several 
kilobases in length and contain stem loop structures. These stem loop structures 
include the miRNA double stranded stem, imperfectly paired and linked by a 
small terminal loop. They are cleaved at the stem by a microprocessor complex 
to produce a 70-nucleotide hairpin structure, termed the pre-miRNA (Lee et al., 
2003). This microprocessor complex is a multi-protein complex in which the key 
components are Drosha and DGCR8 (DiGeorge Syndrome Critical Region in Gene 
8) (Lee et al., 2003; Landthaler et al., 2004). DGCR8 binds to the stem of the 
structure, thus guiding the RNase III enzyme to cleave the double-stranded stem 
around 11 basepairs from the stem-base, generating a 5’-phosphate group and a 
two-nucleotide 3’-overhang at the cleavage site (Basyuk et al., 2003). 
(Invertebrates utilise ‘Pasha’ in place of DGCR8. This will not be discussed 
further (Denli et al., 2004)). 
Nuclear-Cytoplasm Transportation 
Following cleavage by the microprocessor complex, pre-miRNAs are transported 
into the cytoplasm for further processing. Transportation occurs through nuclear 
pore complexes via the Ran guanosine triphosphate (Ran-GTP)-dependent 
nuclear transport receptor, Exportin-5 (Yi et al., 2003; Bohnsack et al., 2004). 
Lund et al. (2004) propose that only pre-miRNAs of defined length and structure 
can be efficiently transported by Exportin-5 from the nucleus, where Ran-GTP 
levels are high, to the cytoplasm, where the relatively low levels of Ran-GTP 
trigger release of the pre-miRNA from Exportin-5. 
MiRNA Induced Silencing Complex (miRISC) 
Following action by Dicer (‘dicing’), unwinding of the strands is catalysed by an 
as yet unidentified RNA helicase and the guide strand incorporated into an Ago 1-
4 protein complex, while the passenger strand is degraded by the enzyme XRN-2. 
The guide strand is preferentially incorporated into the miRISC, the strand of 
choice being that with the less stable 5’ end being chosen (Khvorova et al., 
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2003). Following Argonaute 1-4 loading, the miRNA guides miRISC to its target 
mRNA (Section 1.5.1.4) and mRNA repression initiates (Section 1.5.1.5). There is 
now some evidence of instances where the passenger strand can be incorporated 
into the miRISC and a functional miRNA is produced. The REST and Co-REST 
transcription factors, which are important in Huntington’s disease, have been 
shown to be co-regulated by hsa-miR-9 and hsa-miR-9* (Packer et al., 2008). It is 
not clear how often these instances occur, although, aside from the less 
thermostable strand being preferred, the presence of a 5’uridine base (5’U) 
appears to promote loading into the miRISC complex (Seitz et al., 2011). 
1.5.1.4 Target Recognition 
Classical miRNA action causes repression of the mRNA by direct binding of its 
3’UTR. The majority of miRNAs are believed to act in this manner although there 
is some evidence of miRNA targeting and binding to the coding regions and 
5’UTRs (Duursma et al., 2008; Orom et al., 2008). The miRNA sequence serves as 
a target recognition motif, steering the miRISC to the 3’UTR of the target mRNA. 
The bulges in the structure of the miRNA often lead to imperfect base-pairing. 
The development of bioinformatic databases has lead to the identification of a 
region known as the ‘seed site’. This refers to nucleotides 2-7 from the 5’ end of 
the miRNA. This region is often evolutionarily conserved and is now the basis for 
generating target predictions (Lewis et al., 2005). In silico analyses predicting 
mRNA targets of specific miRNAs on the basis of miRNA:mRNA pairing must 
therefore be evaluated with caution. Perfect base-pairing complementarity 
between miRNA and mRNA leads to site-specific mRNA endonucleolytic cleavage, 
similar to siRNA silencing, and is very much more common in plants than in 
animals. Imperfect base-pairing, however, causes repression either through 
mRNA destabilisation followed by degradation, or by mRNA translational 
repression (summarised in Section 1.5.1.5) 
1.5.1.5 Gene-Silencing Mechanisms / Repression Mechanisms 
The mechanisms behind miRNA-mediated repression are not fully understood. As 
explained in the previous section, the two currently accepted models in animals 
involve translational repression and mRNA destabilisation and degradation. 
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Translational Repression 
Reviews of recent evidence suggest that there are several different modes of 
mRNA translational repression (Filipowicz et al., 2008; Gu and Kay 2010). 
Translation is a complex, multi-step process facilitating the conversion of mRNA 
to protein. Typically, translation begins with a complex initiation step whereby 
the 5’ terminal cap structure, m7GpppN (where N is any nucleotide), of the 
mRNA is recognised by and interacts with the eIF4E subunit of the eukaryotic 
translation initiation factor 4F (eIF4F). Various subtypes of eIF are involved at 
this stage and facilitate the recruitment of the 40S ribosomal subunit (Kapp and 
Lorsch 2004). The eIF complex also associates with the polyadenylate-binding 
protein (PABP), bound to the adenylation site at the 3’ end of the mRNA, which 
brings together both ends of the transcript, effectively ‘circularising’ the mRNA 
(Wells et al., 1998). This circular formation increases translation initiation 
efficiency and the 40S ribosomal subunit begins to scan the mRNA for the AUG 
start codon. The elongation process can then occur upon recruitment of the 60S 
ribosomal subunit, regulated by various elongation factor proteins (Kapp and 
Lorsch 2004). The termination process occurs when the stop codon is reached, 
where upon translation release factors trigger the dissociation of the ribosomal 
subunits from the mRNA. 
There is much evidence to suggest that miRNA-mediated translational repression 
can occur at various stages in the complex translation process. A brief summary 
is provided below: 
1. Competition for 5’-cap binding: Eulalio et al. (2008) contradicted previous 
evidence that miRISC competed with eIF4E for 5’-cap binding by proposing 
that GW182 (Protein with multiple glycine (G)-tryptophan (W) repeats, 
molecular mass 182 kD), recruited by Ago 1-4 in miRISC, was in fact 
responsible. Failure of subunit eIF4E binding therefore causes repression 
at the translation initiation stage. 
2. Inhibition of 60S subunit recruitment: Chendrimada et al. (2007) showed 
that the 60S ribosomal subunit interacts with eIF6 and proposed that one 
or both of these proteins interact with miRISC, thus inhibiting 40S-60S 
interaction and causing translational repression. There is conflicting 
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evidence as to the exact mechanisms. However, the published data are 
consistent with the theory that translational repression can occur post-
initiation.  
3. Premature ‘ribosomal drop-off’: Petersen et al. (2006) suggested that the 
presence of miRISC prompts early ribosomal dissociation from the mRNA in 
the elongation stage of translation. Guo et al. (2010) corroborated this 
proposal with a large ribosomal profiling study in vitro. These and similar 
studies demonstrate miRNA-mediated post-initiation translational 
repression. 
mRNA Destabilisation 
Destabilisation of mRNA occurs when the poly (A) tail is shortened (Wu et al., 
2006). This deadenylation of the mRNA increases its instability and inhibits 
translation initiation by preventing the binding of PABPs (Poly(A)–binding 
proteins). Catalysed by exosomes, mRNA degradation and decay then occurs in a 
3’-5’ direction. Alternatively, destabilisation may cause removal of the 
5’m7GpppN cap by Dcp2 enzyme, allowing 5’-3’ decay. Both mechanisms block 
circularisation of the mRNA, thus decreasing translational initiation efficiency. 
These mRNAs may then accumulate in cellular processing bodies (P-bodies), 
which lack the machinery necessary for translation (Valencia-Sanchez et al., 
2006) and are degraded by XRN1 and other exonucleases (Behm-Ansmant et al., 
2006). Research suggests that the protein GW182, a component of P-bodies, 
associates with the Ago 1-4 complex within miRISC, thus promoting their 
transition from cytoplasm to P-bodies (Eystathioy et al., 2002; Behm-Ansmant et 
al., 2006). Interestingly, Bhattacharyya et al., (2006) proposed a mechanism 
whereby, under certain cellular conditions, mRNA could be released from the P-
body back into the cytoplasm to undergo translation. This gives credence to the 
notion that miRNAs act more as ‘fine-tuners’ of mRNA levels than simply as ‘on-
off’ switches. 
There is conflicting evidence as to whether translational repression and mRNA 
destabilisation are entirely independent processes or whether they are 
interlinked in certain situations (reviewed by Filipowicz et al., 2008). 
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Understanding the exact mechanisms behind mRNA repression by miRNA is 
essential, particularly if miRNA is to be considered for therapeutic use. 
1.5.1.6 miRNAs and the Human Adrenal Gland 
Various studies have shown the importance of microRNAs in adrenal development 
and maintenance in mice (Bernstein et al., 2003; Huang and Yao 2010), but the 
effects of miRNAs in the human adrenal gland are less well studied. Wood  
(2011) used a siRNA approach to knock down Dicer, the protein vital for miRNA 
maturation, in the H295R human adrenocortical carcinoma cell line, and studied 
the effects on levels of steroidogenic mRNAs. Interestingly, only those encoding 
cytochrome P450 enzymes in the pathway were affected (CYP11A1, CYP21A1, 
CYP17A1, CYP11B1, CYP11B2). Steroid production was also significantly altered, 
with the end products aldosterone and cortisol, together with many 
intermediate compounds in their biosynthesis, all increased relative to control 
cells (DOC, corticosterone, 18-OH corticosterone). These results were consistent 
with canonical miRNA action, whereby lower levels of mature miRNAs lead to 
increased target mRNA levels and result in more abundant product. These data 
support a significant regulatory role for miRNAs in human steroidogenesis. 
In 2008, Romero et al. identified miR-21 as a key modulator of aldosterone 
production. Overexpression of miR-21 in vitro significantly increased aldosterone 
production and cell proliferation in H295R cells. These findings support the role 
of miR-21 in both corticosteroid production and oncogenesis. This study, 
however, made little attempt to identify possible target genes of miR-21 or to 
suggest a regulatory mechanism by which miR-21 causes increased aldosterone 
production and cell proliferation. 
Robertson et al. (2013) provides a comprehensive study of the effects of miR-24 
on aldosterone and cortisol production, as well as identifying and confirming 
target genes. This work builds on its previous abstract publication (Wood et al., 
2011) which showed that mRNA levels of CYP11B1 and CYP11B2 mRNA were 
significantly increased after siRNA knockdown of Dicer in vitro. MiRNAs predicted 
to bind both mRNAs were identified and cross-referenced with miRNA expression 
profiles derived from both normal human adrenal tissue and aldosterone-
producing adenoma (APA) tissue. Overexpression and inhibition studies revealed 
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that miR-24 significantly alters CYP11B1 and CYP11B2 mRNA levels as well as 
aldosterone and cortisol production in vitro. Experiments utilising reporter 
constructs mutated at the predicted seed site confirmed that miR-24 binds the 
3’UTRs of each mRNA at sites identified by bioinformatic programs. The 
alterations in mRNA should also be reflected at the protein level but the high 
homology of the two genes has so far prevented the generation of specific 
antibodies. Nonetheless, these data set a benchmark for future research into 
miRNA regulation of corticosteroidogenesis. 
The majority of published research concerning miRNA in the adrenal gland 
concerns miRNA expression profiles in adrenal tumours (Soon et al., 2009; 
Patterson et al., 2011; Schmitz et al., 2011). These studies suggest that various 
miRNAs are dysregulated in adrenocortical carcinomas or adenomas. The 
definition of a miRNA profile specific to a certain type of growth would hold the 
potential to aid in the diagnosis of adrenocortical tumours, using miRNA as 
prognostic markers (reviewed by Singh et al., 2012). 
It is clear from this review of recent evidence that miRNAs are important 
regulators of adrenal function.  Thus, their small, fine-tuning effects must be 
added to the better understood influences, such as those that modulate 
expression through interaction with the gene promoter.  It is important to 
understand the balance between these controls both in normal and disordered 
physiology.  Previous studies have shown that small changes in the activity of 
CYP11B1 and CYP11B2 may contribute to the slow, inexorable rise in blood 
pressure which may establish essential hypertension (Barr et al., 2007; Freel et 
al., 2007; McManus et al., 2012).  How else might the adrenal cortex be 
involved?  
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1.6 Aims: 
Recent genome-wide association studies linked a locus within CYP17A1 to 
greater risk of increased systolic blood pressure. While many studies 
investigating association of CYP17A1 genetic variation with androgen-related 
disorders such as breast and prostate cancers and polycystic ovary syndrome 
have been published, few have investigated its association with blood pressure. 
The position of this gene in the steroidogenic pathway, with its ability 
sequentially to catalyse 17α-hydroxylase and 17,20 lyase reactions, makes it 
crucial to the modulation of adrenocortical output between corticosteroids and 
androgens. The work presented in this thesis tests the hypothesis that common 
genetic variation in both the 5’ and 3’ regulatory regions of the CYP17A1 gene 
lead to subtle changes in blood pressure. There follows an account of a 
programme of experimental work that addresses each of these facets. Its major 
aims were as follows:-  
 To identify the pattern of linkage disequilibrium across the CYP17A1 gene 
and examine the association of CYP17A1 polymorphisms with hypertension 
in a Caucasian population 
 To investigate in vitro the functional effects of candidate polymorphisms 
located in the promoter region of CYP17A1 in order to determine their 
likely effects on glucocorticoid and androgen production. 
 To investigate a potential role for microRNA in the post-transcriptional 
regulation of the CYP17A1 gene. 
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This chapter provides a detailed outline of the general laboratory practices and 
experimental methods used to perform the work described in this thesis. Some 
methods are common to more than one chapter; specific materials and methods 
section are also provided within each individual results chapter. 
2.1 General Laboratory Practice 
A laboratory coat and latex powder-free gloves were worn during all procedures. 
Hazardous substances were handled in accordance with Control of Substances 
Hazardous to Health regulations, with laboratory facemasks, spectacles and 
fume hoods used where necessary. All equipment and reagents were of the 
highest available grades. 
2.2 Sequencing the CYP17A1 Gene in Normotensive and 
Hypertensive Populations 
2.2.1 Study Subjects 
2.2.1.1 Adrenal Function Study 
DNA samples from normotensive volunteers were analysed from the Adrenal 
Function Study (AFS), previously conducted by Dr. Frances McManus (n=60). An 
automated method had been used for DNA extraction (Gentra System Autopure 
LS, Large Sample Nucleic Acid Purification Automated DNA extraction, QIAGEN, 
U.K.) according to the manufacturer’s instructions and DNA had been stored for 
approximately six months at -20°C prior to use.  
2.2.1.2 MRC British Genetics of Hypertension Study 
The MRC BRitish Genetics of HyperTension (BRIGHT) cohort is a large multicentre 
study comprising 3500 affected sibling-pairs (sib-pairs) and 3000 parent-offspring 
trios (TDTs). The data presented in Chapter 4 of this thesis relates to 511 
unrelated hypertensive individuals from the sib-pair group for whom 
corticosteroid and androgen profiles were available. A detailed account of the 
recruitment of the sib-pair group was previously described by Caulfield et al., 
(2003). In brief, blood pressure values of 150/100 mmHg or higher, based on one 
reading, or 145/90 mmHg, as a mean of three readings, were required for 
inclusion in the study with onset of hypertension diagnosed before age 60 years 
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in at least one sibling. DNA was extracted by the BRIGHT consortium, as 
described at http://www.brightstudy.ac.uk/info/sop_9000666.html#processing. 
2.2.2 Determination of Nucleic Acid Quantity and Quality 
Both the quantity and quality of nucleic acids (RNA or DNA) were assessed using 
a Nanodrop® ND-1000 spectrophotometer (Labtech International Ltd, U.K.) with 
ND-1000 v3.1.0 software. 2µl of each sample is loaded on to the end of a fibre 
optic cable and, when the arm of the instrument is lowered, the sample is 
brought into contact with a second fibre optic cable, causing the liquid to bridge 
a specific gap between the two fibre optic ends. Light is then passed through the 
sample and sample concentrations are provided onscreen. Purity of the sample 
can be assessed using the additional information provided onscreen: the 260/280 
value is a ratio of sample absorption at 260nm and 280nm, with values of 1.8 
and 2.0 considered optimal for DNA and RNA respectively. Nuclease-free water is 
used as a reference. 
2.2.3 PCR of CYP17A1 
Primers were designed to amplify DNA at least 2 kilobases upstream from the 
transcriptional start site, encompassing the promoter/enhancer region of the 
CYP17A1 gene. Exons were amplified either singly or in pairs using primers 
previously published by Lin et al. (1991) and Monno et al. (1993), with a reverse 
primer designed to amplify the 3’UTR specifically. Primers to amplify the introns 
were designed as necessary, with all newly-designed primers based on published 
sequences (www.ensembl.org/index.html) and checked for specificity via the 
BLAST database (http://blast.ncbi.nlm.nih.gov/Blast.cgi). All primers were 
obtained from Eurofins MWG Operon (Germany) and had undergone High Purity 
Salt Free (HPSF) purification. Sequences are provided in Appendix 1. The 
promoter region PCR was performed on a 96-well Dyad Disciple™ sample block 
powered by the PTC-0221 thermal cycler with heated lid (MJ Research, MA, 
U.S.A.) using the Expand High Fidelity PCR System (Roche Diagnostics Ltd, 
Burgess Hill, U.K.). All introns, exons and 3’ untranslated regions of the gene 
were amplified using the Thermo-Start Taq DNA Polymerase PCR Enzyme Kit 
(Thermo Fisher Scientific, U.K.), and performed on the Multi Block System 
Satellite 0.2 Thermo Cooler (Thermo Fisher Scientific, U.K.). Specific protocols 
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for each PCR system are shown below. DNA samples were diluted to a working 
stock of 5ng/µl with nuclease-free water. 
Expand High Fidelity PCR System 
Reagent Volume per reaction  Final concentration 
dNTPs 2.00 µl 80µM each 
Forward primer (10µM) 0.75 µl 300nM 
Reverse primer(10µM) 0.75 µl 300nM 
Expand High Fidelity Taq DNA polymerase 0.75 µl 2.6U 
Expand High Fidelity Buffer with MgCl2 (10x) 2.50 µl 1x 
Nuclease-free water 13.25 µl  
Genomic DNA (5ng/µl) 5.00 µl 25ng 
 
 
 
Thermo-Start Taq DNA Polymerase PCR Enzyme Kit 
Reagent Volume per reaction Final Concentration 
dNTPs 5.00 µl 200µM each 
Forward primer (10µM) 1.30 µl 500nM 
Reverse primer (10µM) 1.30 µl 500nM 
Thermostart taq (5U/µl) 0.25 µl 1.25U 
Thermostart Buffer (10x) 2.50 µl 1x 
MgCl2 (25mM) 1.50 µl 1.5mM 
Nuclease-free water 8.15 µl  
Genomic DNA (5ng/µl) 5.00 µl 25ng 
 
A temperature gradient was used to optimise all PCR annealing temperatures, 
with a typical gradient result shown in Figure 2-1. Individual PCR conditions can 
be found in Appendix 1. 
 
Figure 2-1 Typical PCR resulting from a gradient of annealing temperatures. 
The intended product size is 397 bp and is resolved on a 1% agarose gel. 
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2.2.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments resulting from 
PCR or restriction digestion. A 1% agarose gel was prepared by adding 1g of (w/v) 
Ultrapure agarose (Invitrogen, Paisley, U.K.) to 100ml of Tris/Borate/EDTA (TBE) 
(10mM Tris, 10mM boric acid, 10mM EDTA, pH 8.3) and heating in a microwave 
oven for approximately 100 seconds. 1µl of ethidium bromide (10mg/ml) (Sigma-
Aldrich, Poole, U.K.), which intercalates with DNA and fluoresces under UV light, 
was added to the liquid gel in a fume hood before pouring the whole mixture 
into a gel mould with Teflon comb and allowed to set for 15-30 minutes. After 
setting, the gel was submerged in a standard electrophoresis tank in 1x TBE 
buffer and the comb removed. Equal amounts of samples were combined with 
loading dye (0.02% bromophenol blue, 0.02% xylene cyanol and 2.5% glycerol) 
and loaded into the wells alongside an appropriate marker: either 1kb or 100bp 
DNA size ladder (Promega, Wisconsin, U.S.A.). The gel was resolved at a constant 
90V for 45 minutes. DNA fragments were visualised and captured on a molecular 
Imager ChemiDoc(TM) XRS+ Imaging system and Multi-Analyst software v 1.1 
(both Bio-Rad Laboratories, Hemel Hempstead, U.K.), scanning with UV light at 
302nm. 
2.2.5 PCR Product Purification 
The AMPure purification method (Agencourt, Beverly, MA, U.S.A.) was used to 
separate PCR products from unincorporated dNTPs, primers, primer dimers, salts 
and other contaminants left over from the PCR reaction, in preparation for the 
subsequent sequencing reaction. For 25µl PCR reactions, 36µl of resuspended 
AMPure reagent was added to each PCR product and vortexed. The mixture was 
collected at the bottom of the wells in the PCR plate by brief centrifugation and 
incubated at room temperature for 5 minutes to allow PCR products of at least 
100 base pairs (bp) to bind to magnetic beads in the AMPure reagent. The PCR 
plate was then placed on a solid phase reversible immobilisation (SPRI) magnet 
for 10 minutes. With the magnetic beads (along with the DNA) bound to the 
magnet, the remaining liquid was removed by inversion. With the plate 
remaining on the magnet, 150µl of 70% ethanol was added to each sample for a 
total of 30 seconds and this, again, was removed by inversion. To ensure that no 
ethanol remained, the plate, while still on the magnet, was inverted onto a 
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piece of tissue and briefly centrifuged. The plate was then removed from the 
magnet and allowed to dry at room temperature for at least 20 minutes. 40µl of 
nuclease-free water was added to each sample and then vortexed in order to 
elute the DNA from the magnetic beads. The plate was returned to the magnet 
for at least 10 minutes and a small volume of this final solution (specified in 
Section 2.2.6) was used as template for the sequencing reaction. 
2.2.6 Sequencing Reaction 
PCR products and plasmid DNA were sequenced using BigDye Terminator v3.1 
Cycle Sequencing chemistry (Applied Biosystems, Warrington, U.K.) which 
utilises a technique based on the dideoxy chain termination method of 
sequencing. Varying volumes of DNA template were used, depending on the 
preceding PCR. Sequencing reaction mixtures were set up in 96-well PCR plates 
consisting of the following components: 
Reagent Volume per Reaction (µl) 
ABI PRISM Big Dye v3.1 Sequencing Buffer (5x) 3.5 
ABI PRISM Big Dye Termination v3.1 Ready Reaction Mix 0.5 
Sequencing Primer (3.2µM) 1.0 
DNA template: 
 e.g. Plasmid 100-200ng 
PCR product (High Fidelity Taq) 2µl 
PCR product (Thermostart Taq) 5µl 
 
Variable 
Nuclease-free water Up to final volume of 20 
 
Sequencing primers are synthetic oligonucleotides designed to produce 
overlapping fragments of the desired region. As with the PCR primers described 
in Section 2.2.3, primers were based on published sequences, checked for 
specificity, and obtained commercially in HPSF form. Sequences of individual 
sequencing primers can be found in Appendix 1. Primers were designed for each 
opposing strands in order to increase the reliability of results. The program for 
each reaction was chosen based on the melting temperatures (Tm) of the 
sequencing primers: BIGSEQ50 for primers with Tm<60°C and BIGSEQ60 for 
primers with Tm>60°C, the conditions of which are shown below: 
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BIGSEQ50  BIGSEQ60 
Time Temperature Cycles  Time Temperature Cycles 
45 secs 96°C 
25 
 45 secs 96°C 
25 
25 secs 50°C  4 mins 60°C 
4 mins 60°C     
 
 
2.2.7 Sequencing Reaction Purification 
The CleanSEQ purification method (Agencourt, Beverly, MA, U.S.A.) was used to 
remove components of the sequencing reaction from the sample prior to 
automated cycle sequencing. For 20µl sequencing reactions, 10µl of resuspended 
CleanSEQ reagent was added to each sequencing reaction product, followed by 
62µl of 85% ethanol, and vortexed. The mixture was collected at the bottom of 
the wells in the PCR plate by brief centrifugation and placed on a SPRI magnet 
for 10 minutes. The remaining liquid was removed by inversion and discarded 
before 150µl of 85% ethanol was added to each sample. After 30 seconds the 
ethanol was removed by inversion before being briefly centrifuged in the same 
orientation. The plate was then removed from the magnet and allowed to dry at 
room temperature for at least 20 minutes. 40µl of nuclease-free water was 
added to each sample and then vortexed in order to elute the DNA from the 
magnetic beads. The plate was returned to the magnet and 20µl of DNA sample 
transferred to a bar-coded plate for sequencing. 
2.2.8 Automated Cycle Sequencing 
Automated cycle sequencing was performed on an ABI 3730 DNA analyser 
(Applied Biosystems, Foster City, CA, U.S.A). Genomic DNA sequencing results 
were analysed using SeqScape v2.2 genotyping software (Applied Biosystems, 
Foster City, CA, U.S.A) and plasmid DNA sequencing results using CLC Genomics 
Workbench v4.9 (CLC Bio, Swansea, U.K.). For both software programmes, 
sequences were aligned to a reference sequence based on those published for 
the CYP17A1 gene (www.ensembl.org/index.html) and those provided by the 
manufacturer for reporter constructs (Sections 2.7.1, 2.7.2). 
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2.2.9 Data Analysis 
CYP17A1 gene sequencing data from both the AFS Cohort and BRIGHT sib-pair 
subset were analysed using Haploview software version 4.2 
(http://www.broad.mit.edu/mpg/haploview) (Barrett et al., 2005). This 
software enabled the pattern of linkage disequilibrium, Hardy-Weinberg 
equilibrium and haplotype structure to be determined.  
 
2.3 Cell Culture 
Cells were cultured under sterile conditions using class II biological vertical 
laminar flow safety cabinets (Holten Safe 2010). Cabinets were cleaned before 
and after use with 1% Rely+On™ Virkon® (DuPont, Herts, U.K.), 70% ethanol and 
dH2O. All fluid and plastic waste was decontaminated by soaking in 10% H2O2 for 
24 hours. Fluids were then discarded through domestic waste drains and plastics 
incinerated. Cells were grown in a monolayer in 25cm2, 75cm2 and 150cm2 
culture flasks with vented caps (Corning Life Sciences, Amsterdam, the 
Netherlands) with normal growth medium, as detailed below, and incubated in a 
humidified chamber at 37°C with 5% CO2.  
The H295R (strain 2) human adrenocortical tumour cell line were a generous gift 
from Professor William Rainey (Medical College of Georgia, U.S.A). These cells 
were maintained in Dulbecco's modified Eagles medium (DMEM) with F12, 1:1 
(Invitrogen, Paisley, U.K.) supplemented with 2.5% Ultroser G (Pall Bioscience, 
France), 1% insulin-transferrin-selenium (ITS) (BD Biosciences, Oxford, U.K.) and 
1% penicillin/streptomycin: 1IU penicillin, 100µg/ml streptomycin (Invitrogen, 
Paisley, U.K.). 
HeLa cells, an immortalised human cell line derived from a cervical cancer were 
purchased from the European Collection of Animal Cell Cultures (Porton Down, 
Wiltshire, U.K.) and were maintained in DMEM (Invitrogen, Paisley, U.K.) 
supplemented with 10% (v/v) foetal calf serum (FCS), 2mM L-glutamine (Sigma-
Aldrich, Poole, U.K), 100mM sodium pyruvate (Sigma-Aldrich, Poole, U.K.) and 
1% penicillin/streptomycin: 1IU penicillin, 100µg/ml streptomycin (Invitrogen, 
Paisley, U.K.) 
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2.3.1 Cryopreservation 
For long-term storage, cells were harvested as described in Section 2.2.2 but 
resuspended in complete growth medium supplemented with sterile 10% (v/v) 
dimethyl sulphoxide (DMSO) (Thermo Fisher Scientific, Loughborough, U.K.) to 
prevent the formation of ice crystals.  Cell suspensions were aliquoted into 2ml 
cryopreservation vials and cooled at a constant -1°C/minute to -80°C using 
isopropanol and a Nalgene Cryo container (Thermo Fisher Scientific, 
Loughborough, U.K.) before being transferred to liquid nitrogen for long-term 
storage 
Cells were resuscitated from cryopreservation by thawing vials in a 37°C water 
bath and immediately transferring the suspension to a universal container with 
5ml of complete growth medium. Cells were pelleted by centrifugation at 
1500rpm for 5 minutes and the medium containing DMSO was removed. Cells 
were then resuspended in 5ml of complete growth medium and transferred to a 
25cm2 Corning cell culture flask and cultured as detailed in Section 2.3.2. 
2.3.2 Maintenance of Established Cell Lines 
Cells were routinely passaged at approximately 80% confluence. Medium was 
removed and the cells rinsed with an appropriate volume of phosphate buffered 
saline (PBS) solution (Invitrogen, Paisley, U.K.), depending on the volume of flask 
(typically 6-10ml). Up to 5ml of 0.25% Trypsin-EDTA solution (Sigma, Missouri, 
U.S.A.) was added to the flask of cells and, after incubation at 37°C for 2-4 
minutes, the cells were detached from the flask. The Trypsin-EDTA solution was 
then inactivated by adding an equal volume of complete growth medium. Cells 
were transferred to a universal container and pelleted by centrifugation at 
1500rpm for 5 minutes. The supernatant was discarded and the cell pellet 
resuspended in an appropriate volume of fresh complete growth medium, 
depending on the desired sub-cultivation ratio. Typically, complete growth 
medium was replenished every 2-3 days, with a 150cm2 flask of H295R cells being 
sub-cultured into 2 or 3 flasks and HeLa cells into 5 flasks. 
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2.3.3 Counting Cells 
Cell number was calculated using a Bright Line Haemocytometer (Sigma-Aldrich, 
Poole, U.K.). Cells were detached from the flask, pelleted as described in 
Section 2.2.2 and resuspended in 10ml of complete growth medium. 20µl of cell 
suspension was applied across the chamber beneath a coverslip. With the aid of 
a light microscope, cells in each 1mm corner square were counted and an 
average number taken. Each corner square on the haemocytometer represents a 
volume of 104cm3 and, since 1cm3 is approximately equal to 1ml, the 
concentration of cells per ml were calculated: 
Cell number/ml = average cell count per square x 10,000 
Knowing the number of cells per ml in the cell suspension enabled cells to be 
plated at the desired density. 
2.3.4 Stimulation of H295R Cells 
Cell steroidogenesis was stimulated 24 hours after sub-culturing. Normal growth 
medium was removed from the cells before rinsing with PBS, and replaced with 
normal growth medium supplemented with the desired trophin (1mM dibutyryl 
cAMP). A more specific and detailed account of the stimulation of cells for 
particular experiments can be found in the methods section of the appropriate 
results chapter. 
2.4 RNA Isolation & DNase Digestion 
The miRNeasy mini-kit (QIAGEN, Crawley, U.K.) was used for efficient 
purification and isolation of mRNA and miRNA from cells cultured in 6-well 
plates. The direct lysis method from the manual supplied with the kit was 
followed (dated October 2007). The cell medium was removed and the cells 
rinsed with PBS before adding 700µl of QIAzol lysis reagent. The plates were 
then incubated at -80°C for at least 15 minutes to ensure efficient lysis and then 
thawed at room temperature. Each sample was then transferred to an RNase-
free Eppendorf tube and kept at room temperature for 5 minutes; this promotes 
dissociation of nucleoprotein complexes. After the addition of 140µl of 
chloroform, each tube was thoroughly mixed by vigorous shaking for 15 seconds. 
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Samples were then centrifuged at 12,000g for 15 minutes at 4°C. After 
centrifugation, the upper colourless aqueous phase was separated from the 
white interphase and the lower, red, organic phase using a pipette and 
transferred to a fresh Eppendorf tube. 1.5 volumes of 100% ethanol were added 
to each sample and mixed by pipetting. The sample was then passed through an 
RNeasy mini-spin column by brief centrifugation at 8,000g to allow RNA 
molecules to bind to the silica membrane. Flow-through was discarded before 
performing on-column DNase digestion to eliminate residual genomic DNA 
contamination. The spin column membrane was washed by adding 350µl of 
Buffer RWT and centrifuging for 15 seconds at 8,000g, with the flow-through 
discarded immediately. 10µl of DNase I stock solution was added to 70µl of 
Buffer RDD for each sample, both provided by the RNase-free DNase Set kit 
(QIAGEN, Crawley, U.K.), and the resulting 80µl was dispensed directly on to the 
spin column membrane. The column then remained at room temperature for 15 
minutes. The wash step with Buffer RWT was then repeated and the flow-
through discarded. The column was further washed twice with 500µl of buffer 
RPE, with flow-through discarded, first, after brief centrifugation, and second, 
after 2 minutes of centrifuging at 8,000g. The spin column was then placed in a 
fresh collection tube and centrifuged at full speed for 1 minute to prevent 
carryover of wash buffers. Finally, the spin column was transferred to a 1.5ml 
Eppendorf tube; 50µl RNase-free water was dispensed directly onto the spin 
column membrane and centrifuged for 1 minute at 8,000g to elute the RNA. RNA 
quantity and quality was assessed using the method described in Section 2.2.2 
and stored at -80°C. 
2.5 Reverse Transcription 
The miScript II Reverse Transcription kit (QIAGEN, Crawley, U.K.) was used to 
produce cDNA (first strand complementary DNA) from RNA. This allowed 
quantification of both microRNA and messenger RNA by qRT-PCR using a two-step 
protocol. Each reaction mixture was assembled following the manual provided 
with the kit (dated August 2011). They comprised the following components: 
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Reagent Volume 
5x miScript HiFlex Buffer 4 µl 
10x Nucleics Mix 2 µl 
miScript Reverse Transcriptase Mix 2 µl 
200ng of DNase-treated RNA Variable 
RNase-free water Up to total volume of 20 µl 
 
Reactions were loaded on to a standard 96-well PCR plate and run on the Multi 
Block System Satellite 0.2 Thermo Cooler (Thermo Fisher Scientific, 
Loughborough, U.K.) with the following conditions: 
Step Time Temperature 
Reverse Transcription 120 mins 37°C 
Inactivation of RT Mix 5 mins 95°C 
 
For each RNA sample, a control reaction omitting reverse transcriptase was also 
set up. Blank controls omitting RNA were also used. 80µl of RNase-free water 
was added to each sample, which was then stored at -20°C 
2.6 Quantitative Real-Time Polymerase Chain Reaction 
Quantitative real-time PCR (qRT-PCR) assays were carried out using cDNA 
template to assess the quantities of mRNA and miRNA in a sample. All reactions 
were performed in ThermoFast® 384-well PCR plates (Thermo Fisher Scientific, 
Loughborough U.K.) on an ABI PRISM 7900HT PCR System. Measurements of 
samples, positive controls and water blanks were performed in triplicate. 
2.6.1 Universal ProbeLibrary 
The human Universal ProbeLibrary (UPL) system (Roche Diagnostics Ltd, Burgess 
Hill, U.K.) currently consists of 165 pre-validated real-time PCR probes, labelled 
at the 5’ end with fluorescein (FAM) and with a dark quencher dye at the 3’ end. 
Each probe binds to around 7000 transcripts although only one specific transcript 
is detected at a time in a given PCR assay, as defined by the set of chosen PCR 
primers. Primers were designed using the Roche online UPL assay design centre 
(http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000) 
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and obtained from Eurofins MWG Operon (Germany), details of which are shown 
in Table 2-1: 
Table 2-1 Primer sequences for gene expression assays. 
Gene Primer Sequence Probe 
CYP17A1 
(F) CTATGCTCATCCCCCACAG 
(R) TTGTCCACAGCAAACTCACC 
#67 
ACTβ 
(F) CCAACCGCGAGAAGATGA 
(R) CCAGAGGCGTACAGGGATAG 
#64 
 
As well as primers, reagents required for each reaction included ABsolute™ QPCR 
ROX mix (ABgene, Epsom, U.K.) and the appropriate UPL probe (Roche 
Diagnostics Ltd, Burgess Hill, UK). Master mixes were created to provide each 
reaction mixture with the following components: 
Reagent Volume (µl) 
Final  
Concentration 
ABsolute™ QPCR ROX mix 5.0 1x 
Forward Primer (10µM) 0.4 400nM 
Reverse Primer (10µM) 0.4 400nM 
UPL Probe (10µM) 0.1 100nM 
Nuclease-free water 2.1  
 
8µl of master mix was added to 2µl of cDNA (prepared from miScript Reverse 
Transcription kit, Section 2.3) in a 384-well plate which was then sealed with an 
optical QPCR Absolute seal (ABgene Ltd, Epsom, U.K.). The reactions were run 
on the ABI PRISM 7900HT cycler using SDS v2.3 software under the following 
conditions: 
Step Time Temperature Cycles 
Enzyme Activation 15 mins 95°C 1 
Denaturation 15 secs 95°C 
60 
Annealing & Extension 1 min 60°C 
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2.6.2 miScript qRT-PCR System 
The miScript SYBR Green PCR kit (QIAGEN, Crawley, U.K.) was used to detect 
and quantify mature microRNA. 10x miScript Primer Assays, detailed in Table 
2-2, (QIAGEN, Crawley, U.K.) were reconstituted in 550µl of TE (pH 8.0) and 
stored at -20°C. 
Table 2-2 Primer assay molecules. 
Primer Assay miRNA Sequence Product Code 
hsa-miR-320a AAAAGCUGGGUUGAGAGGGCGA MS00014707 
hsa-miR-34c-3p AAUCACUAACCACACGGCCAGG MS00009548 
 
Master mixes were created to provide each reaction with the following 
components: 
Reagent Volume 
QuantiTect SYBR Green PCR Master Mix (2x) 10 µl 
10x miScript Universal Primer 2 µl 
10x miScript Primer Assay 2 µl 
Nuclease-free water 4 µl 
 
18µl of master mix was added to 2µl of cDNA (Section 2.3) in a 384-well plate 
which was then sealed with an optical Absolute seal (ABgene Ltd, Epsom, U.K.). 
The reactions were run on the ABI PRISM 7900HT cycler using SDS v2.3 software 
under the following conditions: 
Step Time Temperature Cycles 
Enzyme Activation 15 mins 95°C 1 
Denaturation 15 secs 94°C 
40 Annealing 30 secs 55°C 
Extension 30 secs 70°C 
Melt Curve 
15 secs 95°C 
1 15 secs 60°C 
15 secs 
95°C  
(slow ramp) 
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A melt curve was performed immediately following the cycling conditions to 
verify the specificity of the PCR products. Data were collected during the ramp 
phase between 60°C to 95°C. A single and unique PCR product was confirmed by 
observing a single peak in the melting curve for each primer assay. 
2.6.3 qRT-PCR Data Analysis 
Results of qRT-PCR were analysed using the relative method of comparative Ct 
(2-ΔΔCt) (Livak and Schmittgen 2001), with β-actin and small nucleolar RNU48 
utilised as an endogenous controls. This permits the standardisation of the 
amount of cDNA added to the reaction, acting as a normalising control to correct 
for sampling discrepancies. The extension phase of the PCR reaction induces 
fluorescence from the respective qRT-PCR probe that is proportional to the 
amount of product generated in each cycle. This is measured directly by the ABI 
PRISM 7900HT thermo cycler. A threshold of fluorescence is set during the 
exponential phase of amplification. The cycle number at which the fluorescence 
signal crosses this threshold is called the cycle threshold (Ct). The housekeeping 
gene expression was used to calculate the ΔCt for the gene of interest as follows: 
ΔCt = Ct (sample) - Ct (β-actin) 
All experiments were then compared to a reference control (e.g. non-
transfected cells or scrambled control cells), details of which can be found in 
the appropriate results chapter methods section. This allowed the calculation of 
ΔΔCt 
ΔΔCt = ΔCt (sample) - ΔCt (reference) 
The relative quantity (RQ) value for the messenger RNA or microRNA was then 
calculated: 
RQ = 2-ΔΔCt 
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2.7 Reporter Constructs 
2.7.1 pEZX - 3’UTR Reporter Construct 
To assess miRNA binding to the 3’UTR, a reporter construct containing the 
CYP17A1 3’UTR (pEZX-17) was purchased from LabOmics (Nivelles, Belgium). A 
negative control empty vector (pEZX-Con) was also purchased. Each construct 
contains a pEZX-reporter backbone, which consists of a renilla reporter gene 
coupled to a SV40 (Simian virus 40) viral promoter; a firefly experimental gene 
coupled to a CMV (Cytomegalovirus) promoter; a multiple cloning site located at 
the 3’end of the gene; and a Kanamycin resistance gene for antibiotic selection. 
Constructs were transformed and grown as described in Section 2.7.3. 
2.7.2 pGL3 - 5’ Regulatory Region Reporter Construct 
The pGL3 Basic vector containing the CYP17A1 5’ region (2898bp) was a generous 
gift from Professor Neil Hanley (University of Manchester, Manchester, U.K.) and 
was used to investigate the effect of polymorphic variation on promoter activity. 
Vectors used as controls were purchased from Promega (Wisconsin, U.S.A.). 
Controls included a negative control empty pGL3 Basic vector, pGL4.13 
containing only the firefly (Photinus pyralis) luciferase gene and pGL4.73 
containing only the coding region for renilla (Renilla reniformis) luciferase which 
was used to control for transfection efficiency. All constructs contained an 
Ampicillin resistance gene for antibiotic selection. 
2.7.2.1 Site-Directed Mutagenesis 
To investigate the effect of polymorphic variation on CYP17A1 promoter activity, 
each SNP of interest was mutated to its alternative allele using the QuikChange 
Site-Directed Mutagenesis kit (Agilent Technologies U.K. Ltd, Berkshire, U.K.). 
The CYP17A1 5’ construct (pGL3-17) was transformed and grown as described in 
Sections 2.7.3 - 2.7.5. Mutagenic primers required to alter each SNP of interest 
were designed using the online Quikchange Primer Design Program 
(www.agilent.com/genomics/qcpd) and ordered from Eurofins MWG Operon 
(Germany); primer sequences can be found in Appendix 1. The Mutant Strand 
Synthesis Reaction section of the kit protocol (Revision C, 2010) was followed, 
with each reaction mixture comprising the following components: 
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Reagent Volume 
10x Reaction Buffer 5 µl 
50ng of dsDNA Template Variable 
125ng of Primer 1 Variable 
125ng of Primer 2 Variable 
dNTP Mix 1 µl 
Double-distilled water Up to volume of 49 µl 
Then… 
Pfu Turbo DNA polymerase (2.5U/µl) 1 µl 
 
The control reaction mixture recommended by the protocol was also followed 
but was of limited diagnostic value as it required vastly different cycling 
conditions. Cycling conditions for the main reactions, however, were as follows: 
Step Time Temperature Cycles 
Enzyme Activation 30 secs 95°C 1 
Denaturation 30 secs 95°C 
12 Annealing 1 min 55°C 
Extension 7.5 mins 68°C 
 
Following thermal cycling, reaction mixtures were cooled to ≤37°C. The DpnI 
endonuclease (target sequence: 5’-Gm6ATC-3’) is specific for methylated DNA 
and is used to digest the parental DNA template, thus selecting for mutation-
containing DNA. 10U of the DpnI restriction enzyme was added directly to each 
reaction mixture and gently mixed by pipetting, before being incubated at 37°C 
for 1 hour. The kit protocol suggests a transformation method using competent 
cells provided within the kit and 1µl of PCR product. However, this proved 
unsuccessful so transformations were performed using the JM109 competent 
cells instead (Promega, Wisconcin, U.S.A.). These were successful using the 
method described in Section 2.7.3. 
2.7.3 Transformation of Competent Cells 
100ng of the pGL3 promoter reporter construct plasmid DNA, or its associated 
control plasmids, was used to transform 100µl of JM109 E.Coli competent cells 
(efficiency >108 cfu/µg, Promega, Wisconsin, U.S.A.). 50ng of either pEZX-17 or 
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pEZX-Con was used to transform 50µl of MAX Efficiency® DH5α competent cells 
(efficiency >109 cfu/µg, Invitrogen, Paisley, U.K.). Cells were transformed in 
parallel with a positive control and a DNA-free control. Competent cells were 
thawed on ice before being gently mixed with the appropriate volume of plasmid 
DNA in a prechilled 14ml BD Falcon polypropylene round-bottom tube (BD 
Biosciences, Oxford, U.K.), as recommended by the QuikChange Site-Directed 
Mutagenesis Kit (Section 2.7.2.1). All transformation reactions were incubated 
on ice for 10 minutes before being subjected to heat-shock treatment (42°C for 
45 seconds). The cells were returned to ice for 2 minutes before 950µl of room 
temperature SOC (Super Optimal broth with Catabolite repression) medium was 
added (Invitrogen, Paisley, U.K.). Tubes were then incubated at 37°C whilst 
shaking at 225rpm for 1 hour in an Innova® 44 incubator shaker (New Brunswick 
Scientific, St. Albans, U.K.). 250µl of each transformation reaction was plated 
onto LB (Luria Broth) agar plates with either kanamycin (25mg/ml) or ampicillin 
(100mg/ml) as appropriate and incubated overnight at 37°C. Single colonies 
were picked and added to 10mls of LB supplemented with kanamycin (25mg/ml) 
or ampicillin (100mg/ml) as appropriate and shaken overnight at 225rpm and 
37°C. 
2.7.4 Small Scale DNA Purification 
The QIAprep Spin Miniprep kit (QIAGEN, Crawley, U.K.) was used to purify DNA 
after overnight incubation. 2ml of the incubated solution was transferred to a 
2ml Eppendorf tube and cells pelleted by centrifugation at 6000g for 10 minutes. 
Instructions provided with the kit (December 2006) were followed. Briefly, cells 
were resuspended and lysed in 250µl of Buffer P1 (50mM 2-amino-2-
hydroxymethyl-1,3-propanediol, pH 8.0; 10mM EDTA, 10µg/ml RNase A) followed 
by the addition of 250µl Buffer P2 (200mM NaOH; 1% sodium dodecyl sulphate) 
and mixed by inversion. 350µl of Buffer N3 (3M potassium acetate pH5.5) was 
added to neutralise the reaction and, again, mixed by inversion. Samples were 
then centrifuged at 13,000g for 10 minutes and the resulting supernatants 
transferred to a QIAprep spin column. Columns were centrifuged at 13,000g for 1 
minute to bind the DNA onto the silica membrane. The column was then washed 
twice, first with 500µl of Buffer PB, and secondly with 750µl of Buffer PE, with 
brief centrifugation and discarding of the eluate each time. The spin column was 
then subjected to a final spin at maximum speed for 1 minute to remove residual 
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wash buffer. The column was then placed in a fresh 1.5ml Eppendorf tube and 
the DNA eluted by adding 50µl of nuclease-free water to the spin column. This 
was allowed to stand for 1 minute prior to being centrifuged at 13,000g for 1 
minute. Plasmid DNA was then quantified as described in Section 2.2.2 and 
sequenced to confirm the identity of the product (Sections 2.2.6 – 2.2.8). 
Primers used for each construct at this stage can be found in Appendix 1. Cycling 
conditions of BIGSEQ60 were utilised for all reactions (Section 2.2.6).  
2.7.5 Large Scale DNA Purification 
Large scale plasmid preparations were obtained using the QIAGEN® Plasmid 
Purification Kit (Maxi) (QIAGEN, Crawley, U.K.). 5ml of starter culture (Section 
2.7.3) was added to 500ml of LB (Luria Broth), supplemented with kanamycin 
(25mg/ml) or ampicillin (100mg/ml) as appropriate, and shaken overnight at 
225rpm and 37°C. 
The manufacturer’s protocol provided with the kit (November 2005 version) was 
adapted to the following method: cells were pelleted by centrifugation at 6000g 
for 15 minutes at 4°C and then resuspended in 10ml of Buffer P1. Cells were 
then lysed with 10ml of Buffer P2 and mixed by inversion. 10ml of chilled Buffer 
P3 was then added and mixed by vigorous inversion before being incubated on 
ice for 20 minutes. The solution was then centrifuged at 20,000g for 30 minutes 
at 4°C and the supernatant applied to a QIAGEN-tip 500, which had been 
equilibrated with 10ml of Buffer QBT. The sample was allowed to enter the resin 
by gravity flow. The QIAGEN-tip was washed twice with 15ml of Buffer QC before 
the DNA was eluted with 15ml of Buffer QF, and precipitated with 0.7 volumes of 
room temperature isopropanol. DNA was pelleted by centrifugation at 15,000g 
for 30 minutes at 4°C. The DNA pellet was resuspended in 5ml of 70% ethanol 
and centrifuged at 15,000g for 10 minutes in 1.5ml Eppendorf tubes. The 
supernatant was discarded and the pellets air-dried for 10 minutes before being 
redissolved in 50µl of nuclease-free water. Contents of each Eppendorf tube 
were combined and the DNA quantified (Section 2.2.2) and stored at -20°C. The 
identity of all products was confirmed by both restriction endonuclease digestion 
and sequencing (Section 2.7.6). 
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2.7.6 Verification of Plasmids 
Following large scale DNA purification (Section 2.7.5) all plasmids were 
subjected to restriction endonuclease digestion to confirm their molecular size 
and circularisation. Sequencing confirmed the presence of the insert in its 
correct orientation. 
2.7.6.1 Restriction Endonuclease Digestion 
Restriction digests were performed using the following enzymes (Promega, 
Wisconcin, U.S.A): 
Enzyme Buffer Target Backbone 
Sma I J pGL3 
EcoRI H pGL3 
Bgl I D pGL3 
Bgl II D pEZX 
Pst I H pEZX 
  
The following components were assembled in an Eppendorf tube in order: 
Component Volume per reaction (µl) 
Restriction enzyme 10x buffer 2.0 
Acetylated BSA (10μg/μl) 0.2 
Plasmid DNA (0.5 - 1µg) variable 
Restriction enzyme (10u/μl) 0.5 
Nuclease-free water Up to final volume of 20 µl 
 
The mixture was then incubated at 37°C for 2 hours. Restriction digests were 
visualised by agarose gel electrophoresis as described in Section 2.2.4. 
2.7.6.2 Plasmid Sequencing 
Sequencing of all constructs was conducted using the methods described in 
Section 2.2.6 to Section 2.2.8. Promoter constructs were sequenced using 
several primers to span the entire insert; other primers annealed to the pGL3 
Basic backbone, details of which can be found in Appendix 1. The pEZX-17 and 
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pEZX-Con plasmids were sequenced across the insert using primers which lay in 
the flanking regions of the insert, thus confirming some backbone sequence and 
the 3’UTR sequence. Again, primers can be found in Appendix 1. Cycling 
conditions of BIGSEQ60 were utilised for all reactions (Section 2.2.6). 
2.8 Transient Cell Line Transfection 
H295R cells and HeLa cells were grown as described in Section 2.3.2. For 
transfection, H295R cells were subcultured onto 6-well or 24-well cell culture 
plates at a density of 5x105 cells/well or 2x105 cells/well respectively (Section 
2.3.3). HeLa cells were subcultured at a density of 8x104 cells/well into 24-well 
cell culture plates. 
2.8.1 5’ Regulatory Region Reporter Construct Transfection 
H295R cells were transfected in 24-well cell culture plates with original (Section 
2.7.2) or mutated plasmids (Section 2.7.2.1) using siPORT™ NeoFX™ Transfection 
Agent (Applied Biosystems, Warrington, U.K.). The manufacturer’s protocol was 
followed and utilised the reverse transfection method. A solution containing 
1.5µl of transfection agent combined with 48.5µl Opti-MEM® reduced serum 
medium (Invitrogen, Paisley, U.K.) was allowed to equilibrate for 10 minutes. 
Achieving a 50:1 ratio, 1000ng of the plasmid of interest was combined with 
20ng of pGL4.73 and made up to a total volume of 50µl with Opti-MEM®. The 
transfection agent/Opti-MEM® solution was added to the DNA/Opti-MEM® solution 
creating a final volume of 100µl and again was allowed to equilibrate for 10 
minutes. This volume was then dispensed into each well before adding 400µl of 
cell solution. The plate was rocked to ensure even coverage. 
Positive controls reactions utilised 500ng of pGL4.13 and pGL4.73, both 
described in Section 2.7.2. Negative controls included pGL3-Basic plus pGL4.73 
(50:1 ratio) as well as cells with no DNA transfected. Reactions were performed 
in quadruplicate. 
The cell culture plates were incubated at 37°C and, after 24 hours, the 
transfectant was removed and replaced with serum-free medium or medium 
containing dibutyryl cAMP (1mM). Cells were again incubated for 24 hours before 
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being rinsed with PBS and lysed with 1x Passive Lysis Buffer (1xPLB). 25µl of each 
sample was assessed in duplicate using the Dual Reporter Luciferase Assay, as 
described in Section 2.9 
2.8.2 3’UTR Reporter Construct Transfection 
2.8.2.1 Preparation of Small Molecules 
To test the effects of specific miRNAs on CYP17A1 in vitro, various small 
molecules were utilised. In order to artificially increase or decrease the levels of 
specific miRNAs, mimics (Pre-miR™) or inhibitors (Anti-miR™) were purchased 
(Applied Biosystems, Warrington, U.K.). Scrambled control molecules were also 
purchased. Details of these molecules can be found in Table 2-3. Each lyophilised 
Pre-miR™ or Anti-miR™ was reconstituted to a stock concentration of 6.25µmoles 
and stored at -20°C. 
Table 2-3 Pre-miR™ and Anti-miR™ molecules. 
miRNA Pre-miR™ Product Code Anti-miR™ Product Code 
Negative Control #1 AM17110 AM17010 
hsa-miR-320a PM11621 PM11621 
hsa-miR-34c-3p PM12342 AM12342 
 
A siRNA targeting the CYP17A1 3’UTR was designed to provide a positive control 
and confirm knockdown of firefly luciferase expression (Table 2.4). The 
lyophilised siRNA molecules were reconstituted to a final concentration of 10µM 
and stored at -20°C. 
Table 2-4 siRNA targeted to CYP17A1 3’UTR. 
siRNA Name Sequence 
17_3UTR_si UGC CAG UGA UGU GCA UAA A 
 
2.8.2.2 3’UTR Reporter Construct Co-transfection 
The pEZX-17 reporter construct (Section 2.7.1) was co-transfected with either 
Pre-miR™ or Anti-miR™ molecules, described in Section 2.8.2.1, into HeLa cells. 
For use in 24-well cell culture plates, 1.5µl of siPORT™ NeoFX™ Transfection 
Agent and 48.5µl of Opti-MEM® reduced serum medium were mixed and allowed 
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to equilibrate for 10 minutes. The pEZX-17 construct (100ng) was mixed with 4µl 
of Pre-miR™ or Anti-miR™, as appropriate (final concentration 50nM) and made 
up to a final volume of 50µl with Opti-MEM®. The transfection agent/Opti-MEM® 
solution was added to the DNA/small molecule/Opti-MEM® solution creating a 
final volume of 100µl and again was allowed to equilibrate for 10 minutes. This 
volume was then dispensed into each well before adding 400µl of cell solution. 
The plate was then rocked to ensure even coverage. 
Positive controls included 500ng of pGL4.13 and pGL4.73, both described in 
Section 2.7.2, which confirmed the specificity of the luminometer (Section 2.9). 
Co-transfection with pEZX-17 and the specific siRNA molecule (Section 2.8.2.1) 
was also performed. Negative controls included pEZX empty vector (pEZX-Con) 
as well as cells with no DNA transfected. Reactions were performed in 
quadruplicate.  
The cell culture plates were incubated at 37°C and, after 24 hours, the 
transfectant was removed and replaced with complete growth medium. Cells 
were again incubated for 24 hours before being rinsed with PBS and lysed with 
1x Passive Lysis Buffer (1xPLB). 10µl of each sample was assessed in duplicate 
using the Dual Reporter Luciferase Assay described in Section 2.9. 
2.8.2.3 Small Molecule Transient Transfection 
Small molecules (Pre-miR™ or Anti-miR™) were transfected into H295R cells. 
Reactions were performed in triplicate and in 6-well cell culture plates. A similar 
transfection protocol to those described in Section 2.8.1 and Section 2.8.2.2 was 
followed, with the volumes of reagents increased accordingly. For each reaction, 
9µl of siPORT™ NeoFX™ Transfection Agent and 291µl of Opti-MEM® reduced 
serum medium were mixed and allowed to equilibrate for 10 minutes. To achieve 
a final concentration of 50nM, 24µl of Pre-miR™ or Anti-miR™ stock solution was 
mixed with 276µl of Opti-MEM®. Both mixtures were then combined, creating a 
final volume of 600µl per reaction, and allowed to equilibrate for 10 minutes. 
This volume was then dispensed into each well before adding 2.4ml of cell 
solution. The plate was rocked to ensure even coverage. The cell culture plates 
were incubated at 37°C and, after 24 hours, the transfectant was removed and 
replaced with 3ml serum-free medium or medium containing dibutyryl cAMP 
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(1mM). Cells were again incubated for 24 hours before being rinsed with PBS and 
lysed with 700µl of QIAzol lysis reagent in preparation for RNA extraction 
(Section 2.4). 
2.9 Dual Reporter Luciferase Assay 
The Dual Luciferase Reporter Assay (Promega, Wisconsin, U.S.A.) was used to 
measure Renilla and Firefly luciferase activity in cells, and performed on a 
Lumat LB 9507 tube luminometer (Berthold Technologies, Herts, U.K.). Injection 
lines were rinsed with distilled water and 70% ethanol before and after use. 
Reagents were thawed at room temperature then prepared by reconstituting the 
lyophilised luciferase assay substrate in 10ml of luciferase assay buffer II (LAR 
II), and by adding 200µl of Stop & Glo substrate to 10ml of Stop & Glo Buffer. 
The tubing of the luminometer was primed immediately prior to samples being 
loaded. A suitable volume (detail provided in methods section of the appropriate 
results chapter) was dispensed into the bottom of a 5ml round-bottomed 
polypropylene tube (75 x 12mm) (Sarstedt, Leicester, U.K.). The luminometer 
was programmed to inject 50µl of LAR II into the tube (firefly measurement) 
followed by 50µl of Stop & Glo reagent (renilla measurement), with a 2-second 
pre-measurement delay, followed by a 10-second measurement period for each 
reporter assay. Samples were each measured twice by this method. The ratio of 
firefly luciferase activity to renilla luciferase activity, as measured in Relative 
Light Units (RLU), was taken, controlling for transfection efficiency. 
2.10 Statistical Analysis 
Statistical analysis was performed using Microsoft Excel 2007, Minitab v15 and 
Prism 4.0 Graph Pad software. All results are expressed as mean ± SEM (standard 
error of the mean) unless otherwise stated. In vitro experiments were performed 
in at least three technical replicates, on at least three independent occasions. In 
vitro results were analysed by either unpaired Student’s t-test or one-sample t-
test as stated. Analyses of results for multiple groups were performed by one-
way analysis of variance (ANOVA). Associations of genotype with corticosteroid 
intermediate phenotype were assessed by the non-parametric Mann-Whitney U 
test. Confidence intervals of 95% were used, with a p-value of <0.05 being 
considered significant. 
103 
 
 
 
 
 
 
3 Characterisation of Genetic Variation at the 
Human CYP17A1 Locus 
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3.1 Introduction 
Variants within the CYP17A1 gene have been studied for association with various 
disorders including PCOS, cancer and premature male baldness (Section 1.3.3.2). 
However, these studies have failed to define any molecular mechanism linking 
such variants to the development of these disorders. In 2009, two genome-wide 
association studies (GWAS) investigating hypertension were published linking 
variants in CYP17A1 to increased systolic blood pressure (Section 1.1.3.2).  One 
variant was located in intron 3 of the gene and the other 250,000 bp upstream of 
the CYP17A1 locus. These GWAS reported both polymorphisms to be in LD with 
each other and therefore, it could be hypothesised that these SNPs are also in LD 
with other as yet unidentified functional polymorphisms. Mutations in CYP17A1 
are already known to cause a rare form of congenital adrenal hyperplasia 
(Section 1.3.3.1) where patients develop hypertension due to excess 
mineralocorticoid. The hypothesis tested in this thesis proposes that more 
common variations within this gene cause subtle increases in blood pressure. 
Such investigations require detailed knowledge of variations across this locus. 
There are publically available repositories where genotyping information can be 
accessed e.g. Hapmap (Gibbs et al., 2003) (http///hapmap.ncbi.nlm.nih.gov/) 
and the 1000 Genomes Project (Via et al., 2010) 
(http///www.1000genomes.org).  At the time the work presented in this chapter 
was conducted, the patterns of LD at the CYP17A1 locus were not described by 
Hapmap in sufficient detail, and genotyping data from just four individuals was 
available from the 1000 Genomes Project. Therefore, in order to investigate the 
patterns of LD at this locus present in a Caucasian population, a detailed 
examination of CYP17A1 was conducted. 
3.2 Aims 
The aim of this study was to analyse genetic variation across the CYP17A1 locus, 
determining haplotype structure and identifying any patterns of LD that may be 
present. The most interesting and informative regions could then be assessed in 
a hypertensive population. 
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3.3 Methods 
3.3.1 Subjects 
3.3.1.1 SNP Discovery Phase 
Normal volunteers living in the West of Scotland had previously been recruited to 
participate in the Adrenal Function Study conducted by Dr. Frances McManus at 
the University of Glasgow. Full details of recruitment and study protocol are 
described by Dr. McManus (2012). Participants were aged 18-70 at the time of 
recruitment, in good health and were not on any antihypertensive medication. 
Genomic DNA was available from 60 participants (27 males, 33 females), 
extracted as described in Section 2.2.1.1. Demographic characteristics are 
displayed below. 
Demographic Characteristics N=60 (median & IQ range) 
Age (years) 51 (32-67) 
Weight (kg) 70 (61-76) 
SBP (mmHg) 126 (116-136) 
DBP (mmHg) 77 (70-84) 
 
3.3.1.2 Hypertensive Population 
A subset of the MRC BRitish Genetics of HyperTension (BRIGHT) cohort was 
selected for a detailed examination of variation within the promoter region of 
the CYP17A1 gene (see Section 2.2.1.2). Corticosteroid and androgen profiles 
were available for 511 unrelated individuals but DNA for only 232 participants 
could be obtained for this study. Demographic characteristics of this cohort are 
displayed in Table 4-2.  
3.3.2 Sequencing 
The entire CYP17A1 locus was sequenced directly in each AFS subject. This 
encompassed a region approximately 2.4 kb upstream of the transcription start 
site and included all exons, introns and the 3’UTR. Sections of the locus were 
first amplified by PCR and verified by gel electrophoresis before sequencing. Full 
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details of the PCR and sequencing reactions are provided in Section 2.2 and 
Appendix 1. 
3.3.3 Statistical Analysis 
Sequencing results were visualised using SeqScape v. 2.1.1 software. Data were 
collated on a Microsoft Excel spreadsheet before export to Haploview v. 4.2 
(Section 2.2.9). This software was used to analyse genotype frequencies, 
calculate genotype distribution using the Hardy Weinberg equilibrium, and to 
assess LD at the locus, as well as interpreting haplotype structure.  
3.4 Results 
The variation at CYP17A1 was first examined by direct sequencing of the locus in 
a cohort of normotensive participants from the Adrenal Function Study (AFS). 
This stage was named the SNP Discovery Phase. After identification of potential 
functional polymorphisms, these were then analysed in a hypertensive 
population. The results from each stage are presented below. 
3.4.1 SNP Discovery Phase 
3.4.1.1 PCR of CYP17A1 
The CYP17A1 gene was amplified in several sections prior to sequencing. Each 
PCR was initially optimised by analysing a gradient of annealing temperatures, as 
outlined in Section 2.2.3. In the first instance, approximately 2.4kb of promoter 
region was amplified and verified by gel electrophoresis (Figure 3-1). Thereafter, 
numerous PCRs were performed using primer pairs (described in Appendix 1) 
designed to amplify individual exons, introns and the 3’UTR. Successful PCR was 
verified by fragment size on gel electrophoresis. 
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Figure 3-1 PCR fragments from 6 different AFS samples. 
25ng of DNA was amplified by PCR then resolved on a 1% agarose gel. Promega 1 kb ladder was 
used for size determination (L).  Lanes 1-6 show a single band 2.4kb in size for AFS samples 1-6, 
respectively. Lane 7 contains a negative control reaction, with no visible band indicating no sample 
contamination. 
 
3.4.1.2 Polymorphism Identification 
Sequence reads for each participant were collated using the SeqScape software 
enabling the entire locus to be scanned for polymorphisms. The reads were then 
aligned to the reference sequence, provided in Appendix 2. An example of 
electropherograms of the sequencing around the polymorphism at position -34 of 
the promoter region is shown in Figure 3-2. 
A total of 36 polymorphisms were identified across the CYP17A1 locus. The 
characteristics of each are described in Table 3-1. 35 were single base changes, 
while rs139275291 consists of a 35 bp region within intron seven which is present 
in the major allele but deleted from the minor allele (+/-
CCATAATAAGGCTACATCCTCAGATCAGGGTTCCC). A schematic diagram of the 
variants’ locations is provided in Figure 3-3. 14 variants were identified in the 
5’UTR and 2.4kb upstream promoter region. 3 synonymous SNPs were located in 
exon 1, meaning that variants did not change the resulting amino acid 
(rs61754263: Arg21Arg; rs6162: His46His; rs6163: Ser65Ser). No variation was 
discovered in the other seven exons. The remaining 19 SNPs were spread across 
the intronic regions. No variation was found in the 3’UTR.  
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None of the variants departed significantly from Hardy-Weinberg equilibrium 
(p<0.001) and were therefore eligible to be included in further analysis. The 
Hardy-Weinberg equilibrium is a principle which states that allele and genotype 
frequencies will remain constant through generations in the absence of other 
evolutionary influencing factors. These factors may include non-random mating, 
mutations and genetic drift. Genetic drift can arise through changes to allele 
frequencies when studying small populations, although this was not evident in 
the AFS cohort.  
 
 
 
Figure 3-2 Sequence analysis of the human CYP17A1 gene. 
An example of the electropherogram reads from three different samples of the AFS cohort, one 
from each genotype group. This example shows the T/C SNP at position -34 in the CYP17A1 
promoter (rs743572). 
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Table 3-1 Characteristics of polymorphisms identified by sequencing across the human 
CYP17A1 locus in subjects from the Adrenal Function Study population. 
SNP: single nucleotide polymorphism; ID: Haploview identification number; Position: chromosomal 
location from ENSEMBL Homo sapiens version 72.37 (GRCh37); MAF: minor allele frequency; 
HWE: Hardy-Weinberg equilibrium p-value; % Geno: % of samples successfully genotyped.  
SNP ID Location Position Alleles MAF HWE (p) %  Geno 
rs2150927 36 -2205 10:104599323 C/T 0.306 0.0973 100 
rs117574307 35 -1933 10:104599051 C/T 0.032 1.0000 100 
rs138009835 34 -1877 10:104598995 C/T 0.089 1.0000 100 
rs183906459 33 -1722 10:104598840 T/A 0.008 1.0000 100 
rs10786714 32 -1488 10:104598606 C/G 0.210 0.1584 100 
-1366 31 -1366 10:104598484 C/T 0.008 1.0000 100 
rs10786713 30 -1204 10:104598322 T/C 0.306 0.2835 100 
-1077 29 -1077 10:104598195 C/T 0.008 1.0000 100 
rs10883784 28 -804 10:104597922 G/A 0.210 0.1584 100 
rs190440742 27 -734 10:104597852 G/A 0.016 1.0000 100 
-638 26 -638 10:104597756 C/T 0.016 0.0163 100 
rs61752856 25 -626 10:104597744 C/T 0.016 1.0000 100 
rs2486758 24 -362 10:104597480 A/G 0.242 0.9939 100 
rs743572 23 -34 10:104597152 T/C 0.282 0.0973 100 
rs61754263 22 Exon 1 10:104597057 G/A 0.008 1.0000 100 
rs6162 21 Exon 1 10:104596981 C/T 0.315 0.1449 100 
rs6163 20 Exon 1 10:104596924 G/T 0.306 0.0249 100 
rs10786712 19 Intron 1 10:104596396 G/A 0.293 0.0232 93.5 
rs45463800 18 Intron 1 10:104596356 G/A 0.017 1.0000 95.2 
INT1+811 17 Intron 1 10:104596011 G/A 0.008 1.0000 95.2 
rs3824755 16 Intron 1 10:104595849 C/G 0.052 1.0000 93.5 
rs284847 15 Intron 1 10:104595828 C/T 0.068 0.4480 95.2 
rs3781286 14 Intron 1 10:104595719 G/A 0.302 0.0396 93.5 
rs3781287 13 Intron 1 10:104595420 A/C 0.322 0.1374 95.2 
rs4919687 12 Intron 1 10:104595240 C/T 0.241 0.0247 93.5 
rs743575 11 Intron 2 10:104594906 A/C 0.208 0.4270 96.8 
rs1004467 10 Intron 3 10:104594507 T/C 0.083 1.0000 96.8 
INT4 +599 9 Intron 4 10:104593194 G/A 0.008 1.0000 95.2 
rs3740397 8 Intron 5 10:104592675 C/G 0.292 0.1196 96.8 
rs4919686 7 Intron 6 10:104592249 T/G 0.220 0.0448 95.2 
rs284848 6 Intron 6 10:104592125 C/T 0.212 1.0000 95.2 
rs45609333 5 Intron 6 10:104591639 C/T 0.025 1.0000 95.2 
rs17115100 4 Intron 6 10:104591393 C/A 0.085 1.0000 95.2 
rs284849 3 Intron 7 10:104591182 C/A 0.234 0.3853 100 
rs10883783 2 Intron 7 10:104591152 A/T 0.218 0.2194 100 
rs139275291 1 Intron 7 10:104590871 +/-35bp 0.218 0.2194 100 
 
 
 
 
Figure 3-3 Positions of the 36 variations identified across the human CYP17A1 locus. 
Red arrows indicate positions of polymorphisms identified through direct sequencing of 62 individuals from the Adrenal Function Study. 
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3.4.1.3 Linkage Disequilibrium 
The most informative regions across the CYP17A1 locus were identified by 
generating LD plots. The simplest measure of LD is D, first proposed by Lewontin 
and Kojima (1960), D quantifies disequilibrium as the difference between the 
observed frequency of a haplotype and the expected frequency if the alleles 
were segregating at random. However, it is not a particularly useful measure of 
the strength or comparative levels of LD. The two more commonly used metrics 
for such measurements are D’ and r2. D’=1 (100%) denotes complete LD, whereby 
the SNPs in question are not separated by recombination. r2=1 denotes perfect 
LD whereby, in addition to the absence of a recombination event between the 
two markers, the alleles of each SNP also have the same frequencies. The 
complex equations to generate both D’ and r2 values have been previously 
explained by Mueller (2004).  
Sequencing data were converted to the appropriate file format for analysis by 
Haploview v4.2 software. In the first instance, an LD plot was generated with all 
sequencing data (Figure 3-4). Regions in red are indicative of a D’ value close to 
or equal to 1, denoting a strong association between the SNPs, scaling down to 
white, which represents a D’ close or equal to 0 i.e. little or no association 
between SNPs. Lilac squares indicate insufficient data to interpret the LD 
between two markers. The plot in Figure 3-4 has a considerable percentage of 
lilac colour and, since the hypothesis of this thesis was to assess the association 
of common genetic variation with hypertension, the SNPs with a MAF of <0.05 
(5%) were removed and the corresponding LD plot examined (Figure 3-5). This 
figure shows association between many of the common polymorphisms. 
 
 
 
 
Figure 3-4 Linkage disequilibrium plot of all polymorphisms identified in the human CYP17A1 gene. 
The LD plot of all 36 variants found across the human CYP17A1 gene in the Adrenal Function Study cohort. The LD plot displays D’ values (%) for each pair of SNPs 
in the box at the intersection of the diagonals from each SNP. 
 
 
 
 
Figure 3-5 Linkage disequilibrium plot of polymorphisms with minor allele frequency >0.05 identified in the human CYP17A1 gene. 
The LD plot of the variants found across the human CYP17A1 gene in the Adrenal Function Study cohort with MAF >0.05. The LD plot displays D’ values (%) for each 
pair of SNPs in the box at the intersection of the diagonals from each SNP. 
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Once the assessment of association across the entire CYP17A1 locus was 
complete, a detailed examination of the SNPs present in the promoter region 
was undertaken. Since variations found within exons and introns were not 
predicted to alter amino acids and resulting protein structure, regulatory control 
of gene expression was the focus of further inspection. The LD plot for all 
variations found in the 2.4kb of the promoter region generated with the D’ 
method is displayed in Figure 3-6. A similar plot containing r2 values is shown in 
Figure 3-7. Similar to the LD plots generated with D’ values, colour intensity 
denotes the strength of association in the r2 LD plots. It can be seen from both 
measurements that approximately half of the variation found in this region is 
uninformative. Therefore the polymorphisms with MAF <0.05 were removed and 
D’ (Figure 3-8) and r2 (Figure 3-9) values reassessed. Examination of these plots 
reveals an association between six of the seven polymorphisms. Data for the 
unassociated rs138009835 was therefore removed and the LD plots in Figure 3-10 
and Figure 3-11 generated. Figure 3-10 shows D’ values and, as the region is 
entirely red in colour, it can be concluded that high LD exists across these 
polymorphisms. The plot displaying r2 values also shows association between 
these SNPs although the LD is weaker, particularly for rs2486758. This was 
expected as the measurement of r2 is a more stringent test than D’ as it also 
assesses allele frequencies.  
Around the same time that the work in this chapter was undertaken, a research 
article was published which analysed the association between SNPs at this region 
of chromosome 10 (Gomez-Rubio et al., 2010). This paper reported three 
intronic SNPs in CYP17A1 (rs3824755, rs1004467, rs17115100) to be part of a 
larger cluster of SNPs in LD across this region. Closer inspection of the LD plots 
generated from the AFS cohort found the same three SNPs to be in high LD with 
a variant at position -1877 upstream from the transcription start site. This SNP 
has since been officially designated as rs138009835. D’ and r2 value plots of 
these four polymorphisms are displayed in Figure 3-12 and Figure 3-13, 
respectively. Interestingly, rs138009835 was the SNP removed from analysis in 
Figures 3-10 and 3-11 due to lack of association with the other six SNPs in the 
promoter region with MAF >0.05. This indicates the presence of two unrelated 
blocks of polymorphisms in high LD across this locus. 
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Figure 3-6 Linkage disequilibrium plot of CYP17A1 promoter polymorphisms (D’values). 
LD plot of all 14 variants found across the 2.4 kb of human CYP17A1 promoter region in the 
Adrenal Function Study cohort. The LD plot displays D’ values (%) for each pair of SNPs in the box 
at the intersection of the diagonals from each SNP. 
 
Figure 3-7 Linkage disequilibrium plot of CYP17A1 promoter polymorphisms (r
2
 values). 
LD plot of all 14 variants found across the 2.4 kb of human CYP17A1 promoter region in the 
Adrenal Function study cohort. The LD plot displays r
2
 values (%) for each pair of SNPs in the box 
at the intersection of the diagonals from each SNP. 
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Figure 3-8 Linkage disequilibrium plot of CYP17A1 promoter polymorphisms with MAF >0.05 
(D’ values). 
LD plot of variants with minor allele frequency <0.05 found across the 2.4kb of human CYP17A1 
promoter region in the Adrenal Function Study cohort. The LD plot displays D’ values (%) for each 
pair of SNPs in the box at the intersection of the diagonals from each SNP. 
 
Figure 3-9 Linkage disequilibrium plot of CYP17A1 promoter polymorphisms with MAF >0.05 
(r
2
 values). 
LD plot of variants with minor allele frequency <0.05 found across the 2.4kb of human CYP17A1 
promoter region in the Adrenal Function Study cohort. The LD plot displays r
2
 values (%) for each 
pair of SNPs in the box at the intersection of the diagonals from each SNP. 
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Figure 3-10 Linkage disequilibrium plot of six CYP17A1 promoter polymorphisms (D’ 
values). 
LD plot of six variants in high LD found across the 2.4kb of human CYP17A1 promoter region in the 
Adrenal Function Study cohort. The LD plot displays D’ values (%) for each pair of SNPs in the box 
at the intersection of the diagonals from each SNP. 
 
 
Figure 3-11 Linkage disequilibrium plot of six CYP17A1 promoter polymorphisms (r
2
 
values). 
LD plot of six variants in high LD found across the 2.4kb of human CYP17A1 promoter region in the 
Adrenal Function Study cohort. The LD plot displays r
2
 values (%) for each pair of SNPs in the box 
at the intersection of the diagonals from each SNP. 
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Figure 3-12 Linkage disequilibrium plot of four variants found across the CYP17A1 locus (D’ 
values). 
LD plot of four variants found across the human CYP17A1 locus in high LD in the Adrenal Function 
Study cohort. The LD plot displays D’ values (%) for each pair of SNPs in the box at the 
intersection of the diagonals from each SNP. 
 
 
Figure 3-13 Linkage disequilibrium plot of four variants found across the CYP17A1 locus (r
2 
values). 
LD plot of four variants found across the human CYP17A1 locus in the Adrenal Function Study 
cohort. The LD plot displays r
2
 values (%) for each pair of SNPs in the box at the intersection of the 
diagonals from each SNP. 
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3.4.1.4 Haplotype Analysis 
As there is significant LD across the CYP17A1 locus, it is possible to generate 
haplotypes, i.e. a combination of alleles that are inherited together. Section 
3.4.1.3 identified two interesting unrelated blocks of SNPs in LD across the 
locus, the first encompassing six polymorphisms located within a 2.4kb region 
immediately upstream of the transcription start site (LD Block 1), and the 
second with four variants, one in the promoter and three located intronically (LD 
Block 2). Haploview v4.2 software generates haplotypes on the basis of inputed 
genotype data. 
The six haplotypes generated from LD Block 1 polymorphisms (Figure 3-14) cover 
97.7% of the normotensive AFS population. Haplotypes 1-4 can be considered 
common (i.e. >5%). Haplotype 1 (44.4%) and Haplotype 2 (22.6%) are the most 
frequent and therefore it is not surprising that they mostly include the major 
form of each SNP. In fact, each haplotype varies only by the allele at position 
-362 (rs2486758) which had lower r2 values than the other five polymorphisms 
when LD was assessed (Figure 3-11). Haplotype 3 contains mostly minor allele 
forms and is present in 20.2% of individuals. Haplotype 4 consists of a 
combination of major and minor alleles and is present in 7.3% of the AFS 
population. 
The three haplotypes generated from LD Block 2 polymorphisms (Figure 3-15) 
cover 99.1% of the normotensive AFS population. The most common haplotype is 
present in 90.8% of individuals, with the major allele present at each SNP. 5% of 
individuals have the minor allele at each SNP, and only 3.3% have a combination 
of major and minor alleles.  
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Figure 3-14 Schematic representation of haplotypes generated from LD Block 1 
polymorphisms. 
Frequencies of each haplotype within the Adrenal Function Study cohort are indicated on the right. 
Major alleles are depicted in red and minor alleles in green. 
 
 
Figure 3-15 Schematic representation of haplotypes generated from LD Block 2 
polymorphisms. 
Frequencies of each haplotype within the Adrenal Function Study cohort are indicated on the right. 
Major alleles are depicted in red and minor alleles in green. 
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3.4.2 Hypertensive Population 
The SNP Discovery Phase identified common polymorphisms in a small cohort of 
normotensive Caucasians. An interesting variant was detected -1877 bases 
upstream of the transcription start site (rs138009835), which is in high LD with 
variants implicated in recent GWAS  (Levy et al., 2009; Newton-Cheh et al., 
2009). Furthermore, an additional unrelated block of SNPs in high LD was also 
found in the promoter region. Variation in the promoter has the potential to 
affect transcriptional regulation of the CYP17A1 gene through altered 
transcription factor binding. Therefore this region was selected for inspection 
within a larger cohort of 232 unrelated hypertensive individuals drawn from the 
BRIGHT cohort for whom both DNA and steroid profiles were available. 
3.4.2.1 Promoter Region Variation in the CYP17A1 Gene 
2.4kb of CYP17A1 promoter region was amplified by PCR (with fragment size 
verified by gel electrophoresis) using identical methods to those in the SNP 
Discovery Phase. Subsequent sequencing enabled genotyping each SNP of 
interest. Characteristics of this genotyping are provided in Table 3-2. Although 
the DNA was extracted approximately ten years prior to this analysis, the 
percentage of successful genotyping at each SNP was consistently high. 
Furthermore, none of the variants departed significantly from Hardy-Weinberg 
equilibrium (p<0.001) and were therefore eligible to be included in further 
analysis. 
Table 3-2 Characteristics of polymorphisms genotyped across the human CYP17A1 locus in 
a subset of the BRIGHT cohort. 
SNP: single nucleotide polymorphism; ID: Haploview identification number; Position: chromosomal 
location from ENSEMBL Homo sapiens version 72.37 (GRCh37); MAF: minor allele frequency; 
HWE: Hardy-Weinberg equilibrium p-value; % Geno: % of samples successfully genotyped.  
SNP ID Location Position Alleles MAF HWE (p) %  Geno 
rs2150927 7 -2205 10:104599323 C/T 0.413 0.9276 99.1 
rs138009835 6 -1877 10:104598995 C/T 0.109 0.9940 100 
rs10786714 5 -1488 10:104598606 C/G 0.304 0.7485 99.6 
rs10786713 4 -1204 10:104598322 T/C 0.417 0.9121 99.6 
rs10883784 3 -804 10:104597922 G/A 0.304 0.6991 100 
rs2486758 2 -362 10:104597480 A/G 0.183 1.0000 96.9 
rs743572 1 -34 10:104597152 T/C 0.420 0.8284 96.9 
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3.4.2.2 Linkage Disequilibrium and Haplotype Analysis 
Following sequencing, genotype data from all 232 hypertensive individuals were 
collated and a LD plot of D’ values generated (Figure 3-16). The red squares 
indicate a D’ value close or equal to 1 meaning that the seven common SNPs 
identified in the AFS cohort show a strong association in this hypertensive 
population. The lilac square signifies a lack of sufficient information to 
determine the association between the SNPs at positions -362 and -1877, 
probably due to the low minor allele frequency of the -1877 variant. 
An LD plot of r2 values was also generated and is displayed in Figure 3-17. Similar 
to the plots produced from sequencing of the AFS cohort, the r2 values here 
typically show weaker association between the SNPs. Most of the SNPs here 
exhibit fairly high LD although those at -362 and -1877 exhibit weak association 
with the other polymorphisms.  
These data were used to derive haplotypes. Since the D’ values indicated 
association between the -1877 SNP and the other polymorphisms, which was not 
the case in the AFS cohort, it was not removed from this analysis. Four possible 
haplotypes were found to be present, accounting for 99.5% of this hypertensive 
population (Figure 3-18). Haplotype 1 contains the major alleles at each site and 
is present in 39.7% of this population. Haplotypes 2, 3 and 4 contain a 
combination of major and minor alleles and are present in 18.5%, 30.4% and 
10.9% of the population, respectively. 
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Figure 3-16 Linkage disequilibrium plot of common promoter polymorphisms genotyped in 
a subset of the BRIGHT cohort (D’ values). 
LD plot of variants genotyped within 2.4kb of the human CYP17A1 promoter region in a subset of 
the BRIGHT cohort. The LD plot displays D’ values (%) for each pair of SNPs in the box at the 
intersection of the diagonals from each SNP. 
 
Figure 3-17 Linkage disequilibrium plot of common promoter polymorphisms genotyped in 
a subset of the BRIGHT cohort (r
2
 values). 
LD plot of variants genotyped within 2.4kb of the human CYP17A1 promoter region in a subset of 
the BRIGHT cohort. The LD plot displays r
2
 values (%) for each pair of SNPs in the box at the 
intersection of the diagonals from each SNP. 
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Figure 3-18 Schematic representation of haplotypes present in 2.4kb of the CYP17A1 
promoter region in a subset of the BRIGHT cohort. 
Frequencies of each haplotype within the subset of the BRIGHT cohort are indicated on the right. 
The major allele are depicted in red, minor alleles in green. 
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3.5 Discussion 
This study has provided a detailed examination of sequence variation across the 
CYP17A1 locus. The SNP discovery phase was conducted in a group of 62 
unrelated normotensive individuals who had previously participated in the 
Adrenal Function Study. The size of this cohort was judged sufficient for the 
detection of common variants, as previous studies with sample sizes of 23 and 24 
had provided >99% chance of detecting SNPs with a frequency of 5% and >87% 
chance for SNPs of 1% frequency (Crawford et al., 2004). 
AFS DNA quality was good and enabled successful call rates of >93% for each SNP 
across the locus. Three synonymous SNPs were reported in exon 1, therefore 
resulting in no change to the corresponding amino acids. Several further 
polymorphisms were located within introns. These could potentially alter 
splicing of the CYP17A1 transcript and affect protein structure. Although none 
were located directly within splice sites at the exon/intron junctions, they may 
disrupt the intronic branch site, which facilitates intronic splicing (Madhani and 
Guthrie 1994). It would be possible to examine the functional effects on splicing 
in vitro using a minigene system, whereby the complete exonic and intronic 
regions are cloned into a vector and transfected into a suitable cell line. Total 
RNA could then be isolated and qRT-PCR performed to compare wild-type and 
mutant constructs. 
No variation was found in the 3’UTR. Polymorphisms in this region may affect 
RNA stability, thus the lack of variation may signify the importance of this region 
in the translation of RNA to protein. Variants in this region may also affect post-
transcriptonal regulation through altered binding of miRNAs. Little is currently 
known about the regulation of CYP17A1 expression by miRNA and is explored in 
Chapter 6. 
A total of 14 polymorphisms were identified in the 2.4kb region immediately 
upstream of the transcription start site. Half of these had a minor allele 
frequency above 5% and were therefore considered to be common genetic 
variant. The SNPs identified in this region were of considerable interest as 
previous research on other steroidogenic genes has shown alteration in 
transcriptional activity to occur in an allele-dependent manner (Section 1.3.3.2). 
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It is entirely possible that any of the 14 SNPs could alter the transcriptional 
regulation of the gene; however, in keeping with the hypothesis of this thesis, 
the 7 common variants were prioritised for further examination. Association 
between the SNPs was assessed though the generation of LD plots. LD is a useful 
concept in the analysis of SNPs and statistical genetics. LD should remain 
relatively stable assuming breeding occurs within those with similar ancestries; 
however LD between alleles may decline over generations due to recombination 
and mutation events. Both D’ and r2 are measurements of LD and both are 
displayed in the LD plots presented above. D’=1 indicates complete linkage 
disequilibrium and is useful for assessing historical recombination at the locus. 
For the data presented here, D’ values were high for the SNPs comprising both 
LD Block 1 and LD Block 2 in the CYP17A1 promoter region, suggesting little 
historical recombination between these loci. In contrast, r2 is a useful concept to 
measure the correlation between alleles i.e. when r2=1, the allele present at 
one SNP will perfectly predict the allele at the other SNP. These values are of 
particular use when selecting ‘tag’ SNPs. A ‘tag’ SNP is a polymorphism selected 
for its ability to represent a particular haplotype depending on the allele 
present. This enables high-throughput and efficient genotyping of a locus on the 
basis of a single SNP and is commonly used in large population studies. Selection 
of a ‘tag’ SNP requires detailed information on LD present at the locus. The r2 
values of associations comparing each SNP to rs2486758 (-362) indicate weak LD 
(Figure 3-11). This contradicts the high D’ values seen in Figure 3-10, and is 
likely to be due to differences in the frequencies of major and minor alleles 
relative to the other SNPs. It therefore may not be the most suitable variant for 
the prediction of alleles present elsewhere in the haplotype.  
The SNP Discovery Phase of this study has identified two distinct blocks of SNPs 
which exhibit high LD. LD Block 1 contains six SNPs located in the promoter 
region and LD Block 2 contains one SNP in the promoter region and three in the 
introns. When the genotypes at all seven promoter SNPs were examined in the 
hypertensive population, D’ values suggested strong association between all the 
variants (Figure 3-16). This was surprising as the polymorphism at position -1877 
(rs138009835) is clearly unrelated to the others in the smaller normotensive 
cohort. It is not appropriate to compare fully the results between the 
normotensive and hypertensive cohorts as this would require a specific case-
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control matched study. However, examination of r2 values suggests very weak 
association between -1877 and the other six SNPs (Figure 3-17). An observation 
from the haplotypes derived from this cohort is that the minor T allele at -1877 
is present only in Haplotype 4, which occurs in 10.9% of this population. Since 
this minor allele is so rare compared to those of the other six SNPs (Table 3-2), it 
is plausible to suggest that the presence of the major C allele in approximately 
90% of subjects is the reason for the high D’ values. Interestingly, a study 
investigating the association of genotype with PCOS reported similar findings. 
Four ‘tag’ SNPs were selected for genotyping in the case-control PCOS cohort, 
which included rs1004467 and rs743572 (Chua et al., 2012). Variant rs1004467 is 
located in intron 3 and is part of LD Block 2 while rs743572 is located at position 
-34 and is in LD Block 1. The authors report D’=1 between these two SNPs, 
although the minor allele frequencies are 0.096 and 0.420 respectively. Again, 
the presence of the major allele at rs1004467 nearly 90% of the time may allow 
it to appear that rs1004467 is in the same LD block as the others. It may be 
useful to genotype the BRIGHT hypertensive cohort for the three intronic LD 
Block 2 SNPs and generate LD plots. In addition, genotyping a suitable case-
control study would enable allele, genotype and haplotype frequencies to be 
compared and perhaps identify a particular risk haplotype for the development 
of hypertension. 
Recent GWAS has identified two SNPs around the CYP17A1 locus in which the 
major allele raises systolic blood pressure (see Section 1.1.3.2). One is located 
within intron 3 of CYP17A1, the other approximately 250 kb upstream, although 
the two are in LD. A follow-up study performed an additional conditional 
regression analysis with both SNPs in the one model and suggested that neither 
variant was likely to be the causal SNP driving the association with hypertension 
(Liu et al., 2011). It is possible that the causal variant lies within any of the six 
genes spanned by this particular LD block, although CYP17A1 is the most obvious 
candidate for blood pressure regulation (Section 1.1.3.2). Therefore, since 
polymorphisms in the promoter region have the potential to alter expression 
through changes in transcriptional properties, this region of CYP17A1 was 
considered the ideal place to search for the causal variant(s). 
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3.6 Conclusions 
This study has examined the genetic variation within the CYP17A1 gene in great 
detail and identified a range of common and less frequent polymorphisms.  
Patterns of linkage disequilibrium were established and common haplotypes 
derived. An interesting polymorphism at position -1877 (rs138009835) has been 
identified which has high D’ and r2 values in relation to rs1004467, a SNP 
implicated in recent hypertension GWAS. It also associates with six other 
promoter SNPs in a hypertensive population. These seven promoter variations 
will be investigated further to establish any phenotypic consequences for each 
allele (Chapter 4), as well as their functional effects in vitro (Chapter 5). 
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4 Investigation of the Phenotypic Consequences 
of CYP17A1 Promoter Region Polymorphisms 
on Corticosteroid Production in a Hypertensive 
Population. 
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4.1 Introduction 
The adrenal cortex synthesises and secretes a number of biologically active 
steroid hormones or corticosteroids that are crucial to the efficient function of 
many of the body’s systems (Section 1.2.1.1). Therefore, the ability to monitor 
the level of adrenocortical activity and to locate precisely any clinically relevant 
malfunction is essential. The corticosteroids are synthesised from cholesterol via 
a small number of pathways, each comprising a series of consecutive enzyme-
catalysed reactions (Figure 1-7). In addition to the end products, a proportion of 
intermediate compounds are also secreted. Changes in the efficiency of any 
constituent enzyme will alter the pattern of secretion, with possible metabolic 
and pathological consequences. The location, size, structure and vascularisation 
of the adrenal gland make direct and specific access to the tissue or to venous 
effluent blood difficult in patients and ethically unacceptable in normal human 
subjects. Detailed direct monitoring of function is therefore rarely possible; 
information on the internal status of the adrenal cortex must be obtained 
‘externally’. There are two principal approaches. Firstly, short term changes in 
the rate of secretion of each compound are reflected in their plasma 
concentration. Secondly, each of these circulating compounds is metabolised, 
principally in the liver, to one or more unique metabolites and excreted as 
conjugates in the urine (Table 1-6). Again, the relative concentrations of these 
urinary metabolites reflect those of their parent compounds within the adrenal 
cortex and can act as surrogate markers of activity. Analysis of an accurate 24-
hour collection provides an average activity over that period and is ideal for 
comparing effects of genetic variation on steroid secretion. In addition to 
measuring the excretion rates of the principal end products, careful scrutiny of 
the overall pattern of metabolites may reveal variations in the efficiency of the 
individual enzyme-catalysed reactions; as efficiency decreases, enzyme kinetics 
dictate that, to maintain optimum conversion, the concentration of precursor 
must increase. Thus, for example, a relatively inefficient 11β-hydroxylase will 
require higher levels of its precursor, 11-deoxycortisol, in order to maintain 
cortisol levels and this will be reflected in the ratio of 11-deoxycortisol to 
cortisol metabolites in the urine. This principle can also be applied to the more 
complex 17α-hydroxylase/lyase enzyme, which catalyses two key 
transformations (Figure 1-8). Thus, altered efficiency will affect not only the 
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relative balance of the 17-hydroxy and 17-deoxy pathways but also the 
relationship between these and adrenal androgen synthesis. A decrease in the 
efficiency of the 17α-hydroxylase/lyase enzyme would be expected to result in 
lower androgen and cortisol levels, with accumulation of the precursors 
pregnenolone and progesterone and an accentuation of the 17-
deoxycorticosteroid pathway producing 11-deoxycorticosterone and 
corticosterone. This has been reported in case studies of CAH due to 17α-
hydroxylase deficiency (Section 1.3.3.1). Alternatively, a more efficient 17α-
hydroxylase/lyase enzyme would be expected to have an inverse effect, tending 
to increase the production of cortisol and androgens but the negative feedback 
loop (Figure 1-6) between ACTH and cortisol ensures maintenance of normal end 
product levels. Nevertheless, the ratios of levels of intermediates to end 
products would still be affected. 
The use of a specific CYP17A1 inhibitor has recently been introduced clinically as 
an effective treatment for men with castration-resistant prostate cancer. The 
consequent effects on the steroidogenic profile of these individuals provides an 
extreme example of what one might expect as a consequence of altered 
transcriptional activity arising from allelic changes in the CYP17A1 promoter. In 
the Phase I clinical trial of the CYP17A1 inhibitor abiraterone acetate, secondary 
mineralocorticoid excess (hypertension, hypokalaemia and fluid retention) was a 
common side effect (Attard et al., 2008). Inhibition of both the 17α-hydroxylase 
and the 17,20 lyase enzymatic functions reduces cortisol and androgen 
production (Figure 4-1). In the absence of cortisol, ACTH drive is increased and 
results in increased levels of 11-deoxycortisosterone and corticosterone, hence 
mineralocorticoid excess. In clinical trials, administration of synthetic 
glucocorticoids (e.g. prednisone or dexamethasone) concurrently with 
abiraterone acetate significantly reduced these side effects (Danila et al., 2010; 
Fizazi et al., 2012). It is therefore reasonable to hypothesise that less severe 
changes to the expression of CYP17A1, possibly as a result of single base changes 
in the promoter region, may result in smaller but similar changes to patterns of 
corticosteroid production.   
132 
 
 
Figure 4-1 Physiological consequences of treatment with a selective CYP17A1 inhibitor e.g. 
abiraterone acetate. 
 
Data from a comprehensive urinary steroid analysis of a subset of 511 unrelated 
hypertensive patients from the BRIGHT cohort presented an ideal opportunity to 
compare differences in CYP17A1 genotype with corticosteroid intermediate 
phenotypes. Chapter 3 describes the genotyping of seven common 
polymorphisms located in the promoter region of CYP17A1. These variants have 
the potential to affect enzymatic function through altered gene transcription. 
Genomic DNA was available for only 232 individuals in this BRIGHT subset. 
4.2 Aims 
This study aimed to examine the influence of genotype on the efficiency of the 
17α-hydroxylase/17,20 lyase enzyme. The association of specific variants in the 
promoter region of CYP17A1 with corticosteroid metabolite excretion rates and 
their inter-relationships in a hypertensive cohort was assessed. 
4.3 Methods 
4.3.1 Study Subjects 
Details of recruitment of subjects for the BRIGHT population have been outlined 
in Section 2.2.1.2. In brief, hypertensive subjects with a mean pre-treatment 
blood pressure of >145/95 mmHg were recruited from primary care. All had 
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onset of hypertension before 60 years of age. Subjects underwent medical 
assessment and details of sex, height, weight and anthropometric measurements 
such as waist-hip ratio (WHR) and body mass index (BMI) were recorded. Those 
with BMI >30 were excluded from the study. Caucasian and British ancestry was 
confirmed for all participants of the BRIGHT study to grand-parental level. 
Ethical approval for the study was granted by the local ethics committees of the 
participating centres and fully informed written consent of the subjects was 
obtained. 
4.3.2 Urinary Corticosteroid Metabolite Measurements 
For the present investigation, urinary corticosteroid metabolite measurements 
were available for a random group of 511 unrelated subjects. Precise details of 
measurement by gas chromatography/mass spectrometry (GC/MS) have been 
described previously (Barr et al., 2007; Freel et al., 2007). Excretion rate data 
were analysed for the 232 members of this BRIGHT subgroup that had been 
successfully genotyped (Chapter 3). 
4.3.3 Data Analysis 
Demographic and steroid excretion data were not normally distributed and were 
therefore analysed by non-parametric methods (Mann-Whitney tests) unless 
otherwise stated. Comparisons of genotype with steroid excretion were 
conducted by adopting the dominant model whereby heterozygotes and minor 
allele homozygotes are grouped and compared with major allele homozygotes. 
Statistical analyses were conducted using Minitab software v15. 
4.4 Results 
Genomic DNA and steroid excretion data were available for a subset of the 
BRIGHT cohort comprising 232 hypertensive individuals. Sequencing of the 
CYP17A1 promoter region was performed on the genomic DNA of these 
individuals and genotypes at the seven common polymorphic locations recorded. 
(These data have been presented in Chapter 3.) Table 4-1 summarises the 
number of individuals of each genotype at each SNP of interest. In order to 
assess the association of genotype with steroid excretion, it would be desirable 
to compare the major homozygote group with the minor homozygote group, but 
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the number of individuals with the minor homozygote genotype at positions 
-1877 and -362 was too low to permit this. Therefore the dominant model 
approach was used. Heterozygotes and minor allele homozygotes were grouped 
together and compared with major allele homozygotes. The merits and 
assumptions of this model are discussed in Section 4-5.  
Table 4-1 Number of individuals with each genotype at the seven CYP17A1 promoter SNPs. 
SNP Major Homozygotes Heterozygotes Minor Homozygotes 
-34 (rs743572) 72 109 37 
-362 (rs2486758) 145 66 7 
-804 (rs10883784) 107 99 19 
-1204 (rs10786713) 75 111 38 
-1488 (rs10786714) 107 98 19 
-1877 (rs138009835) 178 45 2 
-2205 (rs2150927) 76 110 37 
 
4.4.1 Demographics 
Blood pressure and other relevant demographic characteristics of the BRIGHT 
cohort sub-group are displayed in Table 4-2. Age, blood pressure and BMI were 
not significantly different between males and females although, as expected, 
waist-hip ratio was significantly higher in males (p<0.001). 
Similar demographic characteristics of the groups stratified according to their 
genotype at each SNP are shown in Table 4-3 to Table 4-9. The numbers of males 
and females within each genotype group were approximately equal. Age, blood 
pressure, BMI and WHR were not statistically different between the genotyped 
groups. 
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Table 4-2 Demographic data on the BRIGHT study subgroup. 
Demographic data (median and interquartile ranges) of the BRIGHT study subgroup. Demographic 
characteristics of males and females were compared by the non-parametric Mann-Whitney test. 
SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; WHR: waist-
hip ratio. 
 
All Subjects 
N=232 
Males 
N=106 
Females 
N=126 
p-value 
(Male vs. Female) 
Age (Years) 63 (56-69) 63 (56-68) 64 (56-69) 0.47 
SBP (mm/Hg) 157 (153-190) 157 (151.25-187) 181.5 (153-191) 0.07 
DBP (mm/Hg) 103 (98-110) 103 (98-110) 102 (98-109.5) 0.43 
BMI (kg/m2) 27 (25-30) 28 (25-30.75) 27 (25-30) 0.26 
WHR 0.88 (0.81-0.93) 0.93 (0.90-0.97) 0.82 (0.78-0.86) <0.001 
 
 
Table 4-3 Demographic data on the BRIGHT study subgroup stratified by -34 genotype. 
Demographic data (median and interquartile ranges) of the BRIGHT study subgroup stratified by 
-34 genotype. Demographic characteristics were compared by the non-parametric Mann-Whitney 
test using the dominant model. SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: 
body mass index; WHR: waist-hip ratio. 
 
-34 TT 
N=72 
-34 CT 
N=109 
-34 CC 
N=37 
p-value 
(TT vs. CT+CC) 
Age (Years) 63 (58-67) 62 (55-70) 64 (58-68) 0.99 
SBP (mm/Hg) 157 (153-187) 183 (153-190) 155 (152-191) 0.53 
DBP (mm/Hg) 102 (98-107) 103 (99-110) 103 (98-110) 0.51 
BMI (kg/m2) 27 (24-30) 27.5 (25-30) 27 (25-31) 0.47 
WHR 0.86 (0.83-0.92) 0.88 (0.81-0.93) 0.91 (0.83-0.94) 0.49 
 
 
Table 4-4 Demographic data on the BRIGHT study subgroup stratified by -362 genotype. 
Demographic data (median and interquartile ranges) of the BRIGHT study subgroup stratified by 
-362 genotype. Demographic characteristics were compared by the non-parametric Mann-Whitney 
test using the dominant model. SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: 
body mass index; WHR: waist-hip ratio. 
 
-362 AA 
N=145 
-362 AG 
N=66 
-362 GG 
N=7 
p-value 
AA vs. AG+GG 
Age (Years) 63 (56-67.25) 63 (56-70) 63 (60.5-65) 0.52 
SBP (mm/Hg) 157 (153-190) 181.5 (152-190) 186 (169-189.5) 0.42 
DBP (mm/Hg) 103 (99-108) 103 (98-110.75) 99 (98-103) 0.94 
BMI (kg/m2) 27 (24-30) 27 (25-29) 30 (27-30) 0.81 
WHR 0.89 (0.81-0.93) 0.89 (0.81-0.93) 0.79 (0.76-0.85) 0.44 
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Table 4-5 Demographic data on the BRIGHT study subgroup stratified by -804 genotype. 
Demographic data (median and interquartile ranges) of the BRIGHT study subgroup stratified by 
-804 genotype. Demographic characteristics were compared by the non-parametric Mann-Whitney 
test using the dominant model. SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: 
body mass index; WHR: waist-hip ratio. 
 
-804 GG 
N=107 
-804 GA 
N=99 
-804 AA 
N=19 
p-value 
GG vs. GA+AA 
Age (Years) 63.5 (58.25-68) 62 (54.5-70) 63 (60.5-67) 0.43 
SBP (mm/Hg) 157 (153-190) 157 (153-190) 153 (152-186.5) 0.76 
DBP (mm/Hg) 103 (98-108) 103 (98-110) 102 (98-110) 0.97 
BMI (kg/m2) 27 (24-30) 27 (25-30) 28 (26-31) 0.38 
WHR 0.86 (0.80-0.92) 0.88 (0.81-0.93) 0.92 (0.89-0.94) 0.30 
 
 
Table 4-6 Demographic data on the BRIGHT study subgroup stratified by -1204 genotype. 
Demographic data (median and interquartile ranges) of the BRIGHT study subgroup stratified by 
-1204 genotype. Demographic characteristics were compared by the non-parametric Mann-
Whitney test using the dominant model. SBP: systolic blood pressure; DBP: diastolic blood 
pressure; BMI: body mass index; WHR: waist-hip ratio. 
 
-1204 TT 
N=75 
-1204 TC 
N=111 
-1204 CC 
N=38 
p-value 
TT vs. TC+CC 
Age (Years) 63 (58-67) 63 (55-70) 64.5 (58.5-68) 0.94 
SBP (mm/Hg) 157 (153-187) 183 (153-190) 156 (152-191) 0.76 
DBP (mm/Hg) 102 (98-107) 103 (99-110) 103 (98.25-109) 0.58 
BMI (kg/m2) 27 (24-29.75) 28 (25-30) 27 (24.25-30.75) 0.36 
WHR 0.86 (0.81-0.91) 0.88 (0.81-0.93) 0.91 (0.82-0.94) 0.34 
 
 
 
Table 4-7 Demographic data on the BRIGHT study subgroup stratified by -1488 genotype. 
Demographic data (median and interquartile ranges) of the BRIGHT study subgroup stratified by 
-1488 genotype. Demographic characteristics were compared by the non-parametric Mann-
Whitney test using the dominant model. SBP: systolic blood pressure; DBP: diastolic blood 
pressure; BMI: body mass index; WHR: waist-hip ratio. 
 
-1488 CC 
N=107 
-1488 CG 
N=98 
-1488 GG 
N=19 
p-value 
CC vs. CG+GG 
Age (Years) 63.5 (58.25-68) 62.5 (55-70) 63 (60.5-67) 0.49 
SBP (mm/Hg) 157 (153-190) 169 (153-190) 153 (152-186.5) 0.81 
DBP (mm/Hg) 103 (98-108) 103 (98-110) 102(98-110) 0.98 
BMI (kg/m2) 27 (24-30) 27 (25-30) 28 (26-31) 0.39 
WHR 0.86 (0.80-0.92) 0.88 (0.81-0.93) 0.92 (0.89-0.94) 0.26 
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Table 4-8 Demographic data on the BRIGHT study subgroup stratified by -1877 genotype. 
Demographic data (median and interquartile ranges) of the BRIGHT study subgroup stratified by 
-1877 genotype. Demographic characteristics were compared by the non-parametric Mann-
Whitney test using the dominant model. SBP: systolic blood pressure; DBP: diastolic blood 
pressure; BMI: body mass index; WHR: waist-hip ratio. 
 
-1877 CC 
N=178 
-1877 CT 
N=45 
-1877 TT 
N=2 
p-value 
CC vs. CT+TT 
Age (Years) 63 (56-68) 65 (58-70) 67 (66-68) 0.29 
SBP (mm/Hg) 157 (153-190) 183 (153-197) 156 (155.5-156.5) 0.61 
DBP (mm/Hg) 102.5 (98-110) 103 (100-110) 106 (103-109) 0.72 
BMI (kg/m2) 27 (25-30) 27 (24-30) 25.5 (25-26) 0.51 
WHR 0.88 (0.81-0.93) 0.87 (0.79-0.92) 0.99 (0.96-1.01) 0.66 
 
 
 
Table 4-9 Demographic data on the BRIGHT study subgroup stratified by -2205 genotype. 
Demographic data (median and interquartile ranges) of the BRIGHT study subgroup stratified by 
-2205 genotype. Demographic characteristics were compared by the non-parametric Mann-
Whitney test using the dominant model. SBP: systolic blood pressure; DBP: diastolic blood 
pressure; BMI: body mass index; WHR: waist-hip ratio. 
 
-2205 CC 
N=76 
-2205 CT 
N=110 
-2205 TT 
N=37 
p-value 
CC vs. CT+TT 
Age (Years) 63 (58-67) 63 (55-70) 64 (58-68) 0.94 
SBP (mm/Hg) 157 (153-187) 182 (153-190) 155 (152-191) 0.90 
DBP (mm/Hg) 102.5 (98-107) 103 (99-110) 103 (98-110) 0.64 
BMI (kg/m2) 27 (24-30) 28 (25-30) 27 (25-31) 0.42 
WHR 0.86 (0.81-0.91) 0.88 (0.80-0.93) 0.91 (0.83-0.94) 0.30 
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4.4.2 Association of Genotype with Urinary Corticosteroid 
Metabolite Excretion Rates and Patterns 
The CYP17A1 gene is expressed in the zona fasciculata and zona reticularis; the 
excretion rates of major urinary corticosteroid metabolites derived from 
products of these regions in the BRIGHT study subgroup are listed in Table 4-10. 
Corticosterone, cortisol and androgen metabolite excretion rates were 
significantly less in females than in males (p<0.001). 
Spearman correlation coefficients representing the relationships between the 
major urinary corticosteroid metabolite excretion rates are displayed in Figure 
4-2 to Figure 4-4. These results reflect a common regulatory factor: ACTH. There 
was a strong correlation between metabolite excretion rates of total 
corticosterone and total cortisol (r=0.7035, p<0.0001), total corticosterone and 
total androgen excretion rates (r=0.5464, p<0.0001) and total cortisol and total 
androgens (r=0.6569, p<0.0001). These relationships were also analysed 
separately for males and females because gender-dependent effects were 
obvious from Table 4-10. Positive correlations were seen in both sexes for all 
three relationships, although the correlation between total cortisol and total 
androgens was stronger in males (r=0.7267, p<0.0001) than in females (r=0.4974, 
p<0.0001). 
 
Table 4-10 Urinary corticosteroid excretion rates of the BRIGHT study subgroup. 
Urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT study 
subgroup. Metabolite excretion of males and females were compared by the non-parametric Mann-
Whitney test. THB: tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; THA: tetrahydro-
11-dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; THE: 
tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolite (µg/24h) 
All Subjects 
N=232 
Males 
N=106 
Females 
N=126 
p-value 
(Male vs. 
Female) 
Corticosterone metabolites 
(Total B: THB + aTHB + THA) 
103 (61-188) 140 (79-228) 86.5 (54-156) <0.001 
Cortisol metabolites  
(Total F: THF + aTHF + THE) 
1467 (759-2559) 2081 (1130-3526) 1118 (661-1989) <0.001 
Androgen metabolites 
(Total Androgens: DHEA + Aetio + Andro) 
613 (322-1227) 1008 (503-1852) 447 (225-815) <0.001 
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Figure 4-2 Correlation between excretion rates of total cortisol and total corticosterone 
metabolites. 
Correlation between excretion of total cortisol (THF + (a)THF + THE) urinary metabolites and total 
corticosterone (THB + aTHB + THA) urinary metabolites in A) all subjects B) males only and C) 
females only. Spearman correlation coefficients are displayed. 
A  
B 
C 
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Figure 4-3 Correlation between excretion rates of total androgen and total corticosterone 
metabolites. 
Correlation between excretion of total androgen (DHEA + andro + aetio) urinary metabolites and 
total corticosterone (THB + aTHB + THA) urinary metabolites in A) all subjects B) males only and 
C) females only. Spearman correlation coefficients are displayed. 
A  
B 
C 
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Figure 4-4 Correlation between excretion rates of total cortisol and total androgen 
metabolites. 
Correlation between excretion of total cortisol (THF + aTHF + THE) urinary metabolites and total 
androgen (DHEA + andro + aetio) urinary metabolites in A) all subjects B) males only and C) 
females only. Spearman correlation coefficients are displayed. 
A  
B 
C 
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Corticosterone, cortisol and androgen metabolite excretion rates were stratified 
by genotype for each polymorphism and compared by the non-parametric Mann-
Whitney test using the dominant model. Corticosterone, cortisol and androgen 
metabolite excretion rates did not differ significantly between individuals with 
the major homozygote genotype and those with the heterozygote and minor 
homozygote genotype at positions -34, -804, -1488 and -1877. This was also the 
case when assessed separately by gender (Table 4-11, Table 4-13, Table 4-15, and 
Table 4-16 respectively).  
Corticosterone and androgen metabolite excretion rates were not significantly 
different when stratified by genotype at position -362. Cortisol metabolite 
excretion rates, however, were significantly higher in males with the AG 
genotype compared to those with the AA genotype (p=0.05). There were no 
males with the GG genotype. This effect was not replicated in females, nor in 
the cohort as a whole (Table 4-12).  
In females, cortisol metabolite excretion rates were significantly higher in the 
heterozygote and minor homozygote genotype group when compared to the 
major homozygote group at position -1204 (p=0.04). This effect was not seen in 
males, or in the combined group (Table 4-14). Corticosterone and androgen 
metabolite excretion rates were not significantly altered when stratified by 
genotype and gender at this polymorphic site. 
Cortisol metabolite excretion rates were significantly higher in females in the 
heterozygote and minor homozygote genotype group at position -2205 compared 
to the major homozygote group (p=0.04). Again, this effect was not seen in 
males or in the combined group. No difference was observed in corticosterone 
and androgen metabolite excretion rates between genotype groups when 
assessed as a whole or by gender (Table 4-17).   
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Table 4-11 Urinary corticosteroid excretion rates of the BRIGHT study subgroup stratified by 
-34 genotype. 
Urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT study 
subgroup stratified by -34 genotype. Metabolite excretion rates were compared by the non-
parametric Mann-Whitney test. THB: tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; 
THA: tetrahydro-11-dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; 
THE: tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolite (µg/24h) -34 TT -34 CT -34 CC 
p-value 
TT vs. CT+CC 
Corticosterone metabolites 
(THB + aTHB + THA) 
Total 
Males 
Females 
101.5 (59-180) 
163 (90-219) 
81 (53-146) 
112 (69-204) 
156 (77-236) 
90 (55-140) 
99 (75-186) 
123 (86-177) 
87 (56-149) 
0.58 
0.69 
0.57 
Cortisol metabolites  
(THF + aTHF + THE) 
Total 
Males 
Females 
1354 (671-2435) 
2116 (1375-3381) 
904 (530-1789) 
1704 (823-2888) 
2407 (951-3875) 
1366 (746-2103) 
1388 (769-2149) 
1478 (888-2833) 
995 (755-1523) 
0.21 
0.79 
0.08 
Androgen metabolites 
(DHEA + Aetio + Andro) 
Total 
Males 
Females 
614 (317-1182) 
850 (550-1727) 
504 (233-953) 
688 (342-1342) 
1234 (511-1866) 
483 (216-912) 
599 (310-1031) 
737 (439-1581) 
435 (205-682) 
0.57 
0.76 
0.91 
 
Table 4-12 Urinary corticosteroid excretion rates of the BRIGHT study subgroup stratified by 
-362 genotype. 
Urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT study 
subgroup stratified by -362 genotype. Metabolite excretion rates were compared by the non-
parametric Mann-Whitney test. THB: tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; 
THA: tetrahydro-11-dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; 
THE: tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolite (µg/24h) -362 AA -362 AG -362 GG 
p-value 
AA vs. AG+GG 
Corticosterone metabolites 
(THB + aTHB + THA) 
Total 
Males 
Females 
96 (60-168) 
121 (76-221) 
84 (54-125) 
123.5 (65-203) 
167 (101-241) 
77 (52-158) 
171 (120-216) 
- 
171 (120-216) 
0.08 
0.09 
0.27 
Cortisol metabolites  
(THF + aTHF + THE) 
Total 
Males 
Females 
1388 (765-2342) 
1711 (918-3284) 
1026 (715-1798) 
1786 (289-3177) 
2619 (1546-3992) 
1251 (547-2296) 
1104 (674-2089) 
- 
1104 (674-2089 
0.21 
0.05 
0.94 
Androgen metabolites 
(DHEA + Aetio + Andro) 
Total 
Males 
Females 
599 (331-1208) 
933 (475-1844) 
423 (262-701) 
747 (327-1340) 
1062 (582-1804) 
593 (183-1169) 
376 (252-692) 
- 
376 (252-692) 
0.56 
0.48 
0.64 
 
Table 4-13 Urinary corticosteroid excretion rates of the BRIGHT study subgroup stratified by 
-804 genotype. 
Urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT study 
subgroup stratified by -804 genotype. Metabolite excretion rates were compared by the non-
parametric Mann-Whitney test. THB: tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; 
THA: tetrahydro-11-dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; 
THE: tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolite (µg/24h) -804 GG -804 GA -804 AA 
p-value 
GG vs. GA+AA 
Corticosterone metabolites 
(THB + aTHB + THA) 
Total 
Males 
Females 
102 (59-173) 
147 (80-211) 
86 (53-153) 
96 (69-202) 
156 (78-237) 
83 (55-133) 
123 (85-198) 
123 (83-149) 
149 (91-218) 
0.44 
0.61 
0.94 
Cortisol metabolites  
(THF + aTHF + THE) 
Total 
Males 
Females 
1316 (694-2457) 
2053 (1170-3526) 
992 (601-1843) 
1704 (770-2700) 
2407 (2496-4045) 
1300 (730-2054) 
1388 (891-1800) 
1388 (1245-2149) 
1209 (838-1493) 
0.24 
0.96 
0.20 
Androgen metabolites 
(DHEA + Aetio + Andro) 
Total 
Males 
Females 
604 (323-1082) 
758 (511-1586) 
423 (247-934) 
649 (313-1334) 
1242 (1224-1866) 
429 (190-824) 
648 (439-927) 
648 (494-1700) 
574 (408-707) 
0.46 
0.41 
0.61 
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Table 4-14 Urinary corticosteroid excretion rates of the BRIGHT study subgroup stratified by 
-1204 genotype. 
Urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT study 
subgroup stratified by -1204 genotype. Metabolite excretion rates were compared by the non-
parametric Mann-Whitney test. THB: tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; 
THA: tetrahydro-11-dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; 
THE: tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolite (µg/24h) -1204 TT -1204 TC -1204 CC 
p-value 
TT vs. TC+CC 
Corticosterone metabolites 
(THB + aTHB + THA) 
Total 
Males 
Females 
101 (57-181) 
163 (90-219) 
78 (52-148) 
112 (68-193) 
186 (74-233) 
91 (55-146) 
98.5 (76-177) 
123 (86-177) 
86 (58-125) 
0.55 
0.59 
0.44 
Cortisol metabolites  
(THF + aTHF + THE) 
Total 
Males 
Females 
1312 (660-2376) 
2116 (1375-3381) 
863 (520-1754) 
1704 (819-2676) 
2384 (914-3875) 
1414 (759-2139) 
1388 (735-2129) 
1478 (888-2833) 
976 (692-1519) 
0.16 
0.68 
0.04 
Androgen metabolites 
(DHEA + Aetio + Andro) 
Total 
Males 
Females 
606 (316-1122) 
850 (550-1727) 
413 (223-854) 
638 (341-1321) 
1173 (497-1866) 
483 (266-883) 
580 (300-1022) 
737 (439-1581) 
413 (191-678) 
0.54 
0.87 
0.99 
 
Table 4-15 Urinary corticosteroid excretion rates of the BRIGHT study subgroup stratified by 
-1488 genotype. 
Urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT study 
subgroup stratified by -1488 genotype. Metabolite excretion rates were compared by the non-
parametric Mann-Whitney test. THB: tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; 
THA: tetrahydro-11-dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; 
THE: tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolite (µg/24h) -1488 CC -1488 CG -1488 GG 
p-value 
CC vs. CG+GG 
Corticosterone metabolites 
(THB + aTHB + THA) 
Total 
Males 
Females 
102 (59-173) 
147 (80-211) 
86 (53-153) 
97.5 (68-203) 
156 (78-237) 
82 (54-133) 
123 (85-198) 
123 (83-149) 
149 (91-218) 
0.43 
0.61 
0.95 
Cortisol metabolites  
(THF + aTHF + THE) 
Total 
Males 
Females 
1316 (694-2457) 
2053 (1170-3526) 
992 (601-1843) 
1704 (768-2755) 
2407 (1023-4045) 
1272 (727-2060) 
1388 (891-1800) 
1388 (1245-2149) 
1209 (838-1493) 
0.25 
0.96 
0.23 
Androgen metabolites 
(DHEA + Aetio + Andro) 
Total 
Males 
Females 
604 (323-1082) 
758 (511-1586) 
423 (247-934) 
646 (310-1326) 
1242 (511-1866) 
427 (189-797) 
648 (439-927) 
648 (484-1700) 
574 (408-707) 
0.53 
0.41 
0.50 
 
Table 4-16 Urinary corticosteroid excretion rates of the BRIGHT study subgroup stratified by 
-1877 genotype. 
Urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT study 
subgroup stratified by -1877 genotype. Metabolite excretion rates were compared by the non-
parametric Mann-Whitney test. THB: tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; 
THA: tetrahydro-11-dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; 
THE: tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolite (µg/24h) -1877 CC -1877 CT -1877 TT 
p-value 
CC vs. CT+TT 
Corticosterone metabolites 
(THB + aTHB + THA) 
Total 
Males 
Females 
102 (61-191) 
147 (76-234) 
86 (53-153) 
108 (61-164) 
128 (82-218) 
92 (57-134) 
86.5 (86-87) 
86.5 (86-87) 
- 
0.79 
0.50 
0.84 
Cortisol metabolites  
(THF + aTHF + THE) 
Total 
Males 
Females 
1467 (734-2452) 
2116 (1257-3361) 
1037 (658-1946) 
1404 (823-3188) 
2877 (933-4124) 
1188 (718-2010) 
1086 (752-1419) 
1086 (752-1419) 
- 
0.71 
0.84 
0.51 
Androgen metabolites 
(DHEA + Aetio + Andro) 
Total 
Males 
Females 
629 (327-1260) 
1034 (509-1820) 
429 (233-824) 
580 (308-998) 
746 (490-2050) 
435 (205-714) 
725 (540-909) 
725 (540-909) 
- 
0.53 
0.66 
0.81 
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Table 4-17 Urinary corticosteroid excretion rates of the BRIGHT study subgroup stratified by 
-2205 genotype. 
Urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT study 
subgroup stratified by -2205 genotype. Metabolite excretion rates were compared by the non-
parametric Mann-Whitney test. THB: tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; 
THA: tetrahydro-11-dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; 
THE: tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolite (µg/24h) -2205 CC -2205 CT -2205 TT 
p-value 
CC vs. CT+TT 
Corticosterone metabolites 
(THB + aTHB + THA) 
Total 
Males 
Females 
98 (57-180) 
160 (84-211) 
78 (52-148) 
108 (68-186) 
143 (74-236) 
90 (55-144) 
99 (75-186) 
123 (86-177) 
87 (56-149) 
0.49 
0.74 
0.44 
Cortisol metabolites  
(THF + aTHF + THE) 
Total 
Males 
Females 
1306 (660-2358) 
2079 (1312-3331) 
863 (520-1749) 
1671 (816-2529) 
2384 (915-3725) 
1404 (740-2127) 
1388 (769-2149) 
1478 (888-2833) 
995 (755-1523) 
0.15 
0.79 
0.04 
Androgen metabolites 
(DHEA + Aetio + Andro) 
Total 
Males 
Females 
605 (315-1096) 
845 (517-1666) 
413 (223-806) 
629 (340-1307) 
1173 (501-1828) 
475 (223-868) 
599 (310-1031) 
737 (439-1581) 
435 (205-682) 
0.53 
0.76 
0.99 
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In addition to assessing the end products of the three major arms of the 
steroidogenic pathway in the zona fasciculata and zone reticularis, stratified by 
genotype at each of the seven polymorphisms of interest, ratios of components 
from the 17-deoxycorticosteroid pathway to 17-hydroxycorticosteroid pathway 
and of the 17-hydroxycorticosteroid pathway to the androgen arm of the 
pathway were used as indices of 17α-hydroxylase activity and 17,20 lyase 
activity, respectively.  
It would be most beneficial to assess the ratios of immediate precursor 
metabolites to immediate product metabolites for 17α-hydroxylase/17,20 lyase 
in order to ascertain enzymatic efficiency but measurements of these metabolite 
excretion rates were not available. Instead, ratios of the urinary metabolite 
rates of deoxycorticosterone (DOC) to 11-deoxycortisol (S) and of corticosterone 
(B) to cortisol (F) were used as indices of 17α-hydroxylase activity, while ratios 
of 11-deoxycortisol (S) to dehydroepiandrosterone (DHEA) and of cortisol (F) to 
total available androgen metabolites (DHEA + aetiocholanolone + androsterone) 
were used as indices of 17,20 lyase activity. 
These four ratios were first analysed for the total cohort and then separately by 
gender (Table 4-18). The ratios of the urinary metabolite excretion rates of 
DOC:S (p=0.110) and B:F (p=0.130) were not significantly different between 
males and females, although examination of the mean ratio values indicated a 
trend to higher values for both ratios in females. The ratio of S:DHEA rates 
approached significance between males and females, with higher ratios again 
evident in females when looking at the mean values (0.066). The ratio of 
F/androgen metabolite was significantly higher in females (p=0.002).  
The cohort was then stratified by genotype for each polymorphism and the same 
four ratios compared. Ratios between genotype groups were compared by the 
non-parametric Mann-Whitney test using the dominant model. Ratios were also 
assessed separately by gender. None of the four ratios differed significantly 
between the genotype groups for the polymorphisms at positions -362 (Table 
4-20) and -1877 (Table 4-24). 
The ratio of THDOC:THS was significantly lower in females from the 
heterozygote and minor homozygote group at positions -34 (p=0.004), -1204 
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(p=0.005) and -2205 (p=0.005) compared to the corresponding major homozygote 
groups (Table 4-19, Table 4-22 and Table 4-25, respectively). While no significant 
differences were observed in males at any of these polymorphic sites, analysis of 
the cohort as a whole overall reflected the observed effect in females, albeit 
with slightly reduced significance. Similar trends were observed at positions -804 
(Table 4-21) and -1488 (Table 4-23), although statistical significance was not 
attained. These effects were not so clear when examining ratios of the urinary 
metabolite of B:F. Significantly lower ratios were observed in females from the 
heterozygote and minor homozygote group at positions -1204 (p=0.034) and 
-2205 (p=0.034) when compared to the major homozygote group of each. Similar 
trends, though not significant, were observed at positions -34, -804 and -1488. 
Ratios of B:F were not significantly different when analysing the whole cohort or 
males alone. 
Ratios of THS:DHEA and F:total androgen metabolite did not change significantly 
when stratified by genotype and/or gender. However, in the female group, 
higher ratios of F:total androgen metabolite were apparent in the heterozygote 
and minor homozygote group at positions -34 (p=0.077), -1204 (p=0.054), -1488 
(0.076) and -2205 (p=0.054) when compared to their respective major 
homozygote groups, although not reaching statistical significance. 
 
Table 4-18 Ratios of urinary corticosteroid excretion rates of the BRIGHT study subgroup 
stratified by -34 genotype. 
Ratios of urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -34 genotype. Ratios were compared by the non-parametric Mann-
Whitney test. THDOC: tetrahydrodeoxycorticosterone; THS: tetrahydrodeoxycortisol; THB: 
tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; THA: tetrahydro-11-
dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; THE: 
tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolite (µg/24h) 
All Subjects 
N=232 
Males 
N=106 
Females 
N=126 
p-value 
(Male vs. 
Female) 
THDOC:THS 0.57 (0.31-1.10) 0.50 (0.29-1.00) 0.64 (0.35-1.17) 0.110 
Total B:Total F 
(Total B: THB + aTHB + THA) 
(Total F: THF + aTHF + THE) 
0.07 (0.05-0.11) 0.07 (0.05-0.11) 0.08 (0.06-0.12) 0.130 
THS:DHEA 0.71 (0.27-2.00) 0.62 (0.25-1.49) 1.00 (0.35-2.29) 0.066 
Total F:Total Androgens 
(Total F: THF + aTHF + THE) 
(Total Androgens: DHEA + Aetio + Andro) 
2.26 (1.41-3.68) 1.91 (1.28-2.92) 2.68 (1.56-4.52) 0.002 
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Table 4-19 Ratios of urinary corticosteroid excretion rates of the BRIGHT study subgroup 
stratified by -34 genotype. 
Ratios of urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -34 genotype. Ratios were compared by the non-parametric Mann-
Whitney test. THDOC: tetrahydrodeoxycorticosterone; THS: tetrahydrodeoxycortisol; THB: 
tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; THA: tetrahydro-11-
dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; THE: 
tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolites (µg/24h) -34 TT -34 CT -34 CC 
p-value 
TT vs. CT+CC 
THDOC:THS 
Total 
Males 
Females 
0.70 (0.44-1.67) 
0.50 (0.40-0.78) 
1.00 (0.44-2.00) 
0.50 (0.28-0.88) 
0.40 (0.28-1.00) 
0.54 (0.29-0.84) 
0.67 (0.35-1.07) 
0.69 (0.26-1.15) 
0.67 (0.37-0.93) 
0.014 
0.575 
0.004 
Total B:Total F 
(Total B: THB + aTHB + THA) 
(Total F: THF + aTHF + THE) 
Total 
Males 
Females 
0.08 (0.05-0.12) 
0.06 (0.05-0.11) 
0.10 (0.06-0.12) 
0.07 (0.05-0.10) 
0.07 (0.05-0.10) 
0.07 (0.06-0.09) 
0.07 (0.05-0.11) 
0.09 (0.05-0.11) 
0.08 (0.05-0.12) 
0.250 
0.674 
0.052 
THS:DHEA 
Total 
Males 
Females 
0.81 (0.31-2.12) 
0.70 (0.38-1.85) 
1.00 (0.31-2.79) 
0.83 (0.29-2.00) 
0.46 (0.21-1.26) 
1.35 (0.43-2.25) 
0.63 (0.30-1.89) 
0.62 (0.26-1.36) 
0.90 (0.44-2.92) 
0.795 
0.364 
0.608 
Total F:Total Androgens 
(Total F: THF + aTHF + THE) 
(Total Androgens: DHEA + Aetio + Andro) 
Total 
Males 
Females 
2.03 (1.33-3.67) 
2.09 (1.56-3.12) 
2.00 (1.23-4.24) 
2.37 (1.52-4.02) 
1.95 (1.19-2.76) 
3.18 (1.71-5.19) 
1.99 (1.51-3.46) 
1.61 (1.31-2.75) 
3.31 (1.97-3.96) 
0.570 
0.204 
0.077 
 
 
 
Table 4-20 Ratios of urinary corticosteroid excretion rates of the BRIGHT study subgroup 
stratified by -362 genotype. 
Ratios of urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -362 genotype. Ratios were compared by the non-parametric Mann-
Whitney test. THDOC: tetrahydrodeoxycorticosterone; THS: tetrahydrodeoxycortisol; THB: 
tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; THA: tetrahydro-11-
dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; THE: 
tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolites (µg/24h) -362 AA -362 AG -362 GG 
p-value 
AA vs. AG+GG 
THDOC:THS 
Total 
Males 
Females 
0.63 (0.33-1.00) 
0.50 (0.31-1.00) 
0.67 (0.36-1.10) 
0.57 (0.29-1.67) 
0.43 (0.29-1.04) 
0.73 (0.36-2.00) 
0.56 (0.35-1.33) 
- 
0.56 (0.35-1.33) 
0.780 
0.797 
0.564 
Total B:Total F 
(Total B: THB + aTHB + THA) 
(Total F: THF + aTHF + THE) 
Total 
Males 
Females 
0.07 (0.05-0.11) 
0.07 (0.05-0.11) 
0.08 (0.06-0.11) 
0.07 (0.05-0.11) 
0.07 (0.05-0.10) 
0.09 (0.05-0.12) 
0.12 (0.09-0.19) 
- 
0.12 (0.09-0.19) 
0.620 
0.665 
0.259 
THS:DHEA 
Total 
Males 
Females 
0.68 (0.30-2.00) 
0.58 (0.22-1.38) 
1.00 (0.35-2.00) 
0.77 (0.28-1.57) 
0.64 (0.27-1.50) 
0.89 (0.29-2.00) 
4.00 (3.00-7.33) 
- 
4.00 (3.00-7.33) 
0.900 
0.993 
0.886 
Total F:Total Androgens 
(Total F: THF + aTHF + THE) 
(Total Androgens: DHEA + Aetio + Andro) 
Total 
Males 
Females 
2.17 (1.41-3.60) 
1.75 (1.25-2.77) 
2.91 (1.64-4.32) 
2.33 (1.37-4.07) 
2.07 (1.59-3.45) 
2.44 (1.36-4.88) 
4.45 (1.89-6.07) 
- 
4.45 (1.89-6.07) 
0.389 
0.145 
0.902 
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Table 4-21 Ratios of urinary corticosteroid excretion rates of the BRIGHT study subgroup 
stratified by -804 genotype. 
Ratios of urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -804 genotype. Ratios were compared by the non-parametric Mann-
Whitney test. THDOC: tetrahydrodeoxycorticosterone; THS: tetrahydrodeoxycortisol; THB: 
tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; THA: tetrahydro-11-
dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; THE: 
tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolites (µg/24h) -804 GG -804 GA -804 AA 
p-value 
GG vs. GA+AA 
THDOC:THS 
Total 
Males 
Females 
0.64 (0.38-1.33) 
0.50 (0.38-0.83) 
0.76 (0.42-1.67) 
0.50 (0.27-1.00) 
0.40 (0.23-1.00) 
0.57 (0.29-0.86) 
0.63 (0.36-1.11) 
0.61 (0.30-1.23) 
0.63 (0.41-0.94) 
0.064 
0.503 
0.056 
Total B:Total F 
(Total B: THB + aTHB + THA) 
(Total F: THF + aTHF + THE) 
Total 
Males 
Females 
0.07 (0.05-0.12) 
0.06 (0.05-0.10) 
0.09 (0.06-0.12) 
0.07 (0.05-0.10) 
0.07 (0.05-0.12) 
0.07 (0.05-0.09) 
0.08 (0.06-0.11) 
0.07 (0.06-0.09) 
0.13 (0.08-0.16) 
0.610 
0.235 
0.086 
THS:DHEA 
Total 
Males 
Females 
0.75 (0.30-1.82) 
0.55 (0.22-1.58) 
1.00 (0.35-2.08) 
0.89 (0.29-2.09) 
0.60 (0.23-1.34) 
1.55 (0.40-3.00) 
0.63 (0.33-1.00) 
0.63 (0.30-1.36) 
0.75 (0.54-0.97) 
0.836 
0.921 
0.495 
Total F:Total Androgens 
(Total F: THF + aTHF + THE) 
(Total Androgens: DHEA + Aetio + Andro) 
Total 
Males 
Females 
2.21 (1.38-3.68) 
1.99 (1.51-3.05) 
2.37 (1.36-4.18) 
2.47 (1.59-3.89) 
1.91 (1.14-2.62) 
3.39 (2.00-5.28) 
1.85 (1.43-3.10) 
1.56 (1.41-2.88) 
2.07 (1.88-3.02) 
0.800 
0.201 
0.107 
 
 
 
Table 4-22 Ratios of urinary corticosteroid excretion rates of the BRIGHT study subgroup 
stratified by -1204 genotype. 
Ratios of urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -1204 genotype. Ratios were compared by the non-parametric Mann-
Whitney test. THDOC: tetrahydrodeoxycorticosterone; THS: tetrahydrodeoxycortisol; THB: 
tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; THA: tetrahydro-11-
dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; THE: 
tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolites (µg/24h) -1204 TT -1204 TC -1204 CC 
p-value 
TT vs. TC+CC 
THDOC:THS 
Total 
Males 
Females 
0.71 (0.44-1.63) 
0.50 (0.40-0.78) 
1.00 (0.44-2.00) 
0.50 (0.29-1.00) 
0.46 (0.29-1.00) 
0.54 (0.29-0.88) 
0.70 (0.35-1.04) 
0.69 (0.26-1.15) 
0.70 (0.28-0.89) 
0.019 
0.682 
0.005 
Total B:Total F 
(Total B: THB + aTHB + THA) 
(Total F: THF + aTHF + THE) 
Total 
Males 
Females 
0.08 (0.05-0.12) 
0.06 (0.05-0.11) 
0.10 (0.06-0.13) 
0.07 (0.05-0.10) 
0.07 (0.05-0.10) 
0.07 (0.06-0.09) 
0.08 (0.05-0.12) 
0.07 (0.05-0.11) 
0.09 (0.06-0.13) 
0.190 
0.690 
0.034 
THS:DHEA 
Total 
Males 
Females 
0.77 (0.30-2.00) 
0.70 (0.38-1.85) 
1.00 (0.30-2.15) 
0.88 (0.30-2.00) 
0.50 (0.21-1.26) 
1.35 (0.43-2.49) 
0.63 (0.30-1.67) 
0.62 (0.26-1.36) 
0.89 (0.48-2.63) 
0.946 
0.407 
0.479 
Total F:Total Androgens 
(Total F: THF + aTHF + THE) 
(Total Androgens: DHEA + Aetio + Andro) 
Total 
Males 
Females 
2.09 (1.36-3.63) 
2.09 (1.56-3.12) 
2.09 (1.25-4.02) 
2.41 (1.53-4.06) 
1.95 (1.19-2.76) 
3.18 (1.80-5.20) 
2.07 (1.52-3.44) 
1.61 (1.31-2.75) 
3.22 (1.98-3.91) 
0.513 
0.204 
0.054 
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Table 4-23 Ratios of urinary corticosteroid excretion rates of the BRIGHT study subgroup 
stratified by -1488 genotype. 
Ratios of urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -1488 genotype. Ratios were compared by the non-parametric Mann-
Whitney test. THDOC: tetrahydrodeoxycorticosterone; THS: tetrahydrodeoxycortisol; THB: 
tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; THA: tetrahydro-11-
dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; THE: 
tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolites (µg/24h) -1488 CC -1488 CG -1488 GG 
p-value 
CC vs. CG+GG 
THDOC:THS 
Total 
Males 
Females 
0.64 (0.38-1.33) 
0.50 (0.38-0.83) 
0.76 (0.42-1.67) 
0.50 (0.27-1.00) 
0.40 (0.23-1.00) 
0.57 (0.29-0.87) 
0.63 (0.36-1.11) 
0.61 (0.30-1.23) 
0.63 (0.41-0.94) 
0.060 
0.503 
0.052 
Total B:Total F 
(Total B: THB + aTHB + THA) 
(Total F: THF + aTHF + THE) 
Total 
Males 
Females 
0.07 (0.05-0.12) 
0.06 (0.05-0.10) 
0.09 (0.06-0.12) 
0.07 (0.05-0.10) 
0.07 (0.05-0.12) 
0.07 (0.05-0.09) 
0.08 (0.06-0.11) 
0.07 (0.06-0.09) 
0.13 (0.08-0.16) 
0.660 
0.235 
0.107 
THS:DHEA 
Total 
Males 
Females 
0.75 (0.30-1.82) 
0.55 (0.22-1.58) 
1.00 (0.35-2.08) 
0.90 (0.28-2.13) 
0.60 (0.23-1.34) 
1.55 (0.38-3.08) 
0.63 (0.33-1.00) 
0.63 (0.31-1.36) 
0.75 (0.54-0.97) 
0.829 
0.921 
0.477 
Total F:Total Androgens 
(Total F: THF + aTHF + THE) 
(Total Androgens: DHEA + Aetio + Andro) 
Total 
Males 
Females 
2.21 (1.38-3.68) 
1.99 (1.52-3.05) 
2.37 (1.36-4.18) 
2.52 (1.59-3.90) 
1.91 (1.14-2.62) 
3.39 (2.03-5.33) 
1.85 (1.43-3.10) 
1.56 (1.41-2.88) 
2.07 (1.88-3.02) 
0.722 
0.201 
0.076 
 
 
 
Table 4-24 Ratios of urinary corticosteroid excretion rates of the BRIGHT study subgroup 
stratified by -1877 genotype. 
Ratios of urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -1877 genotype. Ratios were compared by the non-parametric Mann-
Whitney test. THDOC: tetrahydrodeoxycorticosterone; THS: tetrahydrodeoxycortisol; THB: 
tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; THA: tetrahydro-11-
dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; THE: 
tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolites (µg/24h) -1877 CC -1877 CT -1877 TT 
p-value 
CC vs. CT+TT 
THDOC:THS 
Total 
Males 
Females 
0.57 (0.32-1.16) 
0.50 (0.29-1.00) 
0.73 (0.35-1.38) 
0.57 (0.32-1.00) 
0.53 (0.30-0.96) 
0.63 (0.34-0.93) 
0.92 (n=1) 
0.92 (n=1) 
- 
0.500 
0.996 
0.325 
Total B:Total F 
(Total B: THB + aTHB + THA) 
(Total F: THF + aTHF + THE) 
Total 
Males 
Females 
0.07 (0.05-0.11) 
0.07 (0.05-0.10) 
0.08 (0.06-0.12) 
0.07 (0.05-0.10) 
0.06 (0.04-0.09) 
0.07 (0.06-0.10) 
0.13 (0.09-0.17) 
0.13 (0.09-0.17) 
- 
0.210 
0.268 
0.351 
THS:DHEA 
Total 
Males 
Females 
0.83 (0.30-2.00) 
0.66 (0.28-1.46) 
1.00 (0.36-2.15) 
0.71 (0.32-2.33) 
0.38 (0.17-1.25) 
1.00 (0.40-3.46) 
0.16 (n=1) 
0.16 (n=1) 
- 
0.960 
0.286 
0.574 
Total F:Total Androgens 
(Total F: THF + aTHF + THE) 
(Total Androgens: DHEA + Aetio + Andro) 
Total 
Males 
Females 
2.21 (1.37-3.61) 
1.91 (1.41-2.88) 
2.53 (1.37-4.50) 
2.79 (1.58-4.18) 
1.98 (1.51-3.49) 
3.41 (2.10-4.67) 
1.39 (1.28-1.50) 
1.39 (1.28-1.50) 
- 
0.257 
0.963 
0.278 
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Table 4-25 Ratios of urinary corticosteroid excretion rates of the BRIGHT study subgroup 
stratified by -2205 genotype. 
Ratios of urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -2205 genotype. Ratios were compared by the non-parametric Mann-
Whitney test. THDOC: tetrahydrodeoxycorticosterone; THS: tetrahydrodeoxycortisol; THB: 
tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; THA: tetrahydro-11-
dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; THE: 
tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone. 
Urinary Steroid Metabolites (µg/24h) -2205 CC -2205 CT -2205 TT 
p-value 
CC vs. CT+TT 
THDOC:THS 
Total 
Males 
Females 
0.73 (0.44-1.58) 
0.50 (0.41-0.82) 
1.00 (0.44-2.00) 
0.50 (0.28-0.91) 
0.40 (0.28-1.00) 
0.57 (0.29-0.88) 
0.67 (0.35-1.07) 
0.69 (0.26-1.15) 
0.67 (0.37-0.93) 
0.015 
0.536 
0.005 
Total B:Total F 
(Total B: THB + aTHB + THA) 
(Total F: THF + aTHF + THE) 
Total 
Males 
Females 
0.08 (0.05-0.12) 
0.06 (0.05-0.11) 
0.10 (0.06-0.13) 
0.07 (0.05-0.10) 
0.07 (0.05-0.10) 
0.07 (0.06-0.09) 
0.07 (0.05-0.11) 
0.07 (0.05-0.11) 
0.08 (0.05-0.12) 
0.220 
0.643 
0.034 
THS:DHEA 
Total 
Males 
Females 
0.81 (0.31-1.95) 
0.71 (0.42-1.80) 
1.00 (0.30-2.15) 
0.86 (0.33-2.00) 
0.50 (0.25-1.31) 
1.17 (0.44-2.37) 
0.63 (0.30-1.89) 
0.62 (0.26-1.36) 
0.90 (0.44-2.92) 
0.985 
0.410 
0.479 
Total F:Total Androgens 
(Total F: THF + aTHF + THE) 
(Total Androgens: DHEA + Aetio + Andro) 
Total 
Males 
Females 
2.14 (1.36-3.62) 
2.21 (1.59-3.09) 
2.09 (1.25-4.02) 
2.52 (1.55-4.07) 
1.95 (1.22-2.79) 
2.98 (1.86-5.20) 
1.99 (1.51-3.46) 
1.61 (1.31-2.75) 
3.31 (1.97-3.96) 
0.478 
0.198 
0.054 
 
 
Aldosterone is a major steroid product and is synthesised in the zona 
glomerulosa. Its production is largely controlled by angiotensin II (ang II) and 
potassium although there is also evidence of ACTH-dependence (Section 4.5). In 
the hypertensive BRIGHT study subgroup, the urinary excretion rate of the 
metabolite of aldosterone (THAldo) was significantly higher in males than 
females (p=0.002) (Table 4-26).  
When stratified by genotype, the major homozygote group (CC) at position -1877 
had significantly higher aldosterone production than the heterozygote and minor 
homozygote group (CT+TT) (4.44±0.41 vs. 3.36±0.69 µg/24h, p=0.049). This 
effect did not appear to be associated with either gender. No significant changes 
were observed for any other polymorphism (Table 4-27 to Table 4-33).  
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Table 4-26 THAldo excretion of the BRIGHT study subgroup. 
Tetrahydroaldosterone (THAldo) excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup. Metabolite excretion was compared by the non-parametric Mann-Whitney test. 
Steroid Metabolite (µg/24h) 
All Subjects 
N=232 
Males 
N=106 
Females 
N=126 
p-value 
(Male vs. 
Female) 
Aldosterone  
(THAldo) 
3 (1-5) 3 (2-6) 2 (1-4) 0.002 
 
 
Table 4-27 THAldo excretion of the BRIGHT study subgroup stratified by -34 genotype. 
Tetrahydroaldosterone (THAldo) excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -34 genotype. Metabolite excretion was compared by the non-
parametric Mann-Whitney test. 
Steroid Metabolite (µg/24h) -34 TT -34 CT -34 CC 
p-value 
TT vs. CT+CC 
Aldosterone  
(THAldo) 
Total 
Males 
Females 
3 (1-5) 
3 (2-4.75) 
2 (1-5) 
3 (2-4) 
3 (2-5) 
2 (1.25-3) 
2 (1-4.75) 
3 (2-6.5) 
2 (1-2) 
0.72 
0.57 
0.94 
 
 
Table 4-28 THAldo excretion of the BRIGHT study subgroup stratified by -362 genotype. 
Tetrahydroaldosterone (THAldo) excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -362 genotype. Metabolite was excretion compared by the non-
parametric Mann-Whitney test. 
Steroid Metabolite (µg/24h) -362 AA -362 AG -362 GG 
p-value 
AA vs. AG+GG 
Aldosterone  
(THAldo) 
Total 
Males 
Females 
2 (1.25-4) 
3 (2-5) 
2(1-3) 
3 (1-6) 
3 (2-8.25) 
2(1-5) 
2(1-3) 
- 
2(1-3) 
0.71 
0.88 
0.37 
 
 
Table 4-29 THAldo excretion of the BRIGHT study subgroup stratified by -804 genotype. 
Tetrahydroaldosterone (THAldo) excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -804 genotype. Metabolite excretion was compared by the non-
parametric Mann-Whitney test. 
Steroid Metabolite (µg/24h) -804 GG -804 GA -804 AA 
p-value 
GG vs. GA+AA 
Aldosterone  
(THAldo) 
Total 
Males 
Females 
2 (1-4) 
3 (2-4.5) 
2 (1-4) 
1 (1.25-5) 
3 (3-6) 
2 (1-3) 
3 (2-4) 
3 (2.5-10.5) 
2 (2-2.75) 
0.54 
0.67 
0.91 
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Table 4-30 THAldo excretion of the BRIGHT study subgroup stratified by -1204 genotype. 
Tetrahydroaldosterone (THAldo) excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -1204 genotype. Metabolite excretion was compared by the non-
parametric Mann-Whitney test. 
Steroid Metabolite (µg/24h) -1204 TT -1204 TC -1204 CC 
p-value 
TT vs. TC+CC 
Aldosterone  
(THAldo) 
Total 
Males 
Females 
2 (1-5) 
3 (2-4.75) 
2 (1-4.5) 
3 (2-4) 
3 (2-4.75) 
2 (1.75-3.25) 
2 (1-4.5) 
3 (2-6.5) 
2 (1-2) 
0.98 
0.48 
0.66 
 
 
 
Table 4-31 THAldo excretion of the BRIGHT study subgroup stratified by -1488 genotype. 
Tetrahydroaldosterone (THAldo) excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -1488 genotype. Metabolite excretion was compared by the non-
parametric Mann-Whitney test. 
Steroid Metabolite (µg/24h) -1488 CC -1488 CG -1488 GG 
p-value 
CC vs. CG+GG 
Aldosterone  
(THAldo) 
Total 
Males 
Females 
2 (1-4) 
3 (2-4.5) 
2 (1-4) 
2 (1-5) 
3 (2-6) 
2 (1-3) 
2 (3-4) 
3 (2.5-10.5) 
2 (2-2.75) 
0.52 
0.67 
0.90 
 
 
Table 4-32 THAldo excretion of the BRIGHT study subgroup stratified by -1877 genotype. 
Tetrahydroaldosterone (THAldo) excretion rates(median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -1877 genotype. Metabolite excretion was compared by the non-
parametric Mann-Whitney test. 
Steroid Metabolite (µg/24h) -1877 CC -1877 CT -1877 TT 
p-value 
CC vs. CT+TT 
Aldosterone  
(THAldo) 
Total 
Males 
Females 
3 (2-5) 
3 (2-5.75) 
2 (1-4) 
2 (1-3) 
2 (1-3.25) 
2 (1-3) 
5.5 (5.25-5.75) 
5.5 (5.25-5.75) 
- 
0.05 
0.14 
0.34 
 
 
 
Table 4-33 THAldo excretion of the BRIGHT study subgroup stratified by -2205 genotype. 
Tetrahydroaldosterone (THAldo) excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by -2205 genotype. Metabolite excretion was compared by the non-
parametric Mann-Whitney test. 
Steroid Metabolite (µg/24h) 
-2205 CC 
N=76 
-2205 CT 
N=110 
-2205 TT 
N=37 
p-value 
CC vs. CT+TT 
Aldosterone  
(THAldo) 
Total 
Males 
Females 
2 (1-4.75) 
3 (2-4.5) 
2 (1-5) 
3 (2-4) 
3 (2-5) 
2 (2-3) 
2 (1-4.75) 
3 (2-6.5) 
2(1-2) 
0.93 
0.67 
0.66 
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As described in Chapter 3, the alleles of the studied SNPs exist in various, but 
not random, combinations (Figure 3-18). Here, the association between groups 
of specific genotypes and demographic and corticosteroid excretion rate data 
was compared. Upon examination of Figure 3-18 and data presented in Table 
4-19 to Table 4-23, SNPs at positions -34, -804, -1204, -1488 and -2205 appear to 
exhibit strong linkage disequilibrium. Data from individuals within the BRIGHT 
subgroup who were major homozygote, minor homozygote or heterozygote at all 
five positions (shown below) were extracted and analysed. 
SNP -34 -804 -1204 -1488 -2205 
Group 1 CC GG TT CC CC 
Group 2 TT AA CC GG TT 
Group 3 CT GA TC CG CT 
 
Demographic variables were assessed by comparing the major homozygotes 
group (Group 1) with the minor homozygotes group (Group 2). Age, SBP, DBP and 
BMI were not significantly different between groups, nor when further stratified 
by gender (Table 4-35). WHR was significantly higher in Group 2 compared with 
Group 1, but this effect was not replicated when males and females were 
assessed independently. This difference may be partly explained by the presence 
of considerably more males (n=13) in Group 2 than females (n=6) since the 
gender-specific effects of WHR are well-documented. Corticosteroid excretion 
rates were not significantly different between the two groups, nor when 
assessed separately by gender (Table 4-36). It is likely that these comparisons 
are underpowered to detect small changes. Therefore, the dominant model was 
adopted whereby the major homozygotes (Group 1) were compared to the 
combination of minor homozygotes (Group 2) and those heterozygote at all five 
positions (Group 3). Age, SBP, DBP, BMI and WHR were not significantly different 
between groups (Table 4-37). Similar to when assessed singly, the heterozygote 
and minor homozygote group had significantly lower THDOC:THS ratios compared 
with the major homozygote group, indicative of increased 17α-hydroxylase 
activity (Table 4-37). When stratified by gender, this effect is evident only in 
females. This ratio was then further examined to investigate a possible 
‘heterozygote effect’ (effect is seen only in heterozygotes) where Group 1 and 
Group 3 were compared and similar significant alterations observed (Table 4-38).  
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Table 4-34 Demographic data on the BRIGHT study subgroup stratified by combinations of 
alleles (Group 1 vs. Group 2). 
Demographic data (median and interquartile ranges) of the BRIGHT study subgroup stratified by 
combinations of alleles at positions -34, -804, -1204, -1488 and -2205 of the CYP17A1 gene. 
Demographic characteristics were compared by the non-parametric Mann-Whitney test. SBP: 
systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; WHR: waist-hip 
ratio. 
 Whole Cohort n=91 Males n=41 Females n=50 
 
Group 1 
n=72 
Group 2 
n=19 
p-
value 
1 vs. 2 
Group 1 
n=28 
Group 2 
n=13 
p-
value 
1 vs. 2 
Group 1 
n=44 
Group 2 
n=6 
p-
value 
1 vs. 2 
Age 
(Years) 
63 
(58-67) 
63 
(61-67) 
0.84 
62 
(58-66) 
63 
(61-68) 
0.33 
64 
(59-69) 
65 
(56-66) 
0.69 
SBP 
(mm/Hg) 
157 
(153-187) 
153 
(152-187) 
0.43 
157 
(149-186) 
153 
(151-183) 
0.67 
169 
(156-187) 
173 
(153-195) 
0.96 
DBP 
(mm/Hg) 
102 
(98-107) 
102  
(98-110) 
0.89 
105 
(98-108) 
105 
(98-110) 
0.89 
101 
(98-106) 
101 
(96-105) 
0.74 
BMI 
(kg/m2) 
27 
(24-30) 
28 
(27-31) 
0.36 
27 
(24-30) 
28 
(27-31) 
0.15 
27 
(25-30) 
26 
(24-30) 
0.77 
WHR 
0.86 
(0.83-0.92) 
0.92 
(0.89-0.94) 
0.04 
0.94 
(0.90-0.95) 
0.92  
(0.91-0.94) 
0.68 
0.84 
(0.80-0.86) 
0.84 
(0.80-0.91) 
0.56 
 
Table 4-35 Urinary corticosteroid excretion rates of the BRIGHT study subgroup stratified by 
combinations of alleles (Group 1 vs. Group 2). 
Ratios of urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by combinations of alleles at positions -34, -804, -1204, -1488 and -2205 
of the CYP17A1 gene. Ratios were compared by the non-parametric Mann-Whitney test. THB: 
tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; THA: tetrahydro-11-
dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; THE: 
tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone; THAldo: tetrahydroaldosterone; THDOC: tetrahydrodeoxycorticosterone; THS: 
tetrahydrodeoxycortisol. 
Urinary Steroid Metabolites (µg/24h) Group 1 Group 2 
p-value 
Group 1 vs. Group 2 
Corticosterone metabolites 
(THB + (a)THB + THA) 
Total 
Males 
Females 
102 (59-180) 
163 (90-219) 
81 (53-146) 
123 (85-198) 
123 (83-149) 
149 (91-218) 
0.49 
0.36 
0.16 
Cortisol metabolites  
(THF + (a)THF + THE) 
Total 
Males 
Females 
1354 (670-2435) 
2116 (1375-3381) 
904 (530-1789) 
1388 (891-1800) 
1388 (1245-2149) 
1209 (838-1493) 
0.90 
0.20 
0.64 
Androgen metabolites 
(DHEA + Aetio + Andro) 
Total 
Males 
Females 
614 (317-1182) 
850 (550-1727) 
504 (233-953) 
648 (439-927) 
648 (494-1700) 
574 (408-707) 
0.73 
0.55 
0.78 
Aldosterone 
(THAldo) 
Total 
Males 
Females 
3 (1-5) 
3 (2-4.75) 
2 (1-5) 
3 (2-4) 
3 (2.5-10.5) 
2 (2-2.75) 
0.64 
0.79 
1.00 
THDOC:THS 
Total 
Males 
Females 
0.70 (0.44-1.67) 
0.50 (0.40-0.78) 
1.00 (0.44-2.00) 
0.63 (0.36-1.11) 
0.61 (0.30-1.23) 
0.63 (0.41-0.94) 
0.48 
1.00 
0.49 
Total B:Total F 
(Total B: THB + (a)THB + THA) 
(Total F: THF + (a)THF + THE) 
Total 
Males 
Females 
0.08 (0.05-0.12) 
0.06 (0.05-0.11) 
0.10 (0.06-0.12) 
0.08 (0.06-0.11) 
0.07 (0.06-0.09) 
0.13 (0.08-0.16) 
0.89 
0.68 
0.39 
THS:DHEA 
Total 
Males 
Females 
0.77 (0.29-2.08) 
0.70 (0.38-1.85) 
1.00 (0.29-2.58) 
0.63 (0.33-1.00) 
0.63 (0.30-1.36) 
0.75 (0.54-0.97) 
0.53 
0.71 
0.55 
Total F:Total Androgens 
(Total F: THF + (a)THF + THE) 
(Total Androgens: DHEA + Aetio + Andro) 
Total 
Males 
Females 
2.03 (1.33-3.67) 
2.09 (1.56-3.12) 
2.00 (1.23-4.24) 
1.85 (1.43-3.10) 
1.56 (1.41-2.88) 
2.07 (1.88-3.02) 
0.54 
0.31 
0.89 
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Table 4-36 Demographic data on the BRIGHT study subgroup stratified by combinations of 
alleles (Group 1 vs. Group 2+3). 
Demographic data (median and interquartile ranges) of the BRIGHT study subgroup stratified 
combinations of alleles at positions -34, -804, -1204, -1488 and -2205 of the CYP17A1 gene. 
Demographic characteristics were compared by the non-parametric Mann-Whitney test using the 
dominant model. SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass 
index; WHR: waist-hip ratio. 
 Whole Cohort n=167 Males n=78 Females n=89 
 
Group 1 
n=72 
Group 2+3 
n=95 
p-
value 
1 vs. 2+3 
Group 1 
n=28 
Group 2+3 
n=50 
p-
value 
1 vs. 2+3 
Group 1 
n=44 
Group 2+3 
n=45 
p-
value 
1 vs. 2+3 
Age 
(Years) 
63 
(58-67) 
63 
(55-69) 
0.73 
62 
(58-66) 
63 
(55-68) 
0.67 
64 
(59-69) 
63 
(55-69) 
0.50 
SBP 
(mm/Hg) 
157 
(153-187) 
157 
(153-190) 
0.70 
157 
(149-186) 
157 
(152-188) 
0.52 
169 
(156-187) 
183 
(153-190) 
0.80 
DBP 
(mm/Hg) 
102 
(98-107) 
102 
(98-110) 
0.71 
105 
(98-108) 
103 
(98-110) 
0.59 
101 
(98-106) 
102 
(98-110) 
0.41 
BMI 
(kg/m2) 
27 
(24-30) 
28 
(25-31) 
0.25 
27 
(24-30) 
28 
(26-31) 
0.09 
27 
(25-30) 
27 
(25-29) 
0.92 
WHR 
0.86 
(0.83-0.92) 
0.90 
(0.82-0.93) 
0.27 
0.94 
(0.90-0.95) 
0.93 
(0.91-0.96) 
0.95 
0.84 
(0.80-0.86) 
0.81 
(0.79-0.87) 
0.30 
 
 
Table 4-37 Urinary corticosteroid excretion rates of the BRIGHT study subgroup stratified by 
combinations of alleles (Group 1 vs. Group 2+3). 
Ratios of urinary corticosteroid excretion rates (median and interquartile ranges) of the BRIGHT 
study subgroup stratified by combinations of alleles at positions -34, -804, -1204, -1488 and -2205 
of the CYP17A1 gene. Ratios were compared by the non-parametric Mann-Whitney test. THB: 
tetrahydrocorticosterone; aTHB: allotetrahydrocorticosterone; THA: tetrahydro-11-
dehydrocorticosterone; THF: tetrahydrocortisol; aTHF: allotetrahydrocortisol; THE: 
tetrahydrocortisone; DHEA: dehydroepiandrosterone; Aetio: aetiocholanolone; Andro: 
androsterone; THAldo: tetrahydroaldosterone; THDOC: tetrahydrodeoxycorticosterone; THS: 
tetrahydrodeoxycortisol. 
Urinary Steroid Metabolites (µg/24h) Group 1 Group 2 + 3 p-value 
Group 1 vs. Group 2+3 
Corticosterone metabolites 
(THB + (a)THB + THA) 
Total 
Males 
Females 
102 (59-180) 
163 (90-219) 
81 (53-146) 
102 (69-199) 
124 (73-226) 
87 (55-226) 
0.62 
0.68 
0.63 
Cortisol metabolites  
(THF + (a)THF + THE) 
Total 
Males 
Females 
1354 (670-2435) 
2116 (1375-3381) 
904 (530-1789) 
1516 (776-2447) 
2076 (967-2964) 
1327 (740-1935) 
0.35 
0.52 
0.13 
Androgen metabolites 
(DHEA + Aetio + Andro) 
Total 
Males 
Females 
614 (317-1182) 
850 (550-1727) 
504 (233-953) 
647 (341-1295) 
1062 (495-1804) 
458 (244-817) 
0.59 
0.84 
0.86 
Aldosterone 
(THAldo) 
Total 
Males 
Females 
3 (1-5) 
3 (2-4.75) 
2 (1-5) 
3 (2-5) 
3 (2-5.25) 
2 (2-3) 
0.69 
0.85 
0.65 
THDOC:THS 
Total 
Males 
Females 
0.70 (0.44-1.67) 
0.50 (0.40-0.78) 
1.00 (0.44-2.00) 
0.50 (0.29-1.00) 
0.40 (0.26-1.07) 
0.57 (0.33-0.88) 
0.03 
0.58 
0.01 
Total B:Total F 
(Total B: THB + (a)THB + THA) 
(Total F: THF + (a)THF + THE) 
Total 
Males 
Females 
0.08 (0.05-0.12) 
0.06 (0.05-0.11) 
0.10 (0.06-0.12) 
0.07 (0.05-0.10) 
0.07 (0.05-0.10) 
0.07 (0.05-0.10) 
0.49 
0.42 
0.10 
THS:DHEA 
Total 
Males 
Females 
0.77 (0.29-2.08) 
0.70 (0.38-1.85) 
1.00 (0.29-2.58) 
0.88 (0.30-1.90) 
0.67 (0.28-1.38) 
1.00 (0.42-2.06) 
0.94 
0.71 
0.64 
Total F:Total Androgens 
(Total F: THF + (a)THF + THE) 
(Total Androgens: DHEA + Aetio + Andro) 
Total 
Males 
Females 
2.03 (1.33-3.67) 
2.09 (1.56-3.12) 
2.00 (1.23-4.24) 
2.28 (1.47-3.57) 
1.77 (1.24-2.79) 
2.97 (1.85-4.79) 
0.76 
0.18 
0.10 
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Table 4-38 Ratios of THDOC:THS of the BRIGHT study subgroup stratified by combinations 
of alleles (Group 1 vs. Group 3). 
Ratios of THDOC:THS (median and interquartile ranges) of the BRIGHT study subgroup stratified 
by combinations of alleles at positions -34, -804, -1204, -1488 and -2205 of the CYP17A1 gene. 
Ratios were compared by the non-parametric Mann-Whitney test. THDOC: 
tetrahydrodeoxycorticosterone; THS: tetrahydrodeoxycortisol. 
Urinary Steroid Metabolites (µg/24h) Group 1 Group 3 
p-value 
Group 1 vs. Group 3 
THDOC:THS 
Total 
Males 
Females 
0.70 (0.44-1.67) 
0.50 (0.40-0.78) 
1.00 (0.44-2.00) 
0.49 (0.29-1.00) 
0.40 (0.25-1.00) 
0.57 (0.29-0.88) 
0.02 
0.49 
0.01 
  
158 
 
4.5 Discussion 
This is the first study to provide a detailed and extensive examination of the 
association between polymorphic variation in the human CYP17A1 gene and 
intermediate steroidogenic phenotype in a hypertensive cohort. Seven common 
polymorphisms located in the promoter region immediately upstream of the 
gene transcriptional start site were selected for investigation. A subset of the 
BRIGHT study cohort (n=511) had previously been analysed in a similar study 
looking at associations between corticosteroid excretion and polymorphisms in 
the CYP11B1 and CYP11B2 genes (Barr et al., 2007; Freel et al., 2007). In the 
current study, however, the remaining DNA was available for just 232 of these 
subjects. The genotype distribution of each polymorphism in this group was 
presented in Chapter 3. The association of the alleles at these polymorphic 
locations in CYP17A1 with corticosteroid metabolite excretion has been assessed 
and the findings will now be discussed. 
Power & Data Analysis 
The earlier studies had calculated that 180 homozygous subjects from this 
cohort would be required in order to achieve 80% power to detect a difference 
in THS/Total F ratio of 0.004 with an α level of 0.05 (Barr et al., 2007; Freel et 
al., 2007). The size of the effect of each allele of SNPs in CYP17A1 on 
corticosteroid excretion was not known however, rendering accurate power 
calculations for the current study difficult. In addition, the number of subjects 
available in this study was approximately half that of previous studies. Although 
this remains a relatively large study, the analysis proceeded in the knowledge 
that a larger number of participants may be required in order to detect 
excretion rate differences at similar levels of significance.  
Choosing a suitable method of analysis was partly dictated by the fact that the 
cohort contained only two individuals with the minor homozygote genotype at 
position -1877 (Table 4-1). The dominant model was therefore adopted, whereby 
the major homozygote group is compared to a group combining heterozygotes 
and minor homozygotes (DD vs. Dd & dd). This model specifically tests the 
association of having at least one minor allele versus none at all i.e. testing 
whether the presence of the minor allele, whether it be one copy or two, is 
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associated with altered corticosteroid excretion. The dominant model is suitable 
for this study as it includes the data from all individuals. Previous studies of this 
cohort examined the allelic effect (i.e. DD vs. dd), ignoring heterozygote data, 
or the genotype effect (DD vs. Dd vs. dd) which addresses possible additive or 
‘dose-dependent’ effects of alleles (e.g. do individuals with dd genotype exhibit 
a greater phenotypic effect than those with Dd genotype when compared to DD 
individuals?). The dominant model does not allow this comparison. Nonetheless, 
the dominant model is more appropriate for genotype groups with low numbers. 
Therefore, it was used to assess association of excretion rates with all seven 
polymorphisms in order to ensure that associations were derived in the same 
way and could be compared without bias.  In future, it would be interesting to 
test the data using different models of analysis, wherever the number of 
individuals is sufficient to permit this. 
Urinary corticosteroid excretion data were not normally distributed and non-
parametric testing was employed. Various transformations, including log, inverse 
and square root, were performed on the data in an attempt to achieve a normal 
distribution pattern that would enable increased statistical power through 
parametric testing, but THAldo, THS, THDOC and the combination of cortisol (F) 
metabolites all failed to conform. Therefore non-parametric analysis was 
conducted on all metabolite excretion rate data. The two main methods of 
analysis in this dataset were the Mann-Whitney U-test and the Spearman co-
efficient of variation. Had the data been normally distributed, linear regression 
analyses might have been utilised allowing adjustment for covariates, such as 
gender. Instead, gender effects were assessed separately.  
Demographic Variables & Steroid Excretion 
The mean BMI of this hypertensive population was 27.5, and therefore not 
grossly over weight. Waist:hip ratio was significantly higher in males compared 
to females due to gender-dependent differences in fat distribution (Table 4-2). 
There were no genotype-dependent effects on blood pressure, BMI or WHR 
(Table 4-3 to Table 4-9). Interestingly, comparison of systolic blood pressure 
between genotype groups showed no significant differences. Recent GWAS 
associated the major allele of a SNP in strong LD with -1877 in the human 
CYP17A1 gene with an increase in systolic blood pressure of 1.16 mmHg (Levy et 
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al., 2009; Newton-Cheh et al., 2009). In fact, the BRIGHT cohort from which this 
subgroup was obtained was part of one of those GWAS (Newton-Cheh et al., 
2009). For a better understanding of the postulated contribution of 
corticosteroids to this systolic blood pressure increase, a comparison of -1877 CC 
vs. TT genotype groups would have been ideal. Furthermore, to assess whether 
the presence of the C allele contributed to increased blood pressure, the 
recessive model of analysis could have been adopted (CC+CT vs. TT). Given that 
the minor allele frequency is approximately 9%, urinary corticosteroid excretion 
data would be required for thousands of hypertensive individuals in order to 
attain a large enough TT genotype group for valid statistical comparison. This 
would be a large and expensive study. A smaller, detailed analysis of 
intermediary and end-product metabolites such as that described here may 
better provide a guide to new lines of investigation that can be pursued further 
using in vitro systems. 
Highly significant correlations between the three major zona fasciculata and 
zona reticularis corticosteroid sub-groups were seen in this cohort. The 
explanation is that corticosterone, cortisol and androgen production rates are all 
ACTH-dependent. In addition, all three were found to be significantly different 
in males compared with females (Table 4-10).  When corticosterone, cortisol and 
androgen excretion rates were stratified by genotype for the whole cohort, no 
significant differences were observed between genotypes at any locus. When 
further split by gender, a significantly higher cortisol metabolite excretion rate 
was noted for males of AG genotype at position -362, compared to the AA 
genotype (there were no males of GG genotype). Similarly, cortisol metabolite 
excretion was higher in the female heterozygote and minor homozygote group at 
positions -1204 and -2205 when compared with the major homozygote group. 
Interestingly, corticosterone and androgen excretion was not altered. Based on 
observations when using an inhibitor of CYP17A1 clinically (Section 4.1), it would 
be expected that alterations in corticosterone and androgen excretion rates 
would occur in tandem with changes in cortisol excretion rates, due to a 
disturbance in the flow of the system. These results indicate a gender-
dependent effect of these alleles on cortisol production alone. It should be 
borne in mind that the urinary androgen metabolite excretion rates in males are 
likely to contain a significant contribution from the testes, hence are not solely 
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representative of adrenal production (Auchus and Arlt 2013). The gender-specific 
differences in plasma cortisol levels and urinary excretion rates have previously 
been reported (Van Cauter et al., 1996; Fraser et al., 1999) but the additional 
genotype-dependent effects seen here are less-well explained. A recent study 
reported an association between increased systolic blood pressure and a variant 
located near CYP17A1 (rs11191548) in female but not male children (Wu et al., 
2012). In isolation, theory suggests the negative feedback inhibition resulting in 
reduced ACTH drive, would preserve normal physiological levels (Section 
1.2.1.1). The reality is more complex. For example, the presence of the minor 
allele at a SNP might alter transcription factor binding to the region, increasing 
enzyme production. An increased supply of cortisol precursors in the 17α-
hydroxy-pathway would increase cortisol production, so long as CYP11B1 is not a 
limiting factor. This theory implies that increased 17α-OH-pregnenolone and 17α-
OH-progesterone would result, providing additional substrate for 17,20 lyase. 
However, insufficient quantities of, for example, the cytochrome b5 co-factor 
may be a limiting factor preventing an increase in this arm of the pathway and 
explaining the lack of increased androgen production.  
Ratios of 17α-Hydroxylase/17, 20 Lyase Activity 
Ratios of levels of substrate to product can provide an index of enzymatic 
activity (Section 4-1). For the respective conversions of pregnenolone and 
progesterone to DHEA and androstenedione, such ratios would have been an 
ideal indicator of 17α-hydroxylase/17,20 lyase efficiency, utilising measurements 
of the intermediary compounds 17α-OH-pregnenolone and 17α-OH-progesterone 
to provide insight into the individual hydroxylase and lyase reactions (Figure 
1-7). These measurements were not made in this cohort. Instead, ratios of the 
urinary metabolites of DOC:S and B:F were used as indices of 17α-hydroxylase 
activity, with DOC and B representing the 17-deoxysteroid pathway and S and F 
the 17α-hydroxysteroid pathway. S:DHEA and F:total androgen metabolites (DHEA 
+ aetiocholanolone + androsterone) acted as indices of 17,20 lyase activity. A 
disadvantage is that the ratios may also be affected by other enzymes in the 
pathway (e.g. CYP11B1, 3βHSDII and CYP21A1) if these are rate-limiting and so 
cannot serve solely as indications of CYP17A1 enzymatic activity. Ratios of DOC:S 
and B:F did not differ significantly between males and females. However, it is 
interesting to observe an apparent gender effect when further stratified by 
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genotype at positions -34, -1204, -2205, and (less convincingly) -804 and -1488. 
In females, ratios of THDOC:THS were lower in the presence of the minor allele 
at these polymorphic locations and may suggest increased activity of 17α-
hydroxylase. This is particularly interesting as increased cortisol excretion rates 
were observed in females carrying the minor allele at positions -1204 and -2205. 
A slightly higher ACTH drive, or greater sensitivity to ACTH by the adrenal cortex 
has previously been postulated in females and may contribute to the effects 
seen here (Horrocks et al., 1990). These five SNPs exhibit high LD (Chapter 3) 
and therefore it is not surprising that similar changes in ratios were observed. 
Further in vitro analysis is required to separate those SNPs serving merely as 
markers co-inherited alongside the causative SNP/SNPs. 
Theoretically, similar significant genotype-dependent ratios may be expected for 
DOC:S and B:F, since the former are precursors of the latter compounds. The 
data presented here do not comply with this prediction (Table 4-18 to Table 
4-25). There are several possible explanations. Firstly the 11β-hydroxylase 
(CYP11B1) enzyme converts DOC to B and S to F. It is possible that this enzyme 
step is at or near capacity, which has previously been suggested (McManus 2012). 
This would be reflected in ratios of the urinary metabolite excretion rates of 
DOC:B and S:F. 11β-hydroxylase has previously been implicated in the 
development of hypertension (Section 1.1.3.1 and Section 1.3.3.2) and may also 
be separately impaired in these subjects. In fact, previous studies on this cohort 
have suggested altered 11β-hydroxylase activity in the presence of a particular 
allele (Freel et al., 2007). Secondly increased levels of DOC (and corticosterone) 
and decreased levels of 11-deoxycortisol (and cortisol) are evident in individuals 
with 17α-hydroxylase deficiency and mineralocorticoid hypertension (Dhir et al., 
2009; Neres et al., 2010). Future work might include collating the data from past 
and present studies and examining the combined effects of polymorphic 
variation in candidate genes. 
In general, ratios of S:DHEA and F:(DHEA + aetiocholanolone + androsterone) 
levels were not significantly different when stratified by genotype. The F:DHEAS 
ratio has previously been shown to be higher in men with the metabolic 
syndrome (MetS) than in normal men (Phillips et al., 2010). MetS is a collection 
of symptoms that increase cardiovascular risk (NCEP 2002). Phillips et al. utilised 
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measurements from blood samples which, given the diurnal rhythm of cortisol, 
may not be directly comparable to 24-hour urinary measurements. 
Aldosterone 
Aldosterone excretion rates of the group carrying the CC genotype at position 
-1877 were significantly higher than those of CT+TT group (Table 4-32). This is 
intriguing, as the zonation and direction of blood flow within the adrenal cortex, 
renders it very unlikely that CYP17A1 could have a direct effect on aldosterone 
production. However, an indirect effect of ACTH has previously been proposed 
following the identification of significant correlation between excretion rates 
and levels of cortisol and androgen metabolites in hypertensive individuals with 
TT genotype at position -344 of the CYP11B2 gene (Freel et al., 2007). In 
addition, several genes required for the production of aldosterone are ACTH 
responsive (Miller 1988). It could be postulated that the CC genotype at position 
-1877 of CYP17A1 is associated with increased ACTH drive which may, in the long 
term, enhance the response of aldosterone to its trophins. Long term, small 
increases may enhance responsiveness whereas massive increases, as seen in 
17α-hydroxylase deficiency, inhibit it completely. 
SNPs in Combination 
The effects of some of the polymorphisms as they exist in combination in man 
have been briefly explored. Investigations here have revealed SNPs at positions 
-34, -804, -1204, -1488 and -2205 exhibit strong linkage disequilibrium. The 
individual analysis of urinary corticosteroid excretion rates stratified by 
genotype at each of these locations displayed similar trends strengthening the 
notion that certain combinations of alleles are inherited together (Table 4-36, 
Table 4-38 and Table 4-39). It was possible that examination of SNPs in 
combination might produce a more pronounced effect or even a neutralising 
one; however, the results presented here give credence to the hypothesis that 
one or more of the SNPs may be functional and the rest are merely markers 
inherited alongside. It is unclear from these analyses whether the comparison of 
major and minor homozygote groups is underpowered or whether the 
heterozygote allelic combination is solely responsible for the effect seen on 
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THDOC:THS ratios. It would be necessary to examine this further in a larger 
population. 
Overall review 
There are limitations to this study imposed by the nature and quantity of the 
experimental material available. A comparable control group with urine 
measurements is lacking but this study, as a comparison of genotypes, is 
internally-controlled. However it would be interesting to observe whether 
differences observed also exist in normotensives. In addition, as described in 
Chapter 3, the polymorphisms of interest exist in haplotype blocks and the 
overall effects of these SNPs in combination have only been briefly explored 
here.   Nonetheless, clear and convincing genotype-dependent changes in 
corticosteroid excretion rates were observed, despite using a smaller, albeit still 
large, cohort than had been employed in previous similar studies. These data 
provide an excellent basis both for an expanded genotype/intermediate 
phenotype analysis and for molecular characterisation studies to elucidate the 
underlying mechanisms. 
4.6 Conclusions 
This is the first study to explore the underlying genetic basis and consequences 
of polymorphic variation across the CYP17A1 locus in a hypertensive population. 
Evidence is presented that genetic variation within the CYP17A1 promoter region 
is related to alterations in corticosteroid levels which may contribute to the 
phenotype of hypertension. Further investigation into the molecular mechanisms 
behind these genotype-dependent corticosteroid alterations is warranted. 
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5 In Vitro Studies of CYP17A1 Transcription. 
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5.1 Introduction 
Since there is minimal storage of steroid hormones in the adrenal cortex, an 
increase in the levels of circulating hormones is principally determined by the 
conversion of cholesterol in response to trophins that initiates in the 
steroidogenic pathway. The trophin of interest in this thesis is ACTH. The 
transcriptional regulation of steroidogenic enzymes upon ACTH stimulation is 
therefore a crucial factor in steroid homeostasis. This chapter will examine the 
functional effects of polymorphic variations in the CYP17A1 promoter region on 
gene transcription. 
As reviewed in Section 1.4.2, there have been numerous investigations into the 
transcriptional regulation of CYP17A1. The majority of these studies were 
undertaken around a decade before the work contained in this thesis. Early 
investigations revealed that the first 227 base pairs immediately upstream of the 
transcriptional start site are responsible for 60-80% of the transcriptional activity 
at this locus (Lin et al., 2001). Transcription factors regulating adrenally-
expressed CYP17A1 are summarised in Figure 5-1, which also shows the location 
of their binding sites.  
 
 
Figure 5-1 Transcription factor binding sites characterised in the human adrenally-
expressed CYP17A1 promoter region. 
Locations of DNA binding regions relative to the transcription start site are provided beneath each 
transcription factor. SREBP-1:  sterol regulatory element binding protein 1; SF-1: steroidogenic 
factor 1; Sp1/3: specificity protein-1/3; GATA-6: family member 6 of GATA transcription factor 
family; NF-1: nuclear factor 1. 
 
The currently favoured human cell model of adrenal steroidogenesis is the 
NCI-H295 cell line. It is derived from an adrenocortical carcinoma that was 
surgically removed from a 48-year-old black female. An adherent cell line, 
H295R, was generated which has the ability to synthesise and secrete most 
adrenal steroids (Gazdar et al., 1990; Rainey et al., 1994). Several modified 
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strains of this cell line are now available, overcoming the requirement for the 
bovine-derived serum substitute Ultroser G which is in limited supply. Steroid-
producing capabilities are, however, greatest using Ultroser G, so this particular 
strain was selected for this study. H295R cells are deemed to combine the 
characteristics of cells from the three zones of the adrenal cortex, hence 
expressing enzymes required for the biosynthesis of mineralocorticoids, 
glucocorticoids and androgens. The cells are responsive to the trophins AngII and 
potassium (K+) but do not express the ACTH receptor and therefore do not 
respond to ACTH stimulation (Bird et al., 1993; Mountjoy et al., 1994). To 
overcome this issue, cells are routinely stimulated with either dibutyryl cyclic 
adenosine monophosphate ((Bu)2cAMP), or Forskolin, as a substitute to mimic 
the intracellular activation of cAMP, which normally occurs upon stimulation by 
ACTH. 
The data presented in Chapter 3 of this thesis identified a total of 14 
polymorphisms in the region upstream from the transcriptional start site of 
CYP17A1. Of the 14, 7 SNPs had a minor allele frequency above 5% and are 
therefore considered a common polymorphism in the studied cohort of 60 
Caucasian normotensive volunteers from the west of Scotland. The same 7 SNPs 
had a minor allele frequency above 5% in the hypertensive subset of the BRIGHT 
cohort (Table 3-2). These 7 polymorphisms were therefore chosen for further in 
vitro investigation of the hypothesis that common genetic variation can lead to 
subtle changes in blood pressure through effects on steroidogenesis. 
5.2 Aims 
The aims of this study were to investigate functional effects of common 
polymorphic variation in the promoter region of CYP17A1. By firstly using 
bioinformatic databases, putative transcription factor binding at the sites of 
polymorphic variation were identified. The polymorphic sites were then assessed 
and prioritised for further in vitro study based on these bioinformatic 
predictions. An in vitro reporter gene system was then used to determine the 
effects of SNP variation on CYP17A1 basal promoter activity and in response to 
stimuli.  
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5.3 Bioinformatics 
5.3.1 Methods 
To investigate whether polymorphisms of interest reside within putative 
transcription factor binding sites, the DNA sequences flanking the SNPs were 
assessed using three databases. The sequences entered into each database are 
displayed in Table 5-1. The Transcription Element Search System (TESS) is an 
internet-based tool for predicting transcription factor binding sites within DNA 
sequences (http://www.cbil.upenn.edu/tess). Searches were performed on 
24/09/10 using default settings; however, this resource has since been removed 
from service. Similar searches were performed using MatInspector software 
within the Genomatrix Software Suite v2.7. This software is previously described 
elsewhere (Quandt et al., 1995; Cartharius et al., 2005). In addition, 
polymorphic sites of interest were evaluated for putative transcription factor 
binding using TRANSFAC® Professional v10.1 database. This database allows DNA 
sequences to be compared to transcription factor binding sequences verified 
experimentally and published in peer-reviewed journals. The database contains 
an internet-based program called Match which assesses putative transcription 
factor binding using matrices. Matrices combine both experimentally validated 
transcription factor binding sequences and data extracted from published 
studies. Match then assigns a score of the relative likelihood of the DNA 
sequence binding to a particular transcription factor. The five most highly 
conserved bases within the sequence are termed the ‘core’. Thresholds were set 
to the suggested value of 0.75 for core binding and 0.70 for matrix binding, with 
1.0 corresponding to 100% similarity. The option to analyse only vertebrate 
matrices was selected. These results were obtained during a free trial of this 
subscription-only database. 
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Table 5-1 Sequences entered into bioinformatic searches for putative transcription factor 
binding around sites of polymorphic variation.  
TSS: transcriptional start site; MAF: minor allele frequency 
SNP 
SNP Position 
Relative to TSS 
MAF 
in AFS 
MAF 
in BRIGHT 
Sequence 
rs743572 
T/C 
-34 0.282 0.420 
tactccacTgctgtcta 
tactccacCgctgtcta 
rs2486758 
A/G 
-362 0.242 0.183 
ttttgcaAcatggaa 
ttttgcaGcatggaa 
rs10883784 
G/A 
-804 0.210 0.304 
ctcagccGgctgacac 
ctcagccAgctgacac 
rs10786713 
T/C 
-1204 0.306 0.417 
agacagtaTgtgcacc 
agacagtaCgtgcacc 
rs10786714 
C/G 
-1488 0.210 0.304 
ataaatggaCatgcaagta 
ataaatggaGatgcaagta 
rs138009835 
C/T 
-1877 0.177 0.109 
gagatgttgCgggaagtc 
gagatgttgTgggaagtc 
rs2150927 
C/T 
-2205 0.306 0.413 
ggtcaaaggaCaccttctggg 
ggtcaaaggaTaccttctggg 
 
Output files from all three searches were compiled within Microsoft Excel and 
duplicates removed. The results for each site of polymorphic variation were then 
compared. 
5.3.2 Results 
After the removal of duplicate results, in excess of 1,000 individual transcription 
factors were predicted to bind to the seven polymorphic sites of interest within 
the CYP17A1 promoter region. Output from each search varied, as may be 
expected, with the freely-accessible databases providing substantially fewer 
matches compared to the subscription-only database. The number of individual 
transcription factors predicted to bind to the DNA sequences containing the 
flanking regions of each SNP can be found in Table 5-2. 
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Table 5-2 Number of transcription factor binding sites predicted by each database for the 
flanking sequence of each polymorphism.  
TSS: transcriptional start site; TESS: Transcription Element Search System 
SNP 
(Position relative to 
TSS) 
Allele TESS MatInspector TRANSFAC® 
rs743572 
(-34) 
T 3 0 48 
C 4 2 57 
rs2486758 
(-362) 
A 5 7 59 
G 1 3 29 
rs10883784 
(-804) 
G 2 4 34 
A 6 6 60 
rs10786713 
(-1204) 
T 2 1 48 
C 2 3 45 
rs10786714 
(-1488) 
C 3 2 108 
G 4 2 90 
rs138009835 
(-1877) 
C 4 3 112 
T 5 2 91 
rs2150927 
(-2205) 
C 9 3 117 
T 7 1 97 
 
Opposing alleles were predicted to alter transcription factor binding for all seven 
SNPs of interest. Many of the predictions saw the same transcription factor bind 
to each site, independent of the allele at the polymorphic site, presumably with 
altered binding affinity. These transcription factors are not presented in this 
thesis, although a selection of those previously reported to regulate CYP17A1 are 
presented in Table 5-3 and discussed below (Section 5.3.3). The remainder of 
transcription factor binding site predictions either introduced an alternative 
transcription factor or abolished a putative site when comparing alleles at each 
site. The results for each SNP are shown in Table 5-4 to Table 5-10. A literature 
search was then conducted to identify any previously reported transcription 
factors implicated in the regulation of adrenal CYP17A1. These are highlighted in 
red. 
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Table 5-3 Transcription factors predicted to bind to each polymorphism irrespective of 
allele. 
SNP 
SNP 
Position 
Relative 
to TSS 
Transcription 
Factor 
Summary Reference 
rs2486758 
A/G 
-362 NF-1 
Nuclear Factor 1, a transcription 
factor shown to interact with the 
Sp1:Sp3 complex and regulate the 
basal transcription of CYP17A1 
Lin et al., 
2001 
rs138009835 
C/T 
-1877 GATA-6 
GATA binding protein 6, a 
transcription factor expressed in 
the zona reticularis of the adrenal 
cortex and shown to regulate both 
CYP17A1 and CYB5A 
Jimenez et 
al., 2003, 
Flück and 
Miller 2004 
rs2150927 
C/T 
-2205 SF-1 (NR5A1) 
Nuclear receptor subfamily 5 group 
A member 1, a transcription factor 
with known involvement in 
steroidogenesis and CYP17A1 
transcription 
Sewer et 
al., 2002, 
Hanley et 
al., 2001 
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Table 5-4 Transcription factors predicted to bind only the T allele or the C allele at position 
-34 of CYP17A1.  
Transcription factors previously implicated in the literature as being transcriptional regulators of 
CYP17A1 are highlighted. 
-34 (rs743572) 
T allele C allele 
BRN1 (POU3F3) POU class 3 homeobox 3 AP-2 Transcription factor AP-2 family 
c-Myb 
Homolog of v-myb myeloblastosis viral 
oncogene 
deltaEF1 (ZEB1/ 
AREB6) 
Zinc finger E-box binding homeobox 1 
HIC1 Hypermethylated in cancer 1 BTEB3 (KLF 13) Kruppel-like factor 13, 
Kid3 (ZNF354C) 
Protein with high similarity to zinc finger 
protein 354c  
CAC binding 
protein 
CAC binding protein 
LTF Lactoferrin CBF  Core binding factor 
NF-Y Nuclear transcription factor Y family CNOT3 CCR4-NOT transcription complex subunit 3 
Nkx-2.5 (CSX) NK2 homeobox 5 
deltaEF1 (ZEB1/ 
AREB6) 
Zinc finger E-box binding homeobox 1 
NKX3A NK3 homeobox 1 E2F E2F transcription factor family 
SMAD5 SMAD family member 5 Egr Early growth response 1/family 
Sox4 SRY-box 4 EKLF (KLF1) Kruppel-like factor 1 erythroid 
TTF-1 (Nkx2-1) NK2 homeobox 1 ETF EGFR-specific transcription factor 
  FKLF (KLF 11) Kruppel-like factor 11 
  FPM315 (ZNF263) Zinc finger protein 263 
  GKLF (KLF4) Kruppel-like factor 4 
  GLI3 GLI family zinc finger 3 
  INSM1 Insulinoma-associated 1 
  LRF Zinc finger and BTB domain containing 7A 
  NF-E4 Transcription factor NF-E4 
  Pbx-1 Pre-B-cell leukaemia transcription factor 1 
  
PEBP (AML1 / 
RUNX1) 
Runt-related transcription factor 1, a 
transcriptional coactivator 
  SNA (SNAI1) Snail homolog 1, a transcriptional repressor 
  Sp1 Sp1 transcription factor 
  Sp1:Sp3 Sp1:Sp3 transcription factor complex 
  Sp2 Sp2 transcription factor 
  Sp4 Sp4 transcription factor 
  T3RALPHA (THRA) Thyroid hormone receptor alpha 
  ZABC1 (ZNF217) Zinc finger protein 217 
  ZBP89 Zinc finger protein 148 
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Table 5-5 Transcription factors predicted to bind only the A allele or the G allele at position 
-362 of CYP17A1.  
Transcription factors previously implicated in the literature as being transcriptional regulators of 
CYP17A1 are highlighted. 
-362 (rs2486758) 
A allele G allele 
Dec1 Basic helix-loop-helix family member e40 AhR Aryl hydrocarbon receptor 
PEBP (AML1 / 
RUNX1) 
Runt-related transcription factor 1 
BEN 
(GTF2IRD1) 
GTF2I repeat domain-containing 1 
deltaEF1 (ZEB1/ 
AREB6) 
Zinc finger E-box binding homeobox 1 
KAISO 
(ZBTB33) 
Zinc finger and BTB domain containing 33 
BRCA1:USF2 
Breast cancer 1 early onset: Upstream 
transcription factor 2  complex 
MafA 
V-maf musculoaponeurotic fibrosarcoma oncogene 
homolog A 
c-Myb 
Homolog of v-myb myeloblastosis viral 
oncogene 
SAP-1a (ELK4) ELK4 ETS-domain protein 
Ebox Enhancer box SMAD1 SMAD family member 1 
Evi-1 (MECOM) MDS1 and EVI1 complex locus SMAD5 SMAD family member 5 
FAC1 (BPTF) 
Bromodomain PHD finger transcription 
factor 
  
FOXO4 Forkhead box O4   
HIF-1alpha Hypoxia inducible factor 1 alpha    
HIF-2alpha 
(EPAS1) 
Endothelial PAS domain protein 1   
HMGIY 
(HMGA1) 
High mobility group AT-hook 1   
HNF-3alpha 
(FOXA1) 
Forkhead box A1   
HNF-3beta 
(FOXA2) 
Forkhead box A2   
MITF 
Microphthalmia-associated transcription 
factor 
  
MRF-2 (ARID5B) AT rich interactive domain 5B (MRF1-like)   
MYB 
Homolog of v-myb myeloblastosis viral 
oncogene family 
  
N-MYC 
V-myc myelocytomatosis viral related 
oncogene neuroblastoma derived 
  
POU5F1 (Oct3) POU class 5 homeobox 1   
Prx2 Paired related homeobox 2   
Sox17 SRY (sex determining region Y)-box 17   
Sox18 SRY (sex determining region Y)-box 18,    
Sox4 SRY (sex determining region Y)-box 4,   
Sox5 SRY (sex determining region Y)-box 5   
TFE (TFEA/TFE3) Transcription factor E3   
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Table 5-6 Transcription factors predicted to bind only the G allele or the A allele at position 
-804 of CYP17A1.  
Transcription factors previously implicated in the literature as being transcriptional regulators of 
CYP17A1 are highlighted. 
-804 (rs10883784) 
G allele A allele 
AP-2beta  Transcription factor AP-2 beta AP1  Activating enhancer binding protein 1 
BTEB3 (KLF 13) Kruppel-like factor 13 CCAAT box CCAAT box 
E2F E2F transcription factor family c-MAF 
v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog 
ELK-1 ELK1 member of ETS oncogene family Dec Basic helix-loop-helix family members 
Erm (ETV5) ETS variant 5 deltaEF1 (ZEB1) Zinc finger E-box binding homeobox 1 
FKLF (KLF 11) Kruppel-like factor 11 E12 (TCF3) Transcription factor 3 (also E2A/E47) 
MECP2 Methyl CpG binding protein-2 Ebox Enhancer box 
Sp1 Sp1 transcription factor Fra-1 (FOSL1) FOS like antigen 1 
  GCMa Glial cells missing homolog 1 
  HTF4 (TCF12) Transcription factor 12 
  JunB Jun B proto-oncogene 
  Kid3 (ZNF354C) Similarity to zinc finger protein 354c 
  Lmo2 (RBTN2)  LIM domain only 2 
  MEIS1A:HOXA9 Meis homeobox 1: Homeobox A9  
  MITF Microphthalmia-associated TF 
  MRF4 (myf6) Myogenic factor 6 
  MyoD Myogenic differentiation 1 
  N-Myc V-myc myelocytomatosis derived 
  p53 (TP53) Tumour protein p53 
  REX1 (ZFP42) Zinc finger protein 42 homolog 
  RP58 (ZBTB18) Zinc finger protein 238, C2H2-type  
  slug (SNAI2) Snail homolog-2 
  SMAD2 SMAD family member 2 
  SNA (SNAI1) Snail homolog 1 
  SREBP1 (SREBF1) Sterol regulatory element binding 1 
  TTF-1 (Nkx2-1) NK2 homeobox 1 
  TWIST Twist homolog 1 
  USF Upstream transcription factor 1 
  USF2 Upstream transcription factor 2 
  YY1 YY1 transcription factor 
  ZF5 (ZPB161) Zinc finger protein 161 homolog 
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Table 5-7 Transcription factors predicted to bind only the T allele or the C allele at position 
-1204 of CYP17A1.  
Transcription factors previously implicated in the literature as being transcriptional regulators of 
CYP17A1 are highlighted. 
-1204 (rs10786713) 
T allele C allele 
Oct1 (POU2F) POU class 2 homeobox 1 Dec1 (BHLHE40) 
Basic helix-loop-helix family 
member e40 
PEBP (AML1 / RUNX1) Runt-related transcription factor 1 ChREBP (MLXIPL) 
MLX interacting protein-like, a 
bHLH transcription factor 
GR (NR3C1) 
Nuclear receptor subfamily 3 group 
C member 1/ glucocorticoid 
receptor 
HSF2 Heat shock transcription factor 2 
MafA 
V-maf musculoaponeurotic 
fibrosarcoma oncogene homolog A 
MITF 
Microphthalmia-associated 
transcription factor 
mef2A Myocyte enhancer factor 2A MyoD Myogenic differentiation 1 
MEF-2C Myocyte enhancer factor 2C p53 (TP53) Tumour protein p53 
MEF-2D Myocyte enhancer factor 2D TR4 (NR2C2) 
Nuclear receptor subfamily 2 
group C member 2 
MRF4 (myf6) Myogenic factor 6 TTF-1 (Nkx2-1) NK2 homeobox 1 
Osf2 (AML3/ RUNX2) Runt-related transcription factor 2 USF2 Upstream transcription factor 2  
SNA (SNAI1) Snail homolog 1 ZF5 (ZBTB14/ZPB161) Zinc finger protein 161 homolog 
Sox5 
SRY (sex determining region Y)-box 
5 
  
SREBP1 (SREBF1) 
Sterol regulatory element binding 
transcription factor 1 
  
TBP TATA box binding protein   
YY1 YY1 transcription factor   
ZNF333 Zinc finger protein 333   
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Table 5-8 Transcription factors predicted to bind only the C allele or the G allele at position 
-1488 of CYP17A1.  
Transcription factors previously implicated in the literature a being transcriptional regulators of 
CYP17A1 are highlighted. 
-1488 (rs10786714) 
C allele G allele 
Dec1 Basic helix-loop-helix family member e40 AP-3 Activating enhancer binding protein 3 
AhR Aryl hydrocarbon receptor AP-4 Activating enhancer binding protein 4 
AR Androgen receptor  ATF5 Activating transcription factor 5 
Arnt 
Aryl hydrocarbon receptor nuclear 
translocator 
CDP CR3+HD Cut-like homeobox 1 
COUP-TF1 
Chicken ovalbumin upstream promoter 
transcription factor 1 
deltaEF1 (ZEB1) 
Zinc finger E-box binding homeobox 
1 
ER-alpha (ESR1) Estrogen receptor 1 E12 (TCF3/ E2A/ E47) Transcription factor 3 
ER-beta (ESR2) Estrogen receptor 2 Gfi1b Growth factor independent 1B  
ERR1 (ESRRA) Estrogen-related receptor alpha HTF4 (TCF12) Transcription factor 12 
Evi-1 (MECOM) MDS1 and EVI1 complex locus ING4 Inhibitor of growth family member 4 
FXR (NR1H4) 
Nuclear receptor subfamily 1 group H 
member 4 
MafA 
V-maf musculoaponeurotic 
fibrosarcoma oncogene homolog A 
HIC1 Hypermethylated in cancer 1 MATH1 (ATOH1) Atonal homolog 1 
HIF-1alpha Hypoxia inducible factor 1 alpha  MRF4 (Myf6) Myogenic factor 6, 
HIF1A:ARNT 
Aryl hydrocarbon receptor nuclear 
translocator:Hypoxia inducible factor 1 
alpha complex 
MyoD Myogenic differentiation 1 
HIF-2alpha (EPAS1) Endothelial PAS domain protein 1 MZF1 Myeloid zinc finger 1 
KAISO (ZBTB33) Zinc finger and BTB domain containing 33 NeuroD Neuronal differentiation 1 
LTF Lactoferrin NF-E2 Nuclear factor erythroid derived 2 
MEIS1 Meis homeobox 1 PAX5 Paired box 5 
MITF 
Microphthalmia-associated transcription 
factor 
POU6F1 POU class 6 homeobox 1 
MIZF Histone H4 transcription factor RFX Regulatory factor X 1  
Msx-1 Msh homeobox 1 Smad2 SMAD family member 2ator 
Nanog Nanog homeobox Smad3 SMAD family member 3 
NR1B1 (RARA) Retinoic acid receptor alpha Sp2 Sp2 transcription factor 
NR1B2 (RARB) Retinoic acid receptor beta Tal-1 T-cell acute lymphocytic leukemia 1 
NR4A2 (NURR1) 
Nuclear receptor subfamily 4 group A 
member 2 
Whn (FOXN1) Forkhead box N1 
p53 (TP53) Tumor protein p53 WT1 Wilms tumor 1 
Pbx Pre-B-cell leukemia transcription factor 1   
RAR-gamma Retinoic acid receptor gamma   
SMAD SMAD family member   
Sox17 SRY (sex determining region Y)-box 17   
Sox5 SRY (sex determining region Y)-box 5   
TFE Transcription factor E3   
TGIF TGFB-induced factor homeobox-1   
TR4 (NR2C2) 
Nuclear receptor subfamily 2 group C 
member 2 
  
XBP-1 X-box binding protein 1   
ZF5 (ZBTB14/ZPB161) Zinc finger protein 161 homolog   
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Table 5-9 Transcription factors predicted to bind only the C allele or the T allele at position 
-1877 of CYP17A1.  
Transcription factors previously implicated in the literature as being transcriptional regulators of 
CYP17A1 are highlighted. 
-1877 (rs138009835) 
C allele T allele 
AhR Aryl hydrocarbon receptor Evi-1 (MECOM) MDS1 and EVI1 complex locus 
AP-2alpha Transcription factor AP-2 alpha FOXD3 (HFH2) Forkhead box D3 
AP-4 
Activating enhancer binding 
protein 4 
GLI1 GLI family zinc finger 1 
CEBPepsilon 
CCAAT enhancer binding protein 
epsilon 
HES1 Hairy and enhancer of split 1  
DMRT4 (DMRTA1) DMRT-like family A1 Kid3 (ZNF354C) 
Protein with high similarity to 
zinc finger protein 354c  
E2F-1 E2F transcription factor 1 KROX (Egr-1) Early growth response 1 
E2F-3 E2F transcription factor 3 NF-1A Nuclear factor IA, 
HIC1 Hypermethylated in cancer 1 p300 (EP300) E1A binding protein p300 
HSF1 Heat shock transcription factor 1 Pax-4 Paired box gene 4 
HSF2 Heat shock transcription factor 2 PEBP (AML1 / RUNX1) 
Runt-related transcription factor 
1 
KAISO (ZBTB33) 
Zinc finger and BTB domain 
containing 33 
RREB-1 
Ras responsive element binding 
protein 1 
RNF96 (TRIM28) Tripartite motif-containing 28 Sox9 
SRY (sex determining region Y)-
box 9 
SAP-1a (ELK4) ELK4 ETS-domain protein SREBP1 (SREBF1) 
Sterol regulatory element 
binding transcription factor 1 
SMAD5 SMAD family member 5 TBP TATA box binding protein 
STAT3 
Signal transducer and activator 
of transcription 3 
TBR2 (EOMES) Eomesodermin 
VBP (TEF) Thyrotrophic embryonic factor TBX5 T-box 5, 
XBP1 X-box binding protein 1 USF Upstream transcription factor 1 
  YB-1 Y-box binding protein 1 
  Zscan4 
Similar to zinc finger and SCAN 
domain containing 4 
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Table 5-10 Transcription factors predicted to bind only the C allele or the T allele at position 
-2205 of CYP17A1.  
Transcription factors previously implicated in the literature as being transcriptional regulators of 
CYP17A1 are highlighted. 
-2205 (rs2150927) 
C allele T allele 
Dec1 Basic helix-loop-helix family member e40 Oct1 (POU2F1) POU class 2 homeobox 1, 
AhR, Arnt, HIF-1 
Aryl hydrocarbon receptor, Aryl hydrocarbon 
receptor nuclear translocator, Hypoxia 
inducible factor 1 alpha 
CDP (CUX1) Cut-like homeobox 1 
AP-4 Activating enhancer binding protein 4 DMRT1 
Doublesex and mab-3 related 
transcription factor 1 
AR Androgen receptor DMRT2 
Doublesex and mab-3 related 
transcription factor 2 
Arnt 
Aryl hydrocarbon receptor nuclear 
translocator 
DMRT3 
Protein has low similarity to mouse 
Dmrta2 
BTEB2 (KLF5) Kruppel-like factor 5 DMRT4 (DMRTA1) DMRT-like family A1 
COUP-TF1 (NR2F1) 
Nuclear receptor subfamily 2 group F 
member 1 
Evi-1 (MECOM) MDS1 and EVI1 complex locus 
COUP-TF2 (NR2F2) 
Nuclear receptor subfamily 2 group F 
member 2 
GATA-1 GATA binding protein 1 
E12 (TCF3/ E2A/ E47) Transcription factor 3 GATA-2 GATA binding protein 2 
Ebox Enhancer box GATA-3 GATA-binding protein 3 
ER-alpha (ESR1) Estrogen receptor 1 GATA-4 GATA binding protein 4 
ER-beta (ESR2) Estrogen receptor 2 GATA-5 GATA binding protein 5 
ERR2 (ESRRB) Estrogen-related receptor beta GATA-6 GATA binding protein 6 
FXR (NR1H4) 
Nuclear receptor subfamily 1 group H 
member 4 
HMGIY (HMGA1) High mobility group AT-hook 1 
GCNF (NR6A1) 
Nuclear receptor subfamily 6 group A 
member 1 
Lmo2 (RBTN2) complex LIM domain only 2 
Gm397 
Similar to zinc finger and SCAN domain 
containing 4 
TEF-1 (TEAD1) TEA domain family member 1 
HES1 Hairy and enhancer of split 1    
HIF-1alpha Hypoxia inducible factor 1 alpha   
HIF-2alpha (EPAS1) Endothelial PAS domain protein 1   
HTF4 (TCF12) Transcription factor 12   
Kid3 (ZNF354C) 
Protein with high similarity to zinc finger 
protein 354c  
  
MATH1 (ATOH1) Atonal homolog 1   
MEIS1 Meis homeobox 1   
MEIS1B:HOXA9 Meis homeobox 1: Homeo box A9 complex   
MRF4 (myf6) Myogenic factor 6   
Myc (c-myc) 
V-myc myelocytomatosis viral oncogene 
homolog 
  
MyoD Myogenic differentiation 1   
Neuro D Neuronal differentiation 1   
Nkx-2.5 (CSX) NK2 homeobox 5   
NKX2B NK2 homeobox 2 (NKX 2-2)   
N-Myc 
V-myc myelocytomatosis viral related 
oncogene neuroblastoma derived 
  
NR1B1 (RARA) Retinoic acid receptor alpha   
NR1B2 (RARB) Retinoic acid receptor beta   
p300 (EP300) E1A binding protein p300   
Pax-4 Paired box gene 4   
RAR-gamma Retinoic acid receptor gamma   
RFX Regulatory factor X 1   
RORalpha1 RAR-related orphan receptor A   
slug (SNAI2) Snail homolog-2   
SMAD SMAD family member   
Sox5 SRY (sex determining region Y)-box 5   
Sp1 Sp1 transcription factor   
SREBP1 (SREBF1) 
Sterol regulatory element binding 
transcription factor 1 
  
SREBP-2 (SREBF2) 
Sterol regulatory element binding 
transcription factor 2 
  
TGIF TGFB-induced factor homeobox-1   
TR4 (NR2C2) 
Nuclear receptor subfamily 2 group C 
member 2, 
  
TWIST Twist homolog 1   
USF Upstream transcription factor 1   
Whn (FOXN1) Forkhead box N1   
WT1 Wilms tumor 1   
Zscan4 
Similar to zinc finger and SCAN domain 
containing 4 
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5.3.3 Discussion 
Bioinformatic searches yielded numerous putative transcription factor binding 
sites for each polymorphic site of interest in the CYP17A1 promoter. 
Furthermore, several transcription factor binding sites are introduced or 
eliminated by single nucleotide substitutions. In an attempt to prioritise 
polymorphic sites for further in vitro investigation, a literature search was 
conducted to identify any predicted transcription factors already known to be 
involved in the regulation of CYP17A1 or steroidogenesis. All seven SNP sites 
yielded at least one potentially interesting putative transcription factor binding 
site, summarised in Table 5-11. 
Table 5-11 Transcription factors implicated in the regulation of CYP17A1. 
TSS: transcription start site 
SNP 
(Position relative 
to TSS) 
Transcription Factor 
Bind to 
Major 
allele 
Bind to 
Minor 
allele 
Reference 
rs743572 
(-34) 
Sp1   Flück and Miller 2004 
Sp1:Sp3   Lin et al., 2001 
rs2486758 
(-362) 
NF-1   Lin et al., 2001 
rs10883784 
(-804) 
Sp1   Flück and Miller 2004 
SREBP1 (SREBF1)   Ozbay et al., 2006 
rs10786713 
(-1204) 
SREBP1 (SREBF1)   Ozbay et al., 2006 
rs10786714 
(-1488) 
COUP-TF1   
Wang et al., 1989, 
Shibata et al., 2003 
rs138009835 
(-1877) 
GATA-6   
Jimenez et al., 2003, 
Flück and Miller 2004 
SREBP1 (SREBF1)   Ozbay et al., 2006 
rs2150927 
(-2205) 
COUP-TF1   
Wang et al., 1989, 
Shibata et al., 2003 
COUP-TF2   
Wang et al., 1989, 
Shibata et al., 2003 
SF-1 (NR5A1)   
Sewer et al., 2002, 
Hanley et al., 2001 
Sp1   Flück and Miller 2004 
SREBP1 (SREBF1)   Ozbay et al., 2006 
GATA-6   
Jimenez et al., 2003, 
Flück and Miller 2004 
 
The literature regarding the transcription factors displayed in Table 5-11 has 
been presented and discussed in Section 1.4.2. The transcription factor SREBP-1 
has been shown to bind a region 520 to 331 bases upstream of the CYP17A1 
transcriptional start site, but bioinformatic analysis does not predict the binding 
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location to include the polymorphic site at position -362. Therefore, none of the 
transcription factors already known to regulate CYP17A1 expression in the 
adrenal gland bind the polymorphic regions of interest.  
The vast majority of published literature focuses on the initial 227 base pairs of 
the promoter region as this is believed to account for 60-80% of basal 
transcription of CYP17A1 (Lin et al., 2001). Therefore a considerable amount of 
basal transcription, and cAMP-dependent transcription too, has yet to be 
accounted for. The promoter region of human CYP17A1 is not precisely defined.  
Studies of other steroidogenic genes have identified functional polymorphisms 
that alter transcription factor binding 1500 to 2000 bases upstream of the 
transcriptional start site (Barr et al., 2007; McManus et al., 2012). The results 
presented here predict that polymorphisms have the potential to alter 
transcription factor binding. 
The majority of transcription factors displayed in Table 5-11 are expressed in the 
human adrenal gland and known to regulate CYP17A1. The COUP-TF family are 
predicted to bind to sites which encompass polymorphisms at position -1488 and 
-2205 of the human CYP17A1 promoter region. Thus far, COUP-TFs have been 
implicated in the regulation of the bovine CYP17 gene, but evidence is lacking 
for a direct role in the human equivalent. Both COUP-TFI and COUP-TFII are 
expressed in the normal human adrenal gland and correlate inversely with 
increased CYP17A1 expression in cortisol-producing adenomas (Shibata et al., 
2001). A study over-expressing COUP-TF in vitro has shown that it influences 
promoter activity of the human CYP11B1 and CYP11B2 genes involved in the 
latter stages of cortisol and aldosterone production (Cheng and Li 2012). 
Therefore a role for COUP-TF in the regulation of CYP17A1, either direct or 
indirect, is entirely plausible. Of course, Table 5-11 does not provide an 
exhaustive list of transcription factors that may bind to these regions, but they 
represent the most likely candidates given their established role in the 
regulation of steroidogenic gene transcription. 
The volume of results generated from the freely accessible databases differed 
vastly from that of the subscription database. The parameters were deliberately 
relaxed to include candidate transcription factors with weak binding to the 
sequence of interest. This is likely to have generated a significant proportion of 
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false positive results in Table 5-4 to Table 5-10. The databases make various 
assumptions in order to compile their search results, which may be an additional 
source of error. For example, as described in Section 5.3.1, the five most highly 
conserved bases within the sequence are termed the ‘core’ binding site of the 
transcription factor. The user can define the threshold level at which alignment 
between promoter sequence and transcription factor sequence is identified. 
However, not all transcription factors have a core binding sequence of five 
nucleotides, so in some cases this may not accurately reflect a real biological 
binding event. Furthermore, the three-dimensional structure of both the 
transcription factor and target DNA strand are crucial to the specificity of 
binding, and may be affected by adjacent protein:DNA interactions (Sarai and 
Kono 2005). The results should therefore be interpreted with caution. Although 
in silico analysis must be followed by suitable laboratory investigation in order 
to determine definitive biological interactions, it is nonetheless a valuable tool 
for generating new research leads. 
In summary, in silico analysis identified putative transcription factor binding 
sites at all polymorphic regions of interest. Some of the predicted transcription 
factors have previously been reported as being to be important in the regulation 
of CYP17A1. As in silico analysis failed to prioritise the polymorphic regions, all 
were deemed worthy of further analysis in vitro. 
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5.4 Reporter Gene Assays 
Reporter construct assays are a useful tool for assessing the transcriptional 
activity of the promoter regions in genes of interest. The desired promoter 
region is cloned into a plasmid immediately upstream of a ‘reporter gene’, e.g. 
firefly luciferase. Plasmids are then transfected into a suitable cell line, which 
should contain the necessary signal transduction pathways and transcription 
factors to induce transcription. In this case, the widely-used adrenocortical 
carcinoma cell line, H295R, was considered the best available model for 
assessment of the CYP17A1 promoter. In theory, the promoter should induce 
transcription of luciferase mRNA, which is, in turn, translated into protein that 
can be detected by a basic luciferase assay. 
5.4.1 Methods 
Based on the results of bioinformatic searches and those presented in Chapter 4, 
the decision was taken to further assess all the variants classed as ‘common’ 
polymorphic variations, i.e. those with a minor allele frequency above 5%. This is 
in keeping with the hypothesis of this thesis that common genetic variants are 
associated with small changes in blood pressure through changes in 
steroidogenesis.  
A reporter construct (Section 2.7.2) containing 2,898 base pairs upstream from 
the transcriptional start site of CYP17A1 (Figure 5-2) was a kind gift from 
Professor Neil Hanley, and its construction is previously described elsewhere 
(Hanley et al., 2001). Upon arrival, the construct was verified using methods 
described in Section 2.7.6. This construct was then used as a template for site-
directed mutagenesis to generate seven new constructs, each varying from the 
original by a single base at each site of interest (Section 2.7.2.1). All plasmids 
were prepared and verified as described in Sections 2.7.3 – 2.7.6. Transient 
transfection was conducted in H295R cells in cell culture dishes using 
appropriate controls (Section 2.8). Transfection efficiency was assessed through 
the co-transfection of control plasmid containing the reporter gene renilla 
luciferase pGL4.73 (Promega, Wisconsin, U.S.A.) at a ratio of 50:1. 24 Hours 
post-transfection, H295R cells were incubated under either basal conditions or 
following stimulation with (Bu)2cAMP (1mM). Cells were lysed after a further 24 
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hours and luminescence measured by Dual-Luciferase Reporter Assay (Section 
2.9).  
A similar protocol was adopted to generate reporter constructs which contained 
the six haplotypes previously described in Chapter 3. Site-directed mutagenesis 
converted each base in turn to its opposing allele, as required. A reminder of the 
haplotypes and their frequencies within each of the populations studied in this 
thesis are displayed in Table 5-12. Again, H295R cells were transfected with 
constructs containing the various haplotypes and transcriptional activity assessed 
under basal and stimulated conditions. 
Table 5-12 Haplotypes found in the promoter region of CYP17A1 and their frequencies in the 
Adrenal Function Study population and subset of the BRIGHT cohort. 
 -34 -362 -804 -1204 -1488 -2205 
Frequency in 
Adrenal Function 
Study Population 
Frequency in 
subset of the 
BRIGHT cohort 
Hap1 T A G T C C 44.4% 39.7% 
Hap2 T G G T C C 22.6% 18.5% 
Hap3 C A A C G T 20.2% 30.4% 
Hap4 C A G C C T 7.3% 10.9% 
Hap5 T A G C C C 1.6% unknown 
Hap6 T A G T C T 1.6% unknown 
 
H295R cells can be difficult to transfect and, as a result, the magnitude of the 
firefly/renilla ratio varied between experiments, although the direction of 
change between alleles was constant. As a consequence, changes in 
transcriptional activity between alleles at each polymorphic site were calculated 
by displaying one allele as a proportion of the other.  When assessing the 
transcriptional activity of constructs containing the various haplotypes, each is 
displayed as the raw firefly luciferase value normalised to renilla luciferase 
value. Statistical analyses were conducted on mean firefly/renilla values, with 
the use of log10 transformation. Results displayed are the mean of four 
experiments, each performed in quadruplicate, with statistical significance 
determined by one-sample t-test using Prism 4.0 Graph Pad software, unless 
otherwise described. 
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Figure 5-2 pGL3-17 - the CYP17A1 promoter reporter construct. 
2898 bp of the CYP17A1 promoter region had been inserted into the pGL3 plasmid which contains 
a luciferase reporter gene. Col E1 origin: origin of replication for replication of plasmid in bacteria; 
SV40 late polyA: viral late polyadenylation signal; Firefly Luciferase: firefly luciferase gene; 
CYP17A1 promoter: 2898 bp section of the CYP17A1 promoter region; F1 ori: origin of replication. 
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5.4.2 Results – Assessment of Allele Transcriptional Activity 
In order to assess the transcriptional activity of alleles at polymorphic sites of 
interest the pGL3-17 reporter construct was sequenced then specifically 
mutated at a single base to generate seven new constructs, varying from the 
original by a single nucleotide. This allowed comparison of the transcriptional 
activity of each allele at the seven polymorphic sites. Plasmids were digested 
before transfection to confirm their size and circular conformation (Section 
5.4.2.1) and mutagenesis was verified by sequencing (Section 5.4.2.2). 
5.4.2.1 Restriction Digestion of Plasmids 
The pGL3-17 construct (7,761 bp) comprises approximately 2.9kb of CYP17A1 
promoter region and was previously described in Section 2.7.2. Restriction 
endonuclease digestion was performed on pGL3-17 and the seven mutant 
plasmids using the enzyme SmaI. SmaI cleaves each construct twice to create 
products 4841 bp and 2920 bp in size. One restriction site was located in the 
pGL3 backbone, the other within in the insert. Each digestion was performed 
alongside a negative control, or ‘uncut’ plasmid. Digestions were resolved on an 
agarose gel and confirm the size and circular conformation of the mutated and 
non-mutated experimental reporter constructs (Figure 5-3). 
5.4.2.2 Confirmation of Mutations 
All plasmids were directly sequenced to confirm the success of site-directed 
mutagenesis and the substitution of the correct allele. In addition, the entire 
insert and flanking regions of the construct were sequenced ensuring no 
nonspecific mutations had been introduced. Examples of electropherograms 
generated for each construct are displayed in Figure 5-4. These show that the 
site-directed mutagenesis procedure was successful in generating constructs 
with the opposing allele from that of the original pGL3-17 for each polymorphic 
site of interest. 
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Figure 5-3 Restriction endonuclease digestion of pGL3-17 and seven mutated constructs. 
1µg of plasmid was digested with SmaI restriction enzyme and resolved on 1% agarose gel. 
Promega 1 kb ladder was used for size determination (L). Lanes 1 and 2 show uncut and cut 
samples of the original pGL3-17 respectively. Lanes 4, 6, 8, 10, 12, 14 and 16 show cut constructs 
mutated at positions -34, -362, -804, -1204, -1488, -1877 and -2205 respectively. Lanes 3, 5, 7, 9, 
11, 13 and 15 show uncut constructs mutated at positions -34, -362, -804, -1204, -1488, -1877 and 
-2205, respectively. 
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Figure 5-4 Sequence analysis of pGL3-17 mutated plasmids. 
Electropherogram reads from sequence analysis of mutated constructs showing the successful 
incorporation of the desired mutation. Red lines show the base changed from the original pGL3-17 
reporter construct. Sequencing was visualised using CLC Genomics Workbench v4.9 software. 
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5.4.2.3 Transcriptional Activity in vitro 
In the first instance, the transcriptional activity of the original unmutated 
pGL3-17 was assessed under both basal and stimulated conditions in H295R cells, 
utilising the commercially available empty vector pGL3-Basic as a control. Figure 
5-5 shows that the pGL3-17 plasmid increases the firefly/renilla ratio to 
4.277±0.314 relative to the empty vector pGL3-Basic under basal conditions 
(p<0.001). When stimulated for 24 hours with (Bu)2cAMP, this effect is amplified 
to 10.080±1.508 relative to pGL3-Basic (p<0.001). The increase in transcriptional 
activity observed under stimulated conditions is also significant relative to basal 
(p<0.001). This experiment successfully demonstrates that the transcriptional 
activity of the reporter construct arises from the insertion of approximately 
2.9kb of the CYP17A1 promoter, not from the backbone of the vector, and that 
this activity is further increased by stimulation with the trophin (Bu)2cAMP. 
 
 
Figure 5-5 Assessment of relative levels of reporter construct activities. 
H295R cells were transfected with pGL3-Basic or pGL3-17 and grown under basal or stimulated 
conditions. The transcriptional activity of each plasmid is displayed as a proportion of pGL3-Basic 
for comparison purposes, with data expressed as the mean of four independent experiments, each 
performed in quadruplicate; error bars represent standard error of the mean (SEM). Statistical 
differences were analysed by a one-way analysis of variance (ANOVA) and Bonferroni’s post-hoc 
tests on log transformed values. ***p<0.001. 
189 
 
Under basal conditions, H295R cells were transfected with pGL3-17 or one of the 
seven mutated plasmids. Cells were lysed 24 hours post-transfection and 
transcriptional activity assessed by measurement of firefly and renilla luciferase 
luminescence. Results are displayed in Figure 5-6. Transcriptional activity 
resulting from the plasmid with a T allele at position -34 (rs743572) was not 
significantly different from that with the C allele. Calculated as a proportion of 
the activity of the C allele construct, the mean activity of the T allele construct 
was 0.936±0.175 (p=0.581). A G allele at position -362 (rs248658) however, 
yielded a significant increase in transcriptional activity compared to its 
counterpart containing an A allele (1.683±0.097, p=0.003). An A allele at position 
-804 (rs10883784) did not produce a significant change in luciferase 
luminescence compared to the G allele (1.015±0.165, p=0.869). Similarly, 
alternative alleles at positions -1204 (rs10786713) and -1488 (rs10786714) did 
not differ significantly: the C allele at -1204 measured 0.993±0.186 as a 
proportion of its opposing T allele (p=0.768); the G allele at position -1488 
yielded expression 0.995±0.076 of the C allele (p=0.865). Transcriptional activity 
with the T allele at position -1877 (rs138009835) was significantly lower 
compared to the C allele at the same site (0.734±0.078, p=0.048). A significant 
change was also observed after transfection with the reporter construct 
containing the C allele at position -2205 (rs2150927), displaying lower activity 
compared to constructs containing the T allele at the same position 
(0.865±0.032, p=0.031). 
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Figure 5-6 Basal expression of mutated reporter constructs relative to opposing allele. 
H295R cells were transfected with identical reporter constructs varying only at the base indicated. 
The transcriptional activity of the base pair change induced by mutation is displayed as a 
proportion of its opposing allele, with data expressed as the mean of four independent 
experiments, each performed in quadruplicate; error bars represent standard error of the mean 
(SEM). Statistical differences were analysed by one-sample t-test on log transformed values. 
*p<0.05, **p<0.01. 
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The above assays were also performed in cells stimulated with (Bu)2cAMP (a 
substitute for ACTH) and the response of the reporter constructs examined. 
Results are displayed in Figure 5-7. Significant changes similar to those seen 
under basal conditions were observed. Transcriptional activity with the T allele 
at position -34 (rs743572) was not significantly different from that with the C 
allele. Again, calculated as a proportion of the activity of the construct 
containing the C allele, the mean activity from the T allele construct was 
0.693±0.083, p=0.053. The G allele at position -362 (rs248658) however, yielded 
a significant increase in transcriptional activity compared to its counterpart A 
allele (1.458±0.089, p=0.009). The A allele at position -804 (rs10883784) did not 
produce a significant change in luciferase luminescence compared to the G 
allele (1.046±0.170, p=0.970). Similarly, the alleles at positions -1204 
(rs10786713) and -1488 (rs10786714) did not result in a significant difference. 
The luciferase luminescence of the construct containing the C allele at -1204 
was 1.075±0.126 as a proportion of its opposing T allele (p=0.705); the G allele 
at position -1488 yielded expression 1.075±0.083 of the C allele at this site 
(p=0.447). Transcriptional activity of the T allele at position -1877 (rs138009835) 
was significantly lower compared to the C allele at the same site (0.840±0.062, 
p=0.049). A significant change was also observed after transfection with the 
reporter construct containing the C allele at position -2204 (rs2150927) 
displaying lower activity compared to constructs containing the T allele at the 
same locus (0.625±0.036, p=0.004). A visual comparison of the raw firefly/renilla 
luciferase ratios saw a 2-3 fold increase in transcriptional activity upon 
stimulation compared with basal in all experiments. This is consistent with the 
results presented in Figure 5-5. 
In summary, transcriptional activity is significantly altered by base changes at 
three of the seven polymorphic sites investigated. At position -362, the minor G 
allele exhibits a greater level of transcriptional activity compared to the major A 
allele. The minor T allele at position -1877 confers significantly lower activity 
when compared to the major C allele at the same site. Finally, the major C 
allele at position -2205 produced lower expression compared to the minor T 
allele. These effects were seen when cells were grown under basal and 
stimulated conditions. 
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Figure 5-7 Stimulated expression of mutated reporter constructs relative to opposing allele. 
H295R cells were transfected with identical reporter constructs varying only at the base indicated. 
Cells were stimulated with 1mM (Bu)2cAMP 24 hours post-transfection. The transcriptional activity 
of the base pair change induced by mutation is displayed as a proportion of its opposing allele, with 
data expressed as the mean of four independent experiments, each performed in quadruplicate; 
error bars represent standard error of the mean (SEM). Statistical differences were analysed by 
one-sample t-test on log transformed values. *p<0.05, **p<0.01. 
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5.4.3 Results – Assessment of Haplotype Transcriptional Activity 
With some interesting results generated by studying the effect of single SNPs on 
transcriptional activity, further experiments were designed to study the effect of 
combinations of polymorphisms in the context of haplotypes. Site-directed 
mutagenesis was utilised to generate six reporter gene constructs varying only at 
selected polymorphic sites and encompassing the six different haplotypes 
(previously presented in Chapter 3).  
5.4.3.1 Verification of Plasmids 
Restriction endonuclease digestion was performed on each of the six reporter 
gene constructs containing the haplotypes of interest to assess their 
conformation. Plasmids were digested with the enzyme EcoRI to produce a linear 
product 7761 bp in size, and separately by the enzyme BglI to produce three 
products of sizes 5717 bp, 1268 bp and 776 bp. Products were viewed by gel 
electrophoresis, with uncut plasmid as a negative control (Figure 5-8).  
The sequence of the plasmid insert and flanking regions were confirmed for each 
reporter construct. The six constructs varied only at the polymorphic sites of 
interest. A schematic representation of the mutations present in each plasmid to 
generate each haplotype reporter construct is displayed in Figure 5-9. 
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Figure 5-8 Restriction endonuclease digestion of pGL-17 haplotype reporter constructs. 
1µg of plasmid was digested with either EcoRI or BglI restriction enzyme and resolved on 1% 
agarose gel. Promega 1 kb ladder was used for size determination (L). Lanes 1, 4, 7, 10, 13 and 16 
show uncut plasmid for each haplotype construct. Reporter constructs in lanes 2, 5, 8, 11, 14, and 
17 were linearised with EcoRI. Reporter constructs in lanes 3, 6, 9, 13, 15 and 18 were cleaved by 
BglI to produce three fragments. 
 
 
 
Figure 5-9 Schematic representation of alleles present in each haplotype reporter construct. 
The major alleles are depicted in red, minor alleles in green. The SNP at position -1877 is not in the 
same LD block and was therefore the same within each haplotype construct, shown in blue. 
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5.4.3.2 Transcriptional Activity in vitro 
Under basal conditions, H295R cells were separately transfected with each of 
the six haplotype reporter constructs. Cells were lysed 24 hours post-
transfection and transcriptional activity assessed by measurement of luciferase 
luminescence. Results are displayed in Figure 5-10. Luciferase luminescence was 
not significantly different in any of the six haplotype reporter constructs. 
The above assays were also performed in cells stimulated with (Bu)2cAMP (a 
substitute for ACTH) and the response of the reporter constructs to stimulation 
examined. Results are displayed in Figure 5-11. Again, transcriptional activity 
was not significantly different in any of the constructs. 
Luciferase luminescence produced by each construct under both basal and 
stimulated conditions was then compared to assess whether any was particularly 
responsive to stimulation. Results are displayed in Figure 5-12.  Reporter 
constructs containing haplotype 1 transfected into cells grown under basal 
conditions had a mean of 0.028±0.007 RLU compared to 0.085±0.020 RLU under 
stimulated conditions; this difference was statistically significant (p=0.03). 
Haplotype 2 was not statistically different, giving means of 0.035±0.103 RLU in 
basal conditions and 0.129±0.047 RLU under stimulation (p=0.08). Haplotype 3 
produced a significant increase in transcriptional activity under stimulation with 
(Bu)2cAMP with an average of 0.136±0.063 RLU compared to 0.029±0.004 RLU 
under basal conditions (p=0.02). Luciferase luminescence from reporter 
constructs containing haplotype 4 was not significantly different in cells grown 
under basal and stimulated conditions (0.051±0.015 RLU and 0.098±0.051 RLU 
respectively, p=0.39). Similarly, the rarest haplotypes, 5 and 6, were also not 
significantly altered by stimulation when compared to activity under basal 
conditions. Basal conditions for haplotype 5 gave a mean of 0.060±0.015 RLU, 
while stimulated conditions resulted in 0.093±0.033 RLU, p=0.48. Haplotype 6 
produced means of 0.050±0.013 RLU and 0.071±0.016 RLU for constructs 
transfected into basal and stimulated cells respectively (p=0.32). 
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Figure 5-10 Basal expression of haplotype reporter constructs. 
H295R cells were transfected with reporter constructs varying only at specific bases to reflect the 
indicated haplotype. The transcriptional activity of reporter constructs are displayed as raw firefly 
luciferase value normalised to renilla luciferase value (RLU: relative light units). Data displayed is 
the mean of four independent experiments, each performed in quadruplicate; error bars represent 
standard error of the mean (SEM). Statistical differences were analysed by one-way analysis of 
variance (ANOVA) and Bonferroni’s post-hoc tests on log transformed values.  
 
Figure 5-11 Stimulated expression of haplotype reporter constructs. 
H295R cells were transfected with reporter constructs varying only at specific bases to reflect the 
indicated haplotype. Cells were stimulated with 1mM (Bu)2cAMP 24 hours post-transfection. The 
transcriptional activity of reporter constructs are displayed as raw firefly luciferase value normalised 
to renilla luciferase value (RLU: relative light units). Data displayed is the mean of four independent 
experiments, each performed in quadruplicate; error bars represent standard error of the mean 
(SEM). Statistical differences were analysed by one-way analysis of variance (ANOVA) and 
Bonferroni’s post-hoc tests on log transformed values.  
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Figure 5-12 Basal versus stimulated expression of haplotype reporter constructs. 
H295R cells were transfected with reporter constructs varying at specific bases to reflect the 
indicated haplotype. Cells were either stimulated with 1mM (Bu)2cAMP 24 hours post-transfection 
or grown under basal conditions. The transcriptional activity of reporter constructs is displayed as 
raw firefly luciferase value normalised to renilla luciferase value (RLU: relative light units). Data 
displayed is the mean of four independent experiments, each performed in quadruplicate; error 
bars represent standard error of the mean (SEM). Statistical differences of basal vs. stimulated 
constructs were analysed by two-sample t-test on log transformed values. *p<0.05. 
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5.4.4 Discussion 
The reporter gene assay utilised in the above experiments is a useful biological 
tool commonly used in research for assessing promoter activity. There are, 
however, certain limitations of this method which should be considered when 
interpreting the results. H295R cells proved difficult to transfect and extensive 
optimisation of the procedure was required. Toxicity from the transfectant 
solution was a key issue, although doubling the cell number and density, as 
recommended by the manufacturer of the transfection reagent did improve 
results. A plasmid expressing renilla luciferase was transfected alongside the 
experimental reporter constructs to control for transfection efficiency. While 
this is a particularly successful and robust method of controlling transfection 
efficiency, simultaneously transfecting two such reasonably large plasmids into 
cells may have hindered transfection success and cell viability. An ideal option 
would have been to use a reporter construct containing both firefly and renilla 
luciferase genes, similar to that described in Section 6.3.4. 
The experiments described above made use of the Dual Luciferase Reporter 
Assay (DLRA) to quantify luciferase luminescence. The procedure benefits from 
this assay as both firefly and renilla luciferase luminescence can be measured 
from a single lysate, thereby simplifying the experimental procedure and 
reducing sample variation. This contributed to the production of reproducible 
and convincing results.  
This is the first study to demonstrate a significant transcriptional effect of 
common polymorphic variation in the promoter region of CYP17A1. A previous 
study investigated the effect of the T/C polymorphism at position -34 and found 
no significant difference in transcriptional activity (Lin et al., 2001). This is 
corroborated by the results presented above. To date, none of the other SNPs 
have been previously investigated in this way. These data show that 
transcriptional activity was significantly altered by the alleles present at sites 
-362, -1877 and -2205. The magnitude of change was similar at -362 and -1877 
under basal and stimulated conditions, but, the reduction in activity from the C 
allele at -2205 relative to the T allele was exaggerated in response to the 
trophin. This suggests that the T allele at this site may be important to the 
regulation of the gene by ACTH and cAMP.  
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It is interesting that the T allele at position -1877 is associated with lower 
transcriptional activity than the C allele: the data presented in Chapter 3 of this 
thesis show this SNP to be in linkage disequilibrium with rs1004467, the SNP 
located in intron 3 of the gene, which was reported by the recent GWAS to have 
significant association with increased systolic blood pressure (Section 1.1.3.2). 
Therefore, it is entirely plausible that rs1004467 is simply a marker for another 
causative SNP within the same LD block. The major allele of rs1004467 was 
reported to associate with an increase in systolic blood pressure of around 1.05 
mmHg, while the above data show that the major C allele at -1877 results in 
higher transcriptional activity than the minor T allele. The exact mechanism by 
which increased CYP17A1 transcription results in increased systolic blood 
pressure, and what other factors may be involved, have yet to be elucidated. 
Nevertheless, the consistency of the results, together with data from the GWAS, 
justifies further investigation. 
The above experiments tested variants at each locus individually and in 
combination. While the experiments assessing effects of single SNPs are fairly 
consistent, the constructs reflecting actual haplotypes produced considerably 
more variable results, particularly following stimulation, reflected in the wider 
error bars. No significant change in transcriptional activity was seen between 
haplotype constructs under basal or stimulated conditions. While greater 
variability may hide significant alterations in activity, it is also possible that a 
compensatory mechanism may be in place whereby the increase in activity as a 
result of one allele is masked by the decrease resulting from another. An 
increase in the number of both technical and biological replicates may reduce 
variability. In addition, each haplotype construct contained the C allele at 
position -1877. This site is not in LD with the other six polymorphisms in the 
normotensive cohort and the TT homozygote is particularly rare in the 
population. It would have been interesting to assess each haplotype construct 
with the T allele at -1877; if transcriptional activity had then been altered 
between haplotypes, it would have provided an insight into possible interactions 
between transcription factors at this locus. 
Studying polymorphisms in combination is clearly more complex than examining 
each SNP individually. It is not known which, if any, transcription factors bind 
these regions or the exact effect that each base change has on transcription 
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factor binding. Useful future studies could focus on identifying the proteins 
binding to each site of interest, and assessing changes caused by the switch of 
allele, which may alter binding affinity or enable binding of an entirely different 
transcription factor.  
In summary, reporter gene assays were used to assess the effect of 
polymorphisms on transcriptional activity at various sites of interest. Examining 
each SNP individually produced convincing results, with significant changes 
observed at positions -362, -1877 and -2205, under both basal and stimulated 
conditions. Reporter constructs were then generated to reflect haplotypes 
identified from the normotensive population described in Chapter 3. However, 
results from these experiments were considerably more variable and no 
significant changes were observed between the various haplotypes. The 
variability of the haplotype data may mask significant functional changes; this 
highlights the difficulty of studying transcriptional regulation of genes, where 
polymorphic regions provide an additional layer of complexity. 
5.5 Conclusions 
In conclusion, bioinformatic analysis has identified numerous putative 
transcription factor binding sites at seven polymorphic sites of interest. The 
transcriptional activities of various alleles differing at seven SNP sites were then 
assessed in vitro, both singly and in combination. Three polymorphisms showed 
significant allele-dependent variation in transcriptional activity. Further studies 
are necessary to definitively identify transcription factors binding at these 
polymorphic sites, with examination of sites at -362, -1877 and -2205 being a 
priority. This is the first study to show that allelic variation upstream of the 
transcriptional start site of the CYP17A1 gene can have significant and 
reproducible effects on transcription. This work has opened up new avenues of 
investigation that may reveal a novel molecular mechanism to explain the 
association been genetic variation and increased blood pressure. 
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6 Investigating the Role of MicroRNAs in the 
Regulation of CYP17A1 Expression.  
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6.1 Introduction 
While the study of the transcriptional regulation of genes is important, research 
in recent years has identified post-transcriptional regulation as a new and 
exciting field of research. Post-transcriptional regulation by microRNA is a novel, 
negative regulator of mRNA abundance and protein expression (Section 1-5). 
Deletion of the RNase III enzyme Dicer, essential for miRNA maturation (Section 
1.5.1.3), in SF-1 positive cells of mouse embryos inhibits the formation of the 
adrenal glands (Huang and Yao 2010), thus implying that miRNAs are of vital 
importance in their embryonic development. The exact role of miRNAs in the 
fully-formed adrenal gland is less clear. Recently published research in this field 
is summarised in Section 1.5.1.6, but many questions about the role of miRNAs 
in the regulation of steroidogenic genes remain. The question to be addressed in 
this chapter is whether CYP17A1 expression in the adrenal cortex is modulated 
by miRNAs. 
In the H295R adrenal carcinoma cell line, Wood et al. (2011) utilised a siRNA 
approach to knock down Dicer1, thus inhibiting the maturation of miRNAs. Two 
siRNAs (A and B) were designed, targeting different regions of Dicer1 mRNA. 
Transfection of H295R cells with these siRNAs resulted in a significantly 
increased abundance of CYP17A1 mRNA relative to control cells, consistent with 
canonical miRNA action (1.73 ± 0.22 fold vs 1.02 ± 0.07 fold; p < 0.01). 24-Hour 
steroid secretion was measured in the medium of transfected cells by liquid 
chromatography tandem mass spectrometry (LC:MS/MS) but found no significant 
change in cortisol production. Unfortunately, the compounds in the androgen 
arm of the steroidogenic pathway were not measured so it is not known whether 
the increase in CYP17A1 mRNA levels translated into increased androgen 
production, while simultaneously leaving cortisol production unaltered. 
Regardless, these preliminary data imply that regulation of CYP17A1 by miRNAs 
is worthy of further investigation. 
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6.2 Aims 
The aim of this study was to assess the effect of miRNAs on the expression of 
adrenal CYP17A1. To achieve this, bioinformatic analysis was first combined with 
microarray expression data in order to predict which adrenal miRNAs are most 
likely to regulate CYP17A1 expression. The expression of miRNAs of interest was 
then analysed in non-tumourous and in diseased adrenal tissue. The effect of 
these miRNAs on CYP17A1 mRNA was also investigated by manipulating their 
levels in the adrenocortical cell line H295R, through transfection of small 
molecule mimics and inhibitors (i.e. Pre-miR™ and Anti-miR™). Finally, reporter 
construct analysis was used to assess targeting of the CYP17A1 mRNA 3’UTR by 
selected miRNAs.  
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6.3 Materials and Methods 
6.3.1 Bioinformatic Analysis 
6.3.1.1 Identification of miRNA Genes Located Within CYP17A1 Sequence   
The genomic co-ordinates and sequence of CYP17A1 were identified using the 
Ensembl Genome Browser (release 69 – October 2012) before being cross-
referenced with known miRNA precursor sequences stored in the miRbase 
database, described previously in Section 1.4.1.2 (release 19 – August 2012). 
Default settings were used and sequences searched using the BLASTN option. 
6.3.1.2 Investigation of the Evolutionary Sequence Conservation of 
CYP17A1 3’UTR 
The 3’UTR of CYP17A1 mRNA was analysed for evolutionary sequence 
conservation using the UCSC Genome Browser Gateway (February 2009 
assembly). A graphical representation of conservation was generated for 
comparison using 3 primates (Chimpanzee, Gorilla and Rhesus monkey) and 5 
mammals (Mouse, Rat, Rabbit, Cow and Dog). 
6.3.1.3 Bioinformatic miRNA Target Prediction 
To identify putative miRNA binding sites on the CYP17A1 mRNA, a combinatorial 
in silico approach was utilised in which the results from 6 databases were 
collated and duplicates removed. Each program has its own unique algorithm 
and parameters with varying levels of stringency. Default settings were used, 
altering the search to include all miRNAs, not only those conserved, where 
possible and set to include all transcripts of the genes of interest unless 
otherwise stated. The miRWalk database uses a unique algorithm, which allows 
the selection of up to 8 independent prediction programs to be searched, while 
examining the entire target gene as opposed to only the 3’UTR. Areas up to 2500 
bases upstream of the transcriptional start site were included in the search. It 
was necessary to independently examine three of the programs used by miRWalk 
in order to access the latest versions. The databases and versions used are 
summarised in Table 6-1. 
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Table 6-1 Bioinformatic databases used for miRNA target prediction. 
Database Version Algorithm Reference 
MicroCosm 
Targets 
(formally 
miRbase) 
5 miRanda 
http://www.ebi.ac.uk/enright-
srv/microcosm/htdocs/targets/v5/ 
(Griffiths-Jones 2006; Griffiths-Jones et 
al., 2008)) 
TargetScan 6.2 TargetScanS 
http://www.targetscan.org/vert_50/ 
(Lewis et al., 2005; Grimson et al., 
2007; Friedman et al., 2009) 
microrna.org 
August 2010 
Release Last 
Update: 
01/11/10 
Target sites by 
miRanda, Scores by 
mirSVR (Support 
Vector Regression) 
http://www.microrna.org/microrna/ho
me.do 
(John et al., 2004; Betel et al., 2010) 
miR-viewer 
June 2005, 
ensembl 27.1 
build 
miRanda 
http://cbio.mskcc.org/cgi-
bin/mirnaviewer/mirnaviewer.pl 
 
miRWalk March 2011 ‘miRWalk’ 
http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/index.
html 
(Dweep et al., 2011) 
TarBase 5c 
Experimentally 
validated miRNAs 
and target genes 
http://diana.cslab.ece.ntua.gr/tarbase/ 
(Papadopoulos et al., 2009) 
 
6.3.2 Assessment of miRNA Expression in Normal Adrenal Tissue 
and APA Tissue    
MiRNA expression profiling of four non-tumorous adrenal glands and four 
aldosterone-producing adenoma (APA) samples was previously conducted using 
µParaflo technology microarray (Robertson et al., 2013). Manufacturers’ 
recommendations were followed and 500 arbitrary units (AU) was used as the 
cut-off point for background threshold levels; microRNAs expressed at levels 
greater than this value were deemed to be expressed in the particular tissue. 
Twenty miRNAs were further selected for validation by qRT-PCR, conducted by 
LC Sciences (Houston, U.S.A) and is fully described elsewhere (Wood 2011). A 
cross-array normalisation was performed between non-tumourous adrenal and 
APA microarray experiments before comparing the relative signal intensities. 
6.3.3 Pre-miR™ or Anti-miR™ Transfection of H295R Cells 
The Pre-miR™ and Anti-miR™ molecules used are listed in Table 2-3 and were 
prepared as described in Section 2.8.2.1. H295R cells were transfected in 6-well 
cell culture dishes as detailed in Section 2.8.2.3. The cell medium was replaced 
at 24 hours post-transfection with either basal or (Bu)2cAMP supplemented 
medium. At 48 hours post-transfection, cell medium was removed. Total RNA was 
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then isolated from cell lysates (Section 2.4) before being prepared for qRT-PCR 
analysis as described in Sections 2.5 and 2.6. Data were analysed using the ΔΔCt 
method (Section 2.6.3) and results expressed relative to the negative control-
transfected cells. 
6.3.4 Investigation of miRNA Binding to 3’UTR Reporter Construct 
Reporter constructs utilising a pEZX backbone were prepared as outlined in 
Sections 2.7.1, 2.73 - 2.76. As described in Section 2.8.2, HeLa cells were co-
transfected with pEZX reporter constructs and small molecules (Pre-miR™, Anti-
miR™, or siRNA) in 24-well cell culture dishes. Cell lysates were prepared 48 
hours post-transfection, diluted 1:10. Firefly and renilla luciferase activities 
were measured using Dual Reporter Luciferase Assays (DRLA, Section 2.9). 
Transfection efficiency was normalised by taking the ratio of firefly luciferase 
activity to renilla luciferase activity, each expressed in relative light units (RLU). 
This ratio was then compared to the appropriate negative control and expressed 
as a percentage. 
6.3.5 Statistical Analysis 
Comparisons of miRNA expression in non-tumourous and APA tissue were 
statistically analysed by Student’s t-test using Prism 4.0 Graph Pad software. 
All transfection experiments were performed at least in triplicate on at least 
three independent occasions. As described above, the effect of the miRNA by the 
addition of Pre-miR™ or Anti-miR™ molecules was normalised to cells transfected 
with scrambled Pre-miR™ or Anti-miR™ negative control molecules, as 
appropriate. The ΔΔCt method, described in Section 2.6.3, was used for 
analyses, with the mean ΔΔCt values of the biologically independent 
experiments taken and statistical analysis performed using a one-sample t-test 
using Minitab v15 software, imputing 0.00 as the reference level to which 
experimental values were compared. For experiments involving co-transfection 
of reporter constructs and small molecules, data is displayed as a percentage of 
the appropriate negative control, and statistical significance determined using a 
Student’s t-test. 
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For all analyses, confidence intervals of 95 % were used and p<0.05 was the 
threshold for statistical significance. Data are expressed as the mean ± SEM. 
6.4 Results 
6.4.1 Identification of miRNAs Originating from CYP17A1 Locus 
In order to identify any miRNAs located genomically within the CYP17A1 
sequence, the genomic co-ordinates of CYP17A1 were identified using the 
Ensembl Genome Browser (Table 6-3). These were then cross-referenced with 
miRbase. Since several miRNAs are synthesised from the introns of other genes, 
the intronic sequence of CYP17A1 was entered directly; matches to numerous 
miRNA precursor stem-loop sequences were found, as summarised in Table 6-2. 
However, utilising the option to search for both mature and miRNA precursor 
sequences based on genomic location, no positive results were returned, 
meaning that no miRNAs are known to arise from this location (Table 6-3).  
 
Table 6-2 Number of precursor and mature miRNA sequences found within CYP17A1 
introns. 
CYP17A1 
Intron # 
Size 
(bases) 
Number of Precursor miRNA 
Sequences 
Number of Mature miRNA 
Sequences 
1 1,672 87 41 
2 239 12 22 
3 662 4 10 
4 827 77 18 
5 312 5 6 
6 899 53 13 
7 522 9 9 
 
 
Table 6-3 Genomic location information required for miRNA sequence prediction. 
Gene 
Chromosome 
Location 
Start 
Co-ordinates 
End 
Co-ordinates 
Size 
(bases) 
Number of 
Mature/Precursor 
miRNA Sequences 
CYP17A1 10 104,590,288 104,597,290 7,002 0 
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6.4.2 Analysis of the 3’UTR of the CYP17A1 Gene 
The evolutionary conservation of the CYP17A1 3’UTR sequence was assessed 
using the UCSC Genome Browser. Results are depicted in Figure 6-1. Figure 6-1a 
displays the 3’UTR between the red dashed lines, with the solid black bars 
indicating sequence conservation. Figure 6-1b shows the entire CYP17A1 3’UTR 
consensus sequence (171 bases), with the corresponding sequence from various 
mammals aligned beneath. The combined figure demonstrates that the sequence 
is well conserved across primates such as Chimpanzee, Gorilla and Rhesus 
monkey, but the degree of similarity is less so for other mammals including 
mouse, rat, rabbit, cow and dog. 
6.4.3 Identification of Putative miRNA Binding Sites in CYP17A1 
Since many of the available programs for miRNA bioinformatic predictions utilise 
different algorithms and levels of stringency when searching, it was necessary to 
collate data from various databases in order to identify putative binding sites. 
The most common method of post-transcriptional regulation by miRNA acts 
through binding to the 3’UTR. The CYP17A1 3’UTR is 171 bp and the number of 
miRNAs predicted by each program to bind to this region is shown in Table 6-4. 
The predicted miRNAs were collated and duplicate results removed, providing 
the list in Table 6-5; the miRWalk database allows for the prediction of miRNA 
target sites in other gene regions and these are also listed in Table 6-5. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1 Mammalian evolutionary sequence conservation of CYP17A1 3’UTR. 
The sequence conservation, generated by the UCSC Genome Browser Gateway for the CYP17A1 3’UTR across the species listed on the left-hand side. A) 3’UTR is 
shown by the blue bar and indicated by red dashed lines. Sequence similarity is illustrated by black bars. B) The entire human CYP17A1 3’UTR sequence is displayed 
with the 3’UTR sequence from the examined species aligned beneath. 
3’UTR 3’UTR 
A 
B 
 
 
Table 6-4 Bioinformatic miRNA target site predictions for CYP17A1 3’UTR. 
Gene 3’ UTR Length (bp) MicroCosm TargetScan Microrna.org Mir-viewer miRwalk Tarbase Total Unique miRNAs 
CYP17A1 171 19 11 69 0 64 0 98 
 
Table 6-5 Identities of miRNAs with putative binding sites in the CYP17A1 3’UTR, coding sequence and 5’UTR. 
3’UTR Coding Sequence 5’UTR 
hsa-let-7c* 
hsa-miR-7 
hsa-miR-19b-2* 
hsa-miR-25* 
hsa-miR-30b* 
hsa-miR-30c-1* 
hsa-miR-30c-2* 
hsa-miR-34b* 
hsa-miR-34c-3p 
hsa-miR-92a-1* 
hsa-miR-92a-2* 
hsa-miR-124 
hsa-miR-125b-2* 
hsa-miR-135a* 
hsa-miR-185* 
hsa-miR-186 
hsa-miR-187* 
hsa-miR-193a-3p 
hsa-miR-193b 
hsa-miR-193b* 
hsa-miR-296-3p 
hsa-miR-320a 
hsa-miR-320e 
hsa-miR-323b-5p 
hsa-miR-363* 
hsa-miR-376c 
hsa-miR-448 
hsa-miR-449c 
hsa-miR-452 
hsa-miR-491-3p 
hsa-miR-491-5p 
hsa-miR-493 
hsa-miR-499-3p 
hsa-miR-501-3p 
hsa-miR-502-3p 
hsa-miR-506 
hsa-miR-541 
hsa-miR-548a-3p 
hsa-miR-548d-3p 
hsa-miR-548e 
hsa-miR-548f 
hsa-miR-548g 
hsa-miR-548x 
hsa-miR-581 
hsa-miR-595 
hsa-miR-598 
hsa-miR-599 
hsa-miR-602 
hsa-miR-603 
hsa-miR-652 
hsa-miR-654-5p 
hsa-miR-658 
hsa-miR-744* 
hsa-miR-759 
hsa-miR-762 
hsa-miR-875-3p 
hsa-miR-892b 
hsa-miR-940 
hsa-miR-1253 
hsa-miR-1256 
hsa-miR-1275 
hsa-miR-1293 
hsa-miR-3122 
hsa-miR-3128 
hsa-miR-3133 
hsa-miR-3138 
hsa-miR-3147 
hsa-miR-3148 
hsa-miR-3149 
hsa-miR-3151 
hsa-miR-3154 
hsa-miR-3162 
hsa-miR-3165 
hsa-miR-3172 
hsa-miR-3179 
hsa-miR-3185 
hsa-miR-4265 
hsa-miR-4283 
hsa-miR-4296 
hsa-miR-4317 
hsa-miR-4322 
hsa-miR-26a 
hsa-miR-26b 
hsa-miR-34b 
hsa-miR-138 
hsa-miR-143 
hsa-miR-147b 
hsa-miR-188-3p 
hsa-miR-338-3p 
hsa-miR-377 
hsa-miR-382 
hsa-miR-453 
hsa-miR-555 
hsa-miR-556-5p 
hsa-miR-646 
hsa-miR-1231 
hsa-miR-10a 
hsa-miR-10b 
hsa-miR-31 
hsa-miR-214 
hsa-miR-624 
hsa-miR-647 
hsa-miR-650 
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6.4.4 Adrenally-Expressed miRNAs Predicted to Bind CYP17A1 
3’UTR 
MiRNA microarray analysis had previously been conducted on tissue from four 
non-tumorous (‘normal’) sections and four aldosterone-producing adenoma (APA) 
sections. These miRNA expression data were cross-referenced with miRNAs 
predicted from bioinformatic analyses to bind the 3’UTR of CYP17A1. This 
yielded three miRNAs expressed in the normal adrenal gland and three in APA 
tissue (Figure 6-2). Hsa-miR-376c expression was detected only in the normal 
adrenal tissue, whereas hsa-miR-34c-3p was detected only in APA tissue. Hsa-
miR-7 and hsa-miR-320a expression was detected in both tissue types. 
The microarray expression data had previously been normalised to allow 
comparisons between miRNA expression in the normal and diseased (APA) 
adrenal gland. Differentially-expressed miRNAs may indicate importance and 
assist in prioritising those to investigate further. Figure 6-3 shows that both 
miR-320a and miR-34c-3p expression are significantly different between the two 
tissue types. Although miR-320a is expressed in both tissues, it is significantly 
up-regulated in APA tissue. Similarly, miR-34c-3p expression is found to differ 
significantly between the tissue types, with detectable expression seen only in 
APA tissue. Expression of miR-7 was not found to be significantly different 
between normal and APA tissue. Similarly, expression of miR-376c is not 
significantly different between normal adrenal and APA tissue, despite only being 
expressed in normal tissue. This is due to the mean value in APA tissue falling 
just below the 500 AU cut-off for determination of expression.  
Further details of the four adrenal miRNAs predicted to bind the 3’UTR of 
CYP17A1 are provided in Table 6-6. 
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Figure 6-2 Venn diagram of miRNAs expressed in normal adrenal tissue and APA predicted 
to bind to the 3’UTR of CYP17A1. 
 
 
 
Figure 6-3 Expression analysis of miRNA predicted to bind to CYP17A1 3’UTR. 
Results show the relative expression levels of miRNAs predicted to bind to CYP17A1 in normal 
adrenal (purple) or APA (blue) tissue. * p < 0.05 
 
 
Table 6-6 Database prediction, sequence and genomic co-ordinates and base pair-matching for selected miRNAs. 
 
miRNA 
Database 
miRNA Sequence & 
Genomic Co-ordinates 
miRNA: mRNA Base Pair Match 
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hsa-miR-376c-3p    
aacauagaggaaauuccacgu 
 
14: 101,506,027 – 101,506,092  [+] 
 
3' ugcaccuUaaagGaGAUACAa 5' miR-376c 
          :    | ||||||  
5' agccccuGuccaCcCUAUGUg 3' CYP17A1 
 
hsa-miR-7-5p    
uggaagacuagugauuuuguugu 
 
9: 86,584,663 – 86,584,772  [-] 
 
3' uguuGuuuuaGUGAUCAGAAGGu 5' miR-7 
       |     |:| | ||||||  
5' caccCuucucCGCCAUUCUUCCc 3' CYP17A1 
 
hsa-miR-320a    
aaaagcuggguugagagggcga 
 
8: 22,102,475 – 22,102,556  [-] 
 
3' AGcgGGAGaGuuGGGUCGAAaA 5' miR-320a 
   ||  |||: :  ::|||||| | 
5' UCUGCCUUCUUUUUCAGCUUgU 3' CYP17A1 
 
hsa-miR-34c-3p    
aaucacuaaccacacggccagg 
 
11: 111,384,164 – 111,384,240  [+] 
 
3' gGAcCGgCacacCaaUCACUAa 5' miR-34c-3p 
    || |: |    |  ||||||  
5' gCUuGUgGcaauGccAGUGAUg 3' CYP17A1 
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6.4.5 Assessment of miRNA Effect on CYP17A1 mRNA 
Abundance 
To investigate the actions of the miRNAs of interest on the full-length CYP17A1 
mRNA, Pre-miR™ and Anti-miR™ molecules were transfected into the H295R 
adrenocortical cell line, the best available model for in vitro investigations. 
Their effects were assessed by measuring the abundance of CYP17A1 mRNA 
relative to transfected control cells. This procedure was previously optimised by 
Dr. Stacy Wood (Wood 2011) who concluded that transfection of Pre-miR™ 
molecules are capable of increasing the specific miRNA levels in H295R cells, 
while Anti-miR™ molecules are efficient at specifically decreasing the mature 
miRNA levels. 
Based on the bioinformatic analysis cross-referenced with microarray data 
described earlier in this chapter, miRNAs expressed in the adrenal gland and 
predicted to bind to CYP17A1 3’UTR were identified. Both miR-320a and 
miR-34c-3p were found to be differentially expressed between non-tumourous 
and APA tissue, thus were initially selected for further investigation. 
In the first instance, qRT-PCR was performed on untreated H295R cells to assess 
background levels of miR-320a and miR-34c-3p. The mean cycle threshold value 
for each miRNA is shown in Table 6-7, measured in technical triplicate on three 
independent occasions. 
Table 6-7 qRT-PCR expression of selected miRNAs in H295R cells. 
miRNA 
Basal H295R Cells H295R Cells + (Bu)2cAMP 
Ct value Standard Error Ct value Standard Error 
miR-320a 19.05 0.39 18.44 0.20 
miR-34c-3p 22.49 0.99 23.40 1.19 
 
Under basal conditions, cells were transfected with miR-320a-specific Pre-miR™, 
miR-34c-3p-specific Pre-miR™, or both Pre-miRs combined, in order to artificially 
increase the levels of those miRNAs in the cells. CYP17A1 mRNA levels were 
measured and are displayed in Figure 6-4b relative to transfected-control cells. 
The relative abundance level (RQ=2-ΔΔCt) of CYP17A1 mRNA after transfection 
with miR-320a Pre-miR™ was 1.02 ± 0.12 and was not significantly different from 
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control cells (p=0.959). However, transfection with miR-34c-3p Pre-miR™ 
significantly reduced CYP17A1 mRNA abundance (0.83±0.02, p=0.012). 
Transfection with both Pre-miRs™ did not significantly alter CYP17A1 mRNA 
abundance (1.05±0.03, p=0.184). Levels of mature miR-320a and miR-34c-3p 
were measured post-transfection to confirm the successful transfection of the 
specific Pre-miRs™. Figure 6-4a shows that transfection with miR-320a Pre-miR™ 
significantly induced the levels of mature miR-320a in the cells with relative 
expression of 599±86.4, p<0.001; while levels of miR-34c-3p remained unaltered, 
as predicted (0.98 ± 0.06, p = 0.715). Transfection with miR-34c-3p Pre-miR™ 
also had the predicted effect, increasing relative mature miR-34c-3p expression 
(137001±52227, p=0.002), with miR-320a levels unaffected (0.93±0.06, p=0.366). 
Transfection with both Pre-miRs™ simultaneously induced expression levels of a 
similar magnitude to the individual transfections with expression relative to 
control-transfected cells of 408.7±86 (p=0.002) for miR-320a and 131726±53156 
(p=0.003) for miR-34c-3p.  
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Figure 6-4 Assessment of A) CYP17A1 mRNA abundance and B) mature miRNA levels post-
transfection with specific pre-miRs™ in H295R cells grown in basal conditions. 
H295R cells were transfected with miR-320a, miR-34c-3p Pre-miRs™, either singly or combined, 
and a scrambled negative control (final concentration 50nM). CYP17A1 mRNA abundance and 
mature miRNA levels were measured 48 hours post-transfection by qRT-PCR. Cycle threshold 
values were normalised to β-actin or RNU48 mRNA, as stated on the y-axis, and expressed 
relative to negative control-transfected cells. Results represent the relative quantification (RQ=2
-
ΔΔCt
) of the mean of three independent biological experiments performed in triplicate; error bars 
represent standard error of the mean (SEM). Statistical differences were analysed by one-sample t-
test on ΔΔCt values. *p<0.05, **p<0.01, ***p<0.001. 
A 
B 
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Cells were transfected, again under basal conditions, with miR-320a-specific 
Anti-miR™, miR-34c-3p-specific Anti-miR™, or both Anti-miRs combined, in order 
to artificially reduce the levels of those miRNAs in the cells. CYP17A1 mRNA 
levels were measured and are displayed, relative to transfected-control cell 
results, in Figure 6-5b. The relative abundance level (RQ=2-ΔΔCt) of CYP17A1 
mRNA after transfection with miR-320a Anti-miR™ was 1.53 ± 0.09, which was 
significantly increased compared to control cells (p=0.016). Transfection with 
miR-34c-3p Anti-miR™, however, did not significantly affect CYP17A1 mRNA 
abundance (1.03±0.03, p=0.473). Transfection with both Anti-miRs™ significantly 
increased CYP17A1 mRNA abundance (1.13±0.03, p=0.042), albeit to a lesser 
degree than transfection with miR-320a alone. Levels of mature miR-320a and 
miR-34c-3p were measured post-transfection to confirm the successful 
transfection of the specific Anti-miRs™. Figure 6-5a shows that transfection with 
miR-320a Anti-miR™ significantly reduced levels of mature miR-320a in the cells, 
with relative expression of 0.15±0.02 (p=0.005), while levels of miR34c-3p 
remained unaltered, as predicted (0.97±0.15, p=0.739). Transfection with miR-
34c-3p Anti-miR™, however, did not significantly reduce levels of mature miR-
34c-3p in the H295R cells (1.07±0.17, p=0.838). Mature miR-320a levels were 
unaffected, as expected (0.93±0.11, p=0.222). Simultaneous transfection with 
both Anti-miRs™ saw similar expression levels to those transfected individually, 
with expression relative to control-transfected cells of 0.15±0.03, p=0.010 for 
miR-320a and 1.19±0.10, p=0.167 for miR-34c-3p.  
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Figure 6-5 Assessment of A) CYP17A1 mRNA abundance and B) mature miRNA levels post-
transfection with specific anti-miRs™ in H295R cells grown in basal conditions. 
H295R cells were transfected with miR-320a and miR-34c-3p Anti-miRs™, either singly or 
combined, and a scrambled negative control (final concentration 50nM). CYP17A1 mRNA 
abundance and mature miRNA levels were measured 48 hours post-transfection by qRT-PCR. 
Cycle threshold values were normalised to β-actin or RNU48 mRNA, as stated on the y-axis, and 
expressed relative to negative control-transfected cells. Results represent the relative quantification 
(RQ=2
-ΔΔCt
) of the mean of three independent biological experiments performed in triplicate; error 
bars represent standard error of the mean (SEM). Statistical differences were analysed by one-
sample t-test on ΔΔCt values. *p<0.05, **p<0.01 
A 
B 
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CYP17A1 is expressed in the zona fasciculata, which is responsive to ACTH 
stimulation. Unfortunately, H295R cells do not express the ACTH receptor so 
(Bu)2cAMP stimulation is commonly used to mimic the intracellular effects of 
ACTH. In H295R cells, upon stimulation with 1mM of (Bu)2cAMP, CYP17A1 mRNA 
production is significantly increased relative to basal conditions (5.68±0.41, 
p=0.008), as displayed in Figure 6-6.  
 
 
Figure 6-6 Assessment of CYP17A1 mRNA abundance in H295R cells grown under basal 
conditions or stimulated with 1mM (Bu)2cAMP. 
CYP17A1 mRNA abundance was measured 48 hours post-transfection by qRT-PCR. Cycle 
threshold values were normalised to β-actin and expressed relative to basal cells. Results 
represent the relative quantification (RQ=2
-ΔΔCt
) of the mean of three independent biological 
experiments performed in triplicate; error bars represent standard error of the mean (SEM). 
Statistical differences were analysed by one-sample t-test on ΔΔCt values. **p<0.01. 
 
Cells were transfected with miR-320a specific Pre-miR™, miR-34c-3p specific 
Pre-miR™, or both Pre-miRs combined, and stimulated with (Bu)2cAMP for 24 
hours post-transfection. Transfections under basal and stimulated conditions 
were carried out simultaneously. CYP17A1 mRNA levels were measured 48 hours 
post-transfection and are displayed in Figure 6-7b. The relative abundance 
(RQ=2-ΔΔCt) of CYP17A1 mRNA after transfection with miR-320a Pre-miR™ was 
0.89±0.01, which was significantly increased relative to control cells (p=0.003), 
although transfection with miR-34c-3p Pre-miR™ had no significant effect on 
CYP17A1 mRNA abundance (1.00±0.05, p=0.965). Transfection with both Pre-
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miRs™ did significantly reduce CYP17A1 mRNA abundance (0.79±0.04, p=0.042). 
Again, levels of mature miR-320a and miR-34c-3p were measured post-
transfection to confirm successful transfection of the Pre-miRs™. Figure 6-7a 
shows that transfection with miR-320a Pre-miR™ significantly induced mature 
miR-320a in the cells, with relative expression of 4029±2676, p=0.010; levels of 
miR34c-3p remained unaltered (1.12±0.25, p=0.783). Transfection with miR-
34c-3p Pre-miR™ increased relative mature miR-34c-3p expression (21781±12663, 
p=0.004), with miR-320a levels unaffected (1.08±0.13, p=0.664). Simultaneous 
transfection with both Pre-miRs™ induced expression to a similar degree as the 
individual transfections, with expression relative to control-transfected cells of 
3568±2174, p=0.006 for miR-320a and 10609±1611, p<0.001 for miR-34c-3p. 
Cells stimulated with (Bu)2cAMP were also transfected with miR-320a-specific 
Anti-miR™, miR-34c-3p-specific Anti-miR™, or both Anti-miRs combined. CYP17A1 
mRNA levels were measured and the results are displayed in Figure 6-8b. The 
relative abundance level (RQ=2-ΔΔCt) of CYP17A1 mRNA after transfection with 
miR-320a Anti-miR™ was 1.15±0.03, which was significantly increased compared 
to control cells (p=0.044). However, transfection with miR-34c-3p Anti-miR™ did 
not significantly affect CYP17A1 mRNA abundance (0.95±0.11, p=0.628). 
Transfection with both Anti-miRs™ failed to alter CYP17A1 mRNA abundance 
significantly (1.16±0.197, p=0.534). Levels of mature miR-320a and miR-34c-3p 
were measured post-transfection to confirm the successful transfection of each 
Anti-miR™. Figure 6-8a shows that transfection with miR-320a Anti-miR™ 
significantly reduced the levels of mature miR-320a in the cells with relative 
expression of 0.28±0.01, p=0.001; while levels of miR34c-3p remained unaltered 
(1.00±0.06, p=0.963). Transfection with miR-34c-3p Anti-miR™, similar to the 
transfection experiments performed under basal conditions, did not significantly 
reduce levels of mature miR-34c-3p in the H295R cells (1.05±0.25, p=0.964); 
mature miR-320a levels were unaffected (0.99±0.06, p=0.781). Simultaneous 
transfection with both Anti-miRs™ saw similar results to individual transfections, 
with expression relative to control-transfected cells of 0.16±0.05, p=0.044 for 
miR-320a and 1.03±0.28, p=0.976 for miR-34c-3p.  
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Figure 6-7 Assessment of A) CYP17A1 mRNA abundance and B) mature miRNA levels post-
transfection with specific pre-miRs™ in H295R cells stimulated with (Bu)2cAMP. 
H295R cells were transfected with miR-320a and miR-34c-3p Pre-miRs™, either singly or 
combined, and a scrambled negative control (final concentration 50nM). Cells were stimulated with 
1mM (Bu)2cAMP 24 hours post-transfection. CYP17A1 mRNA abundance and mature miRNA 
levels were measured 48 hours post-transfection by qRT-PCR. Cycle threshold values were 
normalised to β-actin or RNU48 mRNA, as stated on the y-axis, and expressed relative to negative 
control-transfected cells. Results represent the relative quantification (RQ=2
-ΔΔCt
) of the mean of 
three independent biological experiments performed in triplicate; error bars represent standard 
error of the mean (SEM). Statistical differences were analysed by one-sample t-test on ΔΔCt 
values. *p<0.05, **p<0.01, ***p<0.001.  
A 
B 
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Figure 6-8 Assessment of A) CYP17A1 mRNA abundance and B) mature miRNA levels post-
transfection with specific anti-miRs™ in H295R cells stimulated with (Bu)2cAMP. 
H295R cells were transfected with miR-320a, miR-34c-3p Anti-miRs™, either singly or combined, 
and a scrambled negative control (final concentration 50nM). Cells were stimulated with 1mM 
(Bu)2cAMP 24 hours post-transfection. CYP17A1 mRNA abundance and mature miRNA levels 
were measured 48 hours post-transfection by qRT-PCR. Cycle threshold values were normalised 
to β-actin or RNU48 mRNA, as stated on the y-axis, and expressed relative to negative control-
transfected cells. Results represent the relative quantification (RQ=2
-ΔΔCt
) of the mean of three 
independent biological experiments performed in triplicate; error bars represent standard error of 
the mean (SEM). Statistical differences were analysed by one-sample t-test on ΔΔCt values. 
*p<0.05, ***p<0.001. 
A 
B 
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6.4.6 Assessment of pEZX Reporter Construct as an Experimental 
Tool  
To assess the suitability of the CYP17A1 3’UTR reporter construct as an 
experimental tool, a siRNA molecule was designed with perfect complementarity 
to a region of the 3’UTR (Table 2-4).  The experimental siRNA or a control siRNA 
were then co-transfected into HeLa cells alongside the pEZX-17 reporter 
construct. The ratio of firefly luciferase to renilla luciferase was calculated, and 
the values from the experimental siRNA normalised to those of the control siRNA 
transfections. The CYP17A1 3’UTR-specific siRNA significantly decreased the 
normalised ratio from its 100% control level to 6.58%±0.69, p<0.0001 (Figure 
6-9). The results offer experimental proof of concept that miRNAs targeting the 
3’UTR of CYP17A1 mRNA can induce significant changes in luciferase activity 
that can be measured experimentally. 
 
Figure 6-9 siRNA verification of the pEZX-17 reporter construct. 
HeLa cells were co-transfected with pEZX-17 reporter construct and CYP17A1 3’UTR siRNA. 
Firefly and renilla luciferase were measured 48 hours post-transfections using the Dual-Luciferase 
Reporter Assay (DLRA). The ratio of firefly to renilla was calculated to normalise for transfection 
efficiency then expressed as a percentage of the negative siRNA control value. Results represent 
the mean of four independent biological experiments, performed in quadruplicate; error bars 
represent standard error of the mean (SEM). ***p<0.001 compared to negative control. 
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6.4.7 miRNA Targeting to the 3’UTR of CYP17A1 mRNA 
In order to establish whether miR-320a and miR-34c-3p exerted their effects by 
acting directly on the 3’UTR of CYP17A1, pEZX-reporter constructs containing 
the entire 3’UTR were subjected to analysis. These were co-transfected with 
specific miRNA mimics or inhibitors. For the co-transfection of reporter 
constructs with a specific miRNA inhibitor/Anti-miR™ to have an effect, the 
miRNA of interest must be expressed by the cell type of choice. To confirm this 
was the case, qRT-PCR was performed on untreated HeLa cells to assess the 
background levels of miR-320a and miR-34c-3p. The mean cycle threshold value 
for hsa-miR-320a was 19.25±0.06. For hsa-miR-34a-3p, the mean cycle threshold 
value was 20.95±0.15. Both miRNAs were measured in technical triplicate on 
three independent occasions. 
The presence of both miRNAs of interest at moderate to high levels in HeLa cells 
allowed them to be used to assess targeting of the miR-320a and miR-34c-3p to 
the 3’UTR of CYP17A1 mRNA. The effects of manipulating miR-320a and miR-
34c-3p levels were assessed by calculating the ratio of firefly luciferase to firefly 
renilla, expressed as a percentage of the appropriate negative control. As shown 
in Figure 6-10, co-transfection with miR-320a Pre-miR™ did not significantly alter 
luciferase luminescence (118.6±9.38%, p=0.19); similarly, inhibition with miR-
320a Anti-miR™ failed to produce a significant change in luciferase luminescence 
(114.3±27.81%, p=0.64). The miR-34c-3p Anti-miR™ was utilised in these 
experiments to test suspicions of a faulty design over a cell-line specific issue. 
Although inhibition of miR-34c-3p caused no significant change in luciferase 
activity in cells co-transfected with miR-34c-3p-specific Anti-miR™ (97.1±2.62, 
p=0.34), supplementation with Pre-miR™ increased it to 110.2±2.50, p=0.03 
(Figure 6-11). While this result does not confirm the existence of a miRNA target 
site, nor is it consistent with canonical miRNA action, it may suggest some other 
form of regulation. 
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Figure 6-10 Effect of miR-320a targeting on the luciferase activity of the pEZX-17 reporter 
construct. 
HeLa cells were co-transfected with the pEZX-17 reporter construct and Pre-miR™ or Anti-miR™ 
molecules specific for hsa-miR-320a. Firefly and renilla luciferase were measured 48 hours post-
transfections using the DLRA kit. The ratio of firefly to renilla was calculated to normalise for 
transfection efficiency then expressed as a percentage of the appropriate negative control value. 
Results represent the mean of three (Pre-miR™) or four (Anti-miR™) independent biological 
experiments, each performed in quadruplicate; error bars represent standard error of the mean 
(SEM).  
 
 
Figure 6-11 Effect of miR-34c-3p targeting on the luciferase activity of the pEZX-17 reporter 
construct. 
HeLa cells were co-transfected with the pEZX-17 reporter construct and Pre-miR™ or Anti-miR™ 
molecules specific for hsa-miR-34c-3p. Firefly and renilla luciferase were measured 48 hours post-
transfections using the DLRA kit. The ratio of firefly to renilla was calculated to normalise for 
transfection efficiency then expressed as a percentage of the appropriate negative control value. 
Results represent the mean of four independent biological experiments, each performed in 
quadruplicate; error bars represent standard error of the mean (SEM). *p<0.05. 
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6.4.8 Further Investigation of miR-320a in Steroidogenesis 
Section 6.4.5 describes the significant effects of miR-320a on CYP17A1 mRNA 
abundance after artificially decreasing and increasing its levels in H295R cells. 
However, the results displayed in Section 6.4.7 imply that this effect is not 
caused through direct binding of miR-320a to the 3’UTR of CYP17A1 mRNA. 
Therefore, similar bioinformatic analyses to that described in Section 6.4.3 were 
performed to investigate whether miR-320a is predicted to bind and possibly 
modulate other genes acting upstream from CYP17A1 in the steroidogenic 
pathway. This analysis predicted miR-320a to bind mRNA encoding the side-chain 
cleavage enzyme, CYP11A1, which performs the initial conversion of cholesterol 
to pregnenolone in the steroidogenic pathway. 
To investigate this further, H295R cells were transfected under basal conditions 
with miR-320a-specific Pre-miR™ or Anti-miR™ in order to artificially increase 
and decrease levels of the miRNA in the cells. CYP11A1 mRNA levels were 
measured and are displayed in Figure 6-12a. The relative abundance level 
(RQ=2-ΔΔCt) of CYP11A1 mRNA after transfection with miR-320a Pre-miR™ was 
0.81±0.02, significantly lower than that of control cells (p=0.011). Transfection 
with miR-320 Anti-miR™ significantly increased CYP11A1 mRNA abundance 
(1.40±0.03, p=0.003). These results are consistent with canonical miRNA action. 
Levels of mature miR-320a were also measured post-transfection to confirm 
successful transfection of Pre-miR™ and Anti-miR™. Figure 6-12b shows that 
transfection with miR-320a Pre-miR™ significantly increased levels of mature 
miR-320a in the cells, with relative expression of 602±89.6, p<0.001, while it 
was reduced to 0.14±0.02 (p=0.005 relative to control-transfected cells) in the 
presence of miR-320a Anti-miR™. 
As with CYP17A1, these data are consistent with the modulation of CYP11A1 
mRNA abundance by miR-320a through canonical inhibitory miRNA action.  
However, due to time-constraints, confirmation that this is due to direct binding 
of CYP11A1 mRNA was not performed at this stage.  
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Figure 6-12 Assessment of A) CYP11A1 mRNA abundance and B) mature miRNA levels 
post-transfection in H295R cells grown in basal conditions. 
H295R cells were transfected with miR-320a Pre-miR™, Anti-miR™ and a scrambled negative 
control (final concentration 50nM). CYP11A1 mRNA abundance and mature miRNA levels were 
measured 48 hours post-transfection by qRT-PCR. Cycle threshold values were normalised to 
β-actin or RNU48 mRNA, as stated on the y-axis, and expressed relative to negative control-
transfected cells. Results represent the relative quantification (RQ=2
-ΔΔCt
) of the mean of three 
independent biological experiments performed in triplicate; error bars represent standard error of 
the mean (SEM). Statistical differences were analysed by one-sample t-test on ΔΔCt values. 
*p<0.05, **p<0.01, ***p<0.001. 
A 
B 
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6.4.9 Bioinformatic Analysis to Identify Putative miRNA Binding 
Sites in the 3’UTRs of POR and CYB5A 
As previously described in Section 1.3.1, the selective action of CYP17A1 in the 
adrenal cortex zones relies heavily upon the presence of the co-factors POR and 
CYB5A. It is entirely plausible to hypothesise that miRNAs may modulate the 
expression of these co-factors and affect the action of CYP17A1 in the adrenal 
gland. To this end, similar bioinformatic analyses to those described in Section 
6.4.3 were conducted to identify putative miRNA binding sites in the 3’UTRs of 
POR and CYB5A. Table 6-8 summarises the number of target sites predicted by 
each database within the 3’UTR of each gene, with a total of 264 unique miRNAs 
predicted to bind POR and 203 to bind CYB5A. 
The miRNA expression data from the four normal samples and four aldosterone-
producing adenoma (APA) samples were again cross-referenced with predicted 
miRNAs from bioinformatic analyses. Figure 6-13 lists those microRNAs expressed 
in normal adrenal tissue and APA tissue that were also predicted to bind the 
3’UTRs of POR and CYB5A. Of particular interest are miR-24 and miR-21, which 
are predicted to bind POR and CYB5A, respectively. As reviewed in Section 
1.5.1.6, both miRNAs have been shown to exhibit regulatory effects in adrenal 
steroidogenesis. 
  
   
 
Table 6-8 Bioinformatic miRNA target site predictions for CYB5A and POR 3’UTRs. 
Gene 3’ UTR Length (bp) MicroCosm TargetScan Microrna.org Mir-viewer miRwalk Tarbase Total Unique miRNAs 
POR 374 58 30 131 6 214 0 264 
CYB5A 288 66 2 14 0 182 0 203 
 
 
 
Figure 6-13 Venn diagrams showing microRNAs expressed in normal adrenal tissue and APA tissue that are predicted to bind the 3’UTRs of A) POR and B) 
CYB5A. 
A B 
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6.5 Discussion 
The experiments presented in this chapter investigate the role of microRNA in 
the modulation of adrenal CYP17A1 expression. To achieve this, in silico analysis 
identified miRNAs with putative binding sites in the CYP17A1 mRNA, focussing 
primarily on the 3’UTR. These were then cross-referenced with microarray 
expression data in order to construct a list of miRNAs with the potential to 
regulate adrenal CYP17A1. Based on differential expression patterns between 
non-diseased and APA tissue, two miRNAs were selected for further study. Two 
primary methods were employed to analyse these:  
i)  Assessment of specific miRNA effects on CYP17A1 mRNA abundance 
through miRNA supplementation or inhibition in an adrenocortical cell line.  
ii)  Assessment of direct mRNA:miRNA interactions through 3’UTR reporter 
construct studies. 
The merits of these in silico and in vitro methods, and the findings of each, will 
be discussed below. 
 
Bioinformatic Analysis 
 
The first stage of in silico analysis investigated whether any miRNAs were 
produced from within the CYP17A1 sequence. Many miRNAs arise from intronic 
locations but, despite many precursor and mature miRNA sequences matching 
sections of the CYP17A1 introns, no miRNAs registered within the miRBase 
repository (2042 human miRNAs) have, to date, been mapped to these regions. 
Hence, SNPs located in these regions or splicing variants are not likely to affect 
the transcription of any miRNA. Therefore, any miRNA found to regulate adrenal 
CYP17A1 would be subject to independent transcriptional regulation. 
Comparison of CYP17A1 3’UTR sequence between species revealed high degrees 
of conservation between primates, and moderate conservation between 
mammals. A conserved 3’UTR sequence and, in particular, conserved putative 
miRNA binding sites, has been suggested as being an indicator of miRNA 
regulation (Friedman et al., 2009). On the other hand, studies of basic cell 
homeostasis show that genes with short 3’UTRs are more resistant to miRNA-
mediated repression (Stark et al., 2005) and the CYP17A1 3’UTR is relatively 
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short at just 171 bases. In comparison, the 3’UTR of CYP11B1, for example, has 
2015 bases and is known to be modulated by miRNA (Robertson et al., 2013).  
Several databases were used for bioinformatic prediction of putative miRNA 
binding sites in CYP17A1, POR and CYB5A mRNA. Each program has its own 
unique algorithm and parameters with varying levels of stringency, and so 
collating results from a variety of databases was deemed to be more reliable 
than simply relying on a single source. It is useful to be aware of the limitations 
of each database and to apply caution when analysing their output; 
bioinformatic databases are useful tools but are not definitive proof of 
mRNA:miRNA interaction. For example, the Tarbase program did not yield any 
predictions. This was to be expected since only experimentally validated 
interactions are stored in this database. The miRwalk database is evolving into a 
useful tool as it utilises up to eight different algorithms but, at present, it is 
necessary to search some of the individual databases it uses directly in order to 
obtain the most up-to-date information. Furthermore, the majority of programs 
employed in these searches are preset to only assess the 3’UTR of genes of 
interest, although experimental evidence is now emerging that miRNAs can act 
on other gene regions (Duursma et al., 2008; Orom et al., 2008); miRwalk results 
relate to putative miRNA binding sites in the coding regions and 5’UTR of genes. 
The precise details of mRNA:miRNA interactions are still emerging and therefore 
a combinatorial approach, selecting the lowest levels of stringency where 
necessary was considered advantageous. The degree of variation observed 
between databases highlights the need to improve understanding of miRNA-
target binding, and is consistent with previous studies (Bartel 2009; Saito and 
Saetrom 2010).  
Of the miRNAs predicted to bind to the 3’UTR of CYP17A1, a high proportion are 
miRNA*, derived from the passenger strand of the hairpin structure, which was 
originally believed to be non-functional. The currently favoured nomenclature 
assigns a -3p or -5p suffix to the derivatives of each strand, depending on its 
origin within the hairpin, as recent evidence suggests that either strand may be 
processed as the functional strand (see Section 1.5.1.3). Consequently, miRNA* 
predictions should not be disregarded as potential regulators of gene expression 
at this stage. It may also be useful to perform further in silico analyses: 
programs such as RNAFold or RNAHybrid can respectively predict the secondary 
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structure of the unbound 3’UTR and identify interesting mRNA:miRNA 
interactions (Kruger and Rehmsmeier 2006). Such assessment of the unbound 
3’UTR secondary structure could reveal complex folds that inhibit putative 
miRNA interactions. While such programs are simply predictive tools, they may 
aid in prioritising miRNAs for further study. 
Microarray data from expression profiling studies was available from both human 
non-tumourous adrenal (termed ‘normal’) and aldosterone producing adenoma 
(APA) tissue. The adrenal tissue sections used had not been laser dissected and 
were therefore likely to contain small amounts of adrenal medulla as well as 
cortex, although efforts were made to use blocks that were predominantly 
cortex. Across each sample type, miRNA levels were consistent suggesting the 
original starting material was not particularly variable in terms of its 
composition. The samples were deemed to be of good quality at the time of 
microarray and subsequent qRT-PCR validation. However, although probes 
covered 100% of known human miRNAs when the microarray was performed, 
there are currently 2042 human mature miRNAs listed on miRBase (v.19, August 
2012), compared to the 723 included in the microarray data. This means that the 
work presented in this chapter is limited to the analysis of those 723 miRNAs and 
does not include over half of the currently known miRNAs. It would be useful, 
particularly for the study of the regulation of CYP17A1 by miRNA, to obtain 
zone-specific expression profiles within the adrenal cortex, in order to identify if 
miRNAs modulate CYP17A1 mRNA differently in the zona fasciculata compared to 
the zona reticularis. To date, it has proved difficult to obtain sufficient non-
diseased adrenal tissue for this purpose. 
Cross-referencing miRNAs predicted to bind to the 3’UTR of CYP17A1 with those 
expressed in normal adrenal tissue or APA identified four unique miRNAs. Known 
previously in the literature as miR-368, miR-376c was found only to be expressed 
in normal adrenal tissue although, despite a clear trend, expression levels were 
not significantly different between tissue types. This may be caused by sample 
variation and significance could be altered by increasing the number of samples 
in each category. Hsa-miR-376c is transcribed from chromosome 14q32 as part of 
a large miRNA cluster. This cluster of miRNAs was previously shown to be 
dysregulated in ovarian cancer and gastro-intestinal tumour expression profiling 
studies (Zhang et al., 2008; Haller et al., 2010). Furthermore, eight miRNAs from 
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this cluster have been identified as potential tumour suppressor genes, including 
miR-376c (miR-368), and – of similar sequence and from the same family – miR-
376a and miR-376b (Zhang et al., 2008). Moreover, manipulation of miR-376c 
levels in vitro has recently been shown to affect expression of the insulin growth 
factor 1 receptor (IGF1R) (Zehavi et al., 2012). Despite no published link 
between miR-376c and hypertension, its tumour suppressor role may indicate a 
role in the development and pathology of APA. In the production of this thesis, 
time constraints did not allow this miRNA to be investigated further although, as 
with all four miRNAs of interest, miRNA expression in both normal and APA tissue 
types would need to be validated by qRT-PCR, firstly to confirm the accuracy of 
the microarray and, secondly, to enable more precise quantitative measurement 
of expression changes between tissue types. 
Arising from the 5’ arm of the precursor hairpin, miR-7 was found to be 
expressed at similar levels in both normal adrenal and APA tissue. This miRNA can 
be transcribed from three different genomic locations on chromosomes 9, 15 and 
19, with current nomenclature rules adding the suffixes -1,-2 and-3, 
respectively. In comparison to many other miRNAs, miR-7 is relatively well-
studied. Studies have indicated that it is tightly regulated by the transcription 
factor Homeobox D10 (HoxD10) and its expression is dysregulated in many types 
of cancers, including aggressive breast cancer and glioblastomas (Foekens et al., 
2008; Kefas et al., 2008; Reddy et al., 2008). Furthermore, expression profiling 
studies and subsequent qRT-PCR validation on adrenocortical carcinomas (ACC) 
and adenomas (ACA) show miR-7 expression to be significantly reduced 
compared to normal adrenal tissue (Soon et al., 2009; Singh et al., 2012). This 
may suggest that, in addition to regulating processes surrounding adrenal 
pathology, this miRNA has wider roles in cell-cycle progression and 
tumourogenesis (Foekens et al., 2008). 
In Vitro Investigations 
The subset of four adrenal miRNAs predicted to bind the CYP17A1 3’UTR was 
derived by bioinformatic analysis alone; experimental validation is required to 
confirm a functional effect on CYP17A1 expression. Time constraints meant that 
investigation of miRNAs differentially expressed between normal and APA tissue 
was given priority, as these were deemed more likely to have an important role 
234 
 
in adrenal pathology. Initial in vitro experiments utilised miRNA mimics and 
inhibitors (Pre-miR™ and Anti-miR™), which respectively increase or decrease 
levels of specific endogenous mature miRNAs in cells and are an established 
experimental tool in research (Cheng et al., 2005). As the sequence of some 
miRNAs can vary by only one or two bases, it is important for these molecules to 
be highly specific and to avoid off-target effects. Successful transfection and 
expression of these molecules can be assessed by direct measurement of the 
mature miRNA level post-transfection. The results described in this chapter 
reveal that both miR-320a Pre-miR™ and Anti-miR™ were highly effective at 
modulating the levels of mature miR-320a in H295R cells. However, the Anti-
miR™ supposedly specific for inhibition of miR-34c-3p did not appear to be 
effective. Successful use of a miRNA inhibitor molecule depends upon its target 
miRNA being present within the chosen cell type. The presence of miR-34c-3p 
was assessed by qRT-PCR and confirmed to be present in both H295R and HeLa 
cells. Therefore, the failure of the miR-34c-3p may be due to faults in its 
preparation or design by the manufacturer, although the actual reason was not 
determined. The miR-34c-3p Pre-miR™ did successfully increase levels of the 
mature miRNA in cells although the degree of change differed considerably from 
that of the miR-320a Pre-miR™. From previously conducted optimisation 
experiments, this variation appears typical of these synthetic molecules and, in 
both cases, the increase in miRNA was sufficient for significant changes to be 
detected. The changes in miRNA levels were very large and, particularly for Pre-
miR™ transfections, unlikely to be physiologically representative. However, as is 
often the case when using an in vitro model, supraphysiological changes are 
regularly required to investigate a pathway. Nevertheless, caution must be 
applied when interpreting such data as, for example, false positives may result 
from off-target effects or activation of other pathways due to overloading of the 
natural system. 
The results from miR-34c-3p Pre-miR™ and Anti-miR™ transfections are variable. 
CYP17A1 mRNA abundance was significantly reduced when basal H295R cells 
were transfected with Pre-miR™ but not when stimulated with (Bu)2cAMP, a 
substitute for ACTH. Taken together with reporter construct experiments, which 
were designed to assess whether miR-34c-3p binds the 3’UTR of CYP17A1 
directly, these results suggest a non-canonical form of miRNA action. A clearer 
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impression of miR-34c-3p action should be achieved through Anti-miR™ 
transfections, but such data cannot be considered reliable due to its failure to 
reduce miR-34c-3p significantly within the cells. Although it would have been 
beneficial to also measure the levels of miRNA in the transfected HeLa cells, it 
would be anticipated that changes in miRNA levels would be similar in magnitude 
to those of the H295R cell experiments. Reporter construct studies are currently 
the best available method for assessing miRNA target-site validation. The 
CYP17A1 reporter construct contains the full length 3’UTR sequence, thus giving 
a truer reflection of mRNA:miRNA interactions, compared to constructs with 
smaller segments inserted. Furthermore, in addition to the firefly luciferase 
gene used to assess the insert, this plasmid also contains a renilla luciferase 
gene, which acts as a control for transfection efficiency. This avoids possible 
transfection efficiency problems that may arise from having to co-transfect a 
separate control plasmid, particularly as small molecules also had to be 
transfected as part of the protocol. It may be appropriate to repeat these 
experiments using similar small hairpin molecules which require initial 
processing and Dicer cleavage by the cell itself. This may be more physiologically 
relevant; however, such molecules were not accessible at the time of these 
experiments having only recently become available. Further investigation of this 
miRNA would be needed to elucidate its mechanism of action on CYP17A1 mRNA, 
with a detailed evaluation of other related target sites being a useful starting 
point. Given that expression levels in both types of adrenal tissue were 
significantly different, it is difficult to predict exactly what results would be 
expected from the in vitro systems used in this study. Published studies have 
implicated miR-34c-3p, as well as its family members miR-34a and miR-34b, as 
having a defined role in tumour development, through interaction with p53 
(Hermeking 2010). From this perspective, it may be advantageous to study the 
role of this miRNA in the development of APA and other adrenal tumours rather 
than its effects on CYP17A1. 
The miR-320a data presented in this chapter seem both promising and intriguing. 
Increased levels of miR-320a had no significant effect on basal H295R cells, but 
CYP17A1 mRNA levels were raised following miR-320a inhibition. As discussed 
previously, the use of a specific miRNA inhibitor is probably more physiologically 
relevant than synthetic supplementation, and this pattern is typical of the 
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results seen when using these small molecules (Wood 2011). Upon stimulation 
with (Bu)2cAMP, significant increases in CYP17A1 mRNA levels were observed. In 
the body, the presence of circulating ACTH activates cellular cAMP, which 
triggers a cascade of events stimulating the production of cortisol in the adrenal 
zona glomerulosa. When miR-320a mimics were transfected onto H295R cells, 
CYP17A1 mRNA levels significantly reduced. Transfection with miR-320a inhibitor 
increased CYP17A1 mRNA levels. The data described here are consistent with the 
hypothesis that miR-320a acts as a post-transcriptional negative regulator of 
CYP17A1. Reporter construct experiments, however, suggest that this effect does 
not occur through direct binding of miR-320a to the 3’UTR of CYP17A1. 
Bioinformatic analysis predicted a putative binding site for miR-320a within the 
3’UTR of the CYP11A1 gene, which encodes side chain cleavage enzyme, a key 
gene in the steroidogenic pathway. Data presented here show miR-320a 
modulates CYP11A1 in a typical manner, although, it is still necessary to 
generate and conduct experiments using a CYP11A1 3’UTR reporter construct in 
order to confirm direct interaction. If direct miR-320a modulation of CYP11A1 
expression was confirmed, such regulation could potentially affect all 
downstream steroidogenesis, given the pivotal position of side-chain cleavage 
enzyme at the head of the pathway. 
From the existing literature, it can be concluded that miRNAs act as part of a 
complex network so that, where one miRNA decreases expression of a gene, 
another may be present to compensate. The experiments involving the 
simultaneous supplementation or inhibition of both miRNAs within the same cells 
were designed to study this. In basal H295R cells, no significant effect on 
CYP17A1 mRNA was observed, and the effects from single-miRNA were not 
replicated, although it is not immediately clear why. Potential explanations 
include the possibility that off-target effects are providing a compensatory 
mechanism, or that the presence of mimic or inhibitor in relatively high volumes 
has increased competition for cellular resources. It is also possible that the in 
vitro system is simply overloaded and transfection efficiency reduced. It is 
interesting, however, that the effect exerted by increased miR-320a on CYP17A1 
mRNA is maintained when transfected alone and in combination with miR-34c-3p 
in stimulated cells, and implies that miR-320a is a key regulator of CYP17A1 
expression. It would be ideal to measure CYP17A1 protein levels in order to 
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corroborate mRNA data. In addition, measurement of the steroid products 
themselves would be of use in supporting this association.  
Although the underlying mechanisms are unclear, CYP17A1 expression is reported 
to be significantly decreased in APA tissue (Wang et al., 2011). That publication 
only assessed mRNA abundance, however it assumed that this effect translated 
through to the protein level. On the basis of the evidence assembled here, the 
significant up regulation of miR-320a in APA tissue relative to normal adrenal 
tissue could, through inhibitory miRNA action, account for the reduced CYP17A1 
expression that the previous investigators observed. It is unlikely, however, that 
this would be the sole cause, since many miRNAs are likely to have fine-tuning 
effects on the steroidogenic pathway and the effects of numerous factors would 
probably be required to cause the -0.97 ± 0.41 fold decrease that they observed. 
The data presented in this chapter provide the first analysis of miR-320a effects 
on the human adrenal gland at a molecular level. Previously, levels of mature 
miR-320a were found through microarray analysis to be significantly increased 
1.5-fold in human adrenocortical carcinoma tissue compared to adrenocortical 
adenoma tissue, although this finding was not validated by qRT-PCR (Soon et al., 
2009). This reiterates the need for microarray analysis to be confirmed by qRT-
PCR. The role of miR-320a in cancer appears to be a recurring theme within the 
literature.  Microarray analysis revealed miR-320a to be overexpressed in the 
tumourigenesis of retinoblastoma (Zhao et al., 2009), but a protective role for 
miR-320a has been suggested by other studies, including one showing it to be  
down regulated in prostate cancer tissue (Hsieh et al., 2013). Furthermore, the 
authors of that study found that reducing the levels of mature miR-320a in vitro 
increased the formation of tumour spheres and other cellular cancerous 
properties. Subsequent cDNA microarray showed expression of several genes in 
the Wnt/β-catenin pathway to be reduced in cells expressing miR-320a. 
Investigations similar to those conducted in this chapter using miRNA mimics, 
inhibitors and reporter constructs identified miR-320a as directly modulating 
expression of β-catenin (Sun et al., 2012). Increased miR-320a levels have also 
been associated with reduced cell proliferation in a human leukaemia cell line 
(Schaar et al., 2009). Studies which investigate the therapeutic potential of miR-
320a are also now beginning to emerge. MiR-320a directly modulates the 
expression of Aquaporin 1 and 4, which play key roles in cellular water 
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homeostasis; changes in expression of these proteins associate with cerebral 
ischemia, and investigators have found that locally-administered anti-miR-320a 
significantly reduces infarct volume in rats (Sepramaniam et al., 2010). 
Similarly, having been implicated in the regulation of cardiac ischaemia through 
its direct modulation of Heat Shock Protein 20, anti-miR-320a also reduces 
cardiac infarction size in vivo (Ren et al., 2009). Although further work is 
required before the administration of anti-miRNA medicine is used clinically, its 
potential opens up an exciting field of research. The exact mechanisms and 
effects of miR-320a in the adrenal gland and its role in adrenal tumour pathology 
are yet to be fully elucidated. Local delivery of an anti-miRNA to the adrenal 
gland as a therapeutic treatment would be difficult, and risks off-target effects.  
Regulation of Co-Factors by miRNA 
Since miRNAs are capable of targeting thousands of genes in the genome, it is 
worth considering their effect on the co-factors of CYP17A1 and how regulation 
and expression may be affected. For example, it is feasible to hypothesise that 
post-transcriptional regulation by miRNA may be responsible for the lack of 
CYB5A expression in the zona glomerulosa. Lists of adrenal miRNAs with putative 
binding sites on POR and CYB5A were generated but have not yet been 
investigated further. An initial point of investigation would be the influence of 
miR-21 and miR-24, as both have previously been implicated in the regulation of 
steroidogenesis (Section 1.5.1.6).  
Overall Review 
Common polymorphisms located in the 3’UTR of these — and indeed all — genes 
regulated by miRNAs, have the potential to inhibit or promote binding of the 
target site. Chapter 3 of this thesis found no variation in the 3’UTR of CYP17A1 
in the AFS Caucasian population studied, and POR, CYB5A and CYP11A1 are yet 
to be assessed. Common variations found in other ethnic groups should be also 
considered.  
In summary, these studies have identified and investigated putative miRNA 
binding sites on the 3’UTR of CYP17A1 mRNA. While hsa-miR-320a has been 
shown to modulate CYP17A1 expression in an adrenocortical cell line, this does 
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not occur through direct binding of CYP17A1 transcripts. The effects of hsa-miR-
34c-3p on CYP17A1 expression are less convincing and require further 
clarification. A combination of bioinformatic analysis and in vitro studies has 
shown a possible direct modulatory effect of miR-320a on CYP11A1 mRNA, but 
this is yet to be confirmed. In conclusion, this is the first study to investigate the 
regulatory effects exerted on CYP17A1 by miRNA. Future work is required in 
order to fully unravel the complex system of miRNA regulation and draw 
definitive conclusions about the effects of miRNA on the regulation of CYP17A1. 
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7 General Discussion 
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Essential hypertension is a common disorder of complex aetiology affecting 
around one-third of adults worldwide and is a major risk factor for 
cardiovascular disease. It results from complex interactions between genetic and 
environmental factors, many of which are not fully understood. Genome-wide 
association studies (GWAS) have become the latest research tool to identify 
common genetic variants associated with hypertension and other diseases. 
Recent GWAS identified an association between a common genetic variant 
located in the human CYP17A1 gene and increased systolic blood pressure. The 
CYP17A1 gene encodes a dual-function enzyme critical in the adrenal 
corticosteroid biosynthesis pathway, a major candidate system already 
implicated in the development of essential hypertension, as outlined in Chapter 
1. Therefore, increasing our knowledge of how this gene is regulated within this 
system should improve our understanding of essential hypertension. 
The experimental work presented in this thesis was designed to investigate the 
hypothesis that there are functional polymorphisms in the CYP17A1 gene, 
specifically the promoter region, that are co-inherited alongside the one 
highlighted by recent GWAS (rs1004467). In addition, the existence of a novel 
regulatory mechanism involving microRNAs was explored. Following a detailed 
examination of linkage disequilibrium patterns at the CYP17A1 locus, I 
proceeded to analyse the effects of genotype on intermediate corticosteroid 
phenotype in a hypertension population and to identify possible functional 
variants in vitro. The resulting data presented here support the original 
hypothesis. 
The detailed examination of CYP17A1 in a normotensive Caucasian population 
(Chapter 3) found most variation to be in the promoter region and introns. This 
was achieved by direct sequencing of individual genomic DNA samples by the 
chain termination method. At the time, newer methods such as next-generation 
sequencing were not considered cost-effective. The method employed allowed 
the discovery of previously unreported SNPs. In fact, the polymorphism at 
position -1877 has only recently been assigned an official name (rs138009835), 
presumably as a result of the 1000 Genomes Project. While variants within 
introns may be functional, particularly if located at splice sites, priority was 
given to those located in the promoter region. Two distinct and unrelated blocks 
of SNPs in strong linkage disequilibrium warranted further exploration. One 
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block (LD Block 2) contained the polymorphism reported by the GWAS 
(rs1004467); hence its relationship with the SNP at -1877 was instantly 
attractive, since its location implied that it might alter transcriptional activity of 
the gene, while also supporting the original hypothesis.  
Selected promoter SNPs were directly sequenced in a subset of the hypertensive 
BRIGHT cohort. While it would have been simpler to genotype utilising specific 
fluorescent probes (e.g. SNP genotyping by Taqman®), the DNA was not of 
sufficient quality to yield convincing results by such a method. Genotyping and 
subsequent LD and haplotype analysis found the distinction between the two 
blocks of SNPs to be less clear. The cohorts were not matched in terms of cases 
and controls but each was of Caucasian British descent and it would not be 
unreasonable to observe similar relationships between the SNPs and haplotype 
frequencies in both unless, of course, a particular haplotype is more strongly 
associated with the hypertensive or normotensive group. It would be desirable to 
examine this further in order to determine whether a ‘risk’ haplotype exists. 
Given that the SNP identified by GWAS associated with a small rise in systolic 
blood pressure, the effect from any ‘risk’ haplotype is also likely to be small. 
Personalised medicine is often discussed as the future of medicine and an 
individual who exhibits several ‘risk’ haplotypes within specific genes could 
benefit from alteration to their lifestyle choices. 
Each of the selected SNPs in the promoter region was examined for association 
with intermediate corticosteroid phenotype (Chapter 4). It is clear from these 
studies that there is a case for analysing steroid excretion rates separately by 
gender. Cortisol excretion rates were significantly higher in males of AG 
genotype at position -362 then those of AA genotype (Table 4-12). Interestingly, 
studies of allele-dependent transcriptional activity in vitro (Chapter 5) found the 
G allele at this locus to exhibit significantly higher transcriptional activity 
compared to the A allele (Figure 5-6). It may be that increased transcription of 
CYP17A1 leads to greater cortisol production, although why this is only seen in 
males is unclear. Furthermore, androgen metabolite excretion was similar 
between the two genotypes, possibly due to other transcriptional influences 
within the zona reticularis or to additional urinary androgen metabolite 
excretion from the testes. Higher cortisol excretion rates were also noted for 
females in the presence of the minor allele at positions -1204 and -2205. Similar 
243 
 
trends were observed for the other SNPs within this LD block. When 
transcriptional activity of each allele was assessed in vitro only the T allele at 
position -2205 resulted in significant increase. This is consistent with the idea 
that only one SNP within a LD block may be functional and that the others are 
merely markers co-inherited alongside it. This same block of SNPs has a clear 
association with the ratio of THDOC:THS. In females, the minor allele is 
associated with a lower ratio, indicative of increased 17α-hydroxylase efficiency; 
the in vitro observations are relevant here also.  
In examining the effects of an individual SNP separate from its haplotype block, 
the cumulative effect of the haplotype as a whole may be overlooked. In 
combination, a series of SNPs may have a more pronounced effect or, 
alternatively, the opposing effects of different SNPs may be negated. The 
combined effect of five strongly-related SNPs on urinary metabolite excretion 
was briefly explored here and would benefit from an increased number of 
participants to enable a comparison of the various genotype combinations at all 
seven SNP sites, as different factors may be interacting to influence 
transcription. Even in combination, genotype-dependent effect sizes are likely 
to be small and it is possible that actual effects within the urinary metabolite 
and in vitro studies were obscured by technical variability. In addition, rare 
polymorphisms have been excluded from these studies; these may also exert a 
physiological influence on blood pressure, albeit in a smaller number of 
individuals, and warrant further investigation. 
One striking observation was that THAldo excretion rates were higher in the 
-1877 CC genotype group compared to the CT+TT group (Table 4-32). This 
polymorphic site was of interest due to its strong relationship with the GWAS 
SNP. However, it was not associated with altered excretion of the more obvious 
corticosteroids i.e. cortisol and androgens. Assessment of transcriptional activity 
at this site found activity of the C allele to be significantly higher than that of 
the T allele. An effect of ACTH on aldosterone production has previously been 
postulated (Freel et al., 2007) and it may be that altered transcriptional activity 
of CYP17A1 has an indirect effect on ACTH drive, although the underlying 
molecular mechanism is unclear. 
244 
 
This is the first study to examine directly the regulation of CYP17A1 by miRNAs, 
and this was accomplished using both in vitro and in silico techniques. The 
studies presented in Chapter 6 utilised bioinformatic prediction algorithms to 
identify those miRNAs most likely to target CYP17A1 mRNA. Post-transcriptional 
gene regulation by miRNA is a relatively new and rapidly developing field, and 
even over the course of this three-year research period, the algorithms within 
the databases have been extensively modified. Precise identification of all false-
positive and false-negative results from bioinformatic prediction is difficult and 
would require a lot of time and expense. Even as our knowledge of miRNA target 
recognition improves, there will probably always be an inherent error associated 
with this type of analysis, given the imperfect base-pairing nature of miRNAs 
(Grimson et al., 2007; Shin et al., 2010). This study collated predictions from six 
separate databases in an attempt to compensate for the various algorithms and 
stringency levels, although such prediction lists will require updating as 
individual algorithms are refined. Those miRNAs differentially expressed in 
normal and diseased adrenal tissue were prioritised, and two miRNAs eventually 
selected for further study. Effects of these miRNAs on steroid secretion and 
CYP17A1 protein levels remain to be explored. In addition, miR-7 and miR-376c 
were also predicted to bind to adrenal CYP17A1 but have not yet been 
investigated in vitro. The manufacturer of the microarray used to detect the 
miRNAs in normal adrenal tissue advised a signal intensity cut-off of 500 
arbitrary units (AU). Although a cut-off value is required to minimise 
experimental error and account for the lower detection limit of the scanner, it is 
possible that some miRNAs with intensity value marginally below 500 AU are 
important to adrenal physiology. There is also likely to be zone-specific 
expression of some miRNAs within the adrenal gland and, since the tissue 
samples analysed contain a heterogeneous adrenal cell population, their levels 
may be diluted within the whole sample. It would be beneficial to perform zonal 
micro-dissection and quantitative expression analysis to aid in the identification 
of such miRNAs, including miR-320a. 
MiRNA expression profiling studies are quickly becoming a common research 
theme and have clear potential in the identification of biomarkers for the 
clinical diagnosis of a variety of disorders, including ovarian cancer and heart 
conditions (Chen et al., 2013; Leptidis et al., 2013). However, both practical and 
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ethical considerations make these types of studies on the adrenal glands of 
patients with essential hypertension impossible, and animal models are not ideal 
for a variety of reasons. Firstly, rodent adrenal physiology is not directly 
comparable to that of humans e.g. corticosterone is the major glucocorticoid in 
rat. Secondly, the similarity and conservation of the miRNA-mediated repression 
mechanisms across species are not fully understood.  
In theory, targeting of specific miRNAs has enormous therapeutic potential. The 
control of aberrant disease-causing gene expression through manipulation of 
specific miRNA levels seems promising although, due to numerous potential 
targets a single miRNA may have, there is huge scope for side effects. Targeting 
tissues specifically may reduce such effects and the use of viral vectors for this 
purpose is ongoing. The delivery of anti-miR-122 to the liver of the African green 
monkey was successfully achieved and, subsequently, pharmaceutical companies 
have started early-stage clinical trials in humans. This year, Santaris Pharma 
announced enrolment completion of a Phase II clinical trial utilising anti-miRNA-
based therapy as treatment for the Hepatitis C virus (Wartelle-Bladou et al., 
2012). Such trials for adrenal disorders are unlikely in the near future as further 
understanding of the role of miRNA in both normal and diseased adrenal 
pathology is required. 
Aside from further in vitro suggested studies intended to develop a clearer 
understanding of the molecular basis of the allele-dependent changes in 
transcriptional activity (discussed in Section 5.4.4), it may be useful to examine 
the frequency of selected polymorphisms in other disorders where hypertension 
is a feature. The SNP at position -34 (rs743572) has been investigated for 
association with PCOS (Section 1.3.3.2) with inconsistent results. It would be 
interesting to assess the frequencies of the other promoter polymorphisms in a 
PCOS population and possibly derive a ‘risk’ haplotype. Similarly, other than the 
variation at position -34, polymorphisms have been largely ignored in association 
studies investigating hormone-related cancers and premature male baldness. 
Furthermore, regulation of the gene may be altered through other mechanisms 
and closer examination of the contribution of miRNA may aid understanding of 
PCOS development and treatment. 
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In conclusion, recent GWAS identified a common genetic variant in the CYP17A1 
gene that was associated with a small but significant rise in systolic blood 
pressure. It was hypothesised that a co-inherited SNP may be responsible. 
Several common polymorphisms in the promoter region have been identified and 
this is the first time that significant association with variations in the CYP17A1 
gene has been shown with corticosteroid intermediate phenotypes in a 
hypertensive population. Furthermore, evidence has been provided for allele-
dependent alterations in transcriptional activity at a number of polymorphic 
locations. Early identification of subjects predisposed to hypertension and the 
future identification of susceptible genotypes at the CYP17A1 locus and other 
known loci will allow early lifestyle and medicinal intervention. In addition, a 
regulatory role for miRNA has also been confirmed here, opening up new avenues 
of investigation into the fine control of corticosteroid secretion. It is expected 
that the improved understanding of how steroidogenic genes contribute to 
hypertension will aid the development of therapeutic interventions.  
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8 Appendices 
8.1 Appendix 1 
 
Table 8-1 Primers used to amplify and sequence 2.4kb of CYP17A1 promoter in AFS and 
BRIGHT cohorts. 
 Primer Name Sequence 5’-3’ Tm (°C) Cycling Conditions 
PCR Primers 
(Expand High Fidelity 
PCR System) 
cyp17promF2 ATGCAGTTCGATTGCAACAC 55.3 
See Table 8-2 
cyp17promR2 TTGGGCCAAAACAAATAAGC 53.2 
Sequencing Primers 
cyp17promF2 ATGCAGTTCGATTGCAACAC 55.3 BIGSEQ50 
cyp17promR2 TTGGGCCAAAACAAATAAGC 53.2 BIGSEQ50 
cyp17-1935F AGCTGAGGCGTTAGATCAGG 59.4 BIGSEQ60 
cyp17-1525F GTCACTTCAGGACCACTGTGA 59.8 BIGSEQ60 
cyp17-1213F CCGCTCTGGGAATGTCTATC 59.4 BIGSEQ60 
cyp17-884F TTGTCCTTTCCCTCAGAAGC 57.3 BIGSEQ50 
cyp17-603F GAAATATTGGGGGTGGGTTC 57.3 BIGSEQ50 
cyp17-159F CCCAGATACCATTCGCACTC 59.4 BIGSEQ60 
cyp17-1697R GACTTCCCGCAACATCTCTC 59.4 BIGSEQ60 
cyp17-1388R TGGTTGTTTTCCCTTGTTCC 55.3 BIGSEQ50 
cyp17-1021R CAGCGGTGCACATACTGTCT 59.4 BIGSEQ60 
cyp17-720R TACCCACCTGAGCCTCAAAC 59.4 BIGSEQ60 
cyp17-374R TAAGGGCTGTGGGTTAATGG 57.3 BIGSEQ50 
cyp17-117R CTCCCCATGCTTGAATGACT 57.3 BIGSEQ50 
cyp17+67R GGCTACCCTGATCTTCACCTT 59.8 BIGSEQ60 
cyp17-112R GTCAGTTGATCACCCTCTGA 57.3 BIGSEQ50 
 
 
 
 
Table 8-2 Expand high fidelity PCR system cycling conditions. 
Time Temperature Cycles 
2 min 94°C 1 
15 sec 94°C 
10 30 sec 55°C 
4 min 68°C 
15 sec 94°C 
20 30 sec 55°C 
4 min (+5 sec every cycle) 68°C 
7 min 72°C 1 
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Table 8-3 Primers used to amplify and sequence exonic regions of CYP17A1 in the AFS 
cohort. 
Target Exon  Primer Name Sequence 5’-3’ Tm (°C) Cycling Conditions 
Exon 1 
PCR Primers 
cyp17ex1_f1 CCACTGCTGTCTATCTTGCC 59.4 See Table 8-4 
Annealing temp: 55°C cyp17ex1_r1 TGAAGACCTGAACAATCCCA 55.3 
Sequencing 
Primers 
cyp17ex1_f1 CCACTGCTGTCTATCTTGCC 59.4 BIGSEQ60 
cyp17ex1_r1 TGAAGACCTGAACAATCCCA 55.3 BIGSEQ50 
17Exon1F CAGAGGGTGATCAACTGAC 60.1 BIGSEQ60 
17Exon1R CTAGGCATGGTCTGAAGAC 60.2 BIGSEQ60 
Exons 2 & 3 
(+ intron 2) 
PCR Primers 
cyp17ex2+3_f1 GGTGTGAGATTCCTACAGCC 59.4 See Table 8-4 
Annealing temp: 55°C cyp17ex2+3_r1 TCTACTAGAACCTGAAGGCAG 57.9 
Sequencing 
Primers 
cyp17ex2+3_f1 GGTGTGAGATTCCTACAGCC 59.4 BIGSEQ60 
cyp17ex2+3_r1 TCTACTAGAACCTGAAGGCAG 57.9 BIGSEQ50 
cyp17ex2_r1 TCCTAACCCTTACCCCTG 56.0 BIGSEQ50 
cyp17ex3_f1 TGGTACAGAGAGGGGGTAAG 59.4 BIGSEQ60 
Exon 4 
PCR Primers 
cyp17ex4_f1 GGTGGAGTAGGAACTTCCAG 59.4 See Table 8-4 
Annealing temp: 59°C cyp17ex4_r2 TCCACCCTGCTCTTGTGATT 57.3 
Sequencing 
Primers 
cyp17ex4_f1 GGTGGAGTAGGAACTTCCAG 59.4 BIGSEQ60 
cyp17ex4_r1 TGTGCCAGGTTCTCTGCTTG 59.4 BIGSEQ60 
cyp17ex4_f2 AGCTAAGATCCGCCTCCAG 58.8 BIGSEQ50 
cyp17ex4_r2 TCCACCCTGCTCTTGTGATT 57.3 BIGSEQ50 
Exons 5 & 6 
(+ intron 5) 
PCR Primers 
cyp17ex5+6_f1 TGGCAGGAGTGTCACAGATG 59.4 See Table 8-4 
Annealing temp: 60°C cyp17ex6_r1 TGAATGCATCATGGGGCTAG 57.3 
Sequencing 
Primers 
cyp17ex5+6_f1 TGGCAGGAGTGTCACAGATG 59.4 BIGSEQ60 
cyp17ex5_f1 GGCAGGAGTGTCACAGATG 58.8 BIGSEQ50 
cyp17ex5_r1 TGGGGTCTAGGATCAATGAG 57.3 BIGSEQ50 
cyp17ex6_f1 ACACACTAGTCACCTCCAAC 57.3 BIGSEQ50 
cyp17ex6_r1 TGAATGCATCATGGGGCTAG 57.3 BIGSEQ50 
Exons 7 & 8 
(+3’UTR) 
PCR Primers 
cyp17ex7+8_f1 TTCCTCTTCCACTCTGGAGC 59.4 See Table 8-4 
Annealing temp: 58°C cyp17ex8utr_r1 GAATGAGTGAGCAAATGAATAC 54.7 
Sequencing 
Primers 
cyp17ex7+8_f1 TTCCTCTTCCACTCTGGAGC 59.4 BIGSEQ60 
cyp17ex8utr_r1 GAATGAGTGAGCAAATGAATAC 54.7 BIGSEQ50 
cyp17ex7_r1 TTGGCAGAGGTGAAGGGGTA 59.4 BIGSEQ60 
cyp17ex7+8_r1 GCCACATAGGGTGGACAGG 61.0 BIGSEQ60 
cyp17ex8_f1 TCAACCAGGGCAGAACCATG 59.4 BIGSEQ60 
cyp17ex8_r1 TGTGTTGTGGGGCCACATAG 59.4 BIGSEQ60 
 
 
 
Table 8-4 Thermo-Start taq DNA polymerase PCR enzyme kit cycling conditions. 
Time Temperature Cycles 
15 min 94°C 1 
15 sec 94°C 
30 30 sec insert annealing temp 
1 min 72°C 
1 min 72°C 1 
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Table 8-5 Primers used to amplify and sequence intronic regions of CYP17A1 in the AFS 
cohort. 
Target 
Intron 
 Primer Name Sequence 5’-3’ Tm (°C) Cycling Conditions 
Intron 1 
PCR Primers 
intron1F CACCAAGACTACAGTGATTG 55.3 See Table 8-4 
Annealing temp: 57°C intron1R1 GTGCGCCAGAGTCAGCGAAG 63.5 
Sequencing 
Primers 
intron1F CACCAAGACTACAGTGATTG 55.3 BIGSEQ50 
intron1R1 GTGCGCCAGAGTCAGCGAAG 63.5 BIGSEQ60 
intron1s1f CTTAGCCTAGCACCCAGCAC 61.4 BIGSEQ60 
intron1s1r AGCTGGAAATAGCACCAGGA 57.3 BIGSEQ50 
intron1s2f CCAATCTCAGCTCACTGCAA 57.3 BIGSEQ50 
intron1s2r CTAAGGTGGGAGGATCACGA 59.4 BIGSEQ60 
intron1s4f ACCCTGTCAGCGAAAAGAAC 57.3 BIGSEQ50 
intron1s4r TTGCCCTTACACCTCTGGTC 59.4 BIGSEQ60 
intron1s3f CTTCAGGGTCAGGAAATGGA 57.3 BIGSEQ50 
intron1s3r AGGCTGAGGACTGCACAGAT 59.4 BIGSEQ60 
Intron 3 
PCR Primers 
cyp17ex3_f1 TGGTACAGAGAGGGGGTAAG 59.4 See Table 8-4 
Annealing temp: 59°C cyp17ex4_r1 TGTGCCAGGTTCTCTGCTTG 59.4 
Sequencing 
Primers 
Intron3s1f TGGTTGAAGGTGAGATGCTG 57.3 BIGSEQ50 
Intron3s2f AAGCATTCTATACGCATTCATCG 57.1 BIGSEQ50 
Intron3s1r AAGCTCCTTAACCCCGCTAA 57.3 BIGSEQ50 
cyp17ex3_f1 TGGTACAGAGAGGGGGTAAG 59.4 BIGSEQ60 
Intron3s2r GACCTTCAGCCAGAATGGAA 57.3 BIGSEQ50 
Intron 4 
PCR Primers 
Intron4F1 AAGCAGAGAACCTGGCACAT 57.3 See Table 8-4 
Annealing temp: 57°C Intron4R1 TCACTCCGGAATTTCTCCTG 57.3 
Sequencing 
Primers 
Intron4F1 AAGCAGAGAACCTGGCACAT 57.3 BIGSEQ50 
Intron4R1 TCACTCCGGAATTTCTCCTG 57.3 BIGSEQ50 
Intron4s1r CTTGCCTGGCCTAGTTTTTG 57.3 BIGSEQ50 
Intron4s1f CAGCTATTTGGGAGGCTGAG 59.4 BIGSEQ60 
Intron 6 
PCR Primers 
cyp17ex6_f1 ACACACTAGTCACCTCCAAC 57.3 See Table 8-4 
Annealing temp: 60°C cyp17ex7+8_r1 GCCACATAGGGTGGACAGG 61.0 
Sequencing 
Primers 
Intron6s1f GCTGGCCAACCTAAAGTCAG 59.4 BIGSEQ60 
Intron6s1r ATCTTGGCTCACTGCAACCT 57.3 BIGSEQ50 
Intron6s2r GGAAGCTCCTCTGGGAAGTC 61.4 BIGSEQ60 
intron6s3r GGGACTTCGTACTCCCTTCC 61.4 BIGSEQ60 
Intron 7 
PCR Primers 
cyp17ex7+8_f1 TTCCTCTTCCACTCTGGAGC 59.4 See Table 8-4 
Annealing temp: 55°C  cyp17ex8utr_r1 GAATGAGTGAGCAAATGAATAC 54.7 
Sequencing 
Primers 
cyp17ex8_r1 TGTGTTGTGGGGCCACATAG 59.4 BIGSEQ60 
cyp17ex7+8_r1 GCCACATAGGGTGGACAGG 61.0 BIGSEQ60 
intron7s1r GCCCTTAACGACACAGAGGA 59.4 BIGSEQ60 
Intron7s2r CAGGCCATGATGAGGAAGAG 59.4 BIGSEQ60 
 
  
250 
 
Table 8-6 Primers used for site-directed mutagenesis of pGL3-17 reporter construct. 
SNP  Primer Name Sequence 5’-3’ Tm (°C) Base Change 
-2205 
t193c ATGGGAAATGGTCAAAGGACACCTTCTGGGTAGGG 71.8 
T → C 
t193c_antisense CCCTACCCAGAAGGTGTCCTTTGACCATTTCCCAT 71.8 
-1877 
c521t AAGGGAGAGATGTTGTGGGAAGTCAGGGACC 70.8 
C → T 
c521t_antisense GGTCCCTGACTTCCCACAACATCTCTCCCTT 70.8 
-1488 
c910g GAGAGAGGCTATAAATGGAGATGCAAGTAGGGAAGATAT 69.5 
C → G 
c910g_antisense ATATCTTCCCTACTTGCATCTCCATTTATAGCCTCTCTC 69.5 
-1204 
t1194c TGTTTAAGGTGTTTATCAAGACAGTACGTGCACCGCTGAAC 71.4 
T → C 
t1194c_antisense GTTCAGCGGTGCACGTACTGTCTTGATAAACACCTTAAACA 71.4 
-804 
g1594a GTCTCTCTTTATTTCTCAGCCAGCTGACACTTATAGAAAGAAC 70.4 
G → A 
g159a_antisense GTTCTTTCTATAAGTGTCAGCTGGCTGAGAAATAAAGAGAGAC 70.4 
-362 
a2036g CCAGTGATTTTGATTTTGCAGCATGGAAAGTTCCAAGCCTT 70.4 
A → G 
a2036g_antisense AAGGCTTGGAACTTTCCATGCTGCAAAATCAAAATCACTGG 70.4 
-34 
c2364t CAGCTCTTCTACTCCACTGCTGTCTATCTTGCCTG 71.8 
C → T 
c2364t_antisense CAGGCAAGATAGACAGCAGTGGAGTAGAAGAGCTG 71.8 
 
 
 
Table 8-7 Primers used for sequencing of pGL3-17 (and mutated) reporter constructs. 
Primer name Sequence 5’-3’ Tm (°C) 
GLprimer2 CTTTATGTTTTTGGCGTCTTCCA 57.1 
RVprimer3 CTAGCAAAATAGGCTGTCCC 57.3 
RVprimer4 GACGATAGTCATGCCCCGCG 63.5 
17_-2325R GACTCATTAGCTGGTCCCA 59.4 
17_-2288R GTGTTGCAATCGAACTGCAT 55.3 
17_-2107R CCTGATCTAACGCCTCAGCT 59.4 
17_-2414R TTTGGTGGAATTGCCTTAC 55.3 
17_-2729R TTGGACGGTTTGATTGTTCA 53.2 
17_-2729F TGAACAATCAAACCGTCCAA 53.2 
17_-2595F GGGAATCTTCCCCCTCAGTA 59.4 
17_-2900F CTCGGATTGCTTCTTTACGG 57.3 
17_-2815R GGCTGGAGGTAAACAAAGCA 57.3 
cyp17-1213F CCGCTCTGGGAATGTCTATC 59.4 
cyp17-1935F AGCTGAGGCGTTAGATCAGG 59.4 
cyp17-1525F GTCACTTCAGGACCACTGTGA 59.8 
cyp17-457F CACCGCTCCCCACAGCTTAGCAC 67.8 
cyp17-117R CTCCCCATGCTTGAATGACT 57.3 
cyp17+67R GGCTACCCTGATCTTCACCTT 59.8 
cyp17-112R GTCAGTTGATCACCCTCTGA 57.3 
cyp17promF2 ATGCAGTTCGATTGCAACAC 55.3 
cyp17promF1 TGGGGACCAGCTAATGAGTC 59.4 
 
 
 
Table 8-8 Primers used for sequencing of pEZX reporter constructs. 
Primer name Sequence 5’-3’ Tm (°C) 
pEZX-MT01 For GATCCGCGAGATCCTGAT 59.9 
pEZX-MT01 Rev TTGGCGTTACTATGGGAACAT 58.7 
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8.2 Appendix 2 
Nucleotide sequences were obtained from Ensembl release 56 Sept 2009 
Key: 
 
CYP17A1 5’ promoter region 
CYP17A1 5’ untranslated region (5’UTR) 
CYP17A1 exons 
CYP17A1 introns 
CYP17A1 3’ untranslated region (3’UTR) 
 
TGGGCCTAATTACAGTCACTGCACTGGCCACCACTGCCGGAGTGGCATTACACCAATCTATTCAAATGGCTAATTTTGTTAATGATTG
GTAAGGCAATTCCACCCAAATGTGGAATCCTCAACAAGGCATTGATCAAAAATTAGCTAATGATTTAAGACAGTCTGTTATTTGGCTT
GGGGACCAGCTAATGAGTCTCGAACATCACATGCAAATGCAGTTCGATTGCAACACTTCTGATTTCTATAGCACACCATATTCCTACA
ACGAGACTGATCATGGGAAATGGTCAAAGGACACCTTCTGGGTAGGGAAGATAATTTATCCTTGGACATAACTAAATTAAAGAAAC
AAATTTTTGAAGCCTCTCAAGCTCATTTATCCATTGTGCCTGGAGCTGAGGCGTTAGATCAGGTGGCAGAAAGTCTTTCTGGACTAAA
CTCCACAACTTGGATTAAGTCTACTGGGGGCTCCACTGTAGGAAATTTTGGAATCATGTTTCTCTGTTTAATCGGCTTGTTTTTAGTGT
GCCAGACCAGTCAAAGAATCCTGCATCAAAACCGAGAGAACGAGCAAGCCTTCATCGCCACGGCACATTTATATAAAAAGAAAGGG
AGAGATGTTGCGGGAAGTCAGGGACCCTGAATGGAGGGACTGGCTGGAGCCATGGCAGAGGAACATAAATTGTGAAGATTTCATT
TTAATATGGACATTTATCAGTTCCCAAATAATACTTTTATAATTTCTTATGCCTGTCTTTACTTTAATCTCTTAATCCTGTTATCTTTGTA
AGCTGAGGATGTTTGTCACTTCAGGACCACTGTGATAATTGTGTTAACTGTACAAATTGATTGTAAGACATGTGTTTGAACAATATGA
AATTAGTGCACCTTGAAAAAGAACAGAATAAGAGCAATTTTTAGGGAACAAGGGAAAACAACCATAAGGTCTGACTGCCTGCAGGG
TCGGGCAGAAAGAGCCATATTTTCCTTCTTGAGAGAGGCTATAAATGGACATGCAAGTAGGGAAGATATCACTAAATTCTTTTCCTA
GCAAGGAGTATTATTATTAATACCCTGGGAAAGGAATGCATTCCTGGGGGGAGGTCTATAAACAGCCGCTCTGGGAATGTCTATCTT
GTGCAGTTGAGATAAGGACTGAGATACGCCCTGGTCTCCTGCAGTACCCTCAGGCTTACTAGGGTGGGGAAAAACTCCGCCCTGGT
AAATTTGTGGTCAGACCGGTTCTCTGCTGTCGAACCCTGTTTGCTGTTGTTTAAGGTGTTTATCAAGACAGTATGTGCACCGCTGAAC
ATAGACCCTCATCTGTAGTTCTGCTTTTGCCCTTTGCCTTGTGATCTTTGTTGGACCCTTATCAGTGGTTCTGCTTTTGCCCTTTGCCTT
GTGATCTTTGTTGGACCCTTATCGGTAGTTCTGCTTTTGCCCTTTGTCCTTTCCCTCAGAAGCATGTGATCTTTGTTAGACACTTATTAG
TAGTTCTGCTTTTCGCCCTTTGAAGCATGTGATCTTTGTACCTACTCCCTGTTCTTACACCCCCTCCCCTTTTTGAAACCCTTAATAAAAA
CTTGCTGGTTTGAGGCTCAGGTGGGTATCACAGTCCTACCGATATGTGATGCCACCCCCGGCGGCCCAGCTGTAAAATTCCTCTCTTT
ATACTGTCTCTCTTTATTTCTCAGCCGGCTGACACTTATAGAAAGAACCTACGTTGAAATATTGGGGGTGGGTTCCCCCAGTACGCTA
GTCCTGCTGATGAGCAAAGAAGGTGTTGATGGCATTTTGATCAACAAGAAATGTTATGAAACGGCCTCCCACCTCTGGCATTCCTAG
TACTGACCTATCTCTCCCTTCCCTTCCACCGCTCCCCACAGCTTAGCACCCCTTTCGTTCCCATACACATGTACATTTTTATTTTGGGGA
CCATTAACCCACAGCCCTTATCGCTGCCAAAACCACATGGGCTGGAGGGCCAGGGCTGCATGGACAGTCACACCACTGCACACCAG
CCTGGTGATGGAGCAAGACTCTGAAAAAAAAAAAAAGAAGCATAAAAGACCTTTAACAGTCCCTGCTACTTGTGACCCTCCTGAATC
TGTCATCTGTCCAGTGATTTTGATTTTGCAACATGGAAAGTTCCAAGCCTTGACTCCTGAGCCCAGATACCATTCGCACTCTGGAGTC
ATTCAAGCATGGGGAGCTCCTCAGAGGGTGATCAACTGACCTCCCTTACCTAGCTCCTCCTCCGGAGGTTTGCCCTGGAGTTGAGCC
AGCCCTTGAGGAGGCCTTCACTCCCACCGCCTCTCTCCCTTCTGGATATGAGCTCAGGCCTGGCTGGGCTCCAGGAGAATCTTTCCAC
AAGGCAAGAGATAACACAAAGTCAAGGTGAAGATCAGGGTAGCCCTTTAAAAGGCCTCCTTGTGCCCTAGAGTTGCCACAGCTCTT
CTACTCCACTGCTGTCTATCTTGCCTGCCGGCACCCAGCCACCATGTGGGAGCTCGTGGCTCTCTTGCTGCTTACCCTAGCTTATTTGT
TTTGGCCCAAGAGAAGGTGCCCTGGTGCCAAGTACCCCAAGAGCCTCCTGTCCCTGCCCCTGGTGGGCAGCCTGCCATTCCTCCCCA
GACACGGCCATATGCATAACAACTTCTTCAAGCTGCAGAAAAAATATGGCCCCATCTATTCGGTTCGTATGGGCACCAAGACTACAG
TGATTGTCGGCCACCACCAGCTGGCCAAGGAGGTGCTTATTAAGAAGGGCAAGGACTTCTCTGGGCGGCCTCAAATGGTAAGTGGT
GCCCATCTCCTCCCTGCCCCCTTCACCACCCCCTGGGATTGTTCAGGTCTTCAGACCATGCCTAGAATGGGGCTTCCAGCTCCAACAA
CCTGTAATTCTTCCCAAAGTAGACTAGTGGGATGATGTGAAGGGAGTGAACCTTCAGACCCCCACCCAGCCTCTAAATTAGGCAGGA
AGAATTAAAGGAATGTCTCCTCTACCAGGCTGCCCAGGAGGTGGGATGGGAGGACCACAGTGGTCTGAGGGGTCAAGGAATCCTC
ACTCCACTCCTCTCTCTGAGCCTAGACTTCTCTAATGGACTGAGAAGGTGCATGTACAGCACTTAGCCTAGCACCCAGCACAGTAAGT
GCCCCTTATACAGCCAGGATTCATGTTACTTTTCATGGAAAATGGGGGCAGTGACTACTGTCCTCCATGAAAGCTGCTGGGGAGAAT
TAGCCTAGCTATTGCAGGCTGGGATTGCTGCTTTCCTGGTGCTATTTCCAGCTACTCAGGCTCACAGGGGCAGTTTTCTACAATGACA
TTTCAGGGTTGCTGATGAGCCTCCCACTCAGCAGGGCCCCCAGCCTCTCAGCATTTTTTTTTTTTTTTTTTTTTTTTGAGACAGAGTCTC
TCTCTGTCGCCCAGCCTGGAGTGCAGTGGCCAATCTCAGCTCACTGCAACCTCTGCCTCCCGGGTTCAAGTGATTCTCCTGCCTCAGC
CTCCTGAGTACCTGGGACTACAGGAGCATGCCACCATGCCCGCTAATTTTTTGTATTTTTAGTAGAGATGGTGTTTCACCATGTTAGC
CAGGATGGTCTCGATCTCCTGACCTCGTGATCCTCCCACCTTAGCCTCCCAAAGTGCTAGGATTATAGGCGTAAGCCACTGTGCCCTG
CCAGCCTCTCAGCTTTGATCAAGCCAAGGGTTGGTTTATTTTTTCTTGGACCAATCAGCCAGGTCTGCTGACCAACTACCTAGCTCCCA
CCTCTGCTGGCTTCCTCCCGGGGGCAGAGAAGATGGAGAAGGCTAGTCATGTGGATCTTCAGGGTCAGGAAATGGAAAAGGGAGG
CTTTGGACCCTTTTGCTTTGGGGGGCACCTCTAGGAGGAGGCGGCTCGGCCCAAGTCCAGACTGGGTAGACAAAACATCTGCACTCT
CCAAATGTGGGCTTGTGGCTGGGTATGCAGGCTTGCAATGGAAGGGTAAACCTGAGTGAGGTGAGCTGTGCCTTTAGCTCAGCTAA
GGGCTCAGGGAAAAGCAGAGATCTGTGCAGTCCTCAGCCTCTACAAGCTCACCTGCTCCCTACCCTCTGGACAGGCATAGTTTAGAG
AGTTTATCCCATCCAGAGTTGCCTTCCTGTGGTCAGAAACTGATGAGCAAAAAGAAGCCCAGAGGGCACCCTGTCAGCGAAAAGAA
CCCCAATGCTGCTGCATTCTAATTAAGGGTTCTTTCTTTCTCCTTGATCTACTGTATTTCTGAAGGAATTGGGAGTAGGAGGCCTTAG
GGTCTGTCCTACCAAGTCCTTGCAGTCATGGTGGAGTGCAGTGGGGCTGTGCCCACATGGGAGTCAGCATGCCAGGTACCTGCCTTC
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TCCTCCAGGAAGGAAAGCAGGGACCAGAGGTGTAAGGGCAAGAGTGGGGTGGATGGTGTGAGATTCCTACAGCCTTGCCTGCTCT
CTAAAGGCAACTCTAGACATCGCGTCCAACAACCGTAAGGGTATCGCCTTCGCTGACTCTGGCGCACACTGGCAGCTGCATCGAAGG
CTGGCGATGGCCACCTTTGCCCTGTTCAAGGATGGCGATCAGAAGCTGGAGAAGATCAGTGAGTGCCAGGCTGGCCCCTGGGGCT
GGGGCTGGATCCCACAGGAGCTGCTGGAGGGAGAGGAGGGTTGGGCAGGGGTAAGGGTTAGGACTAGAGCGCAATGCAGCCTTT
TCTTGGCTACTGCTGCCATCTAGTGGCCATCTGCTATCTGTCCCCCGCTCCTGTTAAGAGGCAACTGGTACAGAGAGGGGGTAAGGG
TGCTGATTCATTTCCCACCCTCATGCCCCCTCTCCCTTCAGTTTGTCAGGAAATCAGTACATTGTGTGATATGCTGGCCACCCACAACG
GACAGTCCATAGACATCTCCTTTCCTGTCTTCGTGGCGGTAACCAATGTCATCTCCTTGATCTGCTTCAATACCTCCTACAAGAATGGG
GACCCTGAGTTGAATGTCATACAGAATTACAATGAAGGCATCATAGACAACCTGAGCAAAGACAGCCTGGTGGACCTAGTCCCCTG
GTTGAAGGTGAGATGCTGCCAGCCCTGCCTTCAGGTTCTAGTAGACCCTGACATTGTCCCCAATCTTCCTTCCTTTTTACTTCCCTGCT
CCAGCCGCAATGACCCATCTTTTTCCTGATTACCTCCGCCACCTCTACCTCCTCTGCCACTTAAAACCTTTGCCATTTCTCTGCAGAGAT
AGATTTAGCCTTTTAATTATGCACCTTAGTACTCCAGATAATGACCTTCATTTCTTTTCCAATTACCATGTGCCAGTACTAAGCATTCTA
TACGCATTCATCGCTGAATTCCCCTTGGAAGTAGGTTTTATTATCCCCATTGTGCAGGTGAGAAGCAGGCTTAGCGGGGTTAAGGAG
CTTGTCTGAGCCTTCAGGCTCATGTCTCTCTCACTCCTAAGGGCTGGACACATAGCAGAGTCAGCGCTTGATGTTTGATTGAATGGG
GAAGGAGAGGTGGAGACCACGCCCTCCTCCCTTGTTTAGAATTGTCTTCGTCGTCATGATAAACCCGTTCTGTGTCCCCATCTTGCCT
TCCATTCTGGCTGAAGGTCAGGGGTGGAGTAGGAACTTCCAGAGACAGAAAGCTAAGATCCGCCTCCAGGAGAGACTCTGGCAGCT
GGAGAAGCAAAATGGAAGAAGGGTGGATTTAACATTTCTTTTTATTTCCCAGATTTTCCCCAACAAAACCCTGGAAAAATTAAAGAG
CCATGTTAAAATACGAAATGATCTGCTGAATAAAATACTTGAAAATTACAAGGTAGGTGATAGAGCAGAAGAGAATATGAGTTAGG
CTAAAAGTAATCACAAGAGCAGGGTGGAGTCCATTCTACACACTGTAGAAGCTTCAAAACCAAGCAGAGAACCTGGCACATAGTAG
GTGTACAATAAAAACTGACTTAAGGGCTGGGCGCGGTGGCTCACGCCTGTAATCCCAACACTTTGGGAGGCCGAGGTGGGCAGATC
AATTGAGGTCAGGAGTTCGAGATGAGCCTGGCCAATATGGTGAAACCCCGTCTGTACTAAAAATACAAAAACTAGGCCAGGCAAGA
TGGCTCACACCTGTAATCCCAACATTTTGGGAGGCCAAGGTGGGCAGATCACCTGAGGTTGGGAGTTCGAGACCAGCCTGACCAAC
ATGGAGAAACTCTGTCTCTACTAAAAATACAAAATTAGCCGGGCACGGTGGCGCATGCCTATAATCCCAGCTATTTGGGAGGCTGAG
GCAGGAGACTCACTTGAACCCGAGAAGCAGAGGTTGCAGTGAGCTGAGATCATGCCATTGCACTCCAGCCTGGGCATTGCACCAAG
ATTCTGTCTCAAAAAAAAAAAAAAAACTGACTCAAGGAGTTGGGATCGAAAAGTGAGGAACTGAAGAGGATCCTAGAAGAGACCT
AACCTCTCCACCAAATTTAAAGAGGGCCCGGGGCTGCCTCCTACCTCCACAAGTTCGTAGGTCCTGCCCAGACTTGCTCTACTTCCAA
GTGGAAGGAGCCTTGTTATCTCTAGTCAGGGACAGAAGTATGGCAGGAGTGTCACAGATGGGGCTCCTTCCTTATTAATGTCTCCCA
ACCTCACCCAACCCAGGAGAAATTCCGGAGTGACTCTATCACCAACATGCTGGACACACTGATGCAAGCCAAGATGAACTCAGATAA
TGGCAATGCTGGCCCAGATCAAGACTCAGAGCTGCTTTCAGATAACCACATTCTCACCACCATAGGGGACATCTTTGGGGCTGGCGT
GGAGACCACCACCTCTGTGGTTAAATGGACCCTGGCCTTCCTGCTGCACAATCCTCAGGTGTGCTTCCCCCTCATTGATCCTAGACCC
CAGCCAGCCCAATCTCTGGGCTCCAGAGAAAGGGAGAGCCAATTCTCTCAGGCTTTCTGTGCAGGAAGACTAGGCCTGCCCTGCTCC
TTACCCAAGCAGTAGTTGGCTTTGACCCCAGAGTAGAGCTGCCCCATCTTCTGGAAGCCGGGCCTGGGCCCCAGAGCCACTACTGG
GAAGGGACTGGACAGGCTCTTCTCGATGTCACAGTTGGATTCTTCTCTAAGCCCTTGCTTCTCCTGGGCTTACACACACTAGTCACCT
CCAACCTACTCTGGTCTTCAGGTGAAGAAGAAGCTCTACGAGGAGATTGACCAGAATGTGGGTTTCAGCCGCACACCAACTATCAGT
GACCGTAACCGTCTCCTCCTGCTGGAGGCCACCATCCGAGAGGTGCTTCGCCTCAGGCCCGTGGCCCCTATGCTCATCCCCCACAAG
GCCAACGTTGACTCCAGGTGTGCCTGCCCTCCCAGTGACATCTAGCCCCATGATGCATTCAACACTGCTTGCCAGCCCACCTGGCTCC
CCCTACCCCCGGCCCCTGCTGGCCAACCTAAAGTCAGTCAACCATCAACTACTAAAAATCATCCTGCCGGCCGGGCACGGTGGCTCA
CACCTGTCATCCCAACACTTTGGGAGGTCGAGGCGGGTGGATCATGAGGTCAGGGGTTCAAGACCAGCCTGACCAATATGGTGAAA
CCCCGTCTCTACTAAAAATACAAAAATTAGCCATGCATCGTGGCGCGTGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGAG
AATCACTTGAACCAAGGCGGCGGAGGTTGCAGTGAGCCAAGATTGCACCACTGCACTCCAGCCTGGGTGACAGAGCGGGACTCTGT
CTCAAAATAAATAATTAATTAATTAAATATAAAAATCATCCTGCCCCCAGCCCCGTGGCTCCATGTCTCTACCACCTACAGACACGCAT
TGACTCATCCACAGATCTGCCTGACTTCCCAGAGGAGCTTCCTGCTGCCCTCAGAGACATGTGGTCTGGGATGAAAGGCTGGGAGCT
CCATGTTCCAACCAGCTGCAGCACGCACATAACATGCGCTGCAGCTCCAAACGCACACCCACATACACTGCCAGACACCAAAGTCCA
CAGACACAGGTGTTCAGACAGAAGCGCCTGTTAGGAGGGAAGGGATGGAGAAGGGCTGGATTTAGGTTTGATCTGGCAGAAGCTG
AGGAAAACATGAGTGAGTGGGAATGAGGGAGTAAAGGGCATTTTCCTCACGGCGGAAGAATGAGGGGGCATGAGGCTGAGCAAG
GAAGGGAGTACGAAGTCCCAGACCCACTTTTCCTCTTCCACTCTGGAGCAGCATCGGTGAGTTTGCTGTGGACAAGGGCACAGAAG
TTATCATCAATCTGTGGGCGCTGCATCACAATGAGAAGGAGTGGCACCAGCCGGATCAGTTCATGCCTGGTGAGTCTGTCCTGTCCT
GCGCCCTGGGCCACACAGCGAGCCTGGACTCTGCTCCACCACCCCAGTACCCCTTCACCTCTGCCAAGCTTGCTGCTAGAAAACTCTT
GGCTCCAACTATACGGACCTGTTGACACCCTCATCCTGCCATAGACTTACCCAAACTCTTCACAGCTGGGTTTCCCACGCTCTTCTTCC
AACCAACTGCAAATTCACCCTCCAAGAAGCCCTCTACGCCTCTGTCTGCCATTAAGTCTGTCCCTTCTCCCCTCGGATGGTGCTATTTT
CATAGGTTAATTCCATCTCTTTTCCATCCTTCCTGAATATTTCATTTCCTCTGTGTCGTTAAGGGCTACCTGAAAGCAGGGCTGTATCTC
TCCCCAGGCGGGGGTTCCCCCATAATAAGGCTACATCCTCAGATCAGGGTTCCCTGGGCAGGGCCATGTCTCCCCCTCAACCAGGGC
AGAACCATGCCTCTCCTCCCTCCTGCCCTAACCCCTGGCTGATGCCACTCCTTGCCTGCAGAGCGTTTCTTGAATCCAGCGGGGACCC
AGCTCATCTCACCGTCAGTAAGCTATTTGCCCTTCGGAGCAGGACCTCGCTCCTGTATAGGTGAGATCCTGGCCCGCCAGGAGCTCTT
CCTCATCATGGCCTGGCTGCTGCAGAGGTTCGACCTGGAGGTGCCAGATGATGGGCAGCTGCCCTCCCTGGAAGGCATCCCCAAGG
TGGTCTTTCTGATCGACTCTTTCAAAGTGAAGATCAAGGTGCGCCAGGCCTGGAGGGAAGCCCAGGCTGAGGGTAGCACCTAAAGG
CTGTAACTCACAGCCCCTGTCCACCCTATGTGGCCCCACAACACAGATTTAGAGATACAACCCCCCACCCTTCTCCGCCATTCTTCCCT
ACTCCCAACCCACTCTGCCTTCTTTTTCAGCTTGTGGCAATGCCAGTGATGTGCATAAACAGTTTTTTTTTTTCCATAA  
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